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SUMMARY
Ulcerative colitis (UC), notorious for its unpredictable attacks of inflammation of the large intestine, is
estimated to affect as many as 1.4 million people in the USA and 2.2 million people in Europe with
15000-30000 new cases being diagnosed annually worldwide. The chronic inflammatory process is
limited to various regions of the colonic mucosa and is postulated to occur due to a dysregulated
mucosal response in the intestinal wall, facilitated by defects in the protective barrier function of the
intestinal epithelium and mucosal immune system. Due to the range and extent of disease
manifestations the goals of UC therapy are broad and non-specific. The focus of therapy is thus
primarily placed on the treatment of active disease by ameliorating the signs and symptoms
characteristic of the disease state with concurrent adjunctive and anti-inflammatory therapy. Thus,
ideally a delivery system should facilitate a reduction in the pill burden, daily dosing requirements and
allow for concurrent adjunctive and anti-inflammatory therapy with a single delivery system
administration. Therefore, essentially the purpose of this work was to develop a novel stimuli-
responsive oral tablet system (SROT) that provided targeted drug delivery of 5-ASA to the colon and
loperamide HCl to the small intestine with a single delivery system. For this purpose, the employment
of polymers that are termed ‘stimuli-responsive’ or ‘smart’ were established to be the most attractive
approach for ‘activating’ drug release at the desired site in response to the pre-determined reliable
stimulus. Thus, advantage is taken of the over 400 distinct species of anaerobic bacteria and their
corresponding enzymatic activities in the colon.
Investigations performed according to a Box-Behnken experimental design exposed an optimum
enzyme-responsive colon-targeted tablet that effectively inhibited premature 5-ASA release in
conditions simulating the upper gastrointestinal tract, whilst enabling an immediate initiation of drug
release on exposure to colonic enzymes. The enzyme-responsiveness of the tablet was a direct result
of the employment of only naturally-derived polysaccharides that were susceptible to colonic
degradation. Furthermore, and more importantly, the prevention of premature drug release was
achieved by the enzyme-responsive hydrophobic coating consisting of pectin and an aqueous
ethycellulose dispersion that was applied to tablets until a ±10% total weight gain was achieved. In
addition the in situ crosslinking between pectin and BaCl2 in the tablet matrix as well as the
crosslinked 5-ASA-loaded granules resulted in a zero-order drug release throughout the 18 hour
period in the simulated colonic environment containing enzymes.
The development of the outer pepsin-responsive small intestinally-targeted coating was also
conducted according to the Box-Behnken experimental design. Extensive investigations revealed an
optimized pepsin-responsive coating after conducting the relevant studies on the 15 statistically-
derived formulations. Essentially, the tablets coated with the 40%w/v gelatine solutions resulted in the
greatest increase in weight and shell thickness of the formulations however these were the least
responsive to pepsin. The optimum pepsin-responsiveness was achieved from a gelatine coating of
14.379%w/v which was crosslinked for 6 hours in a glutaraldehyde-lactose dry mixture. Furthermore,
the novel crosslinking method ensured that no entrapped loperamide HCl was prematurely lost during
the crosslinking process. In addition, the optimum formulation also achieved 100% drug release in the
small intestine-at its site of therapeutic action.
In vivo investigations of the SROT in the large white pig model explicated the colon-targeting ability of
the 5-ASA-loaded tablet as well as the benefits of the SROT compared to the conventional
commercially available system, Asacol® (Aventis Pharma (Pty) Ltd.,Midrand, Johannesburg, South
Africa). The success of the loperamide-loaded coating was evident from the minimal presence of
loperamide HCl in plasma in the first 2 hours post-dosing compared to its commercially available
counterpart Imodium® (Janssen Pharmaceutica (Pty) Ltd., Woodmead, Johannesburg, South Africa).
Investigations into an alternate colon-targeted drug delivery system revealed 3 novel composite
polyacrylamide-polysaccharide hydrolyzed electrolytic matrices consisting of either pectin, chitosan or
a combination of both, complexed with hydrolyzed polyacrylamide. Each matrix presented with varying
surface area and porositometric properties which influenced their drug release behaviour. These
formulations hold potential for numerous controlled drug delivery applications and are not exclusively
limited to colon-targeting.
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1CHAPTER 1
THE RATIONALE FOR THE DEVELOPMENT OF A NOVEL STIMULI-RESPONSIVE
ORAL TABLET SYSTEM (SROT) FOR THE SIMULTANEOUS ANTI-INFLAMMATORY
AND SYMPTOMATIC TREATMENT OF ULCERATIVE COLITIS
1.1 Introduction
According to the Centre for Disease Control (CDC) (2007) it is estimated that the overall
healthcare cost associated with Inflammatory Bowel Disease (IBD) approximates to $1.7
billion USD and it is one of the five most prevalent gastrointestinal disease burdens in the
United States of America. IBD is a generic classification for the group of non-specific,
idiopathic inflammatory disorders of the gastrointestinal tract (GIT) (Young and Koda-Kimble,
1995; Abdel-Hady and Bunn, 2004). By convention IBD comprises of three main entities
namely, Ulcerative Colitis (UC), Crohn’s Disease (CD), and indeterminate colitis. The latter of
which represents a patient group that cannot be classified as either UC or CD, but which
constitutes about 10% of IBD sufferers (van Bodegraven and Wijmenga, 2009). Despite the
similarities in the natural history and clinical features of CD and UC, there are significant
differences in the pathophysiology, anatomic distribution and clinical course of these
diseases.
Early medical literature on IBD provided scant scientific data and writers often applied free
reign to their imaginations when explaining this condition. The first documented case of UC
was in 1859 and was described by Sir Samuel Wilks. Similarly, various cases of CD had
appeared in literature even before Crohn and co-workers published data regarding this
condition. In the following two decades the distinction between UC and CD was further
elaborated in macroscopic terms and in 1960, the nature of the inflammatory processes
underlying these conditions was explicated (Moum and Ekbom, 2002). According to most
recent literature, CD is identifiable as chronic inflammation typically affecting the terminal
ileum and right colon, but almost always involves the entire GIT, whereas UC is exclusively
localized to the colon (Van Assche et al., 2009). Table 1.1 systematically differentiates UC
and CD based on their pathophysiological characteristics.
Research has shown that in the past 50 years the incidence of CD has increased 8 to 10
fold, whereas the incidence of UC has remained stable (Bach, 2002). CD is found to be
prevalent in urbanized, developed countries and its change in incidence is thought to be
attributable to the improved hygiene and social standards of these typically western
societies. However UC is more of a global disease (Karlinger et al., 2000). van Bodegraven
2and Wijmenga (2009) later suggested that the incidence of IBD thus varies according to
geographic location, industrialization, and the availability of diagnostic means.
Table 1.1: Pathophysiologic differences between Ulcerative Colitis and Crohn’s Disease
(Young and Koda-Kimble, 1995; Mpofu and Ireland, 2006; Merck Manual, 2007; van
Bodegraven and Wijmenga, 2009)
Characteristics Ulcerative Colitis (UC) Crohn’s Disease (CD)
World-wide incidence (per year) 6.4/100,000 5.5/100,000
Anatomical location Colon and rectum
Rectosigmoid is invariably
involved; colonic involvement is
usually left-sided.
Mouth to anus, small
bowel involvement in 80%
of cases.
Rectosigmoid is often
spared; colonic
involvement is usually
right-sided.
Distribution Continuous, diffuse, mucosal Segmental, focal,
transmural, rigid, thick,
edematous, and fibrotic
Bowel wall Shortened, loss of haustral
markings, generally not
thickened. Bowel wall is
affected symmetrically and
uninterruptedly from the rectum
proximally.
Bowel wall is affected
asymmetrically and
segmentally, with "skip
areas" between diseased
segments.
Gross rectal bleeding Common Infrequent, except in 75 to
85% of cases of Crohn's
colitis.
Crypt abscesses Common Infrequent
Fissuring with sinus formation Absent Common
Noncaseating granulomas Absent Common
Strictures Absent Common
Abdominal mass Absent Common
Abdominal pain Infrequent Common
Toxic megacolon Occasional Rare
Bowel carcinoma Greatly increased Slightly increased
Perianal lesions Significant perianal lesions
never occur.
Perianal lesions are
significant in 25 to 35% of
cases.
1.2 Ulcerative Colitis – Delineating the Disease
UC, a relapsing and remitting disease characterized by chronic non-infectious inflammation
of the colorectal mucosa boasts an annual incidence rate of approximately 10-20 cases to
100,000 of the population in the United Kingdom with over 200 people per 100,000 living with
UC at any given time (Probert et al., 1992; Ghosh et al., 2000, Loftus et al., 2000; Carter et
al., 2004). The clinical pattern of UC is based on the extent of colonic involvement i.e. if only
the rectal mucosa is affected it is termed ‘proctitis’; if it extends into the sigmoid colon it is
termed ‘proctosigmoiditis’, and if the entire colon is involved it is termed ‘colitis’ or ‘pancolitis’
(Mpofu and Ireland, 2006).
The characteristic manifestations of UC exist as spells of bloody diarrhoea, increased
urgency, abdominal pain, fever, fatigue and weight loss, however extra-intestinal
3manifestations of UC may present as arthritis, ocular inflammation, liver and biliary disease,
skin rashes and numerous other pathologies as indicated in Figure 1.1, all of which
significantly reduce quality of life during active phase of the disease (Cohen, 2006).
Figure 1.1: Typical symptomatic manifestations of Ulcerative Colitis.
Generally, the severity of the symptoms parallels the intensity and extent of the inflammation
(Merck Manual, 1997; van Bodegraven and Wijmenga, 2009). An attack may be acute and
fulminant, characterized by sudden violent diarrhoea, high fever, signs of peritonitis, and
profound toxemia. However more typically, an attack begins insidiously, and may be
characterized by an increased urgency to defecate, mild lower abdominal cramps, and blood
and mucus in the stools (Merck Manual, 1997).
1.2.1 Possible theories explicating the aetiology of UC
Since the emergence of UC in the 1800’s the aetiology thereof was but an enigma and
remains as such to the present day. Therefore, since no single agent or distinct mechanism
can be responsible for all aspects of the disease current hypotheses suggest the involvement
of a multitude of factors each with a relatively weak effect acting together to influence the
appearance and pathogenesis of UC. Most theories encompass a combination of
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4environmental influences, genetic predisposition, altered cellular immunity, and inappropriate
and excessive responses to dietary triggers (Oliva-Hemker and Fiocchi, 2002).
1.2.1.1 Environmental influences
Seemingly unrelated environmental factors such as smoking, oral contraception, diet, blood
transfusions, pollution, hygiene, occupation, breastfeeding, drugs, geographical and social
status, stress, microbial agents, intestinal permeability and appendectomy rates have
exhibited an association with UC (Koutrobakis et al., 1996; Corrao et al., 1998; Danese et al.,
2004; Loftus, 2004; Garcia Rodriguez et al., 2004). However the influence of smoking holds
significant prominence since numerous studies have established an intriguing correlation
between smoking and increased protection against UC (Harries et al., 1982; Somerville et
al., 1984; Reif et al., 1995; Russel and Stockbrugger, 1996; Rubin and Hanauer, 2000;
Cosnes, 2004; Danese et al., 2004). Therefore despite the uncertainty as to the components
of tobacco responsible for the positive influence, conventional UC therapy has been
supplemented with transdermal nicotine patches where an improvement in clinical symptoms
in patients with mild to moderate UC had been observed (Pullan et al., 1994). Furthermore,
this modulatory effect of nicotine on the immune responses has since also been observed in
vitro (Madretsma et al., 1996).
Since the colon is the site of nutrient absorption and UC exclusively involves the colon the
association between diet and UC is a logical one (Fiocchi, 1998). Nevertheless, research has
established that implementation of nutritional therapies in UC provided no beneficial
influences whereas an elemental diet substantially improved the condition in CD patients
(Teahon et al., 1991). The only evidence of the role of diet in the appearance of UC is
apparent in breastfed infants where studies have shown that natural feeding provides
protection to the infant GIT and that any damage to the bowels of an infant may lead to the
development of UC in adolescence (Whorwell et al., 1979; Koletzko et al., 1989).
1.2.1.2 Genetic influences
The genetic influence of IBD appears to be more pronounced in CD than UC. This
conclusion arises from results of twin studies and studies of familial aggregation conducted
over several decades (Tysk et al., 1988; Satsangi et al., 1994; Peeters et al., 1996). Most
recently, the concordance rates for UC among monozygotic and dizygotic twins were found
to be 18.2% among the monozygotic pairs and 4.5% among the dizygotic pairs (Orholm et
al., 2000; Halfvarson et al., 2003). In spite of this, UC is not a Mendelian trait and is thus
most likely due to a combination of environmental and genetic influences. Thus, the
predisposition to UC is inherited, but when exposed to the cause, the development of the
disease is promoted (Karlinger et al., 2000).
51.2.1.3 Immune reactivity to microbial antigens
A direct cause-and-effect relationship between a single micro-organism and inflammation still
remains one of the most popular triggers for IBD. Despite the identification of numerous
bacterial pathogens as suspects for CD, an infectious origin of UC is less definitive.
Essentially diplostreptococcus has been suspected of being the causative agent for UC
however the presence of E. coli in patients with UC in relapse, but not in normal controls
suggests the culpability of this organism as well (Burke and Axon, 1987). The traditional
approach to the identification of potential micro-organisms linked to IBD has been through
the identification of antibodies against known micro-organisms, however since all IBD
patients present with elevated titres against bacteria, viruses, and fungi the mere presence of
the antibodies are of limited value (Fiocchi, 1998; Targan, 1998). Investigators have also
postulated the possibility that components of the normal intestinal flora could act as a trigger
to initiate or somehow contribute to UC (Fabia et al., 1993; Bamias et al., 2005; Thompson-
Chagoyan et al., 2005).
In the presence of an impaired mucosal barrier or injury to the mucosa, commensal flora are
thought to function as modulators of intestinal inflammation (Chadwick and Anderson, 1990;
Duchmann et al., 1995; Duchmann et al., 1996). During inflammation there is a counteracting
mechanism with which the intestine defends its integrity. The efficacy of this defence
mechanism is not only dependent on the strength of the pathogen, but also on the resistance
capability of the bowel wall. This is in turn dependent on the composition of the mucus
produced from mucosal cells as well as on the turnover capability of the mucosal epithelial.
During a typical anti-inflammatory defence, inflammation is overcome with no residual
alteration. However if the individual is predisposed to UC this type of down-regulation does
not occur and the inflammation is sustained or even increases due to secondary
immunological processes, resulting in chronic inflammation and possible tissue damage
(Karlinger et al., 2000). The chronicity of inflammation is then not only a result of the
continuous antigenic response but also due to the resultant defective epithelial barrier
function (Ramage et al., 1988).
1.2.2 Pathogenesis and pathophysiologic mechanisms of UC
The characteristic mucosal inflammation of UC is said to be due to a culmination of a series
of events and processes which are initiated by an antigen. Despite the postulation that
microbial pathogens are the source of these antigens it is now generally accepted that the
constant antigenic stimulation is actually provided by the commensal enteric bacteria which
results in continuously activated pathogenic T-cells and chronic inflammation (Sartor, 2006;
Strober et al., 2007; Xavier and Podolsky, 2007). IBD pathogenesis can thus be explicated
6by four broad possible mechanisms that drive the pathogenic immunologic responses to
luminal microbial antigens. The four mechanisms include:
1. Induction of intestinal inflammation by microbial pathogens,
2. Dysbiosis of commensal bacteria,
3. Host genetic defects in containing commensal bacteria, and
4. Defective host immunoregulation.
Mycobacterium avium subspecies paratuberculosis (MAP) was initially thought to be a
credible aetiologic agent of CD however a 2-year prospective trial of clarithromycin, rifabutin
and ethambutol proved otherwise (Selby et al., 2007). Similarly, the identification of a
microbial agent that contributes to UC pathogenesis has also remained elusive. The
commensal bacterial population in healthy individuals remains relatively stable, however
when even subtle changes in the bacterial composition and function occurs the mucosal
barrier function and immune response are profoundly affected. Basically, a larger amount of
bacteria was found to be attached to the epithelia of IBD patients compared to healthy
individuals however the role of the dysbiosis in IBD remains uncertain (Swidsinski et al.,
2002; Teitelbaum and Walker, 2002).
Since the gastrointestinal environment is home to a range of food-derived antigens and
externally-derived micro-organisms a mutual interdependence needs to exist between the
gut microbiota and host immune system in order to avoid unnecessary inflammation and
tissue damage (Thompson-Chagoyan et al., 2005). Generally, a state of ‘oral tolerance’ or
immune non-responsiveness is experienced when a host is exposed to dietary antigens
(Hanauer, 2006). This mechanism prevents the development of an immune reaction to
intestinal intraluminal antigens (Spiekermann and Walker, 2001). Thus a more plausible
pathogenic mechanism for UC may be described by the presence of defects in the
homeostatic functions of the host. These homeostatic functions rely on the efficient exclusion
of commensal bacteria by the secretion of luminal antimicrobial peptides and complexing
IgA/IgM, a relatively impermeable mucosal barrier, extrusion of xenotoxins, rapid repair of
epithelial defects, down-regulation of immune responses and secondary phagocytosis of
bacteria that translocate across the epithelial barrier (Sartor, 2006; Clavel and Haller, 2007).
However defects in these functions result in an enhanced microbial antigenic exposure,
induced and perpetuated by the commensal bacteria, which inevitably overwhelms the host’s
immune tolerance, leading to pathogenic T-cell responses and chronic inflammation
(Shanahan, 2004; Tannock, 2005).
71.2.2.1 The typical epithelial immune regulatory mechanism (mucosal homeostasis)
The role of the intestinal epithelium in the initiation of the mucosal immune response can be
explained by two broad mechanisms which may involve: (1) the release of cytokines,
chemokines and other proinflammatory substances from the epithelium; and (2) the
epithelium itself may serve as antigen presenting cells (APC’s) (Mayer et al., 1991; Kagnoff
and Eckmann, 1997). This latter antigen-driven response may be appropriately directed
against an unrecognized pathogen, or may be an inappropriate response to a typically
inoffensive antigen (Podolsky, 1991).
Typically, commensal bacteria activate a sequence of homeostatic responses by epithelial
cells, macrophages, dendritic cells, T lymphocytes, and B-cells which allows the host to co-
exist with the potentially toxic microbial products (Clavel and Haller, 2007; Strober et al.,
2007). The basis of this co-existence however relies on the down-regulation of bacterial
receptors and the induction of intracellular molecules that terminate the innate and adaptive
immune responses, and furthermore the stimulation of protective molecules that mediate
mucosal barrier function (Sartor, 2008). In a normal host the mucosal immune system has
the ability to mount an immune response to pathogens while remaining tolerant to
commensal antigens (Neuman, 2007).
Cell-mediated immune responses typically occur when an antigen is taken up and processed
by an APC as illustrated in Figure 1.2. This antigen-APC complex in conjunction with T-cells
is then presented in the context of the appropriate major histocompatibility complex (MHC).
An antigenic epitope is formed by the binding of the MHC class II antigen on the APC and T-
cell receptor-CD4 complex which causes T-cell activation. However a co-stimulatory
signal/ligand which is not antigen specific is essential for complete T-cell activation
(Lenschow et al., 1993). Activated T-cells then express a second ligand which inhibits
interleukin-2 (IL-2) expression and further T-cell proliferation (Boussiotis et al., 1993;
Janeway and Bottomly, 1994). Two primary subsets of CD4+ T-cells and their distinct
patterns of T-cell cytokine production allow the distinction between the dominance of cell-
mediated and humoral immunity. Cells producing large amounts of IL-2 and interferon (IFN)-
ɣ are categorized as T helper 1 (Th1) cells, and IL-4, IL-5 and IL-10 are cytokines
characteristically produced by Th2 cells (De Carli et al., 1994). IFN-ɣ produced from the Th1
cells lead to the activation of macrophages which subsequently produce IL-12 and IL-18,
thus favouring the further differentiation of Th1 cells (Wenner et al., 1996; Dinarello, 1999;
Pizarro et al., 1999). IFN-ɣ which is also secreted by the differentiated Th1 cells inhibits the
differentiation of Th2 cells and conversely, production of IL-10 by Th2 cells diminishes Th1
responses (Fiorentino et al., 1989; Creery et al., 1996). These activated macrophages are
8also responsible for the production of pro-inflammatory cytokines such as IL-1, tumour
necrosis factor (TNF), and the chemokine IL-8.
The broad spectrum of pro-inflammatory effects of TNF holds particular significance in IBD.
Production of TNF leads to the activation of other macrophages in an autocrine fashion, and
when bound to cell surfaces TNF may provide a co-stimulatory signal which further
augments T-cell responses (Shreiber et al., 1992). TNF further contributes towards
inflammation by (a) permitting the influx of newly recruited inflammatory cells into the
mucosa, (b) promoting the release of nitric oxide, platelet-activating factor, and prostacyclins,
(c) activating granulocytes and their functions and, (d) enhancing the production of
metalloproteinase that participates in local tissue breakdown (Beutler, 1995; MacDonald and
Pender, 1998). The influx of newly recruited inflammatory cells via integrins, selectins and
members of the immunoglobulin family amplifies the inflammatory response by permitting the
migration of leukocytes along a gradient of chemokines and chemo-attractants into the
submucosa and mucosa (Springer, 1994).
Once present in the mucosa and submucosa these cells release numerous non-specific
inflammatory substances namely, the products of arachidonic acid metabolism which include
thromboxanes, leukotrienes, prostaglandins, and free radicals such as reactive oxygen
metabolites and nitric oxide. The local release of neuropeptides further modulates the
inflammatory response. Finally, once the harmful foreign antigen has been eradicated, the T
lymphocytes attenuate the immune response by means of CD4+CD5+ cells (Iellem et al.,
2003). More importantly, apoptosis of the aggressively overproliferative T-cells, triggered by
a variety of inter- and intracellular signals provide a built-in mechanism for
immunosuppression (Jacobson-Brown and Neuman, 2004). The release of the anti-
inflammatory or immunosuppressive cytokines such as IL-1 receptor agonist, soluble TNF-α
receptor, IL-4, IL-5, IL-10 (released from Tr cells) and transforming growth factor (TGF)-β
(released from Th3 cells), also limits the expansion of specific lymphocytes and returns
activated macrophages and other inflammatory cells to their normal resting state (Mosmann
and Sad, 1996).
1.2.2.2 Immune regulatory mechanism in UC
The loss of tolerance against the autologous commensal bacteria of the colon is believed to
be the primary cause of UC (Kanauchi et al., 2003). Toll-like receptors (TLR), responsible for
this microbial recognition also induces antimicrobial genes and controls the adaptive immune
responses. TLR’s are imperative for the discrimination of pathogenic bacteria from
commensal bacteria (Cario, 2005). TLR4 expression in particular has been found to be up-
9regulated in UC patients, resulting in increased sensitivity/loss of tolerance to the enteric
commensal bacteria (Cario and Podolsky, 2000).
This loss of tolerance is evident from the altered patterns of cytokine release compared to
healthy individuals. Typically, T-cells are classified as either CD4+ or CD8+ T-cells. CD8+
cells are known as the suppressor cells due to their down-regulatory influence on the
immune system and the CD4+ cells are the helper cells (Th1, Th2, Th3, and Tr) which are
distinguishable by their pattern of cytokine production. IBD patients experience an increased
release of IL-1, IL-2, IFN-ɣ, and TNF-α, all of which mediate the cellular immune response
and polarize immune activity towards a Th1 response (Reinecker et al., 1993; Reimund et
al., 1996). However UC has been shown to exhibit additional involvement of a defective Th2
response characterized by secretion of IL-4, IL-5 and IL-10 (Camoglio et al., 1998; Sawa et
al., 2003). However more importantly there is a substantial decrease in secretion of the
immunosuppressive/anti-inflammatory cytokines TGF-β and IL-10 (Thompson-Chagoyan,
2005).
The inhibition of T-cell apoptosis has also been implicated in the development of UC since
the failure to regulate T-cells has a direct influence on the failure to regulate pro-inflammatory
cytokines resulting in an inappropriate, sustained and detrimental immunologic reaction,
ultimately leading to the exaggerated death of enterocytes and pathological inflammation of
the colon (Ciccocioppo et al., 2002). Figure 1.2 systematically details the differences in the
immunologic processes involved in a typical homeostatic response to commensal enteric
bacteria compared to a patient with UC.
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Figure 1.2: Immunology of mucosal homeostasis and tolerance to commensal bacteria in an undiseased individual compared to the inflammatory
cascade experienced by Ulcerative Colitis patients (adapted from Sands, 2000; Sartor, 2008).
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1.3 Goals of therapy and common treatment options
Due to the range and extent of disease manifestations the goals of UC therapy are broad
and non-specific. The focus of therapy is thus primarily placed on the treatment of active
disease by ameliorating the signs and symptoms characteristic of the disease state. However
the achievement of this aim is intertwined with the induction and maintenance of states of
remission, thus permitting mucosal healing and restoration of well-being and an active
lifestyle. Drug therapy can thus be conceptualized as either anti-inflammatory or adjunctive.
1.3.1 Adjunctive therapy
Since various symptomatic manifestations of UC represent persistent and sometimes
incapacitating conditions, adjunctive therapy to anti-inflammatory therapy is essential. These
conditions/symptoms occur secondary to bowel irritability and hence do not form part of the
foundation of UC treatment. Typically, among the acutely ill hospitalized patients attention to
adequate fluid volume and electrolyte replacement is imperative. Furthermore, UC patients
may occasionally require analgesics, blood transfusions, intravenous nutritional support,
chronic iron supplementation, and vitamin B12 therapy (van Rosendaal, 1989; Hartman et
al., 2009). However the most predominant and consistent of the experienced symptoms-
diarrhoea-almost always requires chronic treatment.
1.3.1.1 Anti-diarrhoeal treatment
It is generally recommended that those with diarrhoea reduce their intake of laxative-acting
foods and/or employ anti-diarrhoeal drugs such as loperamide and diphenoxylate (Barrett
and Dharmsathaphom, 1988). However, the use of antidiarrheals is recommended with
caution (Hanauer, 1993). Despite the apprehension associated with chronic anti-diarrheal
use, amongst other resources, the South African Medical Formulary states an approved
dosage of 4-8mg of loperamide HCl for the treatment of chronic diarrhea (Galambos et al.,
1976; SAMF, 2005).
In 1976 loperamide HCl was introduced and approved as a prescription anti-diarrhoeal agent
by the United States Food and Drug Administration (FDA) for the control and symptomatic
relief of acute non-specific diarrhoea and chronic diarrhoea commonly associated with IBD
(Verhaegen et al., 1974; Nelemans and Zelvelder, 1976; Pelemans and Vantrappen, 1976;
Heel et al., 1978; Sandhu et al., 1981; Cann et al., 1984; Johnson et al., 1986; Hovdenak,
1987; Lavö et al., 1987; van Loon et al., 1989; Efskind et al., 1996; Yu et al., 2004). Initially it
was listed as a schedule 5 substance however in 1982 it was de-scheduled based on its low
potential for abuse and dependence (Federal Register, 1982). Finally in 1988 it was further
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deregulated and is currently available without a prescription both in the United States and
South Africa (Fletcher et al., 1995).
Loperamide HCl is a synthetic piperidine derivative with structural similarities to opiates such
as pethidine, morphine and isopropamide (Heel et al., 1978; Awouters et al., 1983). However
the unique benefit of loperamide HCl is attributed to its high affinity for opiate receptors and
its pure opiate agonist activity specific to the GIT (Heykants et al., 1974; Mackerer et al.,
1976; Wuster and Hers, 1978; Niemegeers et al., 1979; Van Nueten et al., 1979; Yoshida et
al., 1979). Despite the numerous mechanisms of action of loperamide, the principle anti-
diarrhoeal action is due to the inhibition of intestinal motility which results from the
enhancement of the circular segmental intestinal muscle contractions which retards the
forward peristaltic motions and consequently increases intestinal transit time (Van Neuten et
al., 1974; Mackerer et al., 1976; Schiller et al., 1984; Basilisco et al., 1985; Kachel et al.,
1986; Basilisco et al., 1987; Kirby et al., 1989). Apart from reducing intestinal motility
loperamide also reduces the daily fecal output volume, inhibits intestinal secretion of fluid
and electrolytes, and increases anal sphincter tone (Van Neuten et al., 1974).
1.3.2 Anti-inflammatory therapy
1.3.2.1 Aminosalicylates
First-line therapy for patients with UC has focussed on sulfasalazine for decades however
the identification of mesalamine, or otherwise known as 5-aminosalicylic acid (5-ASA) as the
active moeity responsible for its anti-inflammatory effects, along with patient allergy and
intolerance to the sulfa-moeity of sulfasalazine, has led to the development of numerous 5-
ASA based conjugates (Azad Khan et al., 1977; Qureshi et al., 2005). Not unlike the
aetiology of UC, the precise mechanism of action of 5-ASA remains unknown, but is likely
due to a combination of anti-inflammatory effects. Most commonly, the aminosalicylates are
known to inhibit the cyclooxygenase pathway thereby inhibiting the production of
prostaglandin E2 in inflamed intestinal mucosa. Furthermore, inhibition of the 5-lipoxygenase
pathway inhibits arachidonic acid metabolism and blocks the production and chemotactic
activity of leukotrienes (Collier et al., 1976; Sharon et al., 1978; Stenson and Lobos, 1982;
Stenson, 1990; Grisham, 1994). 5-ASA is also capable of altering the immune response at a
more fundamental level by reducing antibody secretion and lymphocyte function by blocking
the production of IL-1 and TNF-α (Mahida et al., 1991; Cominelli et al., 1992; Rachmilewitz et
al., 1992).
Despite the indistinct mechanism of action of 5-ASA it is well established that the optimal
therapeutic effect of 5-ASA is predominantly dependent on its topical action at the site of
inflammation within the colon. The clinical aim is thus to achieve minimal systemic absorption
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whilst maximizing 5-ASA delivery to the affected regions of the colonic mucosa (Cohen,
2006). The pioneering agent, sulfasalazine, was shown to exhibit its therapeutic effect in UC
by its ability to withstand gastric breakdown and systemic absorption until entry to the colon.
Sulfasalazine consisted of a sulfapyridine molecule bonded to 5-ASA where on entry to the
colon, bacterial azoreductase enzymes initiated the cleavage of the bond between the two
permitting the anti-inflammatory action of 5-ASA exclusively on colonic mucosa. However the
identification of the sulfa group as the responsible candidate for the dose-related adverse-
effects experienced has led to the development of numerous sulfa-free 5-ASA agents with an
improved safety and tolerance (Nielsen, 1982; Myers et al., 1987; Sandborn and Hanauer,
2003).
These sulfa-free mesalamine conjugates occur either in the form of inactive prodrugs such
as balsalazide and olsalazine, or as special oral controlled release formulations, or further as
rectal formulations (Cohen et al., 2000; Klotz, 2000; Marshall and Irvine, 2000; Qasim et al.,
2001; Gisbert et al., 2002; Rizzello et al., 2003). The efficacy of these marketed 5-ASA
products in UC have been found to be comparable with sulfasalazine (Riley et al., 1988a, b;
Willoughby et al., 1988; Rachmilewitz, 1989; Andreoli et al., 1994) however their release
characteristics rely on specific predetermined mechanisms that ultimately influence the
capability of these products to efficiently target the colon (Table 1.2).
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1987; Evans et
al., 1988;
Norlander et al.,
1990;  Raimundo
et al., 1992a, b;
Fallingborg et al.,
1993; Klotz and
Stracciari, 1993;
Sciarretta et al.,
1993; Wilding,
1999; Nugent et
al., 2001;
Mesalazine,
2003; Sandborn
and Hanauer,
2003; Sinha et
al., 2003; Cohen,
2006.
Claversal®
(GlaxoSmithKline)
Salofalk®
(Dr Falk GmbH & Co)
Mesasal®
(SmithKline Beecham
Pharma)
Mesalamine Distal ileum,
colon
5-ASA coated with Eudragit® L-
100 which exclusively dissolves at
a pH≥6, typically when the pH is
consistently at 6.4.
250mg,
500mg
Tablets 1.5-4.0g 0.75-4.0g
Pentasa®
(Shire US, Inc.)
Mesalamine Stomach,
duodenum,
ileum,
jejunum,
colon
Granules of 5-ASA coated with
ethylcellulose. pH-independent
release occurs through a semi-
permeable membrane.
250mg,
500mg,
1000mg
Tablets,
capsules,
sachets
2-4g 1.5-4g Release occurs throughout the GIT
resulting in systemic absorption.
Ineffective targeting of the colon, requiring
higher doses to ensure therapeutic
efficacy.
High doses are associated with adverse
effects.
Rasmussen et al.,
1983; Goebell et
al., 1993; Layer et
al., 1995; Keller
et al., 1998;
Carter et al.,
2004; Friend,
2005.
Lialda® (US)
Mezavant® (EU)
(Shire
Pharmaceuticals,
Inc.)
Mesalamine Colon Uses MMXTM Multi Matrix System
Technology where lipophilic and
hydrophilic matrices enclosed
within a gastro-resistant, pH-
dependent coating facilitate the
prolonged exposure of the colonic
mucosa to 5-ASA.
1.2g Tablets 1.2-2.4g 1.2-2.4g Despite the efficiency of being a once
daily dosage form, this product still relies
on a pH-dependent coating. This causes
the same limitations as that typically found
in Asacol®, and Claversal®.
However the MMXTM technology allows a
more reproducible and consistent release
pattern.
Prantera et al.,
2005; Sandborn
et al., 2007.
Dipentum®
(Celltech
Pharmaceuticals,
Inc.)
Olsalazine Colon A dimer of 5-ASA molecules linked
by an azo bond which undergoes
azoreduction exclusively in the
colon resulting in the release of
two 5-ASA molecules.
250mg Capsule 2-3g 1g Despite its efficiency in colonic targeting
there is a relatively slow release of the
active agent from the carrier in the colon.
Furthermore, since 5-ASA has a high
dose requirement coupling this drug to a
polymer substantially increases the mass
required to be administered.
Increases net luminal water secretion,
increases intestinal transit time, and
induces diarrhea.
Ryde and Ahnfelt,
1988; Wadworth
and Fitton, 1991;
Klotz, 2000;
Sandborn and
Hanauer, 2003;
Klotz, 2005;
Cohen, 2006.
Salazopyrin®
Azulfidine®
(Pfizer US
Pharmaceuticals)
Sulfasalazine Colon 5-ASA linked to a sulfapyridine
molecule by an azo bond. Release
of 5-ASA occurs as a result of
azoreduction.
500mg
(200mg 5-
ASA)
Tablets 2-4g
0.8-1.6g
5-ASA
2-4g
0.8-1.6g
5-ASA
Its fundamental limitation is the release of
sulfapyridine along with 5-ASA. The sulfa
group is responsible for patient allergy,
intolerance and non-compliance.
Azad Khan et al.,
1977; Nielsen,
1982; Myers et
al., 1987.
Colazal®
(Salix
Pharmaceuticals,
Inc.)
Balsalazide Colon 5-ASA linked to 4-aminobenzoylb-
alanine (4ABA) by azo-bond
750mg
(262mg 5-
ASA)
Capsule 2–6.75 g
0.7–2.4g
5-ASA
2–6.75 g
0.7–2.4g
5-ASA
Since the recommended daily dose is
significantly high, a large number of
capsules are required per dose, ultimately
resulting in patient non-compliance due to
a high pill burden.
Prakash and
Spencer, 1998;
Muijsers and
Goa, 2002; Klotz,
2005.
Table 1.2: Commercially available 5-aminosalicylic acid based products
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1.3.2.2 Corticosteroids
Despite corticosteroids being amongst the most beneficial and longest used agents in the
treatment of IBD and UC, at their therapeutic doses their biologic effects are deleterious and
numerous (Truelove and Witts, 1955; Kane et al., 2002). The use of conventional
corticosteroids such as prednisone is thus generally reserved for patients with moderate to
severe cases of the disease or for patients that have failed to respond to the first-line therapy
of 5-ASA (Lichtenstein et al., 2006). Notwithstanding their benefit to risk ratio, these agents
are almost exclusively effective in inducing remission and have limited efficacy in the
maintenance of remission. Their effectiveness is derived from their profound anti-
inflammatory and immunologic effects specifically acting by reducing the production of pro-
inflammatory cytokines, inhibiting a variety of leukocytic functions, as well as interfering with
the metabolism of arachidonic acid and production of eicosanoids (Goppelt-Struebe, 1997;
Goulding et al., 1998; Angeli et al., 1999).
Budesonide, marketed as Entocort® by AstraZeneca Pharmaceuticals (Wilmington, NC,
USA), is a highly potent corticosteroid that has been formulated in a capsule containing
pellets of budesonide in an ethylcellulose matrix which is then surrounded by an outer
acrylic-based resin coating that dissolves at a pH≥5.5 (Nilsson et al., 1995; Edsbacker et al.,
2003). Budesonide is thus released slowly as it passes through the small intestine with 69%
of the drug being delivered to the ileo-colonic region. Despite its limited bioavailability and
thus improved toxicity profile it has yet failed to show benefits in the maintenance of
remission in UC patients which may also be attributed to its ineffective ability to target the
colon (Truelove and Witts, 1959; Lennard-Jones et al., 1965; Powell-Tuck et al., 1981).
1.3.2.3 Immunomodulators
Due to the recent understanding that the pathophysiology of UC finds derivation from an
upregulated mucosal immune system, immunomodulators such as azathioprine (AZA) and 6-
mercaptopurine (6-MP) are showing increasing promise especially in cases of steroid-
resistance/dependence (Sands, 2000; Hibi et al., 2003). AZA, the prodrug that yields 6-MP,
has been speculated to possess additional immunosuppressive properties however these
two agents are still used interchangeably (Crawford et al., 1996). Despite their efficacy, the
long time to response of these agents (approximately 4 months) limits their use in the
induction of remission and furthermore provides a breach in long-term therapy with these
agents (Present et al., 1980; Pearson et al., 1995).
Cyclosporine, an important immunosuppressant finds application in severe cases of steroid-
refractory UC with responsiveness shown in 82% of patients hospitalized with severe flares
resistant to intravenous corticosteroids (Lichtiger et al., 1994). Furthermore, due to its rapid
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rate of response it is postulated to provide a bridge to long-term immunomodulatory therapy
with AZA (Fernandez-Banares et al., 1996). Tacrolimus, a similar immunosuppressant to
cyclosporine has recently also been shown to be successful in cases of refractory UC when
used in combination with 6-MP or AZA (Fellermann et al., 1998; Gerber et al., 1998).
Arising from the observation that individuals who quit smoking showed an increased
predisposition to UC and UC symptoms, several studies are now focussing on the
development of locally targeted nicotine delivery systems that minimize the systemic effects
of nicotine whilst maintaining its inhibitory action on the production of TNF and IL-2 and
sustaining mucus production (Madretsma et al., 1996; Pullan, 1996; Compton et al., 1997;
Green et al., 1997; Sandborn et al., 1997).
1.3.2.4 Biological Response Modifiers
Historically the treatment goals of UC were only to induce and maintain remission of
symptoms and mucosal inflammation however these goals have since evolved to include
steroid-sparing, endoscopic healing and reduction in hospitalizations and surgery (Sandborn,
2008). As a consequence treatment options are thus dependent on the severity of the
disease, patient responsiveness, and the safety-efficacy profile of the treatment employed.
According to the UC practice guidelines from the American College of Gastroenterology, the
use of biological response modifiers are reserved for patients who have failed therapy with
the aminosalicylates, corticosteroids, and immunomodulators (Kornbluth and Sachar, 2004).
Infliximab, the first biological response modifier to gain FDA approval for use in IBD, has
since shown a short-term response rate of 60% and remission rate of 30% in UC refractory
patients. Furthermore, these patients showed remission rates of 25-30% at 6-12 months
(Sands, 2000; Rutgeerts et al., 2005). Numerous other biological agents are however
currently being investigated as depicted in Figure 1.3.
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Figure 1.3: Emerging biological response modifiers currently being investigated.
1.4 Statement of the problem
Despite the existence of a substantial armamentarium of anti-inflammatory and
immunoregulatory agents available for use in the induction and maintenance of remission it
has been estimated that in North America alone there is approximately one million people
affected with IBD (Bamias et al., 2005) and in Europe it is estimated to be 2.2 million (Loftus,
2004). Each of the numerous marketed 5-ASA delivery systems as depicted in Table 1.2,
used particularly for the treatment of UC, possess numerous limitations that considerably
impacts on patient compliance and ultimately on periods of quiescence and therapeutic
success.
The predominant factor for the reduction in patient compliance with 5-ASA therapy is the
inconvenience of frequent dosing schedules, as well as the pill burden associated with each
dose (Kane et al., 2003; Shale and Riley, 2003). However further reasons for the loss of
compliance relies on a complexity of factors such as gender, employment status, marital
status and periods of symptomatic remission (Kane et al., 2001). Despite the effectiveness of
rectal 5-ASA preparations their method of administration is associated with numerous
tribulations not limited to leakage, retention, burning sensations and bloating (Frieri et al.,
1999; Gionchetti et al., 1999; Cohen et al., 2000; Lim and Hanauer, 2004). Furthermore,
since UC patients typically suffer from concurrent diarrhoea the retention of these
formulations for the time required for onset of its therapeutic effect can be challenging.
Anti NF-
κB
Probiotics
Biological
Response
Modifiers
CDP571
IL-10
IL-11
ISIS-2302Anti-α4antibody
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The oral route thus remains the most common and convenient method of drug administration
with between 60-80% of marketed drugs being used orally (Lennernas and Abrahamsson,
2005; Masaoka et al., 2006). The 5-ASA commercially available orally administered delivery
systems possess exceptional and comparable safety profiles. In addition, no significant
difference exists in terms of their systemic exposure however there is an almost 1000-fold
variation in their mucosal 5-ASA concentrations (Sandborn and Hanauer, 2003). This was
observed during an assessment of multiple biopsies taken at the same locations through the
patients’ lower GIT after cessation of a single week of therapy with each 5-ASA formulation
(De Vos et al., 1992). The large variations in the mucosal 5-ASA concentrations can thus be
postulated to be the cause for the difference in efficacy of each formulation. Therefore, the
local delivery of an adequate concentration of 5-ASA to the colonic mucosa is substantially
more critical than the systemic delivery of this agent (McLeod et al., 1990; De Vos, 2000;
Frieri et al., 2005; Marteau et al., 2005).
The concept of colon-targeted drug delivery via the oral route is a simple one. Ideally, the
formulation must inhibit drug release in the gastric and small intestinal environments (upper
GIT), and allow drug release in the colon. The simplicity of this concept is however
challenged by the exposure of the formulation to a range of conditions and environments
along its passage through the GIT. The currently exploited mechanisms for targeting 5-ASA
to the colon rely on one or more of the following variables namely, gastrointestinal transit
times, pH, enzyme activity, oxidation-reduction potential, and intraluminal pressure (Friend,
2005). Notwithstanding the inconsistency of these variables between each individual, the
impact of disease conditions such as UC may have a profound influence on these variables
and consequentially on the release characteristics of the delivery system (Duthie et al., 1964;
Barrow et al., 1991; Hebden et al., 2000; Nugent et al., 2001; Sinha et al., 2003). There is
thus an urgent need to develop an orally administrable colon-targeted drug delivery system
where the release characteristics are independent of fluctuating gastrointestinal conditions,
and where an effective concentration of the drug can be delivered to the colonic mucosa.
Apart from the pill-burden associated with remission maintenance therapy with 5-ASA, the
need for concurrent adjunctive therapy with anti-diarrhoeal agents such as loperamide HCl
poses an additional burden to patient compliance. Thus, ideally the delivery system should
facilitate a reduction in the pill burden, daily dosing requirements and allow for concurrent
adjunctive and anti-inflammatory therapy with a single delivery system administration.
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1.5 Approach to the problem
Apart from the therapeutic efficacy of colon-targeted drug delivery in the treatment of local
colonic conditions such as UC and CD, this form of drug delivery also holds immense
potential for the systemic delivery of proteins and therapeutic peptides (Davis, 1990; Van den
Mooter and Kinget, 1995). Proteins and peptides are typically degraded and poorly absorbed
in the upper GIT attributable to the relatively elevated levels of luminal and mucosal digestive
enzymes in this region. Therefore the reduced vigor of the enzymatic behaviour in the colon
facilitates an improved bioavailability of these molecules when release is targeted to this
region (Saffran et al., 1986; Gibson et al., 1989; Van den Mooter et al., 1998; Chourasia and
Jain, 2004). Furthermore, the beneficial influence of colon-targeted drug delivery may be
extended to the treatment of diseases that are sensitive to circadian rhythms such as
asthma, angina pectoris and arthritis, where an intentional time delay in absorption is
required (Youan, 2004).
As stated previously, despite the effectiveness of rectal formulations in targeting the colon
they rarely succeed in extending proximally beyond the distal colon, notwithstanding their
numerous other disadvantages (Jay et al., 1985; Hardy et al., 1986; Marshall et al., 2010).
Orally administered drugs for colon-targeting are thus preferred in spite of the difficulties
associated with this route of administration (Basit, 2005). Taking into account the distal
location of the colon in the GIT, a colon-targeted drug delivery system should ideally prevent
premature drug release in the stomach and small intestine but effect an abrupt onset of drug
release upon entry to the colon. Typically, this is achieved by formulating the system such
that conditions specific to the colon are utilized to effect release. Similarly, based on the site
and mechanism of the therapeutic action of loperamide HCl it is expected that by targeting
the drug to the myenteric plexus of the small and/or large intestine a greater therapeutic
benefit will be experienced at the same or reduced conventional dosage.
Generally the physiological changes that occur along the GIT is characterized as a
continuum with decreases in enzymatic activity, motility and fluid content, and an increase in
pH, from the oesophagus to the rectum. By exploiting these GIT characteristics numerous
approaches and systems have been explored and developed for colon-targeted drug delivery
but the majority of these have never reached the stage of clinical evaluation. Moreover, the
impact of disease on the delivery system also poses a challenge in developing
therapeutically effective products (Friend, 2005). As an example, the luminal pH of the distal
intestine in UC is actually lower than that seen in healthy individuals. This was demonstrated
by a study conducted by Fallingborg and co-workers (1993) where the colonic pH of UC
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patients was found to be between 2.3 and 7.0. Similarly, intestinal transit time is also variable
on account of diarrhoea experienced in UC (Sandborn and Phillips, 1995).
After consideration of the complexity of physiological constraints associated with the
development of a colon-targeted drug delivery system, the most appropriate approach to
achieving a targeted delivery of a therapeutic concentration of the drug at the colonic mucosa
is by the development of an enzyme-responsive system. Colonic microflora have been
extensively explored as a mechanism of modulating drug delivery in the colon due to the vast
array of bacterial species as well as the large bacterial count (Vandamme et al., 2002; Sinha
and Kumria, 2003; Chourasia and Jain, 2004). Moreover, these colonic bacteria are
predominantly anaerobic in nature and secrete enzymes capable of metabolizing a range of
substrates that escape digestion in the upper GIT (Cummings et al., 1989). Thus the
fundamental point is to exploit a specific bacterial population that exists uniquely to the target
site. Similarly, targeting of loperamide HCl to the small intestine should ideally also be based
on exploiting an enzyme specific to the required site of action.
For this purpose, the employment of polymers that are termed ‘stimuli-responsive’ or ‘smart’
are suggested to be the most attractive approach to ‘activating’ drug release at the desired
site in response to a pre-determined reliable stimulus. Thus for colon-targeting, materials that
are recalcitrant to conditions in the stomach and small intestine but susceptible to bacterial
fermentation in the colon serve as promising carriers for 5-ASA. By implementing such
materials a system that ensures minimal drug release in the upper gastrointestinal regions
and preferential triggering of drug release upon entry to the colon can be achieved.
Consequentially, by ensuring that a maximum concentration of drug contained within the
delivery system is released specifically in the colon an improved therapeutic efficacy with
smaller doses and a less frequent dosing schedule will be achieved.
1.6 Novelty of the Approach
The inherent benefits and innovative nature of the formulation approach can be ascribed to
the role of the delivery system in the circumvention of the challenges typically associated
with current UC therapy and the relevant treatment options. Essentially, the novelty of the
approach is derived from several formulation properties which are listed below.
1. Only naturally occurring polysaccharide polymers are employed.
These polymers are available in abundance, are inexpensive and exist in a variety of
structures with varying properties. Furthermore, they can be easily chemically
modified, and are highly stable, safe, non-toxic, and hydrophilic. However, most
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importantly, they are biodegradable and thus fall within the category of ‘generally
regarded as safe’ (GRAS) materials (Klein, 2009).
2. The formulation allows for the targeted delivery of two different drugs to different regions of
the GIT with the oral administration of a single delivery system.
Since the treatment of UC necessitates concurrent adjunctive and anti-inflammatory
therapy the targeting of loperamide HCl to the small intestine and 5-ASA to the colon
with just a single delivery system would permit not only a reduced dosage required
but also an improved therapeutic efficacy and improved patient compliance due to the
reduced pill burden.
3. Physiological stimuli in the relevant gastrointestinal region serve as a trigger for initiating
drug release.
The exploitation of the enzyme pepsin in the stomach and the polysaccharidases in
the colon for triggering targeted drug release serve as consistent stimuli that remain
unaffected by the disease condition and which ensures reliable and reproducible drug
release characteristics. The ability of the formulation to respond to the specific
enzyme populations implicates the formulation as an ‘intelligent’ drug delivery system.
4. The formulation preparatory process is simple and holds easily scale-up potential.
1.7 Aim and Objectives of this study
The aim of this study was to design and develop a novel stimuli-responsive oral tablet
(SROT) system for the treatment of UC which enabled the induction of concurrent states of
remission and anti-inflammatory action with the administration of a single delivery system
that provided targeted drug delivery of 5-ASA to the colon and loperamide HCl to the small
intestine.
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a)
Figure 1.4: Schematic representation of a) the configuration of the stimuli-responsive oral
tablet with the outer coating containing loperamide HCl, and the inner 5-aminosalicylic acid
tablet component and; b) the postulated passage of the delivery system through the
gastrointestinal tract.
 Inner tablet
containing  5-ASA
 Outer coating
containing loperamide
HCl
1. Intact delivery system is
administered orally.
2. Outer polymeric coating
remains intact and inhibits
loperamide HCl release due to
the presence of pepsin in the
stomach.
3. The SROT passes through
the pyloric sphincter and
enters the small intestine
where loperamide HCl release
is immediately initiated.
4. Tablet containing 5-ASA
passes through the small
intestine intact.
5. On entry to the colon, the
outer hydrophobic coating of
the tablet disintegrates.
6. Colonic media diffuses into
the tablet resulting in in situ
crosslinking of polymers, and
gradual swelling of the delivery
system.
7. 5-ASA is released
throughout the colon as a
result of the cleavage of
polymers due to colonic
enzymes, resulting in the
gradual erosion of the tablet.
b)
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In order to accomplish this aim the following objectives were outlined:
i. To review the current and novel techniques employed for achieving colon-targeted
drug delivery and to assess their limitations and advantages.
ii. To evaluate various stimuli-responsive polymers and assess their applicability in
colon-targeting as well as for small intestinal targeting.
iii. To explicate theoretical considerations of the GIT and the influence of such factors in
small intestinal and colonic drug delivery.
iv. To identify the most appropriate stimulus to be targeted for colonic delivery whilst
avoiding any limitations experienced by other reviewed systems.
v. To identify the most appropriate stimulus to be targeted for small intestinal drug
delivery.
vi. To identify a selection of appropriate polymers for application in both components to
ensure optimum stimuli-responsiveness.
vii. To determine a suitable method of preparation of each component of the delivery
system.
viii. To synthesize variants of each component of the delivery system according to the
Box-Benkhen Experimental Design followed by physicomechanical and
physicochemical analysis of the variants.
ix. To establish optimum parameters for the formulation of the inner 5-ASA tablet
component and the outer loperamide HCl containing shell component.
x. To undertake in vivo animal studies on a pig model to determine the in vitro-in vivo
correlation of the delivery system and to assess the pharmacokinetics of the delivery
system in relation to the marketed ‘gold-standard’ formulations of both drugs.
xi. To investigate alternatives to the formulation of a tablet component and to assess the
physicochemical and physicomechanical characteristics of such configurations.
1.8 Overview of this dissertation
This dissertation has been structured so as to provide the literature reviewed and data
acquired in a logical manner so that the process of the development of the SROT is outlined
in a clear, coherent and concise manner as depicted in Figure 1.5 whilst in keeping with the
objectives outlined above.
CHAPTER 1 focuses on IBD with specific attention to UC. This chapter aims to establish a
clear understanding of the disease condition including the hypothesized aetiologies thereof,
as well as the disease pathogenesis. By understanding the condition in its totality the
importance of site-specific delivery of the necessary pharmaceutical agents is stressed. An
overview of the current systems available on the market for remission maintenance of UC
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and their respective shortcomings are described, thus providing the rationale and motivation
for conducting this study.
CHAPTER 2 outlines the numerous gastrointestinal characteristics that require consideration
prior to development of orally administered targeted delivery systems. Furthermore, various
novel colon-targeted drug delivery systems are reviewed in terms of their benefits and
limitations. Stimuli-responsive polymers and their potential application in drug delivery are
described, with particular attention to those employed for targeting of drugs to the colon
CHAPTER 3 describes the preliminary studies conducted for the development of the inner 5-
ASA loaded tablet component for delivery to the colon. Preformulation studies included the
determination of the appropriate polymers to be employed, the methods of tablet preparation,
optimum tablet coating, as well as the most appropriate in vitro dissolution conditions.
CHAPTER 4 describes the preformulation studies conducted on the outer loperamide HCl
containing shell layer such that an ideal responsiveness to pepsin is achieved. Preliminary in
vitro evaluation was conducted to determine the influence of the type of polymer, tablet-shell
configuration and crosslinking on the pepsin-responsiveness of the shell.
CHAPTER 5 focuses on the preparation of variants of the 5-ASA loaded colon-targeted
tablet formulation as constructed according to the Box-Benkhen Experimental Design,
followed by optimization. Furthermore, physicomechanical and physicochemical properties
were analyzed to determine the influence of colonic enzymes on the formulation’s ability to
respond to these enzymes in vitro.
CHAPTER 6 focuses on the preparation of variants of the loperamide HCl-loaded pepsin-
responsive shell formulation as constructed according to the Box-Benkhen Experimental
Design, followed by a constrained statistical optimization process. Physicomechanical and
physicochemical studies were performed to establish the mechanistic action of pepsin on the
release characteristics of the shell.
CHAPTER 7 describes the determination of an ideal procedure for dosage administration
and blood sampling from a pig model. Furthermore, this chapter places emphasis on the in
vivo drug release characteristics of the SROT and therefore the determination of the plasma
concentration profiles of 5-ASA and loperamide HCl from the SROT in comparison to the
relevant marketed ‘gold-standard’ formulations.
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CHAPTER 8 focuses on an alternative approach to employing polysaccharide polymers for
colon-targeted drug delivery applications. The novel formulations consisting of hydrolyzed
polyacrylamide and polysaccharide blends were evaluated for the influence of surface area
and porositometric influences on the drug release properties. The formulations were also
analyzed for the physicomechanical properties.
CHAPTER 9 outlines the conclusions derived from this work, the recommendations for future
work, the potential prospects of the developed delivery system, as well as the principle
challenges experienced during the study.
Figure 1.5: Map of the dissertation.
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2.1 Introduction
The paradigm of drug discovery and development has undergone a shift from the
serendipitous approach to one that is more rational. Nevertheless, this process still remains
costly, time consuming, and risky. The director of economic policy at the world’s largest
research-based pharmaceutical company, Pfizer, recently estimated the cost of developing a
new drug to vary between $800 million to nearly $2 billion per drug (Masia, 2008). As a
result, the development of new drug delivery systems have been gaining increasing attention
as they can be developed at a fraction of the cost and time, providing a ‘re-birth’ of old drugs,
with improved efficacy and patient compliance, whilst maximizing the return on investments
for pharmaceutical companies (Speers, 1999).
Initially, drug research emerged with the focus placed on the botanical origin of drugs. This
occurred in the early human civilizations, with subsequent progression to a synthetic
chemistry phase in the mid 20th century. However currently, focus in drug research has
shifted to the biotechnological approach to drug discovery (Sneader, 2005). The foundations
of novel drug delivery systems were laid down as early as 1952 with the inception of the
pioneering sustained release capsule which subsequently led to the introduction of concepts
such as prolonged, time and extended release systems or sophisticated programmable
systems (Starr, 2000). Furthermore, drug delivery has also changed from being orientated
towards the systemic delivery of drugs to more specific targeting of affected organs and
cellular targeting (Pillai et al., 2001).
2.1.1 Influence of gastrointestinal physiology on targeted drug delivery system design
The implied simplicity of oral drug delivery is a misconception stemming from the elusive
physiology of the gastrointestinal tract (GIT). Despite the strides being made in
understanding the physiology and mechanisms of the GIT large gaps remain in our
knowledge, resulting in the complexity and dynamicity of the organ being underestimated.
For this reason, typically, only one or two variables are taken into account during drug
delivery system design and drug targeting. It is thus obvious that the design of functional
drug delivery systems which behave in a reproducible manner will remain out of reach as
long as a clear understanding of the conditions it will be subjected to remains unknown.
CHAPTER 2
OVERVIEW OF STIMULI-RESPONSIVE POLYMERS AND THEIR APPLICATION IN
GASTROINTESTINAL TARGETED DRUG DELIVERY
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The GIT, otherwise known as the alimentary canal, is basically a hollow muscular digestive
tube that winds through the body and essentially functions to acquire nutrients and remove
physiological waste products. In other words, it is a selective barrier between the systemic
circulation and the environment which digests food, absorbs nutrients, electrolytes and fluid,
whilst preventing the absorption of potentially harmful substances (Marieb and Mallatt, 1997;
Reed and Wickham, 2009). Thus, based on the complexity of the processes and functions
involved the GIT is differentiated into various segments with unique characteristics along its
length (Liu et al., 2003a; Basit, 2005). Figure 2.1 illustrates a simplistic view of this organ.
Figure 2.1: Illustration of a simplified representation of the gastrointestinal tract.
As presented earlier Ulcerative Colitis (UC) represents a local inflammation of the colon;
therefore it would be ideal to target the therapeutic principle namely, 5-aminosalicylic acid (5-
ASA) directly at the affected luminal site resulting in an effective drug concentration in the
colonic mucosa, a reduction in the systemic availability of the drug and in turn a reduction in
the adverse effects (Klotz, 2005). In addition, for the concurrent adjunctive treatment of UC it
is preferable to target the loperamide HCl at its site of action namely, to the small intestine.
For the most part, the lack of appreciation and understanding of the disease state on the
gastrointestinal environment limits the design of efficient targeted drug delivery systems. In
addition inter-individual variability with regard to gastrointestinal physiology for example,
intra-luminal pH profiles, motility, pressure, and transit times amongst others must be
considered. Several of the most prominent of these physiological parameters are explicated
Transverse colon
Descending colonAscending colon
Proximal small
intestine
Pyloric sphincter
Stomach
Distal small intestine
Caecum
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in Table 2.1 with specific reference being made to each major site within the GIT of a healthy
individual, as well as the influence of UC on the relevant physiological characteristic.
Based on the reviewed literature, the overall physiological changes along the GIT can
generally be regarded as a continuum of decreases in motility and fluid content, and
increases in the pH profiles, enzymatic activity, and luminal pressure occurring from the
oesophagus to the rectum. The concept of drug targeting can thus be based on the
identification and exploitation of a specific characteristic that is unique to the target organ so
as to effect drug release at the required site and at the desired rate. This is typically achieved
by employing stimuli-responsive polymers that are capable of responding to specific stimuli in
the target organ.
Since targeting of drugs to the small intestine does not pose an immense challenge, the
impetus of this chapter is placed on colon-targeting technology. Targeting of drugs to the
small intestine is almost always performed by employing an enteric coating that disintegrates
at a pH≥6. These coatings typically consist of polymethacrylate copolymers but may also
consist of cellulose acetate phthalate etc.
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Table 2.1: Physiological characteristics of specific regions of the gastrointestinal tract of a healthy individual compared to an individual with Ulcerative Colitis
Physiological parameter Healthy individual Ulcerative Colitis References
Stomach Small intestine Colon
Transit and motility “almost everything seems to affect
gastric emptying” (Olsson and
Holmgren, 2001)
The variability of gastric transit times
(GTT) and emptying times is
dependent on the fed or fasted state of
the individual, body posture, food type,
concomitant drug administration, as
well as the size and density of the
delivery system.
The GTT of single-unit delivery
systems is reported to vary from 15
minutes to more than 3 hours.
Small intestinal transit time (SITT) is
theorized to be relatively constant at 3-
4 hours and independent of external
influences. However, more recently
Coupe and co-workers determined the
SITT variability of single and multiple-
unit systems to range between 0.9 to
6.2 hours. Intra-subject variability was
also observed as the SITT of a single
individual varied between 1.5 to 5.4
hours. Furthermore, intestinal motility
is governed by the migrating
myoelectric complex (MMC) which
dominates in the fasted state.
Like the small intestine, movement of
substances through the colon is non-
continuous and slow. The total transit
time in this region is highly variable
due to the dependency on factors such
as diet, mobility, stress, disease states
and drugs. The colon often has a
residence time in excess of 24 hours.
Patients affected by IBD typically
experience an accelerated intestinal
motility due to the presence of
inflammation and diarrhea.
Furthermore, patients with UC were
shown to have an increased colonic
transit compared to controls (51.7
hours vs. 24.3 hours).
Hunter et al., 1982; Kaus et al., 1984;
Davis et al., 1986; Metcalf et al., 1987;
Devereux et al., 1990; Coupe et al.,
1991; Cummings et al., 1992; Vassallo
et al., 1992; Price et al., 1993; Meier et
al., 1995; Hebden et al., 2000; Olsson
and Holmgren, 2001; Weitschies et al.,
2005; McConnell et al., 2008a.
Evaluation of a radio-labelled osmotic tablet via gamma-scintigraphy revealed an average gastric transit time of 0.8 hours,
average SITT of 3 hours, and highly variable average colonic transit time of 6.6 hours.
Pressure Since there is sufficient fluid present in
the stomach, the luminal pressure in
this region is not as significant as that
of the colon.
The pressure generated by the
muscular contractions of intestinal wall
required for the grinding and
propulsion of luminal contents varies in
intensity and duration along the small
intestine.
The action of haustral contractions
coupled with the increased viscosity of
the colonic environment is believed to
be the cause of the higher effective
luminal pressure of this region.
Since UC is a chronic inflammatory
state, the inflammation and injury that
occurs results in increased luminal
pressures. The altered contractile
rhythms, villous motility and mucosal
deformation in UC propagates this
change in luminal pressures.
Fallingborg et al., 1985; Reddy et al.,
1991; Yang et al., 2002; Basit, 2005;
Flanigan et al., 2008.
pH profiles It is well established that the pH of the GIT increases from the stomach to the distal small intestine. This gradual increase
has however since been assumed to continue from the small intestine to the colon.
The gastrointestinal pH of UC patients
is considerably lower than that of
healthy individuals. This effect is most
pronounced in the colon for example
Raimundo and co-workers observed a
pH of 4.7 in the right colon in a case of
acute UC, and a subsequent study
exposed colonic pH’s as low as 2.3.
Evans et al., 1988; Raimundo et al.,
1992b; Fallingborg et al., 1993; Nugent
et al., 2001; Vandamme et al., 2002;
Basit, 2005; Jose et al., 2009.
The pH of the gastric region remains
fairly consistent within the pH range of
1 and 3.5, maintaining an acidic
environment for the proteolytic action
of gastric enzymes.
Intraluminal intestinal pH’s
demonstrate a substantial inter-
individual variability but is generally
considered to range between 5.5 and
6.8. The pH is said to increase distally
from 6.63±0.53 in the jejunum,
reaching a peak of 7.49±0.46 at the
ileocaecal junction.
As early as 1988, it was determined
that the pH of the distal small intestine
was 7.5, and that of the caecum was
6.4. This drop in pH on entry to the
colon is attributed to the fermentation
of polysaccharides present in the colon
resulting in the production of short
chain fatty acids. The pH then only
rises to 7 in the descending colon.
Enzymes and bacteria The gastric bacterial and enzyme
populations are modest with only
102 CFU/g of contents with pepsin
being the most important in this region.
The bacterial population increases
along the GIT with 104 CFU/g in the
proximal small intestine and 107 CFU/g
in the ileum.
The colon contains over 400 distinct
species of mostly anaerobic bacteria
having a population of 1011–1012
CFU/g with Bacteroides,
Bifidobacterium, Eubacterium and
Lactobacillus being the most prevalent.
Furthermore, enzymes responsible for
the degradation of polysaccharides
such as α-L-arabinofuranosidase, β-D-
fucosidase, β-D-galactosidase, β-D-
glucosidase, β-xylosidase are also
widely active in this region.
It is believed that in conditions where
the transit time is altered, a change in
the bacterial numbers occurs. In UC in
particular the number of facultative
anaerobes increases and this altered
microbial composition consequently
results in increased immune
stimulation, epithelial dysfunction, or
enhanced mucosal permeability.
However, the types and activities of the
bacterial glycosidases remain
unchanged in UC.
Cooke, 1967; Gorbach et al., 1968;
Gorbach, 1971; Van der WielKorstanje
and Winkler, 1974; Simon and
Gorbach, 1984; Englyst et al., 1987;
Bernhardt and Knoke, 1997; Eckburg
et al., 2005; McConnell et al., 2008b;
Sartor, 2008.
Fluid volumes The fluid volume throughout the GIT is
highly variable. The free fluid volume of
the stomach can range from
118±82mL post-mortem and 45±18mL
in the fasted state.
The small intestinal fluid volume can
range from 212±110mL post mortem,
and 54±41mL and 105±72mL in the
fed and fasted states respectively.
In 1990, Cummings and co-workers
determined that the colonic fluid
volume post mortem was 187mL,
however in the fed and fasted states
this volume was substantially lower
since it only quantified the volume of
fluid not bound to digesta.
Chronic diarrhoea which is common
during active UC results in an
increased loss of fluid and consequent
dehydration. As a result colonic
contents are less viscous and less
solid.
Gotch et al., 1957; Cummings et al.,
1990; Schiller et al., 2005.
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2.2 Application of stimuli-responsive polymers in targeted drug delivery
With the emergence of more novel and effective drug therapies, increased importance is
being placed upon the methods by which these drugs are being delivered to the body. Even
though commercially available controlled release systems have been proven to be
therapeutically advantageous over conventional systems their shortfall lies in their
insensitivity to the changing metabolic states of the body. Mechanisms capable of
responding to these physiological variations must be provided in order to synchronize drug
release profiles with the changing physiological conditions. Ideally, a drug delivery system
should respond to physiological requirements, sense the changes and alter the drug release
profile accordingly (Gupta et al., 2002).
Stimuli-responsive polymeric drug delivery is a field of controlled drug delivery whereby the
dynamics of the typical physiological process of a particular disease state is closely
monitored and the quantity and site of drug release is affected only according to the
physiological need (Kost and Langer, 2001). The realization of the site-specific and self-
regulated drug delivery is achieved by the incorporation of specific polymers that are
distinguishable by their ability to undergo rapid changes in their microstructure from a
hydrophilic to a hydrophobic state which is triggered by small changes in the environment.
The macroscopic changes that occur are reversible; therefore the system is theoretically
capable of returning to its initial state when the trigger is removed (Galaev and Mattiasson,
1999; Kumar et al., 2007).
Common stimuli that drive these changes are represented in Figure 2.2 (Galaev and
Mattiasson, 1999; Kost and Langer, 2001; Gupta et al., 2002; Schmaljohann, 2006; Kumar et
al., 2007). These stimuli are then further categorized as either external or internal stimuli.
Externally controlled systems rely on externally applied stimuli that are produced with the
help of different stimuli-generating devices, which ultimately results in pulsed drug delivery.
Internally regulated systems are also known as self-regulated devices, where the release
rate is controlled by a feedback mechanism that is produced within the body to control the
structural changes in the polymer network and to exhibit the desired drug release, without
any external intervention (Kost and Langer, 2001; Gupta et al., 2002). Responses to these
stimuli may be manifested as changes in shape, surface characteristics, solubility, formation
of intricate molecular assemblies or sol-gel transitions (Kumar et al., 2007).
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STIMULI
Figure 2.2: Potential stimuli and responses of synthetic stimuli-responsive polymers
(adapted from Schmaljohann, 2006).
In the last decade a vast majority of pharmaceutical research has been focused on the
development of targeted drug delivery systems that allow for the delivery of pharmaceuticals
to specific sites, organs, tissues or cells in the body where drug therapy is necessary, for
example the specific targeting of chemotherapeutics to only cancer cells (Nakayama et al.,
2006). Stimuli-responsive polymers have been explored as a means of achieving such drug
targeting by exploiting site-dependent stimuli such as pH and the presence of high quantities
of particular enzymes. However numerous other stimuli and polymers have been explored
and are explicated further.
2.2.1 Thermo-responsive polymers
Temperature may act as both an external and internal stimulus. Physiologically, thermal
stimuli show substantial significance for example during a fever when there is an elevation of
body temperature due to the presence of pyrogens. This elevation in temperature is
mediated by an elevated concentration of prostaglandin E2 within certain areas of the brain
thus altering the firing rate of neurons that control thermo-regulation (Aronoff and Neilson,
2001; Chaterji et al., 2007). Changes in temperature that can trigger drug release can be
either due to increased body temperature in a diseased state or due to an external
modulation for example in the form of heat-triggered subdermal implants amongst others.
RESPONSES
Temperature
pHElectric
Magnetic
Solvents/ions
Mechanical
Permeability
Surface
Mechanical
Phase separation
Shape change
Electrical
Optical
32
Thermo-responsive monolithic hydrogels are being investigated for their potential to obtain
‘on-off’ drug release profiles in response to stepwise temperature changes (Okano et al.,
1990; Bae et al., 1991a, b). In one such case poly(N-isopropylacrylamide) crosslinked butyl
methacrylate (BMA) hydrogels were loaded with indomethacin and analyzed for their on-off
release profile. ‘On’ was achieved at low temperatures and ‘off’ at high temperatures. This
occurred due to the formation of a skin-type barrier that formed a dense, less permeable gel
surface layer when the temperature was suddenly changed. The barrier was formed due to
the faster collapse of the gel surface than the interior and was regulated via the length of the
methacrylate alkyl side-chain (Okuyama et al., 1993).
The limited therapeutic activity and insolubility of anti-cancer drugs, problems of accessibility
and heterogeneity of tumours, and toxicity/immunogenicity of the delivery agent all intensify
the need for newer drug delivery modalities that are capable of eradicating these challenges.
Despite the development of many diverse chemotherapeutic systems such as low molecular
weight prodrugs, liposomes and micro- and nanoparticles, there is yet limited therapeutic
efficacy in the available chemotherapeutic drug delivery systems (Fung and Saltzman, 1997;
Allen, 1998; Jones and Leroux, 1999; Liu et al., 2003c; Barbe et al., 2004; Lin et al., 2005;
Ambruosi et al., 2006; Dong and Feng, 2006; Farokhzad et al., 2006; Vicent and Duncan,
2006; Cheng and Kuhn, 2007).
Soluble polymeric drug carriers are amongst the more popular modes of chemotherapeutic
drug delivery. This is owed to its improved drug pharmacokinetic profiles, thus leading to
increased tumour accumulation over free drug via passive targeting or also known as the
enhanced permeability and retention (EPR) effect (Matsumura and Maeda, 1986; Iyer et al.,
2006). However, a major drawback of these carriers is their inability to intrinsically target a
particular physiological site. Since hyperthermia increases the permeability of tumour
vasculature compared to normal vasculature a combination of chemo and radiotherapy
establishes a synergistic activity that enhances solid tumour cytotoxicity (Engin et al., 1995;
Engin, 1996; Issels, 1999).
2.2.2 Electro-responsive polymers
Delivery systems that exploit electrical fields as externally regulated stimuli benefit not only
from the ready availability of equipment but also from the ability to precisely control the
magnitude of the applied current, the duration of electrical pulses and the interval between
these pulses (Anal, 2007). These systems are formulated from polymers called
polyelectrolytes which contain a relatively high concentration of ionizable groups along the
backbone chain, thus bestowing pH-responsive as well as electro-responsive properties
upon them (Qiu and Park, 2001; Anal, 2007).
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Technologies such as sonophoresis, iontophoresis and infusion pumps have benefited from
being electrically controlled (Aoki et al., 2004). A polymer reservoir with a pair of electrodes
placed across its rate limiting membrane was developed as a drug delivery device.
Controlled and predictable drug release rates were achieved and postulated as being as a
result of an alteration of the magnitude of the electrical field between the electrodes
(D’Emanuele et al., 1988; D’Emanuele and Stainforth, 1989; Kagatani et al., 1997; Murdan,
2003; Kulkarni et al., 2010).
2.2.3 Magnetically-responsive polymers
Magnetic drug targeting is based on the attraction of magnetic micro- and nanoparticles to an
external magnetic field source. In principle, in the presence of a magnetic field gradient, a
translational force will be exerted on the particle/drug complex. This effectively traps the
complex in the field at the target site and pulls it toward the magnet (Pankhurst et al., 2003;
Grief and Richardson, 2005). However several factors always require consideration namely,
the magnetic properties of the carrier particles, field strength, field geometry, drug/gene
binding capacity; as well as physiological parameters such as the depth to the target site, the
rate of blood flow, vascular supply and body weight (Neuberger et al., 2005).
Current chemotherapeutic approaches rely on highly non-specific means of delivery. These
drugs are generally administered intravenously and the resulting systemic circulation of these
agents indefinitely results in numerous adverse effects. In addition, healthy cells are targeted
along with the cancer cells. The premise that cytotoxic drugs could be attached to magnetic
micro- and nanoparticles was explored by injecting these particles into a subject either via
intravenous or intra-arterial injection (Senyei et al., 1978; Mosbach and Schröder, 1979;
Alexiou et al., 2000; Zebli et al., 2005; Alexiou et al., 2006; Martina et al., 2008). The drugs
were then guided and concentrated at the tumour site by aid of high gradient, external
magnetic fields generated by rare earth permanent magnets.
Although theoretically very effective, these carriers are partnered with a range of challenges.
In order to retain the magnetic carrier-drug complex at a specific location, the externally
applied field must have a relatively strong gradient. Additionally, as soon as the drug is
released from the magnetic complex, it is no longer responsive to the applied field. It is then
free to resume its normal distribution patterns in the body and if the drug is released while
the complex is still within the vasculature, even if they are held at the target site, there will
then be some degree of systemic distribution. There is also the potential for embolization as
the particles are capable of accumulating and blocking blood flow or they may also
concentrate in the liver (Dobson, 2006). There is also the problem as to the depth that the
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magnet may function, as is encountered when scaling up from small animals with near-
surface targets to larger animals and humans.
2.2.4 Ultrasonically-responsive polymers
The application of ultrasound in drug delivery proves to be highly advantageous as it is non-
invasive and capable of penetrating deep into the interior of the body allowing targeted drug
delivery by controlling parameters such as frequency, power density, duty cycles and time of
application (Lavon and Kost, 1998; Rapoport et al., 2004). Its main mechanism of action
relies on the generation of thermal energy, perturbation of cell membranes under the
influence of micro-convection or inertia cavitation, and enhanced permeability of blood
capillaries (Gao et al., 2005).
One of the pioneering approaches of exploiting ultrasound in drug delivery involved directing
ultrasonic waves directly at the polymers or the hydrogel matrix (Sershen and West, 2002).
Kost and Langer (2001) evaluated various bio-erodible and non-erodible polymers as drug
carrier matrices and found that enhanced polymer erosion and drug release was observed
when the samples were exposed to ultrasound. The systems responses to the ultrasonic
triggering were rapid (within 2 min) and reversible. Enhanced release was also observed in
non-erodible systems exposed to ultrasound where the release was diffusion dependent
(Kost et al., 1988, 1989).
2.2.5 Light-responsive polymers
Since the stimulus of light can be imposed instantaneously and can be delivered in specific
quantities with high accuracy, it renders light-responsive hydrogels highly advantageous over
others. Also, the capacity for instantaneous delivery of the sol-gel stimulus renders light-
responsive polymers potentially applicable in the development of optical switches, display
units and ophthalmic drug delivery systems. Light-responsive polymers may be UV or visible
light sensitive; however, visible light-responsive polymers and hydrogels are more beneficial
in that they are safe, inexpensive, readily available, clean and easily manipulated (Qiu and
Park, 2001).
By introducing a light-sensitive chromophore, for example trisodium salt of copper
chlorophyllin to poly(N-isopropylacrylamide) hydrogels, visible light-responsive hydrogels can
be formulated (Suzuki and Tanaka, 1990). When light is applied to the hydrogel, the
chromophore absorbs the light which is then dissipated locally as heat by radiationless
transitions, increasing the ‘local’ temperature of the hydrogel. This increase in temperature
alters the swelling behaviour of the hydrogel. By addition of another functional group, such as
an ionizable group of polyacrylic acid, the light-responsive hydrogel can be rendered pH-
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sensitive as well and may be activated (i.e. induced to shrink) by visible light and can be
deactivated (i.e. induced to swell) by increasing pH (Suzuki et al., 1996). Although the action
of the light stimulus is instantaneous, the reaction of the hydrogels to the action is slow since
light energy first has to be converted into thermal energy.
2.2.6 pH-responsive polymers
All pH-responsive polymers contain pendant acidic or basic groups such as carboxylic and
sulfonic acids or ammonium salts, that are capable of either accepting or releasing protons in
response to environmental changes in pH (Qiu and Park, 2001; Gupta et al., 2002;
Schmaljohann, 2006). These changes thus lead to conformational changes of the soluble
polymers and a change in the swelling behaviour of the hydrogels when ionizable groups are
linked to the polymer structure. On exposure to aqueous media of appropriate pH and ionic
strength, pendant groups ionize and develop fixed charges on the polymer network, causing
electrostatic repulsive forces responsible for pH-dependent swelling or deswelling of the
hydrogel, which ultimately controls drug release (Gupta et al., 2002). Since variations in pH
occur within the body, unlike temperature changes, this property can be exploited to direct a
response to a certain tissue or cellular compartment. Furthermore, local pH changes in
response to specific substrates can be generated and exploited for modulating drug release.
Poor oxygen perfusion within the interstitial matrix of a tumour results in a different metabolic
profile of the tumour to surrounding tissues. This leads to elevated lactic acid levels and
consequently a reduction in the pH (Kurisawa and Yiu, 1998). The triggering, targeting and
controlling of drug release according to variations in pH can thus be achieved by targeting
the extracellular tissue or the lysosomes. Tumour tissue has an extracellular pH between
6.5-7.2, which is slightly lower than the normal pH of 7.4; and after cellular uptake, drug
conjugates reach lysosomes which have a pH of 4.5-5.0. In the latter case, hydrolytic
enzymes such as cathepsin B may also be exploited for effecting drug release (Duncan,
2003).
2.2.7 Ionic strength-responsive polymers
Polymers that contain ionizable groups typically respond to changes in ionic strength which
may ultimately manifest as changes in the size of polymer chains, polymer solubility and the
fluorescence quenching kinetics of the chromophores bound to the electrolytes (Morrison et
al., 1994; Kathmann et al., 1997; Szczubialka et al., 2003). Polyampholytes generally
incorporate both anionic and cationic charged moieties into a single polymer chain. This
accounts for the unusual rheological behaviour of these polymer systems as a result of the
attractive Coulombic interactions between the oppositely charged species (Salamone et al.,
1985; Corpart and Candau, 1993; Kathmann et al., 1997).
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Different concentrations of salts, which determine the ionic strength, may cause phase
transitions in ionic strength-responsive polymers. Cu(II) metal ion was immobilized on
poly(NIPAAm-co-vinylimidazole) for protein separation using the affinity binding of specific
proteins to Cu(II) (Kumar et al., 1998). With an increase in the ionic strength, the polymer
chains which bind the proteins precipitate. The high salt concentration reduces the repulsive
electrostatic strength of the copolymer, which results in an increase in the hydrophobic
interactions and thus leads to precipitation.
2.2.8 Glucose-responsive polymers
Glucose-responsive hydrogel systems have the ability to provide self-regulated insulin
release in response to the concentration of glucose in the blood, thereby controlling the
concentration of insulin within a normal range (Gil and Hudson, 2004). The most common of
these hydrogel systems utilize immobilized enzymes or biocatalysts, more specifically
glucose oxidase (Kang and Bae, 2003; Ghanem and Ghaly, 2004; Srivastava et al., 2005).
The rationale behind this is that generally when an enzyme is covalently coupled to a smart
polymer, environmental changes result in drastic changes in the polymer conformation which
significantly affects the enzyme activity and substrate access to the enzyme molecule. These
biocatalysts act by catalyzing an enzymatic reaction in their soluble state and the products of
this enzymatic reaction then triggers the gel phase transition.
In the case of insulin delivery, glucose oxidase exploits the pH sensitivity of the polymer used
to immobilize the enzyme. The glucose oxidase oxidizes glucose to form gluconic acid which
causes a pH change in the environment (Qiu and Park, 2001). The pH-sensitive hydrogel
then exhibits a volume transition in response to the lowered pH, which occurs due to the
formation of gluconic acid. Therefore, the swelling ratio of the hydrogel is regulated by the
body’s glucose levels (Chaterji et al., 2007). Figure 2.3 depicts a schematic of this process.
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Figure 2.3: Schematic representation of a glucose-responsive glucose oxidase-loaded
membrane. = Glucose oxidase,     = Glucose,      = Gluconic acid (adapted from Miyata et
al., 2002).
2.2.9 Enzyme-responsive polymers
As described previously, self-regulated or internally-regulated systems allow drug release
rates to be adjusted by the system itself in response to feedback information provided by the
physiological needs of the body (Heller, 1985; Pitt, 1986; Heller, 1988; Kost, 1990; Cullander,
1992). Enzyme-responsive systems are such that no external intervention is required,
however apart from this, these systems provide a high specificity of interactions and a broad
range of possibilities attributed to the large number of enzymes known (Goldbart et al.,
2002).
It is well documented that the gastrointestinal bacterial population increases continuously
from the mouth to the rectum, with a dramatic increase in bacterial numbers in the colon
(Simon and Gorbach, 1984; Bernhardt and Knoke, 1997; Eckburg et al., 2005). The
flourishing colonic bacterial population exists since the pH and motility of this region is
appreciably more conducive to bacterial growth compared to the stomach and small
intestine. The unmistakably demarcated difference between the population and type of
bacterial growth in the various regions of the GIT, as well as the variety of enzymes
produced by colonic bacteria provides a substrate which can effectively be exploited as a
trigger for drug release in this region. Thus, this formulation approach has been and currently
i) Glucose diffusion ii) Enzymatic reaction
reaction
iii) Swelling
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is being extensively explored for targeting of drugs and other pharmaceuticals directly to the
colon.
2.3 Approaches to colon-targeting by exploiting site-specific stimuli
Since the revelation of the effectiveness of 5-ASA in the treatment of UC, as well as the
recognition of the sulphonamide component of sulfasalazine as the causative agent
responsible for the adverse effects experienced, numerous 5-ASA compounds and delivery
systems have emerged to provide a more attractive approach to UC treatment. In general,
four primary approaches have been proposed for targeted delivery of 5-ASA and other
pharmaceuticals to the colon. These approaches have been implemented in an attempt to
meet the following criteria imperative for effectively delivering drugs to the colon:
 the delivery system should remain intact when travelling through the upper GIT;
 the incorporated drugs should be protected from chemical and enzymatic degradation
in the stomach and small intestine;
 the delivery system should initiate drug release immediately upon reaching the colon;
and
 the relevant drug should be released in a manner such that a consistent and effective
rate of drug release is achieved that ensures optimum therapeutic efficacy in a local
or systemic capacity.
Based on these criteria various design strategies have been investigated primarily focusing
on the exploitation of a characteristic unique to the colonic environment as a means of
triggering drug release whilst maintaining the integrity of the delivery system throughout its
passage through the upper GIT. The gastrointestinal features that are typically exploited as
triggering mechanisms include pH, transit time, pressure and microflora. Table 2.2 provides a
detailed description of each of these approaches, as well as examples of the most effective
and extensively explored novel delivery systems based on each of the above characteristics.
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Table 2.2: Stimuli-responsive colon-targeted drug delivery approaches
Design Approach Mechanism of Drug
Release
Polymers typically
employed
Experimental and
theoretical limitations
Examples Conclusion References
pH-dependent systems Formulations are typicallycoated with an enteric polymer
coating that remains insensitive
to the acidic conditions of the
stomach by existing in the
unionized form, and dissolving
at a more neutral pH of 6-7,
theoretically found in the colon.
The most commonly employed
pH-dependent polymers include
the methacrylic acid
copolymers, Eudragit® S and
Eudragit® L.
Methacrylic acid copolymers
such as:
 Eudragit® S100
 Eudragit® L100
 Eudragit S
 Eudragit FS
 Eudragit P4135 F
 Eudragit L 30 D-55
 Eudragit FS 30 D
 The presence of a disease
state such as UC
considerably influences
the pH characteristics of
the GIT.
 The concept is based on
the assumption that the
luminal pH continues to
rise from the small
intestine to the colon.
 Time of fragmentation of
these systems is highly
variable and time of tablet
disintegration ranges from
5-15 hours.
 Site of disintegration
ranges from the small
intestine to the distal
colon, and in some cases
the system passes through
the GIT intact.
The pioneering study of pH-
dependent systems was
conducted in 1982 by Dew and
co-workers, where Eudragit® S
was employed as a coating over
a capsule. The results from this
study provided the basis for the
commercialization of Asacol®.
Other marketed pH-dependent
systems are shown in table 1.2.
To improve the colon-specificity
numerous avenues are being
explored such as enteric
polymer modification,
development of new polymers
and combining of existing
polymers. The latter is
exemplified by the development
of TARGITTM-a targeting
technology comprised of a
mixture of Eudragit® L and S.
The gastrointestinal pH is not a
sufficiently reliable mechanism
for colon-targeted drug delivery.
Despite the efficacy of enteric
polymers in targeting the small
intestine, their success in
targeting the colon is mixed.
The erratic behaviour of these
pH-dependent colon targeted
systems is also evident in vivo.
Basit (2005) made the
observation, “given our current
knowledge of the
gastrointestinal pH, one can
only speculate whether some of
these products would have
reached the market had this
information been available in
the early 1980’s.”
Dew et al., 1982; Schroeder
et al., 1987; Ashford et al.,
1993a ; Fallingborg et al.,
1993; Peeters and Kinget,
1993; Sciarretta et al., 1993;
Watts and Illum, 1997;
Wilding, 1999; Rudolph et
al., 2001; Tuleu et al., 2001;
Cole et al., 2002; Sinha et
al., 2003; Basit, 2005; Safdi,
2005; Asghar and Chandran,
2006; Ibekwe et al., 2006a,
b, 2008.
Time-dependent
systems
These formulations are
designed so as to ensure
release of the drug load after a
predetermined lag time. Usually
a nominal lag time of 5-6 hours
is incorporated into the system.
 Hydroxypropyl
methylcellulose
(HPMC)
 Hydroxyethylcellulose
(HEC)
 Ethylcellulose (EC)
 Microcrystalline
cellulose
 Hydroxypropyl
methylcellulose
acetate succinate
 The concept is based on
the assumption that the
pre-set lag time of 5-6
hours is the time required
for the system to reach the
colon and that transit times
are a consistent
parameter.
 Gastric emptying and
gastrointestinal fluid
volumes considerably
influences the position of
the delivery systems at the
time of release.
 Factors such as the
presence of concurrent
disease states, inter- and
intra-individual variability,
as well as diurnal rhythms
significantly influence
gastrointestinal transit
times.
The earliest device developed
based on this principle is known
as PulsincapTM, which consists
of an impermeable capsule
sealed at one end with a
hydrogel plug. The plug
hydrates and swells in contact
with gastrointestinal fluids, and
ejects from the capsule body
after a pre-set lag time, enabling
drug release. However, studies
found the position in the GIT at
the time of drug release varied
from the stomach to the
descending colon.
A combined pH- and time-
dependent mechanism which
has been evaluated proved to
be plagued by similar variability
in the site of drug release.
The fact that time-dependent
systems are unable to sense
and adapt to an individual’s
transit time, and merely
releases drug after the pre-set
lag time, irrespective of whether
the system is in the colon or
not, significantly limits its use.
Therefore, these systems are
not ideal to deliver drugs
specifically to the colon for the
treatment of UC.
Goo et al., 1987; Coupe et
al., 1991; Reddy et al., 1991;
Wilding et al., 1992;
Ishibashi et al., 1998;
Hebden et al., 1999a,b;
Fukui et al., 2001; Halsas et
al., 2001; Yang et al., 2002;
Crison et al., 2003; Alvarez-
Fuentes et al., 2004; Lee et
al., 2004; Sangalli et al.,
2004.
Pressure-dependent
systems
Pressure-dependent systems
are based on the premise that
the muscular contractions of
the intestinal wall which are
responsible for the grinding and
propulsion of luminal contents
creates a pressure differential
which varies in intensity and
duration throughout the GIT.
 Ethylcellulose as the
hydrophobic coating
 Polyethylene glycols
(PEG) as the
suppository base.
 There is limited data
regarding the various
luminal pressures of the
GIT, as well as whether
these pressures are
subject to inter- and intra-
individual variability as is
the case with pH and
transit times.
A pressure-controlled colon
delivery capsule (PCDC)
composed of a drug dispersed
in a suppository base, coated
with a water-insoluble polymer
was developed. Once
swallowed, the suppository
base melts and increases
volume, resembling a liquid-
The exploitation of the
gastrointestinal pressure is an
innovative means of targeting
drugs to the colon however the
absence of sufficient data of the
various luminal pressures
places the viability of these
systems into question.
Digenis and Sandefer, 1991;
Ritschel, 1991; Moës, 1993;
Takaya et al., 1995; Basit,
2005.
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Due to the reabsorption of
water from the colon the
viscosity of its luminal contents
increases. As a result the
colonic pressure increases and
along with the haustral
contractions, an exploitable
trigger for colon targeting is
provided.
 As a result the in vitro
evaluation of such
systems poses a
considerable challenge.
filled balloon. The balloon
withstands the pressures of the
stomach and small intestine as
there is sufficient fluid in the
lumen to dissipate the pressure.
However, due to the increase in
viscosity of colonic contents the
balloon is unable to withstand
the colonic pressure and
consequently ruptures.
Prodrugs These are pharmacologicallyinactive drug derivatives where
the promoeity (inactive portion
of the drug) minimizes
absorption until the active
component is released at its
target site. This typically occurs
as a result of enzymatic action.
The promoeity thus functions to
either increase the
hydrophilicity of the parent drug
or to increase its molecular size
or both, thus minimizing
absorption of the drug prior to
reaching the colon.
 Sulphapyridine linked
to 5-ASA via an azo
bond (Sulfasalazine)
 p-aminohippurate
linked to 5-ASA via an
azo bond (Ipsalazine)
 4-amino benzoyl-b-
alanine linked to 5-
ASA via an azo bond
(Balsalazide)
 Dimer of 5-ASA linked
via an azo bond
(Olsalazine)
 Each new prodrug is
classified as a new
chemical entity and is
therefore subjected to
stringent regulations prior
to market approval being
granted.
 A universal system of
promoeity-drug system is
elusive thus thwarting the
implementation of various
different existing drugs into
such a formulation.
The classic example of a
prodrug is that of sulfasalazine
where 5-ASA is linked to a
sulpha group via an azo bond.
Despite its efficacy in targeting
the colon its adverse effects
profile has led to the
development of numerous other
5-ASA based prodrugs such as
olsalazine, balsalazide and
ipsalazine.
Other examples of non-
commercialized prodrug
approaches include
biorecognizable HPMA
copolymer conjugates of 9-
aminocamptothecin (9-AC),
where 9-AC is bound via
spacers of amino acid residues
and aromatic azo bonds or, low
molecular weight saccharide-
based prodrugs of
dexamethasone and
budesonide.
Apart from the advantage of
prodrugs for targeting specific
regions of the GIT, they also
provide potential for patent
protection as the newly
synthesized compound can be
patented as a new composition.
Peppercorn and Goldman,
1972; Azad-Khan et al.,
1977; Chan et al., 1983;
Svartz, 1988; Wadworth and
Fitton, 1991; Cui et al., 1994;
Fedorak et al., 1995;
Sakuma et al., 2001; Sinha
and Kumria, 2001;
Chourasia and Jain, 2003;
Friend, 2005.
Enzyme-dependent
systems
Enzyme-dependent systems
primarily involve the
fermentation of non-starch
polysaccharides by colonic
anaerobic bacteria. These
polysaccharides are typically
incorporated into delivery
systems via a film coating or
matrix formation, thus providing
a substrate for enzymatic
cleavage and subsequently the
initiation of drug release in the
colon.
 pectin
 chitosan
 guar gum
 amylose
 alginates
 chondroitin sulphate
 amylopectin
 starch
 xanthan gum
 Even though these
polysaccharide-based
systems provide an ideal
substrate for enzymatic
cleavage in the colon the
hydrophilicity of the
polymers employed often
result in the swelling and
premature dissolution of
the polymers in the upper
GIT.
In an attempt to restrain the
hydrophilic characteristics of the
polysaccharide polymers
chemical modification or
combination of the polymer with
a hydrophobic polymer has
been explored. This generally
limits the swelling of the system
in the upper GIT, whilst
permitting the bacterial
degradation of the system in the
colon. Using this approach
numerous novel systems have
been investigated over two
decades. With time these
systems have evolved into more
effective and complex
technologies.
The exploitation of colonic
enzymes as a trigger is the
most appealing approach for
targeting drugs to the colon as
it relies solely on the unique
enzymatic ability of colonic
microflora thus enabling a more
specific targeting, independent
of the pH variations along the
GIT and the presence of a
concurrent disease condition.
Rubinstein et al., 1992b;
Shun and Ayres, 1992;
Rubinstein et al., 1993;
Milojevic et al., 1996;
Wakerly et al., 1996; Wong
et al., 1997; Krishnaiah et
al., 1998; Lorenzo-Lamosa
et al., 1998; Park et al.,
2002; Al-Saidan et al., 2005;
Varshosaz et al., 2006;
McConnell et al., 2008b; Wei
et al., 2008.
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2.4 Enzyme-responsive colon-targeting
Taking advantage of the over 400 distinct species of anaerobic bacteria and their
corresponding enzymatic activities in the colon a more adaptable means of colon-targeting is
achieved by implementing various naturally acquired polymeric materials into various
delivery systems. Extensive research in the last two decades has explicated the attractive
characteristics that natural polysaccharides possess as potential substrates for enzymatic
degradation and consequently for enzyme-responsive colon-targeting. Since many of these
polymers are already used as pharmaceutical excipients their safety, toxicity and availability
is vastly simplified. Furthermore, despite the immense promise that this formulation approach
holds there are yet no marketed enzyme-responsive products of 5-ASA available.
The resistance of polysaccharides to the digestive action of gastrointestinal enzymes allows
the retention of the integrity of these polymers in the physiological environments of the
stomach and small intestine. However on entry to the colon they are acted upon by bacterial
polysaccharidases which ultimately results in the degradation of these materials.
Furthermore, these polymers consist of a large number of derivatizable groups, a wide range
of molecular weights, and varying chemical compositions which result in the immense appeal
in drug delivery (Chourasia and Jain, 2003). Numerous polysaccharide polymers hold
promise in enzyme-responsive colon-targeting and the most popular of these are illustrated
in Figure 2.4.
Figure 2.4: Several polysaccharide polymers that hold applicability in colon-targeting.
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Even though mostly non-starch polysaccharides have been said to be useful in colon-
targeting, the components of starch have also been found to be applicable for this purpose.
Starch is comprised of two major components namely, amylose and amylopectin. The former
of which has been the most exploited for colon-targeted drug delivery (Basit, 2000). Initially it
was believed that starch is broken down by pancreatic enzymes in the small intestine.
However it was later established that certain forms of starch remain resistant to conditions of
this region (Englyst et al., 1992). A form of this resistant starch, retrograded amylose,
escapes digestion in the small intestine and is available for fermentation by colonic
polysaccharidases. Amylose is fermented by a wide range of colonic bacteria and it is
believed that it is susceptible to more than 50% of the colonic bacterial population (Salyers et
al., 1977a, b; Macfarlane and Englyst, 1986; Milojevic et al., 1996; Siew et al., 2004). Like
other polysaccharides the use of amylose is limited by its premature solubility in the upper
GIT and an effective approach to resolving this challenge is by the combination of amylose
with the hydrophobic polymer, ethylcellulose, to form a mixed coating (Milojevic et al., 1996;
Siew et al., 2000; Leong et al., 2002).
2.4.1 Investigated enzyme-responsive colon-targeted drug delivery systems
The inception of this concept dates back to the early 1990s and the evolution of the
technology has continued to the present day. Figure 2.5 provides a snapshot of the various
enzyme-responsive colon-targeted drug delivery systems that have been explored. The
majority of these systems have focused on the implementation of polysaccharides that fulfill
the characteristics of remaining resistant to small intestinal pancreatic degradation, whilst
being susceptible to bacterial degradation in the colon (Cummings et al., 1996; Englyst et al.,
1996). However, despite the numerous polymers explored as well as the extensive
exploration into more effective enzyme-responsive colon-targeted drug delivery systems,
only a selection of these have undergone in vivo studies in man. Furthermore, only one of
these has reached large scale clinical trials namely, the COLALTM system composed of
amylose-ethylcellulose coated pellets.
43Figure 2.5: Timeline of the evolution of novel polysaccharide based enzyme-responsive colon-targeted drug delivery systems.
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2.4.2 Bio-relevant in vitro dissolution testing of enzyme-responsive colon-targeted
drug delivery systems
An integral component of pharmaceutical research and the development of novel oral
modulated drug delivery systems is the process of in vitro dissolution testing. The necessity
of the dissolution method to be discriminative, reproducible, scientifically justifiable and most
importantly bio-relevant arises from the decisive information that may be acquired from this
study. This may include information regarding (Yang et al., 2002; Yang, 2008):
 drug release kinetics;
 implications of formulation changes;
 manufacturing process changes;
 critical processing variables;
 quality assurance during clinical manufacturing;
 in vitro/in vivo correlation;
 impact of pH and hydrodynamic conditions on drug release characteristics;
 drug releasing mechanism involved; and
 the possibility of an in vivo surrogate.
Therefore, dissolution testing should be performed in physicochemically and
hydrodynamically relevant conditions that simulate the environments that the delivery system
may encounter. It has been proposed that the Biopharmaceutics Classification System (BCS)
correlates in vitro product dissolution and in vivo systemic bioavailability for immediate
release formulations (Amidon et al., 1995). However no such framework exists for drugs
acting locally in the GIT, especially for colon-targeted drug delivery systems. Since 5-ASA is
fundamentally a locally acting drug it is recognized that its release profile is the determinate
factor of an adequate local bioavailability. Furthermore, the systemic absorption of 5-ASA in
the small intestine is the cause of increased side effects (Lewis, 2003). Based on these facts
a method for determining the dissolution profile of 5-ASA under bio-relevant conditions is
essentially the most effective means of evaluating 5-ASA delivery systems (Steed et al.,
1997).
Currently, the USP recommends the use of four dissolution methods which includes the
basket method, paddle method, reciprocating cylinder method, or flow-through cell method.
However, several constraints relating to the dissolution of ‘complex’ delivery systems have
necessitated the need for modification of these methods (Pillay and Fassihi, 1999). Currently,
there is no prescribed dissolution method in the pharmacopoeia for colon-targeted drug
delivery systems (USP 33, NF 28). However the ideal method of dissolution testing for such
a delivery system should as closely as possible mimic the in vivo gastrointestinal conditions
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with regard to pH, bacteria, enzyme population and activity, fluid volume, and motility.
Despite the difficulty in the standardization and validation of these complex specifications
numerous dissolution methodologies have been reported and evaluated (Larsen et al., 1989;
Rubinstein et al., 1992a; Molly et al., 1993; Rubinstein et al., 1993; Van den Mooter et al.,
1994; Hovgaard and Brøndsted, 1995; Milojevic et al., 1996; Wong et al., 1997; Prasad et al.,
1998; Jung et al., 2000; Katsuma et al., 2002; Raghavan et al., 2002; Yang et al., 2002;
Krishnaiah et al., 2003; Fetzner et al., 2004; Shyale et al., 2005; Sinha et al., 2005; Das et
al., 2006; Jain et al., 2007; Ji et al., 2007; Pitarresi et al., 2007; Schellekens et al., 2007;
Sinha et al., 2007; Ugurlu et al., 2007; Wei et al., 2007).
2.5 Concluding Remarks
The focus of this chapter was placed on the factors of the gastrointestinal physiology that
influence the design of delivery systems and in particular that of colon-targeted delivery
systems. Impetus was placed on colon-targeted drug delivery systems since it essentially
formed the more challenging yet beneficial aspect of the SROT. Furthermore, this chapter
elaborated on the concept of stimuli-responsive drug delivery with particular emphasis on the
typical polymers employed. The most commonly explored approaches to colon-targeted drug
delivery were described and the most effective of these approaches identified. Consequently,
the evolution of this technology namely, enzyme-responsive colonic drug delivery was
illustrated from its inception in the early 1990’s to the present day, with particular emphasis
being placed on the novel delivery systems developed and the polymers typically employed.
Finally, the importance and relevance of a bio-relevant dissolution testing system for
enzyme-responsive colon-targeted drug delivery systems was described.
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CHAPTER 3
PRELIMINARY DESIGN OF THE INNER ENZYME-RESPONSIVE COLON-TARGETED
ORAL TABLET COMPONENT OF THE STIMULI-RESPONSIVE ORAL TABLET SYSTEM
3.1 Introduction
3.1.1 Approach to preliminary formulation design
An extensive range of systems are currently available that ensure the controlled release of
drugs to various regions of the gastrointestinal tract (GIT), where the nature of the delivery
system is dictated by the properties and dose of the drug, the reason for controlling release
of the drug, as well as the interactions of constraining physiological and pathological factors
(Davis, 1985). However:
“the rational design and evaluation of effective controlled release delivery systems needs to
take into account the trinity of drug, delivery and destination”,
-Davis (1985)
Davis further explicated that ‘controlled release systems’ also encompassed those that were
intended for site-specific targeting. Essentially, this means that each factor of the trinity is
interrelated and it is therefore imperative to take into consideration each aspect and their
corresponding constraints when developing a new drug delivery system. Therefore, variables
such as the solubility and stability of drugs, the regions of absorption throughout the GIT, the
in vitro and in vivo release characteristics of the delivery system, as well as the physiological
parameters of gastrointestinal transit have to be evaluated during formulation development.
Expanding on this concept, Davis and Illum (1998) later proposed a ‘4D’ approach for drug
delivery system design and development (Figure 3.1).
Figure 3.1: Illustration of the ‘4D’ approach to drug delivery design and development
(adapted from Pillai et al., 2001).
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This concept follows a logical approach where the drug, the disease and the destination
should be considered first based on where in the body the drug should achieve its effect or
the preferred route administration (Davis and Illum, 1998). Once these factors are
addressed, only then is it appropriate to consider what the most effective mode of delivery
should be. It is therefore preferable to choose a drug delivery system for a drug rather than a
drug for a drug delivery system (Pillai et al., 2001).
3.1.2 Understanding colon-targeted drug delivery
3.1.2.1 Benefits of targeting drugs to the colon
Colon-targeted drug delivery offers numerous therapeutic advantages ascribed to the near
neutral pH and the extended transit time of this region (Basit and Bloor, 2003; Jose et al.,
2009). Drugs that are typically destroyed/degraded by the digestive enzymes in the stomach
and metabolized by pancreatic enzymes in the small intestine are generally minimally
affected in the colon (Kinget et al., 1998; Chourasia and Jain, 2003). Furthermore, due to the
diminutive hydrolytic and hostile environment of the colon it exists as a promising site for the
absorption of proteins and peptides, and is also a highly responsive site for the absorption of
poorly absorbable drugs or for the delivery of diagnostic agents (Bai et al., 1995; Watts and
Illum, 1997; Tamara, 2004). In addition, disease states such as nocturnal asthma, arthritis
and cardiac arrhythmias are typically affected by circadian rhythms and thus require a delay
in drug release for therapeutic efficacy (Jose et al., 2009).
The colon can however also be liable to numerous local pathological conditions such as
constipation, Crohn’s disease, Ulcerative Colitis (UC), carcinomas and infections. UC in
particular is a chronic inflammatory disease that exclusively affects the colonic mucosa.
However since the precise underlying cause of the disease remains doubtful, treatment is
aimed at alleviating the symptoms of the disease and maintenance of states of remission
(Kane, 2006). For this latter purpose 5-aminosalicylic acid (5-ASA) is recognized as the first-
line treatment option but due to the mucosal confinement of inflammation this drug should
ideally be targeted to the colonic mucosa, with minimization of systemic absorption (Travis,
2002; Klotz, 2005).
3.1.2.2 Is there a need for yet another colon-targeted 5-ASA formulation?
Despite the efficacy of 5-ASA, outside of the clinical trial setting this drug suffers from poor
patient adherence attributable to the inconvenient and multiple daily dosing schedule of large
doses of the available 5-ASA containing formulations. This patient non-compliance of 5-ASA
formulations essentially impacts on the therapeutic outcome which snowballs to an increased
risk of symptomatic relapse, increased morbidity, increased risk of colorectal cancer and
ultimately an increase in the overall cost of healthcare (Kane, 2006). It has been documented
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that the compliance rates for patients suffering from chronic medical conditions that require
long-term drug therapy is estimated to be 50%, or may even be as low as 30% for certain
specific medical conditions (Rudd, 1995; Morris et al., 2000).
Furthermore, despite the extensive range of 5-ASA containing formulations available on the
market, as depicted in Chapter 1 Table 1.2, the popularity of a specific 5-ASA containing
formulation varies for example, Asacol® is the choice of 65% of the UK market, Pentasa® in
France (72%), Salofalk® in Germany (57%), and Asacol® in Canada (46%) (Travis, 2002).
This variability is suggested to be as a direct result of the specific diagnosis and disease
location of individual patients as well as the activity, side effect profile, efficacy, and cost
associated with each 5-ASA containing formulation. However ultimately, the efficacy is
dependent on the ability of the formulations to effectively target the affected region resulting
in maximal colonic mucosal concentrations with the lowest dose and dosing schedule. Thus,
the continuing research and development of newer 5-ASA formulations suggests that the
ideal product has not yet been found and hints towards the need for a more effective and
reproducible orally administered colon-targeted formulation (Klotz, 2005).
The ultimate goal of pre-formulation studies is thus to identify a candidate system that
achieves a targeted delivery of 5-ASA to the colonic mucosa whilst preventing premature
release of the drug in the stomach and small intestine (upper GIT). The anatomical and
physiological considerations for the development of such a system were delineated in
Chapter 1, with the conclusion in Chapter 2 that the targeting of enzymes specific to the
colon would be the most efficient for achieving such site-specific targeting. As a
consequence the release of 5-ASA in the colon should be initiated and controlled by the
specific enzyme population in the region. Preliminary formulation design on the tablet was
thus performed in a sequential manner that considered the formulation constraints whilst
acknowledging the ‘4D’ approach as theorized by Davis and Illum (1998). This process is
outlined in Figure 3.2. The subsequent identification of the candidate system was then based
on coherent comparison of dissolution data through each step of formulation design in order
to determine if any one of the preliminary formulations could be considered for further
optimization.
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Figure 3.2: Schematic illustration of the process involved in the design of the oral enzyme-
responsive colon-targeted tablet delivery system.
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Part I: Preliminary formulation development employing DPH
3.2 Materials and Methods
3.2.1 Materials
Mesalamine (5-ASA, approximately 99%, Mw=153.14g/mol, solubility=1.7mg/mL at 25°C in
water) and diphenhydramine HCl (DPH, Mw=291.82g/mol, solubility=100mg/mL at 21.5°C in
water) were obtained from Sigma-Aldrich (St.Louis, MO, USA) with the former employed for
its anti-inflammatory action on the colonic mucosa and the latter to establish the flexibility of
the system for incorporation of drugs with a high solubility. The polysaccharide polymers
employed included chitosan (CHT) (food grade) (Wellable Group Marine Biological &
Chemical Co., Ltd., Shishi City, Fujian, China), pectin (LM-105-AS) (CP Kelco, Lille
Skensved, Denmark), xanthan gum (XG) from xanthomonas campestris (Fluka, Buchs, AG,
Switzerland), carboxymethylcellulose sodium salt (CMC), medium viscosity (Fluka, Buchs,
AG, Switzerland), sodium alginate (SA) (Protanal®) from FMC Biopolymer (Brakerøya,
Drammen, Norway), and lastly pectin AM 901 (low methoxy, degree of esterification 38-
44%), pectin AMID CF 005 (low methoxy, amidated citrus pectin, degree of esterification 33-
39%, degree of amidation 11-17%), and pectin AMID CF 020 (low methoxy, amidated citrus
pectin, degree of esterification 25-31%, degree of amidation 19-23%) all obtained from Tate
& Lyle (Northriding, Gauteng, South Africa). The hydrophobic polymers cellulose acetate
phthalate (CAP) and ethylcellulose (EC) were supplied by Sigma-Aldrich (St.Louis, MO,
USA). The hydrophilic polymers investigated included hydroxyethylcellulose (HEC)
purchased from Merck-Schuchardt (Schuchardt, Hohenbrunn, Germany),
hydroxypropylmethyl cellulose (HPMC, Methocel K4M CR Premium) purchased from
Colorcon (Dartford, Kent, England) and polyethylene oxide (PEO, PolyoxTM WSR-303)
purchased from The Dow Chemical Company (Midland, MI, USA).
Sodium tripolyphosphate (TPP) (technical grade, 85%, Mw=367g/mol) and barium chloride
2-hydrate (BaCl2) (minimum 99%) were implemented as crosslinking agents and were
purchased from Sigma-Aldrich (St. Louis, MO, USA) and Saarchem-Merck (Wadeville,
Gauteng, South Africa) respectively. Other crosslinking agents also investigated included
zinc sulphate (ZnSO4, Mw=287.54g/mol) and calcium chloride dihydrate (CaCl2,
Mw=147.02g/mol) obtained from Rochelle Chemicals (Johannesburg, Gauteng, South Africa)
and aluminium sulphate (Al2(SO4)3, Mw=342.15g/mol) purchased from Saarchem-Merck
Laboratory Supplies (PTY) Ltd. (Midrand, Gauteng, South Africa). The ethylcellulose
aqueous dispersion (Surelease®, E-7-19040) was obtained from ColorconTM (Dartford, Kent,
England) and methacrylic acid-methyl methacrylate copolymer (1:2) (Eudragit® S-100) (ES-
100) was obtained from Rӧhm Pharma Polymers (Degussa) (Darmstadt, Germany). The
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ammonia solution (25%, NH4OH, Mw=35.05g/mol) was supplied by Rochelle Chemicals
(Johannesburg, Gauteng, South Africa) and ethanol rectified (95%) was obtained from Merck
Chemicals (PTY) Ltd. (Wadeville, Gauteng, South Africa). The commercial colonic enzymes
employed included pectinase from Aspergillus aculeatus (aqueous solution, ≥9,500U/mL)
purchased from Sigma-Aldrich (Copenhagen, Denmark) and β-glucosidase from almonds
(lyophilized powder, 276U/g) purchased from Fluka analytical (Gillingham, Dorset, England).
All other reagents employed were of analytical grade and used without further purification.
De-ionized water was obtained from a Milli-Q water purification system (Milli-Q, Millipore,
Billerica, MA, USA).
3.2.2 Formulation and evaluation of the various means of achieving in situ
crosslinking of various grades of pectin for sustained drug release
Essentially, the distinctive properties of various grades of pectin are directly related to their
degree of esterification (DE) and amidation (DA). Low-methoxylated (LM) pectins (<50%
esterified) are derived from highly methoxylated (HM) pectins (>50% esterified) after a
process of de-esterification and when this process is carried out in the presence of ammonia
some carboxylic acid groups present on the galacturonic chain become amidated resulting in
amidated LM pectins (Tho et al., 2005). The presence of free carboxylic acid groups in LM
pectins enables the crosslinking of this polymer with various divalent cations through a
postulated ‘egg-box’ model. In this model junction zones are created by ordered, side-by-side
associations of the pectin chains where specific sequences of the galacturonic acid
monomers form cavities where the cations may fit and link the polymer chains together by
electrostatic and ionic bonding (Grant et al., 1973; Morris et al., 1982; Powell et al., 1982;
Fang et al., 2008).
An investigation into the viability of in situ crosslinking as a possible mechanism for
sustaining drug release in the colon, whilst employing enzyme-responsive polymers was
undertaken by exploring various grades of commercially available pectin in conjunction with
various crosslinking agents by the preparatory process of either wet granulation (WG) or
direct compression (DC). This was performed in a sequential manner as shown in Table 3.1.
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Table 3.1: Experimental formulations evaluated for the identification of the optimum
crosslinking agent and method of preparation for in situ crosslinking various grades of pectin
Form. Grade of Pectin Crosslinking agent Method of
Preparation
1Ratio
2Apple 3Citrus 4Citrus ZnSO4 Al2(SO4)3 BaCl2 DC WG 1:1 2:1
1 x X x x
2 x X x x
3 x X x x
4 x X x x
5 x x x x
6 x x x x
7 x X x x
8 x x x x
9 x x x x
1 Ratio of pectin to crosslinking agent (w/w)
2 Pectin AM 901
3 Pectin AMID CF 005
4 Pectin AMID CF 020
Briefly, the directly compressed tablets were prepared by initially triturating the crosslinking
agent in a mortar and pestle and subsequently blending it with the relevant pectin in the
appropriate ratio and with a consistent quantity of model drug, DPH. Blending was performed
for 10 minutes using a cube blender (Erweka AR 400, Apparatebau GmbH, Heusenstamm,
Germany). Magnesium stearate (MgSt) was subsequently incorporated into the blend as a
lubricant in a 0.5%w/w concentration. This was then compressed into flat-surfaced tablets
(13mmx5mm) at a compression force of 5N using the Beckmann Hydraulic Press (Beckman
Instruments, Inc., Fullerton; USA).
In a similar manner, the wet granulated tablets were prepared by combining the triturated
crosslinking agent with DPH and pectin. This was subsequently blended for 20 minutes using
the cube blender. An ample quantity of 95% rectified ethanol was then pipetted onto the
blend to allow for sufficient wetting of the powder blend so that a wet mass was formed. The
wet mass was subsequently granulated through a 500µm mesh sieve (Laboratory Test
Sieve, Endecotts Ltd., London, England) and granules were allowed to dry at 40°C for 3
hours in a convection oven (Memmert, Schwabach, Germany). The granules were
subsequently dispersed in a 1%w/w concentration of MgSt for lubrication and compressed into
13mmx5mm flat-surfaced tablets using the Beckmann Hydraulic Press. Each formulation
was maintained at a consistent weight irrespective of the method of preparation, crosslinking
agent and the ratios of such employed.
3.2.3 Incorporation and evaluation of various synthetic hydrophilic polymers on the
drug release characteristics of an in situ crosslinked DPH-loaded tablet
A selection of polymers complying with a range of physicochemical and physicomechanical
properties were evaluated for their efficacy in sustaining drug release. Preliminary studies
evaluated their ability to sustain drug release in conditions simulating the gastric and small
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intestinal environments. Initially, tablets comprising of pectin (Pectin AM 901), BaCl2 and
DPH were combined with the pH-sensitive synthetic polymer, ES-100, by either WG or DC.
After determination of the most effective means of ES-100 incorporation, the influence of
various synthetic hydrophilic polymers on the drug release characteristics of these tablets
were investigated. The five formulations comprising of varying constituting polymers and their
corresponding quantities are indicated in Table 3.2. The quantities are expressed as a
percentage of the total weight of the formulations.
Table 3.2: Experimental formulations consisting of polymeric constituents with varying
hydrophilic properties
Form. ES-100 Pectin BaCl2 HEC HPMC PEO WG DC DPH MgSt
1 28.8 40.3 3.6 x 25.9 1.4
2 28.8 40.3 3.6 x 25.9 1.4
3 28.6 14.3 1.4 28.6 x 26.7 0.4
4 28.6 14.3 1.4 28.6 x 26.7 0.4
5 28.6 14.3 1.4 28.6 x 26.7 0.4
When a DC approach of preparation was employed, the combination of polymers were
thoroughly blended for 15 minutes with a cube blender which was modified to hold a number
of 20mL glass vessels that each enclosed smaller quantities of the blend, thus permitting
efficient blending on a smaller scale. Thereafter, each blend was compressed into flat-
surfaced tablets (13mmx5mm) at 5N with the Beckmann Hydraulic Press. WG employed an
identical approach to that of DC however prior to compression a sufficient quantity of 95%
rectified ethanol was pipetted onto the dry blend to form a wet mass. This mass was
subsequently passed through a 2mm mesh sieve (Laboratory Test Sieve, Endecotts Ltd.,
London, England) and the granules were allowed to dry at 40°C for 3 hours in a convection
oven. The dried granules were then compressed at 5N using the Beckmann Hydraulic Press
into 13mmx5mm flat-surfaced tablets.
3.2.4 Fabrication of crosslinked DPH-loaded SA granules dispersed within polymeric
matrices for sustained drug release
In an attempt to further sustain drug release in simulated gastric and small intestinal
environments investigations were ushered toward the fabrication of crosslinked DPH-loaded
granules comprised essentially of an anionic polysaccharide polymer, in particular SA
crosslinked with an assortment of crosslinking agents. These granules were subsequently
dispersed within matrices comprised of an ideal combination of polymers as determined from
previous investigations. The crosslinking agents investigated for incorporation into the
granules and/or matrices included zinc gluconate (C12H22O14Zn), ZnSO4, CaCl2 and BaCl2.
Furthermore, a cationic polysaccharide polymer, namely CHT in conjunction with SA was
also evaluated in an attempt to further sustain drug release. More specifically, formulations
were scrutinized using each of these crosslinking agents in various combinations, and
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subsequent to the identification of the most effective crosslinking agent for this purpose,
variations of the ratio of polymer to the specific crosslinking agent was evaluated as depicted
in Table 3.3.
Table 3.3: Polymer and crosslinking agent variations in preparation of granules and matrices
Form. Granules Matrix
Polymer 1CA 2Ratio Polymer 1CA 2Ratio
1 SA C12H22O14Zn 2:1 Pectin BaCl2 2:1
2 SA BaCl2 2:1 Pectin BaCl2 2:13 SA C12H22O14Zn 2:1 Pectin C12H22O14Zn 2:1
4 SA CaCl2 2:1 Pectin CaCl2 2:15 SA ZnSO4 2:1 Pectin BaCl2 2:16 SA/CHT ZnSO4 3:1:1.5 Pectin BaCl2 2:1
7 SA/CHT ZnSO4 3:1:1 Pectin BaCl2 2:18 SA/CHT ZnSO4 4:1:1 Pectin BaCl2 2:1
9 SA/CHT ZnSO4 5:1:1 Pectin BaCl2 2:1
1Crosslinking agent
2 Ratio of polymer to crosslinking agent (w/w) or sodium alginate:chitosan:salt (w/w/w)
Thus, in preparation of these experimental formulations, SA or the combination of SA and
CHT was thoroughly blended with the relevant triturated crosslinking agent, in the relevant
polymer to crosslinking agent ratio with DPH, using the previously described modified cube
blender. De-ionized water was pipetted directly onto the dry blend and was employed as a
solvent to facilitate the formation of a wet mass. The wet mass was then passed through a
2mm mesh sieve and the resultant granules were allowed to dry at 40°C for 12 hours in a
convection oven. Once dried, the granules were dispersed within the relevant matrix
determined according to Table 3.3. All experimental formulations also included PEO, ES-
100, and MgSt in quantities as determined previously. The combinations were subsequently
compressed into 13mmx5mm flat-surfaced tablets at a compression force of 5N. Tablets
from each formulation were maintained at a consistent weight whilst accounting for the
different crosslinking agents investigated as well as the change in ratios with the inclusion of
CHT in the granules.
3.2.5 The influence of various hydrophobic polymers and their method of
incorporation into the tablet for sustaining drug release
Following the identification of the most effective crosslinking agent for forming SA-CHT
granules, as well as the identification of an appropriate SA and CHT combinatory ratio,
studies were undertaken to elucidate the influence of the incorporation of three hydrophobic
polymers namely, EC, CAP and ES-100 for further sustaining drug release. The
incorporation of these polymers were essentially performed by either 1) dry blending of the
relevant polymer with the components of the DPH-loaded granules prior to granulation, or 2)
‘misting’ of the formed granules with a prescribed quantity of the relevant polymer solution, in
the appropriate concentration, or 3) by employing the relevant polymer solution as the
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solvent for WG. The method of incorporation of the hydrophobic polymers with the
appropriate polymer ratio is depicted in Table 3.4.
Table 3.4: Methods of incorporation of hydrophobic polymers with diphenhydramine HCl-
loaded granules
Form. Hydrophobicpolymer Method of Incorporation
1Ratio of
SA:CHT:ZnSO4
1 ES-100 2ES-100 latex employed as the solvent for
WG.
4:1:1
2 De-ionized water employed as the solvent for
WG. ES-100 latex was then ‘misted’ onto the
moist granules and allowed to dry at 40°C for
12 hours.
4:1:1
3 EC EC was dry-blended with SA, CHT and
ZnSO4 prior to granulation and de-ionized
water employed as the solvent.
4:1:1
4 2:2:1
5 Granules were prepared with de-ionized
water as a solvent. 3EC solution was misted
onto the moist granules and allowed to dry at
40°C for 12 hours.
2:2:1
6 1:1:1
7 3:2:1
8 CAP Granules were prepared with de-ionized
water as a solvent. 4CAP solution was
‘misted’ onto the moist granules and allowed
to dry at 40°C for 12 hours.
3:2:1
9 1:1:1
1Ratio of sodium alginate:chitosan:zinc sulphate (w/w/w)
2ES-100 latex was prepared by adding 6.63g of ES-100 powder to 36.7mL of de-ionized
water. The solution was stirred for 5 minutes with subsequent addition of 3.38g of a 1M
ammonia solution in a drop-wise fashion to the periphery of the vortex whilst being stirred.
This solution was agitated for a further 60 minutes at 25°C. The plasticizer, triethyl citrate
(3.32g), was then added to the solution in the same manner as the ammonia solution and
again allowed to stir for 60 minutes.
3EC solution was prepared by slowly dissolving 10g of EC in 100mL of acetone at 25°C to
result in a 10%w/v concentration.4A 10%w/v CAP solution was prepared by dissolving 10g of the polymer in small quantities in
100mL of acetone maintained at 25°C.
Granules consisting of SA, CHT, ZnSO4 and DPH were prepared as described previously in
section 3.2.4 and in accordance with the ratios depicted in Table 3.4. This briefly involved the
blending of the components in their relevant ratios with subsequent addition of the
appropriate solvent for wet mass formation. The wet mass was then passed through a 2mm
mesh sieve. If required, the relevant hydrophobic solution was ‘misted’ over the formed moist
granules which were then allowed to dry at 40°C for a further 12 hours in a convection oven.
The dried granules were then dispersed within matrices consisting of pectin and BaCl2 (2:1
w/w ratio), PEO, ES-100 and MgSt, which were then compressed into 13mmx5mm flat-
surfaced tablets at a compression force of 5N. Irrespective of the variations in the
combinations of SA, CHT and ZnSO4 the weight of the tablets were kept constant.
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3.2.6 Construction of calibration curves by spectroscopic determination of DPH in
simulated fluids
Calibration curves for DPH were conducted in both simulated gastric fluid (SGF) (pH 1.2;
37°C) and simulated intestinal fluid (SIF) (pH 6.8; 37°C) using a known series of
concentrations of DPH (0-0.7mg/mL) in both simulated fluids. Linear curves were plotted
such that the observed absorbances from spectroscopic analysis, analyzed at a wavelength
of 254nm were plotted on the y-axis and the concentrations (mg/mL) on the x-axis. With the
intercept set at 0, the R2 values were determined to be 0.996 in SGF and 0.997 in SIF.
3.2.7 In vitro release studies of preliminary formulations containing DPH
Characterisation of DPH release from the various investigated formulations was assessed
employing the USP 33 rotating paddle apparatus (Caleva Dissolution Apparatus, Model 7ST)
(Caleva Ltd., Sturminster Newton, Dorset, England). The parameters employed included
900mL of the relevant test media maintained at 37°C and a paddle speed of 50rpm. The test
media included either SGF (pH 1.2) or SIF (pH 6.8). The duration of dissolution studies
varied for each formulation and the relevant simulated medium employed. Formulations were
placed on a steel mesh assembly within each vessel to facilitate an even distribution of test
medium around the formulations. Sampling was performed by manually withdrawing 5mL
aliquots at the relevant time periods and sink conditions maintained by replacing the fluid
withdrawn with an equivalent quantity of the relevant drug-free simulated fluid. Samples were
subsequently analyzed by UV spectroscopy (Lambda 25, UV/VIS Spectrometer,
PerkinElmer®, Waltham, MA, USA) at a maximum excitation wavelength of 254nm. The
fractional drug release achieved at each time point was then quantified based on the
calibration curves constructed in the relevant simulated fluid.
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3.3 Results and Discussion
3.3.1 Calibration curves for the determination of DPH concentration in SGF and SIF
Figure 3.3 displays the calibration curves obtained for DPH in SGF (pH 1.2; 37°C) and SIF
(pH 6.8; 37°C) at a maximum excitation wavelength of 254nm.
Figure 3.3: Diphenhydramine HCl calibration curves in a) simulated gastric fluid (pH 1.2;
37°C) and b) simulated intestinal fluid (pH 6.8; 37°C).
3.3.2 Most appropriate grade of pectin for in situ crosslinking
ZnSO4 was initially employed as a ‘model’ crosslinking agent carrying divalent cations that
were capable of crosslinking the various amidated and non-amidated pectins. Release
studies conducted over a 24 hour period in SGF and SIF provided vastly different release
characteristics dependent on the type of pectin employed. The LM apple-derived non-
amidated pectin showed a reduced DPH release over the 24 hour period in both SGF and
SIF when incorporated with ZnSO4 (Figure 3.4a). However this effect was more pronounced
in SIF where the fractional release of DPH was only 0.616 (with ZnSO4) compared to 0.975
(without ZnSO4) after 24 hours.
However, the incorporation of ZnSO4 into tablets comprised of amidated citrus pectin (DA 11-
17%, DE 33-39%) resulted in an elevated rate of fractional drug release in both SIF and
SGF. A fractional release between 0.873-0.971 (with and without ZnSO4) was achieved in
both SGF and SIF after 24 hours (Figure 3.4b). In contrast, tablets prepared with amidated
pectin (DA 19-23%, DE 25-31%) showed an elevated rate of drug release in SGF when
ZnSO4 was included. However after 24 hours >0.931 fractional release was achieved from
both formulations in SGF. In SIF, a reduction in the release rate in the formulations
a) b)
y=1.304x
R2=0.996
y=1.335x
R2=0.997
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containing ZnSO4 is only evident after the first 3 hours of release studies where both
formulations exhibited a ±0.263 fractional release of DPH (Figure 3.4c).
Figure 3.4: Composite release profiles of diphenhydramine HCl release from in situ
crosslinked tablets of a) apple pectin (DE 38-44%), b) amidated citrus pectin (DE 33-39%,
DA 11-17%), and c) amidated citrus pectin (DE 25-31%, DA 19-23%) (N=3, SD<0.08 in all
cases).
Basically, the ultimate result of crosslinking is the gelation of pectin. Crosslinking however is
influenced by various intrinsic and extrinsic factors such as the degree of methoxylation,
charge distribution along the backbone chain, average molecular weight, ionic strength, pH,
temperature etc. (Axelos and Thibault, 1991; Clark and Farrer, 1996; Lootens et al., 2003).
Thus the release data acquired from the in situ crosslinked DPH-loaded tablets of various
grades of pectin can thus be explained based on the crosslinking ability founded on two key
principles namely, the influence of DA and DE, as well as the influence of solution pH on
crosslinking (pH of the simulated fluid).
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It is speculated that the amide groups present on the amidated pectin chain contributes to
the higher formation of intra- and inter-molecular hydrogen bonds. Therefore an increase in
the degree of amidation of pectin should theoretically result in an increase in the formation of
strong inter- and intra-molecular hydrogen bonds, resulting in a more hydrophobic character
and a consequently lower solubility (Tho et al., 2005). Conversely, an increase in the DE
results in an increase in the solubility of pectin. Even though crosslinking of pectin typically
occurs when completely dissolved in an aqueous solution forming entanglements that result
in a co-operative network at gel point, the situation for an in situ crosslinkable matrix should
be evaluated on a more macroscopic level. Basically, on exposure of the formulation to
simulated fluids, only the surface of the pectin particles are exposed and hydrated. Thus, the
surface molecules of this highly swellable polymer swells, allowing the introduction of cations
and the consequent crosslinking between the relevant pectin and cations on the surface of
the powder particles with entrapped drug, thereby prohibiting the total dissolution of the
particle and complete dissolution of the drug.
Since the apple pectin had a greater solubility in the simulated fluids and a greater degree of
swelling it resulted in improved crosslinking and retardation of drug release. The two
amidated pectins likely exhibited a lower solubility in the simulated fluids resulting in their
ineffectual crosslinking and accelerated drug release profiles. The ability of the amidated
pectin (DE 25-31%, DA 19-23%) to crosslink and thus retard drug release in SIF but not in
SGF can be explained by the reduced presence of H+ ions in SIF. Thus there is less
interaction of the carboxyl groups of pectin with free H+ facilitating the interaction of pectin
with the free Zn2+ cations from the incorporated ZnSO4.
3.3.3 Most effective crosslinking agent for facilitating the in situ crosslinking of the
apple pectin
Irrespective of the valence and type of salts incorporated, the method of WG was ineffective
in reducing the release rate of DPH as >80% of the drug was released within the first hour in
all cases (Figure 3.5a). Similarly, the DC method achieved >90% of DPH release in the first
hour from the formulations containing ZnSO4 and Al2(SO4)3. A more sustained rate of
fractional DPH release was achieved with the incorporation of BaCl2. In the latter case, only
0.868 fractional release of DPH was achieved in 3 hours, with 0.706 fractional release in the
first hour (Figure 3.5b). Apart from the initial ‘burst’ release of DPH within the first hour, the
incorporation of BaCl2 in the formulation proved to be the most promising for sustaining drug
release in SGF. In addition, based on previous studies it was established that the in situ
crosslinked apple pectin provided a reduction in the release rate in both SGF and SIF,
therefore the ability of BaCl2 to crosslink with pectin in situ in SGF may be extrapolated to its
ability to crosslink in SIF.
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Figure 3.5: Fractional drug release profiles of in situ crosslinked diphenhydramine HCl-
loaded tablets with either zinc sulphate, aluminium sulphate or barium chloride prepared by
a) wet granulation and b) direct compression (N=3, SD<0.05 in all cases).
Furthermore, the ratio of the crosslinking agent to pectin also contributes to the efficiency of
in situ crosslinking and ultimately on the ability to sustain drug release. This is evident from
the release profiles of the apple pectin in situ crosslinked with ZnSO4 in a 2:1 (w/w) ratio
(Figure 3.4a) compared to the same pectin grade crosslinked with ZnSO4 in a 1:1 (w/w) ratio
(Figure 3.5b). After 1 hour of dissolution studies in SGF a 0.923 fractional DPH release was
achieved from tablets in a 1:1 (w/w) ratio compared to only 0.111 fractional DPH release
from tablets in a 2:1 (w/w) ratio. Therefore an optimal ratio of the polymer to crosslinking
agent existed and once this optimum ratio was exceeded an accelerated rate of release was
achieved. Therefore, further studies evaluated the influence of varying ratios of pectin to
BaCl2 on the drug release characteristics, even though based on this study a 2:1 (w/w) ratio
exhibited the most promise.
3.3.4 Effect of incorporating a pH-sensitive synthetic polymer and a synthetic
hydrophilic polymer in the in situ crosslinked DPH-loaded tablet
Prior to the inclusion of the synthetic hydrophilic polymers, the two preparatory methods of
ES-100 incorporation exhibited vastly different release profiles. WG resulted in complete
DPH release being achieved in only 3 hours whereas in this same time only 0.340 fractional
release of DPH was achieved when prepared by DC (Figure 3.6a). ES-100 is a random
copolymer of methacrylic acid and methylmethacrylate with a distinctive property of being
resistant to dissolution in pH’s less than 7 (Arasaratnam et al., 2000). By implementation of
this polymer a drastic reduction in the release rate in SGF was expected. Even though a
sustained release of DPH over the 24 hour period was achieved, the initial ‘burst’ release in
the first 3 hours provided the basis for incorporation of a highly swellable hydrophilic polymer
a) b)
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that was capable of further reducing the premature release of DPH whilst maintaining the
sustained release character over the 24 hour period.
Figure 3.6: Release profiles of a) in situ crosslinked tablets with Eudragit® S-100 prepared
by wet granulation and direct compression and b) in situ crosslinked tablets with Eudragit®S-
100 prepared by direct compression with the incorporation of various hydrophilic polymers
(N=3, SD<0.086 in all cases).
Furthermore, even though the 11:1 (w/w) ratio of pectin to BaCl2 proved to be effective in
controlling drug release when in the presence of ES-100 it was uncertain whether this effect
was as a result of the ES-100 or the change in the pectin to BaCl2 ratio. Nevertheless, for the
quantitative and qualitative comparative analysis of the influence of the hydrophilic polymer
on release data a similar ratio (10:1 w/w) of pectin to BaCl2 was employed.
The grade of HPMC employed in the study was of a high viscosity, fast hydrating non-ionic
type typically employed for controlling the release of medium to high solubility drugs from
hydrophilic matrix systems. Nevertheless, in vitro release studies conducted over a 6 hour
period in SGF and SIF showed that HPMC provided no additional barrier to drug release in
SGF (Figure 3.6b) compared to when no HPMC was present (Figure 3.6a). This is obvious
based on the 0.338 fractional release from tablets with HPMC compared to a 0.340 fractional
release from tablets without HPMC after 3 hours. The influence of HPMC was only seen in
SIF where a 0.268 fractional release was achieved in this same time. Tablets that contained
HEC showed no significant difference in the rate of drug release in both SGF and SIF with a
fractional release of 0.529 and 0.533 respectively after 6 hours. The most attractive of the
hydrophilic polymers employed was PEO which exhibited a 0.297 and 0.261 fractional
release in SGF and SIF respectively after 3 hours (Figure 3.6b).
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3.3.5 Effect of crosslinked DPH-loaded SA granules and crosslinked DPH-loaded SA-
CHT granules on the drug release characteristics in SGF
Investigations into the most appropriate crosslinking agent for implementation in DPH-loaded
SA granules led to the identification of ZnSO4 as the most appropriate salt that effectively
reduced the fractional release of DPH in the first 2 hours of release studies. The initial ‘burst’
release of DPH during this period was limited to 0.111 fractional release compared to a
fractional release ranging from 0.152 to 0.268 with the other investigated salts.
Therefore, for the evaluation of SA-CHT DPH-loaded granules only ZnSO4 was employed
and since the mean gastric residence time of formulations typically range from 1 hour to a
maximum of 3 hours, in vitro release studies were conducted exclusively in SGF for a period
of only 2 hours (Cheng et al., 2004). Based on the release characteristics of the various
formulations (Figure 3.7) it is evident that incorporation of BaCl2 in the matrix as well as the
granules of the formulations provided the most accelerated fractional release compared to
when ZnSO4 was employed in the granules. The most effective reduction in the premature
release of DPH was achieved from granules composed of SA, CHT and ZnSO4 in a 4:1:1
(w/w/w) ratio, with only 0.106 fractional release in 2 hours compared to 0.158 fractional
release from the granules in a 3:1:1 (w/w/w) ratio in the same time.
Figure 3.7: Release profiles from a) diphenhydramine HCl-loaded sodium alginate, chitosan
and zinc sulphate granules dispersed within matrices of pectin, barium chloride, polyethylene
oxide and Eudragit®S-100 with inset b) indicating the identical release profile except with the
maximum fractional drug release scaled down (N=3, SD<0.045 in all cases).
a)
b) 0.25
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Furthermore, the potential formation of a polyelectrolyte complex (PEC) between the anionic
SA and cationic CHT may provide a further means of reducing premature drug release (Lee
et al., 1998). Even though this phenomenon typically only occurs in aqueous solutions, the
permeation of the acidic SGF medium into the tablet is theorized to cause solubilisation of
the CHT and SA facilitating this PEC formation. Thus, a 4:1:1 (w/w/w) ratio of SA:CHT:ZnSO4
is believed to strike an optimal balance between PEC formation and crosslinking of the
anionic sites on the SA molecule with ZnSO4.
3.3.6 Effect of the hydrophobic polymer and its method of incorporation on the ability
of the tablet to minimize premature drug release in SGF
Since the purpose of hydrophobic polymer incorporation was to prevent/inhibit the premature
release of DPH from the tablet in the upper GIT, data was collected based exclusively on the
in vitro release behaviour of the various formulations in SGF for a period of 2 hours. The data
obtained is shown in Table 3.5.
Table 3.5: Results acquired from in vitro drug release studies on the formulations
incorporating the various hydrophobic polymers
Polymer
1Ratio
(w/w/w) Method of Incorporation
2Fractional
Drug
Release
ES-100 4:1:1 ES-100 latex was employed as the solvent for facilitation of
wet mass formation prior to granulation.
0.088
4:1:1 De-ionized water was employed as the solvent for wet
granulation. ES-100 latex solution was then ‘misted’ onto the
moist granules and allowed to dry at 40°C for 12 hours.
0.061
EC
4:1:1 EC was dry-blended with SA, CHT and ZnSO4 prior togranulation and de-ionized water employed as the solvent.
0.212
3:2:1 0.141
2:2:1 Granules were prepared with de-ionized as a solvent. EC
solution was misted onto the moist granules and allowed to
dry at 40°C for 12 hours.
0.149
1:1:1 0.110
3:2:1 0.103
3:2:1 Granules were prepared with de-ionized as a solvent. CAP
solution was ‘misted’ onto the moist granules and allowed to
dry at 40°C for 12 hours.
0.157
CAP 1:1:1 0.243
1Ratio of SA:CHT:ZnSO4 (w/w/w)2 Fractional drug release of DPH achieved after 2 hours in SGF (N=3, SD<0.024 in all cases)
The most effective inhibition of premature DPH release in SGF was exhibited by the tablets
composed of crosslinked DPH-loaded granules which were subsequently ‘misted’ with the
ES-100 latex. These tablets achieved a fractional DPH release of only 0.061 in 2 hours.
Despite the efficacy of this formulation the method of preparation presented with numerous
manufacturing challenges that resulted in an erratic and irreproducible formulation, which
necessitated the identification of an alternative means of preventing premature drug release.
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Part II: Preliminary formulation development employing 5-ASA
3.4 Materials and Methods
3.4.1 Materials
Materials used were as described in section 3.2.1.
3.4.2 Formulation and evaluation of novel tablet coatings comprising various
polymeric combinations that prevent premature drug release in the upper GIT
Crosslinked drug-loaded granules were prepared by combining SA and CHT in a 4:1 (w/w)
ratio with 200mg of 5-ASA. These components were thoroughly blended in a mortar and
pestle. Instead of incorporating the crosslinking agent in a triturated, non-hydrated form, a
20%w/v aqueous solution of ZnSO4 was directly pipetted onto the dry blend to facilitate the
formation of a wet mass and an even distribution of the crosslinking agent. This coagulation
was subsequently manually granulated through a 2mm mesh sieve and the resultant
granules were allowed to dry at 30°C for 24 hours in a convection oven. An ES-100 latex
solution was subsequently ‘misted’ onto the dry granules and these were allowed to dry for a
further 6 hours. The final dehydrated granules were then dispersed within a matrix of pectin
and BaCl2 in a 2:1 (w/w) ratio, PEO, XG and MgSt, which was then compressed into
13mmx5mm flat-surfaced tablets. The total weight of granules per tablet was 700mg, with a
final tablet weight of 950mg. XG and PEO featured in equal quantities. The schematic
illustrated in Figure 3.8 indicates the 5 different coating combinations investigated, the
solution preparatory process, as well as the total weight gain (TWG) achieved after coating.
It must be noted that the contents of the tablets were consistent for all formulations and each
tablet was coated by a manual dip-coating process. The basic premise of the dip-coating
process essentially involved the dipping/submerging of the tablets in the coating solution,
immediate removal of the tablets from the solution and subsequent drying of the tablets
under a fume hood. The drying time was dependent on the concentration of the coating
solutions however the volatility of the solvent expedited this process substantially. The total
weight gain achieved post-coating was calculated based on Equation 3.1.
0011(%) 


  y
xTWG Equation 3.1
Where x is the weight of coated tablets and y the weight of uncoated tablets.
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Figure 3.8: Outline of the coating combinations evaluated.
3.4.3 Formulation and evaluation of crosslinked 5-ASA loaded CHT granules dispersed
within a polymeric matrix and dip-coated with a bi-layer of EC and CAP
In order to increase the susceptibility of the tablet formulation to colonic enzymes, specifically
to β-glucosidase, CHT drug-loaded crosslinked granules were formulated. This was
performed by thoroughly blending 5-ASA with CHT using a mortar and pestle. However, prior
to this process a 1M acetic acid solution was pipetted directly onto the CHT powder, in order
to acidify the CHT thus forming NH3+ sites available for crosslinking. A 10%w/v aqueous TPP
solution was pipetted onto the blend and a wet coagulation was formed. This was
subsequently passed through a 1mm mesh sieve and allowed to dry at 30°C for 24 hours in
a convection oven. The dried granules were then dispersed within a matrix consisting of
Coating
combinations
EC-Pectin
10%w/v EC solution inacetone
1g pectin added to EC
solution to result in a
4%w/v concentration ofpectin
Glycerine (4%v/v)added as plasticizer
EC-CHT
5%w/v solution of ECin acetone
1g CHT added to the
EC solution to result in
a 2%w/v concentrationof CHT
Glycerine (2%v/v)added as plasticizer
CAP
5%w/v solution of CAPin acetone
2%v/v glycerine addedas plasticizer
EC
5%w/v solution of EC inacetone
Glycerine (2%v/v)added as plasticizer
CAP
CHT
LAYER 1:
2%w/v solution of CHTin 1M acetic acid
0.5%v/v glycerineadded as plasticizer
LAYER 2:
5%w/v solution of CAPin acetone
Glycerine (2%v/v)added as plasticizer
TWG = 20.13%
TWG = 6.13%
TWG = 10.56%
TWG = 5.4%
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pectin and BaCl2 (2:1 w/w ratio), XG and PEO (in equal quantities) and MgSt all with a
combined weight of 600mg. The total tablet weight was 1200mg, with 200mg of 5-ASA per
tablet, and the granules employing 600mg of the tablet weight. The components
(matrix+granules) were subsequently compressed into shallow bi-concave tablets with a
diameter of 13mm and a thickness of 5mm using a mini rotary tablet press (Karnavati Mini
Press II, Rimek Products, Gujarat, India). The process of dip-coating was performed as
described in section 3.4.2 and the bi-layer coating consisted of an inner layer of 10%w/v EC
and an outer layer of 10%w/v CAP.
3.4.4 Formulation and evaluation of novel coating solutions of a combination of pectin
or CHT with an EC aqueous dispersion
Crosslinked 5-ASA loaded granules were fabricated as described in section 3.4.3. However
the dried granules were dispersed within a matrix of pectin and BaCl2 (2:1 w/w ratio), XG,
CMC and MgSt, so that the final tablet weight was 1200mg and contained 200mg of 5-ASA.
PEO was excluded from the formulation and the quantity made up with XG. The matrix and
granules were then compressed into shallow bi-concave tablets using the mini rotary tablet
press. An investigation was then undertaken to determine the capability of two separate
polymeric solutions namely 1) a pectin-EC aqueous dispersion and 2) a CHT-EC aqueous
dispersion to form an efficient tablet coating that ensured the prevention of premature drug
release in the upper GIT. These coatings were applied using a pan coater apparatus.
3.4.4.1 CHT-EC aqueous coating dispersion
Briefly, a 10%w/v solution of CHT was prepared in 1M acetic acid. The EC aqueous
dispersion was reconstituted by creating a dispersion of 60%w/w of the initial solution and
water (40%w/w). The water was added to the dispersion and mixed with a low shear mixer for
approximately 15 minutes and was maintained at 25°C. The CHT solution (100mL) was then
added to the dispersion and stirring was continued for a further 15 minutes to ensure a
uniform dispersion. Gentle agitation was continued throughout the coating process to prevent
sedimentation. Coating was performed according to the parameters in Table 3.6.
Table 3.6: Pan coater parameters for coating with various ethylcellulose combinations
Parameter Setting
Pump
Pump speed 3
Spray rate 1.5g/min
Coating parameters
Drum speed 4.5
Temp set point 45°C
Actual Bed temp 40°C
Atomizing pressure 250kPa
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3.4.4.2 Pectin-EC aqueous coating dispersion with an HPMC pre-coat
An Opadry® HPMC pre-coat was investigated as a means of preventing any possible
interactions between the EC aqueous dispersion and 5-ASA. The HPMC coating solution
was prepared by rapidly adding 125g (10%) of Opadry® to 1125g (90%) of de-ionized water.
The solution was stirred for 45 minutes prior to coating and agitation was maintained for the
duration of the coating process to prevent coagulation of the solution. Coating was
conducted in the pan coater apparatus where tablets were individually weighed prior to
heating and combined with 100g of placebo tablets as a means of bulking up the coating
batch. Opadry® was applied until a 1% TWG (based on Equation 3.1) was achieved. The
coating parameters are shown in Table 3.7.
Table 3.7: Pan coater parameters employed for the Opadry® pre-coat
Parameter Setting
Pump
Pump speed 5
Spray rate 2.8g/min
Coating parameters
Drum speed 6.5
Temp set point 45°C
Actual Bed temp 40°C
Atomizing pressure 250kPa
The pectin-EC aqueous coating dispersion was prepared by blending 500g of the initial EC
dispersion with 250g of a 2%w/v aqueous pectin (LM-105-AS) solution. 375g of de-ionized
water was added to this blend and stirred for 15 minutes prior to coating and was maintained
at 25°C for the duration of coating. After the achievement of the 1% TWG with the pre-coat,
the tablets were removed from the pan coater, re-weighed and subsequently replaced into
the pan. The pectin-EC aqueous coating dispersion was then applied for a period of 2 hours
based on the parameters in Table 3.6.
3.4.5 Development and optimization of the Wurster coating process parameters and
determination of the optimal TWG of the tablets
The Wurster coating process, also known as the Fluid Bed Dryer (FBD) coating process is
such that innumerable processing parameters such as the atomizing pressure, bed
temperature, pump speed, spray rate, spray pattern, distance between the orifice plate and
the partition, amongst others, have to be strategically optimized prior to an optimally coated
tablet being achieved. The basic design of the commercially available FBD is comprised
essentially of a slightly conical coating chamber (Wurster chamber) with a cylindrical partition
at the bottom which regulates the flow pattern of particles within this chamber.
Fundamentally, the optimization of the regions of flow within this chamber forms the
foundation for the effective and uniform coating of granules, pellets and tablets. The purpose
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of the air flow in the down bed region (region outside of the partition) is to maintain the
substrate in a near weightless suspension with the primary goal being to have the tablet
travel rapidly downward, and then be drawn horizontally toward, and ultimately into the gap
at the base of the partition and orifice plate (Jones, 2008). A simplistic illustration of the flow
pattern within the Wurster chamber is provided in Figure 3.9.
Figure 3.9: Illustration of the optimal flow pattern within the Wurster chamber.
The pectin-EC aqueous coating dispersion was prepared as described in section 3.4.4 and
the 5-ASA loaded enzyme-responsive tablets were fabricated as described in section 3.4.3.
Optimization of the coating process parameters based on this coating dispersion (excluding
the HPMC pre-coat) identified the following parameters: constant inlet temperature of 40°C, a
flow rate of 2.54mL/min for the first hour and 3mL/min for the subsequent 3 hours, constant
spray pressure of 0.1kPa and blower speed between 1700-2000 rpm.
The optimal TWG of the tablets was then determined based on the ability of the coating to
prevent/minimize premature release of 5-ASA in conditions simulating the upper GIT
(stomach and small intestine) whilst permitting an initiation of drug release on entry into the
colon. This process was conducted based on a trial and error basis where a minimum
(3.8%), maximum (22.9%) and a mid-point (8.4%) TWG was investigated.
3.4.6 Construction of calibration curves by spectroscopic determination of 5-ASA
Calibration curves were constructed in all the relevant dissolution media using initial stock
solutions of known concentrations of 5-ASA. Six-level dilutions were performed to result in
Compressor
Wurster chamber
Orifice plate
PartitionDown bed region
Optimal flow pattern
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various standard concentrations. Linear curves of the observed absorbances at the relevant
wavelengths from spectroscopic analysis were then plotted against the known concentrations
(mg/mL). All intercepts were set at 0 and the corresponding correlation coefficients were all
greater than 0.99. A detailed explication of the concentrations, simulated fluids, wavelengths
and corresponding R2 values are shown in Table 3.8.
Table 3.8: Method of preparation of the various simulated media as well as the
corresponding R2 values on construction of the corresponding calibration curves
Simulated
Fluid pH Method of preparation Wavelength
Standard
concentrations R
2
1Gastric fluid
(SGF) without
pepsin
1.2 2g sodium chloride (NaCl) was
dissolved in 1000mL de-ionized
water. 7mL of concentrated HCl
was then added to the solution to
result in a solution pH of 1.2.
301.5nm 0-0.0313mg/mL 0.999
1Gastric fluid
(SGF) with
pepsin
1.2 SGF was prepared as above with
the inclusion of 3.2g of pepsin (from
porcine gastric mucosa) to 1000mL
of the solution.
301.5nm 0-0.0417mg/mL 0.997
2Intestinal fluid
(SIF) without
pancreatin
6.8 A solution of sodium hydroxide was
prepared by dissolving 4g NaOH in
1000mL de-ionized water and a
separate potassium dihydrogen
phosphate solution was prepared
by dissolving 13.6g of the salt in de-
ionized water. The two solutions
were combined until a pH of 6.8
was obtained.
334.5nm 0-0.0313mg/mL 0.999
3Colonic fluid
(SCFa) without
enzymes
7.4 SCFa was prepared from identical
solutions as that of SIF however the
solution was made up to a pH of
7.4.
330nm 0-0.0313mg/mL 0.999
3Colonic fluid
(SCFa) with
pectinase and
β-glucosidase
7.4 SCFa was prepared as above with
the inclusion of 40mg of β-
glucosidase and 12mL of pectinase
per 1000mL of SCF.
330nm 0-0.0313mg/mL 0.999
4Colonic fluid
(SCFb) without
enzymes
5.9 SCFb consisted of an acetate buffer
prepared by dissolving 8.2g of
sodium acetate anhydrous in
1000mL de-ionized water. 280µL of
glacial acetic acid was then added
to result in a solution pH of 5.9.
331nm 0-0.055mg/mL 1.000
4Colonic fluid
(SCFb) with
pectinase and
β-glucosidase
5.9 SCFb was prepared as above with
the inclusion of 40mg of β-
glucosidase and 12mL of pectinase
per 1000mL of SCF.
331nm 0-0.04mg/mL 0.999
1 SGF with and without pepsin was prepared according to USP 33, NF 28 specifications.
2SIF without pancreatin was prepared according to USP 33, NF 28 specifications.
3 SCFa without enzymes was prepared according to USP 33, NF 28 specifications, and the
quantity of β-glucosidase in SCFa was prescribed by Nunthanid et al., 2008, and the quantity
of pectinase by Turkoglu and Ugurlu, 2002.
4 SCFb without enzymes was prepared based on a modified method described Klein et al.,
2008, and the quantity of β-glucosidase and pectinase was determined by Nunthanid et al.,
2008 and Turkoglu and Ugurlu, 2002 respectively.
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3.4.7 In vitro release studies of the preliminary formulations containing 5-ASA
In vitro release studies were performed using the reciprocating cylinder apparatus (Bio-Dis®
CALEVA RRT8, Caleva Ltd., Sturminster Newton, Dorset, England) which enabled a more
realistic approach to the environments and conditions that the delivery system may
encounter along the passage through the GIT. This apparatus employed a consistent test
medium volume of 220mL, maintained at 37±0.5°C, with mesh sizes of 420μm for both the
top and bottom of the glass cylinders and a dip rate of 10dpm in all experiments (Rohrs et al.,
1995). Formulations were subjected to SGF for a period of 2 hours, SIF for the subsequent 4
hours, and finally SCFa or SCFb for the final 18 hours. The preparatory process and pH of
the simulated fluids are explicated in Table 3.8. SCF with a pH of 7.4 and 5.9 were employed
since initially it was believed that the pH of the colon was slightly alkaline, with more recent
evidence suggesting that the colonic pH is actually acidic due to the production of fatty acids
in this region.
Sampling was conducted by manually withdrawing 5mL aliquots at the relevant time periods
and sink conditions maintained by replacing the fluid withdrawn with an equivalent quantity of
the relevant drug-free simulated fluid. Samples were subsequently analyzed by UV
spectroscopy and drug content quantified based on the relevant standard linear curves
analyzed at a λmax of 301.5nm for 5-ASA in SGF (R2=0.999), 334.5nm in SIF (R2=0.999) and
330nm in SCF (R2=1 no enzymes, and R2=0.999 with enzymes) (Nunthanid et al., 2008).
The fractional drug release achieved at each time point was then quantified based on the
calibration curves constructed in all the necessary simulated fluids.
3.5 Results and Discussion
3.5.1 Effect of various hydrophobic polymeric coatings and their combination with
pectin or CHT for inhibiting premature drug release
XG was included in formulations consisting of SA-CHT granules loaded with 5-ASA as a
means of enhancing enzymatic degradation by colonic enzymes. Since it was previously
established that the release characteristics of matrices with either XG or PEO were identical
half of the PEO quantity in the formulation was substituted with an equivalent quantity of XG.
Due to the low TWG of the EC coated formulations (TWG=5.4%) the fractional 5-ASA
release in the first 6 hours was between 0.434 and 0.481 (Figure 3.10a). This signified >40%
of the loaded 5-ASA being released in the upper GIT, resulting in less than 60% of drug
available for release in the colonic region. Nevertheless, the enzyme-responsiveness of the
system was evident from the slight elevation in the fractional release of 5-ASA when in the
presence of colonic enzymes. Formulations coated with CAP to a TWG of 10.56% showed a
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slight improvement in the minimization of drug release in the upper GIT. However, most
significantly was the clear evidence of enzyme-responsiveness as only 0.248 fractional
release was achieved in SCFa without enzymes after 24 hours compared to complete drug
release in the presence of enzymes after the same time (Figure 3.10b). Formulations coated
with pectin-EC showed minimal drug release over the 24 hour period in the presence and
absence of enzymes where only 0.143 fractional release of 5-ASA occurred in SCFa without
enzymes and 0.129 in SCFa with enzymes. This phenomenon was likely due to the ‘over-
coating’ of the formulations to a TWG of 20.13% which resulted in the inhibition of the
permeation of colonic media into the formulation thus preventing polymeric degradation by
colonic enzymes (Figure 3.10c). Formulations coated with a CHT-EC combination released
5-ASA immediately on initiation of drug release studies due to its TWG of only 6.13% thus
preventing the determination of its enzyme-responsiveness (Figure 3.10d).
Figure 3.10: Release profiles of formulations coated with a) ethylcellulose (N=3, SD<0.034),
b) cellulose acetate phthalate (N=3, SD<0.013), c) pectin-ethylcellulose (N=3, SD<0.005),
and d) chitosan-ethylcellulose (N=3, SD<0.046).
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Lastly, the bi-layer CHT-CAP coated formulations showed identical release profiles for the
first 12 hours of dissolution studies irrespective of the presence of enzymes however after
the 24 hour period a 0.902 fractional release was achieved in the presence of colonic
enzymes compared to only 0.245 in the absence of colonic enzymes. This can be explained
by the inhibition of entry of colonic media into the formulation by the outer CAP layer thus
preventing the action of β-glucosidase on the CHT layer for the first 6 hours in SCFa.
Eventually, when a sufficient volume of colonic media permeated through the outer CAP
layer, degradation of the CHT layer was initiated resulting in the elevated drug release after
the 6th hour in SCFa with enzymes. Despite the efficacy of this formulation as well as the
CAP coated formulation in both preventing premature drug release in the upper GIT as well
as showing responsiveness to colonic enzymes, these formulations could not be reproducibly
manufactured. This was attributable to the flat-surfaced nature of the tablets. The ‘sharp’
edges of the tablets were not coated to the same degree as the rest of the tablet, forming
several regions of the tablet that were unevenly coated resulting in irreproducible drug
release characteristics. Furthermore, the process of dip-coating augmented the
irreproducibility of the formulations.
3.5.2 Effect of crosslinked CHT drug-loaded granules in tablets coated with a bi-layer
of EC and CAP
As a means of increasing the responsiveness of the formulation to β-glucosidase present in
the colon, whilst minimizing the number of preparatory steps, SA was excluded from the
granules and CHT was crosslinked with TPP. Despite the irreproducible manufacturing
process of dip-coating flat-surfaced tablets, this process was nevertheless implemented on
the shallow bi-concave tablets which proved to be substantially more successful due to the
more rounded and less defined edges of the tablets. The improved enzyme-responsiveness
of the crosslinked CHT granules is evident when comparing the release profiles attained from
the tablets exposed to colonic enzymes to those that were unexposed. For the first 4.5 hours
the formulations exhibited an identical release profile with less than 1% of 5-ASA being
released. However from 4.5 to 11.5 hours only 0.085 fractional release of 5-ASA was
achieved in the absence of enzymes compared to 0.569 fractional release in the presence of
colonic enzymes (Figure 3.11).
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Figure 3.11: Release profiles of chitosan crosslinked granules compressed into bi-concave
tablets and coated with a bi-layer of ethylcellulose and cellulose acetate phthalate (N=3,
SD<0.104 in all cases).
Despite evidence of the enzyme-responsiveness of this formulation, the tablets behaved in
an erratic manner with the large standard deviations attributable to the irreproducible erosion
of the coating of the tablets due to the inconsistent coating procedure. In addition, even
though the ‘misting’ of the granules with ES-100 latex was excluded, a sustained release of
5-ASA was still achieved.
3.5.3 The effect of combination coatings consisting of pectin or CHT with an EC
aqueous coating dispersion on the drug release profiles of tablets
The solubility of CHT in exclusively dilute acidic solutions necessitated the need to dissolve
the CHT in a 1M acetic acid solution prior to its incorporation with the aqueous EC
dispersion. This was imperative since the EC dispersion was essentially composed of a
concentrated solution of ammonium hydroxide. Tablets undergoing coating with this solution
were periodically visually inspected to determine the quality and degree of coating achieved
after certain time points. During this time it was established that the coating was insufficiently
adhering to the surface of the tablets, irrespective of the duration of coating application as
depicted in Figure 3.12. This non-adherence is primarily attributed to the incompatibility
between the acidic CHT solution and the alkaline EC aqueous dispersion which results in an
unstable dispersion (Wei et al., 2009). However, other possible causes for the ineffective
adherence of the coating and the consequent ‘chipping’ of the tablets may be explained by a
possible interaction between 5-ASA in the tablet and the ammonium hydroxide, or even due
to the highly hydrophilic nature of the tablet core absorbing the coating solution.
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Figure 3.12: Digital images of a) chitosan-ethylcellulose coated formulations with the
chipped edges, and b) with capping.
Therefore, since the latter two possible reasons for the non-adherence of the coating could
not be ruled out subsequent studies substituted the CHT solution for an aqueous pectin
solution however a pre-coat of a hydrophilic polymeric solution (Opadry®) was applied to
avoid the possible interaction between 5-ASA and the ammonium hydroxide. After achieving
a 1% TWG with the pre-coat of Opadry® it was established that this coating layer effectively
adhered to the surface of the tablets however the edges of the tablets showed evidence of
chipping. Nevertheless, the pectin-EC coating solution was subsequently applied to the
tablets based on identical parameters as that of the CHT-EC coating process. After 3 hours
of coating, the tablets were visually inspected and showed evidence of not only coating over
the pre-coat but also on the previously chipped tablet edges (Figure 3.13). The ability of this
solution to effectively coat the ‘naked’ edges of the tablet led to the conclusion that an
incompatibility between CHT and the EC aqueous dispersion definitely existed. Furthermore,
the chipping of the tablets occurred as a result of the high friability of the tablets, which could
be overcome by introducing a binder into the formulation.
Figure 3.13: Digital image of pectin-ethylcellulose coated formulations with chipped edges.
a) b)
75
3.5.4 Optimization of FBD coating process parameters and determination of an optimal
TWG
Subsequent to the identification of the optimized coating process parameters the optimal
TWG of the tablets was evaluated at 3 levels namely, a minimum, maximum and mid-point
TWG. The optimal TWG was then identified based on the achievement of the ideal in vitro
release characteristics when performed in the Bio-Dis® release rate tester and subjected to
SGF for 2 hours, SIF for 3 hours and SCFb (pH 5.9) with and without commercial colonic
enzymes for a further 19 hours. The tablets were coated to weight gains of 3.8%, 8.4% and
22.9% which employed coating durations of 1 hour, 3 hours and 5 hours respectively.
Essentially, the maximum TWG of 22.9% revealed no drug release in the entire 24 hour
period. These tablets remained physically intact and showed no evidence of coating erosion.
The minimum TWG of 3.8% revealed a maximum fractional release of 0.116 in conditions
simulating the upper GIT  (Figure 3.14a) and tablets coated to a weight gain of 8.4%
revealed a maximum fractional release of 0.038 in identical conditions (Figure 3.14b).
Furthermore, along with the reduction in the premature 5-ASA release in the first 6 hours, the
tablets coated to 8.4% TWG still ensured enzyme-responsiveness of the delivery system in
simulated colonic conditions. Based on these results, an optimal TWG was identified to be
slightly greater (10%) than the evaluated 8.4% to ensure no drug release in SGF and SIF
whilst enabling an initiation of drug release on entry to simulated colonic conditions.
Figure 3.14: Drug release profiles of identical tablets coated to weight gains of a) 3.8%
(N=3, SD<0.052 in all cases) and b) 8.4% (N=3, SD<0.016 in all cases).
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3.6 Concluding Remarks
Part I of preliminary formulation studies was performed with the incorporation of a highly
soluble drug namely, DPH. The results obtained from these preliminary studies identified
numerous crucial formulation constituents which included:
 the efficacy of apple pectin for in situ crosslinking;
 identification of BaCl2 as the most appropriate crosslinking agent for this purpose; and
 determination of the optimal ratio of the pectin and BaCl2 to be 2:1 (w/w).
Furthermore, these studies also identified numerous formulation preparatory processes and
polymers that were ineffective in achieving the desired formulation characteristics by a
process of elimination. As a consequence, subsequent pre-formulation studies (Part II)
employed these previously identified formulation variables with the incorporation of 5-ASA.
The hydrophilic polysaccharide polymers such as XG and CMC proved to be beneficial in
improving not only the responsiveness of the formulations to colonic enzymes but also in
providing a sustained release of 5-ASA in simulated colonic conditions. Furthermore, based
on the constraining influences of a successful colon-targeted drug delivery system the
prerequisite of the tablet was to achieve a minimization of 5-ASA release in the stomach and
small intestine. Of the numerous investigated approaches for achieving this aim, the
combinatory coating solution of pectin and EC aqueous dispersion proved to be the most
promising. The optimum TWG of this coating solution was also determined to be 10%. Thus
preliminary formulation development enabled the identification of a candidate system that
could be further optimized to achieve the ideal enzyme-responsive colon-targeted drug
release characteristics.
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CHAPTER 4
PRELIMINARY DESIGN OF THE OUTER PEPSIN-RESPONSIVE POLYMERIC
COATING COMPONENT OF THE STIMULI-RESPONSIVE ORAL TABLET SYSTEM
4.1 Introduction
Characteristically, chronic diarrhoea is reported in 66-92% of IBD sufferers, the severity of
which is dependent on the degree of intestinal inflammation (Ciancio and Chang, 1992).
Diarrhoea is essentially defined as an intestinal disorder that is characterised by an abnormal
or increased frequency (>3/day) and liquidity of faecal evacuations (Talley et al., 1991; Talley
et al., 1994; Wenzl et al., 1995; Fine and Schiller, 1999; Shah et al., 2001; Farthing, 2007).
However there is still no consensus as to the definition of chronic diarrhoea, even though it
has been suggested that the definition encompass a period long enough to allow most cases
of acute diarrhoea, mostly attributed to a self-limited infection, to run its course. Generally for
clinical purposes diarrhoea occurring for a period of 4 weeks can be considered as chronic
(mostly due to non-infectious etiologies), with a duration of 6-8 weeks providing a greater
distinction (Stanton and Clemens, 1989; Fine and Schiller, 1999).
In developed countries chronic diarrhoea has been attributed to conditions such as Irritable
Bowel Syndrome (IBS), IBD, malabsorption syndrome, chronic infections and idiopathic
secretory diarrhoea (Read et al., 1980; Bayless, 1989; Bytzer et al., 1990; Bertomeu et al.,
1991; Afzalpurkar et al., 1992; Schiller et al., 1994; Ravikumara, 2008) whereas in lesser
developed countries chronic bacterial, mycobacterial and parasitic infections are the
predominant causes of chronic diarrhoea. However, chronic diarrhoea derived from
functional disorders, IBD and malabsorption are also common in these countries (Tandon et
al., 1966; Awori et al., 1972; Ahmed et al., 1976; Chatterjee, 1977; Kotwal et al., 1978;
Manatsathit et al., 1985; Kent and Banks, 2010).
Essentially, the 4D approach to drug delivery system development is founded on the notion
that in order to develop an effective drug delivery system, the drug, disease, destination and
route of delivery must be taken into consideration as an entirety, and not each factor
exclusively (Pillai et al., 2001). Basically, this leads to the general tenet that a drug delivery
system may be chosen for a specific drug, but a drug may not be chosen for a drug delivery
system. As described in Chapter 1, section 1.7, the aim of the study was to formulate a
single-unit orally administered tablet that facilitated the targeted delivery of 2 drugs to
different regions of the gastrointestinal tract (GIT). Furthermore, the structure of the tablet
should essentially comprise of a compressed tablet containing one of the drugs, and an outer
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coating that surrounds the tablet and which contains the second drug. For the simultaneous
symptomatic and remission-inducing treatment of Ulcerative Colitis (UC), it was established
that 5-aminosalicylic acid (5-ASA) be preferentially targeted to the colon in response to the
unique enzyme and bacterial population of the region. In addition, loperamide HCl should be
targeted to the stomach and release thereof initiated and controlled in response to pepsin
found exclusively in the region. Targeting of the stomach was based on the incorrect notion
that the site of the therapeutic effect of loperamide HCl existed in the stomach. Nevertheless,
the site-specific delivery of numerous drugs to the stomach could be beneficial for example,
in the treatment of gastric ulcers using antibiotic and/or acid-suppressing agents, or further
yet for drugs with narrow absorption windows.
Therefore, initial preliminary formulation development attempted to establish a suitable
pepsin-responsive outer formulation that targeted and controlled the release of loperamide
HCl in the stomach. However, it was subsequently established that loperamide HCl showed
a high affinity for the opioid receptors (µ, δ, κ) present in the myenteric plexus and
submucosal plexus of the small and large intestine (Bueno, 2005). Furthermore, it is poorly
absorbed from the GIT and does not exert any systemic opioid agonist influences. Thus its
the therapeutic action is dependent on the site and rate of drug delivery (Heykents et al.,
1974; Wuster and Herz, 1978; Niemegeers et al., 1979; Van Nueten et al., 1979; Reynolds et
al., 1984). Ideally, loperamide HCl should be targeted to the small intestine and release
thereof sustained throughout this region.
Pre-formulation studies on the outer pepsin-responsive shell was thus conducted based on
the two methods of exploiting pepsin present in the stomach namely, by being positively
responsive to pepsin and increasing drug release in its presence (Figure 4.1a) or by being
negatively responsive where drug release is inhibited in its presence (Figure 4.1b). The
subsequent identification of the candidate system/s was then performed through the
coherent comparison of dissolution data through each step of preliminary formulation design.
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Figure 4.1: The differing 4D approaches applied in the pre-formulation of the outer pepsin-
responsive shell with a) depicting the approach employed using a model drug showing
positive pepsin-responsiveness, and b) depicting the approach using loperamide HCl for
small intestinal drug delivery by being negatively responsive to pepsin.
Part I: Preliminary formulation development of positive pepsin-responsive shells
4.2 Materials and Methods
4.2.1 Materials
Chitosan (CHT) (food grade) was purchased from Wellable Group Marine Biological &
Chemical Co. (Shishi City, Fujian, China) and chitosan (medium molecular weight) was
purchased from Sigma-Aldrich (St. Louis, MO, USA). The model drugs, diphenhydramine
HCl (DPH, Mw=291.82g/mol, solubility=100mg/mL at 25°C in water) and theophylline (THP,
Mw=108.16g/mol, solubility=5.5-8mg/mL at 25°C in water) were obtained from Sigma-Aldrich
(St.Louis, MO, USA) and Fluka, Biochemika (Buchs, AG, Switzerland) respectively. Tri-
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sodium citrate dihydrate (Na3C6H5O7.2H2O) was purchased from Saarchem-Merck
(Wadeville, Gauteng, South Africa) and sodium bicarbonate (NaHCO3) from Rochelle
Chemicals (Johannesburg, Gauteng, South Africa). Gelatine (gel strength: 160 bloom) and
glutaraldehyde (GA) (50% solution in water) were purchased from Sigma-Aldrich (Munich,
Bavaria, Germany), and lactose was supplied by Saarchem-Merck (UniLAB®, Wadeville,
Gauteng, South Africa). De-ionized was obtained from a Milli-Q water purification system
(Milli-Q, Millipore, Billerica, MA, USA) and all other reagents were of analytical grade and
used without further purification.
4.2.2 Formulation of pepsin-responsive crosslinked and non-crosslinked CHT shells
The chitosanolytic activity of pepsin had been previously established (Yalpani and
Pantaleone, 1994) however more recently a study conducted on the degradation
characteristics of CHT by pepsin revealed that initially this degradation reaction occurs
considerably fast then gradually slows down. Furthermore, maximal chitosanolytic activity
occurs when the pH of pepsin is maintained between pH 4-5 and the temperature is elevated
to 55°C (Tao et al., 2005). Since the pH of the stomach is between pH 1-3 and thus the pH of
simulated gastric fluid (SGF) cannot be altered, an attempt was made to alter the micro-
environmental pH of the CHT shells to a pH of 5.5 with the addition of NaHCO3. Essentially,
the CHT shell structure was formulated according to a casting and solvent evaporation
technique and the resultant shells were incorporated with the inner colon-targeted tablet as
depicted in Figure 4.2.
Figure 4.2: Schematic illustration of the incorporation of the outer shell with the inner colon-
targeted tablet of the stimuli-responsive oral tablet system.
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The rationale for the fabrication of a shell (from 2 half shells) surrounding the inner tablet was
dependent on the intended site of targeting of the drug within the GIT. Essentially, this was
based on the following observation: once the shells were hydrated by the gastric medium
(SGF), they swelled and detached from the inner colon-targeted tablet, these shells then
remained buoyant on the gastric contents and therefore would be retained in the stomach for
a longer period of time. Consequently, the increased gastric retention time of the shells
would allow for a sustained release of the entrapped drug in the stomach over a longer
period of time and thus an improved formulation efficacy.
These shells were fabricated by preparing a 0.1g/mL CHT solution in 1M acetic acid. The
model drug DPH was then added to this solution (0.02g/mL) and agitation was permitted for
20 minutes to ensure a homogenous distribution of the drug. Subsequently, glycerol serving
as a plasticizer was added to the solution in a 2:1 w/w ratio to CHT and again allowed to stir
for a further 20 minutes. A sufficient quantity of NaHCO3was gradually added to this solution
until a solution pH of 5.5 was achieved. 1mL aliquots of this solution were then pipetted into
pre-lubricated cylindrical polystyrene moulds with individual wells with inner diameters of
13.5mm. The moulds were then placed to dry in a convection oven (Memmert, Schwabach,
Germany) maintained at 40°C for 24 hours. After 24 hours in the oven, the moist shells were
gently removed from each well. Essentially, each well contained one half of the shell
(13.5mm diameter and 2.5mm height) to be incorporated with the tablet. The moulds were
such that it allowed the CHT solution to adhere to the edges of each well resulting in the shell
structure (hollow inside) (Figure 4.2).
Crosslinking of the shells was performed by submerging the shells in a 10%w/v aqueous
BaCl2 solution maintained at 25°C for 1 hour. The shells were then removed from the
crosslinking solution, dried under a fume-hood for 24 hours and subsequently washed with
de-ionized water to remove excess surface salt. These shells were subsequently allowed to
dry for an additional 6 hours. The drying time of 6 hours facilitated the formation of slightly
hydrated and enlarged shells that were capable of encapsulating the flat-surfaced placebo
tablets (13mmx5mm). Subsequent to the incorporation of the shells with the inner tablets, the
formulations were allowed to dry under a fume-hood for a further 18 hours. This drying time
enabled the sufficient drying of the shells as well as effective encapsulation and adherence
of the shells to the inner tablet. The non-crosslinked shells were incorporated with the tablets
in the same manner (excluding the crosslinking procedure only). The pepsin-responsiveness
of these formulations was then assessed according to in vitro drug release specifications as
described in section 4.2.8.
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4.2.3 Formulation and evaluation of the pH-responsiveness of crosslinked CHT shells
As previously described, the concept of positive pepsin-responsiveness essentially means
that there is an acceleration of drug release in the presence of the enzyme. Thus, by
ensuring concurrent pH-responsiveness to the acidic environment of the stomach there will
effectively be a greater acceleration in the rate of drug release. Therefore, a study was
conducted to determine the pH-responsiveness of the crosslinked CHT shells to simulated
gastric fluid (SGF) (pH 1.2; 37°C) and simulated intestinal fluid (SIF) (pH 6.8; 37°C). CHT
shells were prepared identical to the procedure described in section 4.2.2 with the exclusion
of NaHCO3 from the CHT solution. Crosslinking of these shells was then conducted by
submerging each shell in a 10%w/v aqueous solution of tri-sodium citrate for 1 hour at 25°C.
Thereafter the shells were removed from the crosslinking solution and underwent an identical
washing procedure as well as an identical procedure for incorporation with the flat-surfaced
placebo tablets as described previously. These formulations were then evaluated in SGF and
SIF based on the conditions described in section 4.2.8.
4.2.4 Formulation and evaluation of a combination of chitosan and gelatine
crosslinked and non-crosslinked shells
In an attempt to ascertain the applicability of the protein polymer, gelatine, in a pepsin-
responsive formulation, two formulations of different concentrations of gelatine with the
incorporation of either DPH or THP were prepared. Combinations of chitosan or CHT and
gelatine in various concentrations and ratios were also formulated. DPH (high water
solubility) and THP (low water solubility) were incorporated in the formulations as model
drugs to determine the influence of the solubility of the drug on the release characteristics of
the formulation. The formulations were prepared according to Table 4.1.
Table 4.1: Experimental formulations investigated for potential responsiveness to pepsin
Form. Chitosan Gelatine 1Ratio Drug Crosslinked
Grade 2Conc. 2Conc.
1 - - 21% - DPH No
2 - - 15% - THP No
3 Food grade (CHT) 20% 21% 76:20 DPH No
4 Medium Mw 3% 15% 50:50 THP Yes
1 Ratio of chitosan or CHT to gelatine (v/v)
2 Concentration (w/v)
Each formulation was prepared according to the casting and solvent evaporation technique
described previously. However, prior to the casting procedure, the relevant chitosan solutions
were prepared in a 1M acetic acid solution and the relevant gelatine concentrations were
prepared in de-ionized water maintained at 35°C. All solutions were agitated until the
relevant polymers were observed to be completely dissolved. The polymer solutions were
then blended, if required, in the ratios as depicted in Table 4.1 and the relevant drug was
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subsequently incorporated and the solution agitated for 30 minutes to ensure an even
distribution. The subsequent casting and solvent evaporation process, as well as the
incorporation of the shells with the placebo tablets was performed as in section 4.2.2.
Crosslinking of experimental formulation 4 was performed by submerging the resultant
dehydrated shells in an aqueous solution of GA (5.263%v/v) maintained at 25°C for a period
of 10 minutes. The shells were subsequently washed with de-ionized water and allowed to
dry encapsulated over the flat-surfaced placebo tablets over 24 hours under a fume hood.
The formulations were then evaluated for responsiveness to pepsin according to conditions
described in section 4.2.8.
4.2.5 Construction of calibration curves by spectroscopic determination of DPH
The calibration curves for DPH in SGF (pH 1.2; 37°C) without pepsin as well as in SIF (pH
6.8; 37°C) were constructed as described in Chapter 3, section 3.2.6. However the
calibration curve for DPH in SGF (pH 1.2; 37°C) with pepsin (3.2g pepsin per 1000mL SGF)
(R2=0.969) was constructed using serial dilutions of DPH in concentrations of 0-1mg/mL
which were analyzed at a maximum excitation wavelength of 254nm. The linear curve was
then plotted such that the observed absorbances from spectroscopic analysis were shown on
the y-axis and the concentrations (mg/mL) on the x-axis.
4.2.6 Construction of calibration curves by spectroscopic determination of THP in SGF
Calibration curves for THP were conducted in SGF (pH 1.2; 37°C) with pepsin (3.2g pepsin
per 1000mL SGF) (R2=0.987) and without (R2=0.996) using a known series of concentrations
of THP (0-0.016mg/mL) analyzed at a maximum excitation wavelength of 280nm. Linear
curves were plotted such that the observed absorbances from spectroscopic analysis were
shown on the y-axis and the concentrations (mg/mL) on the x-axis.
4.2.7 Determination of the quantity of DPH or THP present in each shell
With the aim of ascertaining the quantity of DPH or THP entrapped within each shell,
individual shells were dissolved in 100mL of SGF. After complete dissolution, the solutions
were filtered through a hydrophilic 0.45µm Millipore membrane filter (Millipore® Millex-HV)
(Millipore Corporation, Billerica, MA, USA) and analyzed spectroscopically (Lambda 25,
UV/VIS Spectrometer, PerkinElmer®, Waltham, MA, USA) at the relevant wavelength. The
absorbances attained were then fitted into the relevant calibration curve.
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4.2.8 Assessment of the pH- and/or pepsin-responsiveness of the investigated
experimental formulations by in vitro drug release studies
Characterisation of DPH and THP release from the various investigated formulations was
assessed employing the USP 33 rotating paddle apparatus (Caleva Dissolution Apparatus,
Model 7ST) (Caleva Ltd., Sturminster Newton, Dorset, England). The dissolution parameters
and sampling procedure were delineated in Chapter 3, section 3.2.7 and the test media
consisted of either SGF with and without pepsin and/or SIF. Sample analysis and
quantification of drug release at each time point was also performed as described in section
3.2.7.
4.3 Results and Discussion
4.3.1 Evaluation of the pepsin-responsiveness of crosslinked and non-crosslinked
DPH-loaded CHT shells
In vitro drug release studies conducted on the non-crosslinked shells revealed that in the
presence of pepsin complete drug release was achieved in the first 30 minutes, however in
the absence of pepsin only 0.851 fractional DPH release was achieved in this same time.
Complete drug release was only achieved after 1.5 hours in the absence of pepsin (Figure
4.3). Furthermore, the degradation of CHT by pepsin is immediate and rapid with 0.937
fractional release of DPH in the first 15 minutes of release studies compared to 0.590
fractional DPH release in the absence of pepsin.
Figure 4.3: Fractional release profiles diphenhydramine HCl from non-crosslinked chitosan
(food grade) shells in simulated gastric fluid with and without pepsin (N=3, SD<0.043 in all
cases).
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In an attempt to sustain the release of DPH over the entire 2 hour period in SGF, the CHT
shells were crosslinked with BaCl2. However Figure 4.4 depicts the identical release profiles
of the crosslinked shells both in the presence and absence of pepsin. These profiles serve as
proof of the inefficacy of crosslinking CHT with BaCl2 for ensuring sustained drug release. On
the contrary the crosslinked shells became non-responsive to pepsin as is evidenced from
the identical release profiles in SGF with and without pepsin.
Figure 4.4: Fractional drug release profiles of diphenhydramine HCl from crosslinked
chitosan (food grade) shells in simulated gastric fluid with and without pepsin (N=3,
SD<0.004 in all cases).
4.3.2 Effect of the pH of simulated media on the drug release characteristics of the
crosslinked CHT shells
The previous study established the inefficacy of BaCl2 in crosslinking the CHT shells, thus tri-
sodium citrate was evaluated instead. Figure 4.5 provides evidence of the improved efficacy
of this crosslinking agent since 0.974 fractional release of DPH was achieved from these
shells after 2 hours in SGF compared to 0.997 fractional DPH release from the BaCl2
crosslinked shells in only 15 minutes (no pepsin) (Figure 4.4). Furthermore, the shells
crosslinked with tri-sodium citrate were also found to possess pH-responsive characteristics
since after 4 hours in SIF only 0.535 fractional DPH release was achieved compared to
0.974 fractional release in SGF after only 2 hours.
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Figure 4.5: Fractional release profile of diphenhydramine HCl from crosslinked shells in
simulated gastric fluid (N=3, SD<0.052 in all cases) and simulated intestinal fluid (N=3,
SD<0.078 in all cases).
It is known that the charge densities of citrate and CHT are controlled by the pH of the
solutions. Essentially, at neutral and weakly acidic conditions there is a decrease in the
degree of ionization of citrate and a decrease in the number of ionized carboxyl groups. At
pH>6 there is a reduction in the ionization of the amine groups of CHT. Therefore the pH-
responsiveness of these shells can be attributed to the ability of the shells to swell in weakly
acidic conditions, resulting in an increased permeation of dissolution media into the shells
and thus an increased rate of DPH release. This phenomenon is however not evident in SIF.
4.3.3 Effect of chitosan (medium Mw/food grade) and gelatine on the responsiveness
of the crosslinked and non-crosslinked shells to pepsin
Release studies of the non-crosslinked CHT (food grade)-gelatine shells containing DPH
showed that in the absence of pepsin complete drug release was achieved in 45 minutes,
whereas in the presence of pepsin complete drug release was achieved in 1 hour. Despite
the reduced drug release rate over 1 hour in the presence of pepsin there was a sharp spike
in the fractional DPH released in the first 30 minutes (Figure 4.6).
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Figure 4.6: Release profiles of chitosan (food grade)-gelatine shells containing
diphenhydramine HCl in simulated gastric fluid with and without pepsin (N=3, SD<0.034 in all
cases).
However, to more conclusively determine the influence of gelatine in the shells, non-
crosslinked DPH-loaded gelatine shells excluding CHT were also formulated and evaluated.
The release profiles indicated a distinct decrease in the rate of DPH release when in the
presence of pepsin with 0.200 fractional DPH release in 15 minutes compared to 0.470
fractional release in the absence of pepsin (Figure 4.7). Therefore, the spike in DPH release
from the CHT-gelatine shells can be attributed to the chitosanolytic action of pepsin on CHT
whilst the reduced overall rate in drug release in the presence of pepsin can be attributed to
the conflicting action of pepsin on gelatine.
Figure 4.7: Release profiles of gelatine shells containing diphenhydramine HCl in simulated
gastric fluid with and without pepsin (N=3, SD<0.016 in all cases).
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4.3.4 The effect of drug solubility on the pepsin-responsiveness of the shells
In the presence of pepsin, only 0.455 fractional release of THP was achieved in 1 hour
compared to 0.804 in the absence of enzymes (Figure 4.8a). Furthermore, the chitosan
(medium Mw)-gelatine shells containing THP were crosslinked for a short period to enable
further sustaining of drug release both in the presence and absence of pepsin.
Consequently, in the presence of pepsin these crosslinked shells exhibited 0.362 fractional
THP release after 1 hour compared to 0.605 fractional THP release from the non-crosslinked
shells (Figure 4.8b). The influence of the grade and concentration of chitosan employed on
the release characteristics was not determined.
Figure 4.8: Drug release profiles of a) gelatine shells containing theophylline and b)
chitosan-gelatine crosslinked shells containing theophylline in simulated gastric fluid with and
without pepsin (N=3, SD<0.023 in all cases).
Part II: Preliminary formulation development of the negatively pepsin-responsive outer
coating
Previously conducted studies based on approach 1 identified the attractive property of
gelatine being negatively responsive to pepsin. This characteristic behaviour promoted the
use of gelatine for achieving targeted small intestinal drug delivery by the inhibition of drug
release in gastric contents containing pepsin whilst ensuring drug release in simulated small
intestinal conditions. The fundamental drawback of the preparation of shells by casting
polymer solutions in polystyrene moulds resulted in inconsistent shells due to the formation
of bubbles in the polymer solutions after casting. Thus a more appropriate approach to
forming these shells was investigated. Essentially, numerous investigations established that
directly dip-coating the inner tablets with the gelatine solutions provided a more reproducible
as well as aesthetically attractive formulation. Moreover this manufacturing process
significantly reduced the formulation preparatory steps.
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4.4 Materials and Methods
4.4.1 Materials
Gelatine, glutaraldehyde (GA), and de-ionized water were obtained as described in section
4.2.1. The additional chemicals employed included loperamide HCl (Mw=513.50g/mol)
purchased from Sigma-Aldrich (St. Louis, MO, USA) and lactose supplied by Saarchem-
Merck (UniLAB®, Wadeville, Gauteng, South Africa).
4.4.2 Formulation and evaluation of crosslinked pepsin-responsive loperamide HCl-
loaded gelatine coatings for targeted small intestinal delivery
Loperamide HCl-loaded gelatine solutions were prepared by initially dissolving the water-
insoluble drug, loperamide HCl (25mg), in 3mL of ethanol. Thereafter, 50mL of de-ionized
water was added to the ethanol-drug solution and stirred for 30 seconds at room
temperature. The relevant quantity of gelatine, to produce a 20%w/v and 30%w/v gelatine
solution, was then gradually added to the solution and allowed to stir at 35°C for 3 hours
(until a clear amber-coloured solution was attained). Shallow bi-concave placebo tablets
consisting of lactose were compressed using the mini rotary tablet press (Karnavati Mini
Press II, Rimek Products, Gujarat, India) and subsequently dip-coated with the gelatine
solutions maintained at 35°C. The tablets were placed on a petri dish and allowed to dry
under a fume hood. The drying time varied depending on the gelatine concentration
employed. Each tablet was dip-coated thrice with the relevant gelatine solution.
Crosslinking of the dried tablet coating was performed in a GA-lactose mixture consisting of
20g of lactose and 5mL of GA. The 20%w/v tablet shells were enveloped within this dry
mixture maintained at 35°C for 15 hours, and the 30%w/v tablet shells for 2, 4 and 6 hours.
4.4.3 Construction of calibration curves by spectroscopic determination of loperamide
HCl in SGF
Calibration curves for loperamide HCl were conducted in SGF (pH 1.2; 37°C) with (3.2g
pepsin per 1000mL SGF) and without pepsin using a known series of concentrations of
loperamide HCl (0-0.008mg/mL) in both simulated fluids. Linear curves were plotted such
that the observed absorbances from spectroscopic analysis were plotted on the y-axis and
the concentrations (mg/mL) on the x-axis. The regression coefficients for the calibration
curves were 0.982 in the presence of pepsin and 0.996 in the absence of pepsin.
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4.4.4 Determination of the quantity of drug within each non-crosslinked gelatine
coating
With the aim of ascertaining the quantity of loperamide HCl entrapped within each gelatine
coating, the non-crosslinked 20%w/v and 30%w/v shells were dissolved in 100mL of SGF.
After complete dissolution the solutions were filtered through a hydrophilic 0.45µm Millipore
membrane filter and analyzed spectroscopically at a maximum excitation wavelength of
260nm. The absorbances attained were then fitted into the constructed calibration curve.
4.4.5 Assessment of the pepsin-responsiveness of the crosslinked gelatine shells
In vitro release studies were performed using the reciprocating cylinder apparatus (Bio-Dis®
CALEVA RRT8, Caleva Ltd., Sturminster Newton, Dorset, England) and according to
parameters specified in Chapter 3, section 3.4.7. However, the experimental formulations
were only subjected to SGF with and without pepsin for a period of 2 hours. Sample
withdrawal, UV analysis at a wavelength of 260nm and drug release quantification was
performed as described in section 3.4.7.
4.5 Results and Discussion
4.5.1 The effect of gelatine concentration and duration of crosslinking on the pepsin-
responsiveness of the outer coating
In vitro release studies of the crosslinked tablet coatings consisting of 20%w/v gelatine
showed complete drug release within 30 minutes in the absence of pepsin however at this
same time in the presence of pepsin only 0.207 fractional release of loperamide HCl was
achieved. After the 2 hours in SGF containing pepsin only 0.346 fractional release of
loperamide HCl was attained (Figure 4.9).
Figure 4.9: Release profiles in simulated gastric fluid with and without pepsin of 20%w/v
gelatine coatings crosslinked for 15 hours (N=3, SD<0.093 in all cases).
Fra
ctio
na
l D
rug
 Re
lea
se
91
Time (hours)
0.0 0.5 1.0 1.5 2.0
0.0
0.2
0.4
0.6
0.8
1.0
Crosslinked for 2 hours
Crosslinked for 4 hours
Crosslinked for 6 hours
Time (hours)
0.0 0.5 1.0 1.5 2.0
0.0
0.2
0.4
0.6
0.8
1.0
Crosslinked for 2 hours
Crosslinked for 4 hours
Crosslinked for 6 hours
The minimization of drug release in the presence of pepsin is attributable to the duration of
crosslinking which is substantiated by the fractional release attained from the 30%w/v shells
that underwent crosslinking for a period of 2, 4 and 6 hours. With an increase in the duration
of crosslinking there is a reduction in the fractional release of loperamide HCl after 2 hours in
SGF containing pepsin for example, 0.634 (2 hours crosslinked), 0.454 (4 hours crosslinked),
and 0.228 (6 hours crosslinked) (Figure 4.10a). The correlation between the duration of
crosslinking and the rate of fractional loperamide HCl release in SGF containing pepsin may
be depicted as 2 hours>4 hours>6 hours. The duration of crosslinking also influenced the
time at which complete drug release was achieved in the absence of pepsin for example, 1.5
hours (2 hours crosslinked), and 2 hours (4 hours crosslinked) (Figure 4.10b).
Figure 4.10: Release profiles of 30%w/v gelatine shells crosslinked for 2 hours, 4 hours and 6
hours a) in the presence of pepsin (N=3, SD<0.007 in all cases), and b) in the absence of
pepsin (N=3, SD<0.035 in all cases).
4.6 Concluding Remarks
The initial preliminary formulation development studies attempted to develop a pepsin-
responsive outer shell that responded to pepsin positively so that drug release was
accelerated in its presence. However, after definitively establishing the actual site of action of
loperamide HCl it was determined that drug release should be preferably targeted to the
small intestine. Nevertheless, preliminary studies identified an attractive polymer, namely
gelatine that exhibited an unusual response to pepsin present in SGF. In the presence of
pepsin gelatine minimized the release of loperamide HCl from the shells. Furthermore, by
varying the concentration of the gelatine composition of the shells as well as altering the
duration of crosslinking the ideal release characteristics could be achieved. Thus preliminary
formulation development enabled the identification of a candidate system that could be
further optimized to achieve pepsin-responsive small intestinal targeted drug delivery.
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CHAPTER 5
FABRICATION AND STATISTICAL OPTIMIZATION OF THE ENZYME-RESPONSIVE
COLON-TARGETED TABLET THROUGH AN EXPERIMENTAL DESIGN STRATEGY
5.1 Introduction
Naturally derived polysaccharide polymers obtained from plants (pectin, guar gum or inulin),
animals (chitosan, chondroitin sulphate), algae (alginates) or even microbes (dextran) have
been extensively explored for colon-targeting applications. Irrespective of the source, these
polysaccharides are hydrolyzed by colonic microflora to simple saccharides. Essentially, the
principle of exploiting colonic microflora for colon-targeted drug delivery is based on the
notion that on arrival to the colon hydrolysis of the glycosidic linkages of the polysaccharide
chains occur, resulting in the release of the entrapped drug (Jose et al., 2009).
Preliminary studies on the development of an enzyme-responsive colon-targeted drug
delivery system yielded a comprehensive database that facilitated the establishment of a
prototype quality formulation that acknowledged and overcame the constraints associated
with typical colon-targeted drug delivery systems. The optimum formulation characteristics
relied primarily on the incorporation of polymers that were sensitive to colonic enzymes
resulting in the initiation and control of drug release exclusively in the presence of these
enzymes.
5.1.1 Polysaccharide polymers identified for application in the colon-targeted tablet
5.1.1.1 Pectin
Pectin is a linear non-starch heterogenous polysaccharide polymer composed of α-(1→4)-
linked D-galacturonic acid groups with some 1→2 linked L-rhamnose groups. The application
of pectin in colon-targeted drug delivery systems had emerged in the early 1990’s, primarily
due to the stability of the polymer in the stomach and small intestine as well as its
susceptibility to colonic enzyme degradation (Ashford et al., 1993b; Rubinstein et al., 1993).
The degree of methoxylation of pectin (DM) is the distinguishing factor that determines many
of its properties for example, pectins with a high DM are poorly soluble and those with a low
DM are highly soluble but hold the advantage for their capability to crosslink with cations
(Ashford et al., 1994). In addition to reducing the solubility of pectin in the upper
gastrointestinal tract (GIT), crosslinking also controls the drug release rate from crosslinked
matrices (Friend, 2005).
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Various other means of delivering an effective pectin substrate to the colon have been
explored for example, compression coating around a drug core, film coating of a combination
of pectin and a hydrophobic polymer or combination of pectin with a second polysaccharide
polymer or pH-sensitive polymer (Rubinstein et al., 1993; Rubinstein, 1995; Rubinstein and
Radai, 1995; Wakerly et al., 1996; Wakerly et al., 1997; Fernandez-Hervas et al., 1998;
Semdé et al., 1998; Semdé et al., 2000; Liu et al., 2003a; Ahmed, 2005; He et al., 2007).
Film coatings of pectin-based solutions appear as one of the most promising approaches for
colon-targeted drug delivery (Macleod et al., 1999a, b; Ofori-Kwakye and Fell, 2001;
Marianne et al., 2003; Ofori-Kwakye and Fell, 2003a, b; Ofori-Kwakye et al., 2004). Even
though the combinatory coating solution of pectin and ethylcellulose has been extensively
evaluated, the appropriate balance between the inhibition of premature drug release in the
upper GIT and the activation of drug release on exposure to colonic enzymes has not yet
been achieved.
5.1.1.2 Chitosan
Similarly, chitosan also undergoes enzymatic degradation by the action of colonic bacteria.
Chemically, it is a poly(N-glucosamine) with a high molecular weight and is unique in the
sense that it is polycationic in character (Chourasia and Jain, 2003). Furthermore, the
presence of amine groups renders chitosan soluble in weakly acidic conditions but insoluble
in higher pH conditions due to protonation of the amine groups (Ravindra et al., 1998). Thus
the limitation of its hydrophilicity has led to various avenues being explored with the aim of
reducing this characteristic in the upper GIT. Some such formulation approaches include
amongst others, the microencapsulation of chitosan in a pH-responsive coating, dispersing of
chitosan in a hydrophobic polymer or combining chitosan with an additional polymer to
function as a coating surrounding a drug core (Lorenzo-Lamosa et al., 1998; Shimono et al.,
2002; Kaur and Kim, 2009).
5.1.1.3 Xanthan Gum
Xanthan gum is an anionic microbial exopolysaccharide that consists of a cellulose backbone
and trisaccharide side chains that are composed of a glucuronic acid residue between two
mannose units (Alvarez-Manceñido et al., 2008). Apart from its effectiveness as an excipient
in sustained release formulations, xanthan gum offers the further benefit of achieving near
zero-order drug release kinetics (Talukdar and Kinget, 1995). Along with its high intrinsic
viscosity and drug release kinetics the presence of mannose units in xanthan gum renders it
susceptible to enzymatic degradation by β-mannanases present in colonic microflora thus
making it ideal for incorporation in an enzyme-responsive colon-targeted drug delivery
system.
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5.1.2 Multiparticulate vs. single-unit colon-targeted drug delivery systems
Single-unit colon-targeted drug delivery systems pose the burden of possible premature
dose-dumping prior to entry into the colon and/or dose-dumping in the colon resulting in the
possible ‘flooding’ of absorption/affected sites causing ineffectual therapy and evacuation of
‘unused’ drug (Sinha and Kumria, 2001). In contrast, multiparticulate colon-targeted systems
offer the advantage of being less likely to be affected by food and demonstrate a more
consistent absorption compared to single-unit systems. In addition, these systems are
particularly advantageous for the topical therapy of inflammatory bowel diseases, in
particular Ulcerative Colitis (UC) due to the greater potential of providing a uniform
distribution of drug to the inflamed parts of the GIT (Davis et al., 1991). Therefore
multiparticulate systems have gained popularity over the single-unit systems however the
cumbersome manufacturing process and limitations in drug-loading capacity remain the
major drawbacks. The novel in situ crosslinked enzyme-responsive colon-targeted drug
delivery system aims to amalgamate the benefits of multiparticulates and tablets into a
single-unit tablet system, whilst avoiding the drawbacks of each. The system and its
components are illustrated in Figure 5.1.
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Figure 5.1: Schematic illustration of the individual components of the novel enzyme-
responsive colon-targeted system and the method by which the benefits of multiparticulates
are incorporated into a single-unit tablet.
Therefore, this chapter focussed on the development of the enzyme-responsive colon-
targeted single-unit tablet in a systematic and sequential manner guided through a high
performance statistically robust experimental design approach, with the fundamental aim of
identifying an optimal formulation that achieved an initiation of drug release in conditions
simulating the colon, whilst avoiding drug release in the upper GIT.
Enzyme-responsive
colon-targeted tablet
3. Drug-loaded
granules
2. Polymeric
matrix
1. Outer enzyme-
responsive hydrophobic
coating Pectin entrapped in the coating is
degraded by colonic enzymes creating
minute pores through which dissolution
media enters
Dissolution media
(blue dots) enters
the tablet through
the pores in the
coating and
causes swelling of
the matrix. The
matrix is
comprised of
pectin and barium
chloride, xanthan
gum, and
carboxymethyl-
cellulose.
5-ASA is then released from the multiple
granules as a result of enzymatic cleavage of the
crosslinked chitosan drug-loaded granules. Drug
permeates through the swollen matrix to be
released in a sustained manner.
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5.2 Materials and Methods
5.2.1 Materials
The materials including mesalamine (5-ASA), chitosan (CHT), pectin, xanthan gum (XG),
carboxymethylcellulose sodium salt (CMC), sodium tripolyphosphate (TPP), barium chloride
2-hydrate (BaCl2), the ethylcellulose aqueous coating dispersion (EC), the commercial
colonic enzymes, pectinase and β-glucosidase were all obtained as described in Chapter 3,
section 3.2.1. Asacol® was supplied by Aventis Pharma (Pty) Ltd. (Midrand, Johannesburg,
South Africa). De-ionized water was used from a Milli-Q water purification system (Milli-Q,
Millipore, Billerica, MA, USA). All other reagents employed were of analytical grade and used
as purchased without further purification.
5.2.2 Preparation of the enzyme-responsive colon-targeted oral tablet in accordance
with a randomized Box-Behnken experimental design template
Tablets were comprised of CHT and 5-ASA granules crosslinked with an aqueous solution of
TPP, which were then dispersed within a polymeric matrix comprising of pectin, BaCl2, XG
and CMC. The granule-polymer dispersion was then compressed into shallow bi-concave
tablets and coated with an enzyme-responsive hydrophobic polymeric coating as depicted in
Figure 5.1. The tablets were prepared according to the Box-Behnken statistical experimental
design (Minitab® V15, Minitab Inc., PA, USA) and the outer hydrophobic coating layer of the
tablet remained consistent for all formulations. The three factor three-tier statistical
experimental design had a single central point with three replicates and was used to
determine the concentrations and ratios of the tablet components that ensured maximal
responsiveness to colonic enzymes whilst ensuring a sustained release of 5-ASA throughout
the colon (Table 5.1). The formulation input factors that were evaluated at the three levels
included:
 CHT concentration: 200-600mg of total tablet weight
 TPP aqueous solution: 2-10%w/v
 XG concentration: 1-10%w/w of tablet matrix
These factors and the corresponding experimental levels were selected based on results
from preliminary screening studies which showed that only CHT, TPP and XG had any
significant influence on the drug release characteristics of the tablets. Quadratic response
surfaces and second order polynominal models were generated to facilitate the prediction of
the tablet response (drug release characteristics in the presence and absence of colonic
enzymes) in terms of the independent variables (CHT, TPP and XG concentration)
investigated. A time-point approach to analyzing the drug release data was employed by
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determining the mean dissolution time of the formulations in the presence (MDTE) and
absence (MDT) of colonic enzymes over a 24 hour period. MDT and MDTE were selected as
the only formulation responses to be investigated since the mean dissolution times enabled
the assessment of the enzyme-responsiveness of the tablet whilst the corresponding drug
release profiles established the colon-targeting ability of the formulations.
Table 5.1: Box-Behnken design template of the 15 statistically derived formulations for the
fabrication of the enzyme-responsive colon-targeted tablet
Experimental Formulation Granules MatrixCHT (mg) TPP (%w/v) XG (%w/w)
1 200 10 5.5
2 600 6 10.0
3 200 6 10.0
4 400 6 5.5
5 400 10 1.0
6 600 10 5.5
7 200 6 1.0
8 400 6 5.5
9 400 2 1.0
10 600 2 5.5
11 400 2 10.0
12 400 6 5.5
13 400 10 10.0
14 200 2 5.5
15 600 6 1.0
5.2.3 Preparation of the enzyme-responsive colon-targeted oral tablet excluding the
outer enzyme-responsive hydrophobic coating
Drug-loaded crosslinked granules of CHT and 5-ASA were prepared by blending the required
quantity of CHT, determined in accordance with the randomized Box-Behnken experimental
design (Table 5.1), with a constant quantity of 5-ASA (200mg per tablet). Prior to the
incorporation of 5-ASA with CHT, a 1M acetic acid solution was pipetted directly onto the
CHT powder to facilitate the ionization of CHT. The relevant concentration of TPP was then
added to the blend in a consistent ratio of 1:800 (v/w) TPP:CHT and blended with a mortar
and pestle for 5 minutes to ensure an even distribution of the crosslinking agent. The moist
coagulation formed was then passed through a 1mm stainless steel mesh sieve (Laboratory
Test Sieve, Endecotts Ltd., London, UK) and the resultant granules were subsequently
allowed to dry at 30°C for 24 hours in a convection oven (Memmert, Schwabach, Germany).
The dehydrated 5-ASA loaded granules were then incorporated and dispersed within a
matrix of polymers that included pectin, ground BaCl2, XG and CMC. The concentration of
XG, an independent formulation variable, was based on a percentage of the matrix
components and was prescribed by the Box-Behnken experimental design (Table 5.1). This
concentration was dependent on a tablet weight of 1200mg (excluding binder and lubricant)
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and the quantity of granules to be included. From preliminary screening studies it was
determined that the most effective ratio of pectin to crosslinking agent (BaCl2) that ensured in
situ crosslinking was 2:1 (w/w). However, the quantity for incorporation was dependent on
the quantity of XG included in the matrix as per the Box-Behnken experimental design. CMC
was subsequently added in a concentration of 12%w/w of a tablet weight of 1200mg to act as
a binder, and magnesium stearate (MgSt) was added in a 0.5%w/w concentration as a
lubricant. The matrix components were thoroughly blended with the relevant quantity of 5-
ASA loaded granules using a cube blender (Erweka Apparatebau, Heusenstamm, Germany)
and compressed into shallow bi-concave tablets with a final weight before coating of 1350mg
and 13.6x4.5mm dimensions using a mini rotary tablet press (Karnavati Mini Press II, Rimek
Products, Gujarat, India).
5.2.4 In-process validation of the enzyme-responsive colon-targeted oral tablet prior to
coating
The elucidation of the mechanical properties of the tablets prior to coating holds substantial
significance as a critical formulation characteristic since the ability of the tablets to withstand
the vigorous coating process is dependent on the successful manufacture of a physically
robust tablet. Textural profile analysis was therefore conducted with the intention of
characterizing the compressibility of the polymers employed via determination of the matrix
indentation hardness of the uncoated tablets, using a TA.XTplus Texture Analyzer (Stable
MicroSystems, England) fitted with a probe having a spherical indenter of 3.125mm diameter
and a 5kg load cell. Essentially, the indentation hardness of the tablets was represented by
conversion of the maximum force withstand by the tablet to the Brinell Hardness Number
(BHN) as dictated by Equation 5.1.
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Equation 5.1
Where F is the force applied to the tablet, D is the diameter of the probe and d the
indentation diameter.
Typically, the ball-probe which is connected to a force transducer in the analyzer measures
the force of resistance encountered by the probe during advancement into the sample. This
probe is advanced into the sample at a predetermined velocity in accordance with the
following textural parameters listed in Table 5.2.
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Table 5.2: Textural settings employed for the calculation of matrix indentation hardness
Textural parameter Setting
Test mode Compression
Pre-test speed 1mm/sec
Test speed 0.5mm/sec
Post-test speed 1mm/sec
Distance 0.25mm
Trigger type Auto (force)
Trigger force 0.05N
The matrix indentation hardness was subsequently determined based on data acquired
through the generation of Force-Distance profiles. A typical profile acquired is depicted in
Figure 5.2.
Figure 5.2: Typical Force-Distance profile acquired for the determination of the matrix
indentation hardness of tablets before coating.
In addition to ensuring the reproducibility of the tablet manufacturing process friability studies
were conducted on the tablets prior to coating as a means of establishing the ability of the
tablets to withstand the vigorous conditions implemented during the coating process. Thus,
friability studies were conducted on 10 samples of uncoated tablets from each formulation
prepared according to the Box-Behnken experimental design using a Friabilator (Pharma
Test Friabilator PTF, Pharma Test, Hainburg, Austria). This was conducted according to USP
test parameters for tablets of weight ≥1g (USP 33, NF 28). Briefly, 10 pre-weighed tablets
were subjected to a 100 revolutions at 25rpm for 4 minutes, and friability was set at an upper
limit of 1%. The tablets were subsequently removed from the friabilator, dusted and re-
weighed. The percentage difference between the initial and the final weights were recorded
as the percentage friability based on Equation 5.2.
Maximum force
100
100)(
0
0  W
WWWL tt Equation 5.2
Where WLt is the total weight loss expressed as a percentage, W0 is the initial weight of the
tablets, and Wt is the final weight of the tablets.
Mass uniformity analyses and determination of the uniformity of tablet dimensions prior to
coating were also performed to ensure the reproducibility of the tablet manufacturing process
as well as the intra- and inter-batch consistency.
5.2.5 Coating of the enzyme-responsive colon-targeted oral tablet with the enzyme-
responsive hydrophobic solution to ensure site-specific colonic delivery
An enzyme-responsive coating solution was prepared by blending a 4%w/v aqueous pectin
solution with an EC aqueous coating dispersion in a 1:2 proportion (w/w). The process of the
preparation of this coating solution was elaborated in Chapter 3, section 3.4.4. Furthermore,
the optimized coating process parameters were maintained as prescribed in section 3.4.5.
The subsequent degree of coating achieved was then expressed as the theoretical
percentage of the total weight gain (TWG) according to Equation 3.1.
Figure 5.3: Three-dimensional illustration of the fluid bed dryer (FBD) and its components.
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5.2.6 Construction of calibration curves of 5-ASA in simulated media
The construction of calibration curves of 5-ASA in simulated gastric fluid (SGF) (pH 1.2;
37°C), simulated intestinal fluid (SIF) (pH 6.8; 37°C) and simulated colonic fluid (SCF) (pH
5.9; 37°C) with and without pectinase (3mL per 250mL SCF) and β-glucosidase (10mg per
250mL of SCF) were performed as described in Chapter 3, section 3.4.6.
5.2.7 In vitro drug release characteristics of the coated enzyme-responsive colon-
targeted oral tablet in response to commercially available colonic enzymes
In principle, the use of the USP apparatus III is the most attractive when evaluating modified
and modulated release formulations since the effect of the continuous and dynamic pH
change that occurs with time along the passage through the GIT can be easily and
reproducibly simulated. In vitro drug release studies were thus performed based on the
parameters and protocol outlined in Chapter 3, section 3.4.7.
The pH gradient and residence times evaluated were based on the mean physiological pH
values in each segment, as well as the mean residence times of delivery systems in each
segment (Davis et al., 1986; Klein et al., 2002; Basit, 2005). This entailed a gastric residence
time of 2 hours in SGF, small intestinal residence time of 4 hours in SIF, and finally SCF with
a residence time of 18 hours (Nunthanid et al., 2008). Commercially available colonic
enzymes, specifically pectinase (3mL per 250mL SCF) and β-glucosidase (10mg per 250mL
of SCF) were included in SCF. The upper gastrointestinal enzymes, in particular pepsin and
pancreatin, were excluded from SGF and SIF respectively since the outer coating layer
consisting of only pectin and EC was shown, from preliminary studies, to be insensitive to
these enzymes. For comparative purposes release studies were conducted in SCF with and
without colonic enzymes. Furthermore, the gold-standard marketed 5-ASA formulation,
Asacol®, was also subjected to in vitro release studies based on identical in vitro release
parameters. Sample withdrawal, analysis and 5-ASA quantification were performed as
described in section 3.4.7.
Computation of the release data was subsequently performed in a manner compliant with a
model-independent comparison of all formulations in terms of their respective 5-ASA release
behaviour. This was conducted by determining the mean dissolution time (MDT24) values of
all formulations and in each dissolution medium calculated at 24 hours.
5.2.8 Constrained statistical optimization of the enzyme-responsive colon-targeted
oral tablet
Surface response methodology is an empirical modelization technique that is devoted to the
evaluation of the relationship of a set of controlled experimental factors and the observed
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results (Annadurai and Sheeja, 1998). Thus the primary aim of the statistical process was to
develop an optimized enzyme-responsive colon-targeted oral tablet that is preferentially
targeted to the colon and upon ‘activation’ by colonic enzymes drug is released in a
sustained manner in the colon. Computation of results was performed using multiple
regression analysis using the least squares method, where in a system involving three
significant independent variables, the mathematical relationship of the response on these
variables was approximated by a quadratic (second order) polynomial equation. For
optimization purposes, the response parameters evaluated were the mean dissolution time
after 24 hours (MDT24) in the presence (MDTE) and absence (MDT) of colonic enzymes.
Therefore for optimization purposes the MDT was minimized in the absence of colonic
enzymes and maximized in the presence of enzymes.
5.2.9 Evaluation of the simulated fluid uptake ability of the enzyme-responsive colon-
targeted oral tablet in response to colonic enzymes
The presence of pectinase and β-glucosidase in SCF may influence the degree of imbibition
of media into the delivery system and can be correlated to the in vitro release data obtained.
This supposition provided the motivation for establishing the SCF uptake ability of the tablet
as a consequence of colonic enzymes. Essentially this process was conducted
gravimetrically where the tablets were subjected to conditions identical to those employed
during drug release studies however at predetermined time points (9, 12, 15, 18, 21, and 24
hours) each tablet was removed from the relevant SCF and allowed to drip-dry for a period of
2 minutes at room temperature to remove excess SCF. The drip-drying process was
conducted in a manner that ensured no introduction of bias since the tablets were held on
the bottom mesh of the glass cylinder of the Bio-Dis® apparatus and no physical ‘blotting’ of
the tablets was performed. As a control, this process was replicated in SCF void of enzymes.
Fresh samples were used for each individual time point. The degree of SCF uptake at each
time point, expressed as a percentage, was then determined based on the increase in weight
of the formulation due to imbibed SCF and was calculated according to Equation 5.3.
100)((%)
0
0  W
WWSCF tuptake Equation 5.3
Where SCFuptake is the percentage of SCF uptake by the tablet at the relevant time point, Wt
is the weight of the tablet at the relevant time point, and W0 is the initial weight of the tablet.
The physical dimensions of the tablets could not be determined since with an increase in
exposure time to SCF there was an increase in SCF uptake by the tablets which resulted in
the rupturing of the coating causing the tablets to have non-consistent dimensions.
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Subsequent to establishing the amount of imbibed fluid in the tablet, the hydrated samples
were dried in a convection oven at 40°C for 48 hours, and allowed to cool under a fume hood
for a further 30 minutes after which they were re-weighed. Since the hydrophilic polymers
employed in the tablet possessed the ability to absorb a substantial volume of SCF masking
the simultaneous erosion of polymer at that point, this process was conducted to establish
the degree of polymer loss/erosion at each time point after the samples were completely
dehydrated. Thus the degree of erosion, expressed as a percentage, at each time point was
calculated according to Equation 5.4.
100)((%)
0
0  W
WWErosion t Equation 5.4
Where Wt is the weight of the dried tablet at the relevant time point, and W0 is the initial
weight of the tablet.
5.2.10 Evaluation of the polymeric structural and vibrational frequency variations of
the tablet and its components relative to its exposure to colonic enzymes
The structure of the native polymers CHT, pectin, XG, and CMC, as well as that of 5-ASA
were assessed by Fourier Transmission Infrared Spectroscopy (FTIR) using a Spectrum
2000 FTIR spectrometer with a MIRTGS detector (PerkinElmer Spectrum 100, Lliantrisant,
Wales, UK). Furthermore, the drug-loaded crosslinked CHT granules were also evaluated to
assess any variations in the vibrational frequencies as a result of crosslinking during granule
formation. To categorically elucidate the influence of colonic enzymes on the structural
polymeric backbone of the tablet as well as on the coating of the tablet, samples acquired
through erosion studies (each time point) were also analyzed by FTIR. Samples were placed
on a diamond crystal and processed by a universal ATR polarization accessory for the FT-IR
spectrum series at a resolution of 4cm-1. Samples were analyzed at wavenumbers ranging
from 400-4000cm-1.
5.2.11 Molecular mechanic simulations of the influence of colonic enzymes on the
crosslinked chitosan granules
Molecular Mechanics Computations in vacuum, which included the model building of the
energy-minimized structures of multi-polymer complexes, were performed using the
HyperChemTM 8.0.8 Molecular Modeling System (Hypercube Inc., Gainesville, Florida, USA)
and ChemBio3D Ultra 11.0 (CambridgeSoft Corporation, Cambridge, UK) on an HP Pavilion
dv5 Pentium Dual CPU T3200 workstation. The structure of TPP was generated as a 3D
model from standard bond lengths and angles employing ChemBio3D Ultra whereas the
structures of CHT and pectin (ten oligosaccharide units each) were generated using sugar
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builder module on HyperChem 8.0.8. The structure of pectinase, polygalacturonase and β-
glucosidase peptide analogues were downloaded using GetNetFile online structure retrieval
option on ChemBio3DUltra. However, the representative recognition sequences of the
respective peptide i.e., polygalacturonase and β-glucosidase were generated using
sequence editor module on HyperChem 8.0.8. The generation of the overall steric energy
associated with the energy-minimized structures was initially executed initially via energy-
minimization using MM+ force field and the resulting structures were again energy-minimized
using the Amber 3 (Assisted Model Building and Energy Refinements) force field. The
conformer having the lowest energy was used to create the polysaccharide-crosslinker and
polysaccharide-peptide complexes. A complex of one molecule with another was assembled
by disposing them in a parallel way, and the same procedure of energy-minimization was
repeated to generate the final models: CHT-TPP crosslinked granules, β-glucosidase acting
on CHT and polygalacturonase acting on pectin. Full geometry optimizations were carried
out in vacuum employing the Polak–Ribiere conjugate gradient method until an RMS
gradient of 0.001kcal/mol was reached. Force field options in the AMBER (with all hydrogen
atoms explicitly included) and MM+ (extended to incorporate non-bonded cut-offs and
restraints) methods were the HyperChem 8.0.8 defaults. For calculations of energy
attributes, the force fields were utilized with a distance-dependent dielectric constant scaled
by a factor of 1. The 1-4 scale factors are following: electrostatic 0.5 and van der Waals 0.5.
Molecular mechanics energy relationship (MMER), a method for analytico-mathematical
representation of potential energy surfaces, was used to provide information about the
contributions of valence terms, non-covalent Coulombic terms, and non-covalent van der
Waals interactions for solute partitioning from the bulk aqueous/organic phase. The MMER
model for potential energy factor in various molecular complexes can be written as depicted
in Equation 5.5.
Emolecule/complex= V∑ = Vb + Vθ+ Vφ + Vij + Vhb+ Vel Equation 5.5
Where V∑ is related to total steric energy for an optimized structure, Vb corresponds to bond
stretching contributions (reference values were assigned to all of a structure's bond lengths),
Vθ denotes bond angle contributions (reference values were assigned to all of a structure's
bond angles), Vφ represents torsional contribution arising from deviations from optimum
dihedral angles, Vij incorporates van der Waals interactions due to non-bonded interatomic
distances, Vhb symbolizes hydrogen-bond energy function and Vel stands for electrostatic
energy.
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5.2.12 Surface morphological characterization of the enzyme-responsive colon-
targeted oral tablet after exposure to colonic enzymes
Surface morphological characterization was undertaken as a means of qualitatively
evaluating the influence of colonic enzymes on the tablet. Scanning electron microscopy
(SEM) was performed on the coated and uncoated tablet prior to exposure to colonic
enzymes as well as on the eroded samples at each time point obtained from SCF uptake
studies after exposure to SCF with and without colonic enzymes. This allowed an illustration
of pore presence, pore distribution, polymer cleavage or other anomalies that occurred as a
result of exposure to colonic enzymes and in relation to the duration of such exposure.
Samples were firmly mounted on aluminium stubbs with carbon tape and gold sputter coated
with argon gas whilst under a vacuum of 0.1Torr using a SPI-MODULETM Sputter Coater and
SPI-MODULETM Control (SPI Supplies, Division of Structure Probe Inc., West Chester, PA,
USA). Each sample required 4.5 minutes of coating at 90 second intervals to ensure
complete coverage of the sample which minimized sample activation during viewing.
Subsequent viewing was performed at various magnifications under the PhenomTM desktop
scanning electron microscope (FEI CompanyTM, Hillsboro, OR, USA).
5.3 Results and Discussion
5.3.1 Evaluation of the physicomechanical characteristics of the enzyme-responsive
colon-targeted oral tablet prior to coating
Textural analysis of all 15 formulations (N=3) revealed an average BHN of 58.17±2.80N/mm2
(Figure 5.4). The BHN of each formulation showed no significant evidence of being
dependent on the concentrations of the polymers and crosslinking agents employed. The
results also suggest that the variation in the indentation force withstood by the formulations
and thus the corresponding BHN values were likely due to slight inconsistencies that
occurred during the manufacturing process. However these inconsistencies were not
substantially significant to drastically alter the hardness of the tablets. Figure 5.4 indicates
the absence of any discernable pattern with regards to the influence of the concentrations of
the polymers and crosslinking agents employed and the corresponding tablet hardness.
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Figure 5.4: Graphical illustration of the Brinell Hardness Number of all 15 formulations (SD:
0.591-7.633).
The USP (USP 33, NF 28) states that a friability of <1% is acceptable for tablets ≥1g after
undergoing 100 revolutions in a friabilator. Figure 5.5 shows the friability of each formulation
and provides evidence that all formulations were compliant with USP specifications.
Therefore, theoretically each formulation would be capable of withstanding the vigorous
fluidization conditions implemented in the Wurster chamber of the FBD.
Figure 5.5: Graphical illustration of the variations in the friability of all 15 formulations (SD:
0.002-0.106).
The average tablet weight for all 15 formulations (N=20) was 1329.51±2.99mg per tablet.
Since the theoretical final tablet weight was 1350mg this represented a loss of 1.52%.
However, the dimensions of the tablets (13.6x4.5mm) remained consistent throughout.
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5.3.2 Box-Behnken Experimental Design for optimization of the enzyme-responsive
colon-targeted oral tablet
5.3.2.1 Measured responses for experimental optimization
Diverse drug release patterns were observed with all 15 formulations as illustrated in Figure
5.6a-f. However, based on these profiles it was evident that an elevated fractional drug
release was observed from all formulations exposed to colonic enzymes in SCF as opposed
to when the enzymes were absent. Furthermore, despite the acceptable friability limits of all
formulations, three separate attempts at coating of formulations 3 and 14 proved
unsuccessful preventing the evaluation of 5-ASA release from these formulations. This may
be attributable to the specific concentrations/quantities of the independent formulation
variables incorporated which influenced the compressibility of the combination of polymers
and thus the ability of the tablets to withstand not only the fluidization conditions within the
FBD but also the temperature change therein.
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Figure 5.6: Composite fractional drug release profiles of formulations a) 1 and 2, b) 4 and 5,
c) 6 and 7, d) 8 and 9, e) 10 and 11, and f) 12-15; where ‘E’ denotes simulated colonic fluid
containing pectinase and β-glucosidase.
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Due to the diversity of the dissolution patterns acquired a model-independent time-point
approach was selected as a means of analyzing and substantiating the release behaviour of
all formulations from the Box-Behnken experimental design template. The MDT, defined as
the sum of the different fractions of drug release obtained per period of time divided by the
initial dose of drug loaded into the system, was calculated for each formulation in the
presence and absence of colonic enzymes after 24 hours employing Equation 5.6 (Pillay and
Fassihi, 1998).
   nt MMttiMDT 1 Equation 5.6
Where Mt is the fraction of dose released in time ti and ti=(ti+ti-1)/2, M∞ corresponds to the
loading dose.
Since all 15 formulations were identically coated it was expected that until exposure to
colonic enzymes all formulations would not release any 5-ASA. This was evident in Figure
5.6a-f where all formulations exhibited no drug release for the first 6 hours (in SGF and SIF).
Therefore MDT24 was actually based on the fractional release from the 6th hour onwards (T6-
T24 hours). The MDT values of each formulation (in the absence and presence of colonic
enzymes) are shown in Table 5.3.
Table 5.3: Mean dissolution time (MDT6-24) of all 15 formulations in the presence and
absence of colonic enzymes
Experimental Formulation MDT6-24 (hours) MDT6-24 1(E) (hours)
1 32.58 36.74
2 18.60 41.51
3 2N/A
4 26.64 45.20
5 9.45 40.70
6 5.83 33.43
7 19.56 32.18
8 15.19 52.83
9 43.76 53.67
10 11.67 30.72
11 44.86 55.17
12 41.70 67.76
13 34.95 49.14
14 2N/A
15 45.92 52.03
1Pectinase and β-glucosidase are present in SCF
2Data is unavailable since the formulations disintegrated during the coating process
Subsequent to the first 6 hours of drug release studies, all formulations not exposed to
colonic enzymes showed a variable maximum fractional drug release ranging from 0.179
(formulation 10) to 0.749 (formulation 15) resulting in MDT6-24 values ranging from 5.83 to
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45.92. In contrast, in the presence of colonic enzymes the maximum fractional drug release
of all formulations was substantially elevated ranging from 0.456 (formulation 10) to 1.0
(formulation 8 and 12) resulting in higher MDT6-24 values. Despite the presence of this
phenomenon in all formulations, the fundamental objective of the study design was to
achieve a formulation that showed distinct responsiveness to colonic enzymes by having an
elevated rate of drug release in SCF containing enzymes and minimal drug release in the
absence of enzymes.
5.3.2.2 Correlation of the experimental and predicted response values
A comparative analysis of the experimental vs. the predicted response values, in particular
the MDT in the presence and absence of colonic enzymes, was plotted to establish the
applicability of the regression models and the robustness of the Box-Behnken design
employed for the optimization of the enzyme-responsive system. The plot depicting the MDT
(in the absence of enzymes) of the experimental vs. the predicted values of each formulation
show a general conformity with a correlation coefficient (R2) of 0.897 (Figure 5.7a). Similarly
the MDTE (in colonic enzymes) of the correlating experimental and predicted response
values showed an R2 value of 0.877 (Figure 5.7b). These R2 values provide evidence of the
success of the Box-Behnken experimental design and thus the efficiency of the design in
aiding the determination of an optimized enzyme-responsive colon-targeted oral tablet.
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Figure 5.7: Regression plots of a) the mean dissolution time in the absence of colonic
enzymes, and b) mean dissolution time in the presence of colonic enzymes (MDTE) for the
determination of the correlation between the experimental vs. the predicted response values.
5.3.2.3 Analysis of the Box-Behnken Response Surface Design
5.3.2.3.1 Response analysis for MDT
Response surface plots of the MDT (no enzymes in SCF) of the enzyme-responsive colon-
targeted oral tablet showed that a desirable reduction in the MDT (MDT is minimized) is
achievable with a gradual increase in the quantity of CHT incorporated in the formulation with
either a minimum (2%w/v) or maximum (10%w/v) concentration of aqueous TPP as the
crosslinking agent, when a XG hold value of 5.5%w/w is implemented (Figure 5.8a). This
desirable reduced MDT is also evident when the CHT quantity is 600mg and XG is present in
a 5-10%w/w concentration. This was relatively the most significant interaction (p=0.083).
When XG is excluded from the formulation or exists in a low concentration (2%w/w), a
a)
b)
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reduction in MDT is only achievable with a TPP concentration of 10%w/v and a CHT quantity
of 400mg (Figure 5.8b).
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Figure 5.8: Response surface plots correlating mean dissolution time in simulated colonic
fluid (no enzymes) with a) chitosan quantity and tripolyphosphate concentration (xanthan
gum hold value of 5.5%w/w), and b) xanthan gum quantity and tripolyphosphate concentration
(chitosan hold value of 400mg).
5.3.2.3.2 Response analysis for MDTE
In contrast to the MDT (in the absence of colonic enzymes) a desirable increase in MDTE is
achievable at a CHT quantity of 350-450mg and TPP concentration of 5-7%w/v when a XG
hold value of 5.5%w/w is implemented. In order to achieve a maximum MDT in the presence
of colonic enzymes the TPP concentration should be maintained between 5-7%w/v and XG
between 9-10%w/w, when 400mg of CHT is employed (Figure 5.9a). Furthermore, a
significant increase in MDTE is evidenced when 6%w/v TPP is employed with a minimum CHT
quantity (200mg) and a maximum XG concentration (10%w/w) (Figure 5.9b). It is thus evident
that achieving the optimum balance of CHT quantity, and TPP and XG combinations so that
there is a reduction in the MDT (when no enzymes are present) and an increase in MDTE
(when enzymes are present) from the enzyme-responsive colon-targeted oral tablet would
prove challenging primarily due to the conflicting influences the polymers exhibit when
exposed to SCF with colonic enzymes and SCF without enzymes.
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Figure 5.9: Response surface plots correlating mean dissolution time in simulated colonic
fluid with enzymes (MDTE) with a) xanthan gum quantity and tripolyphosphate concentration
(chitosan hold value of 400mg) and b) chitosan quantity and xanthan gum concentration
(tripolyphosphate hold value of 6%w/v).
5.3.2.4 Residual Analysis of the Box-Behnken Experimental Design for the
optimization of the enzyme-responsive colon-targeted oral tablet
Residual analysis is performed to assess the suitability of the multiple regression model and
to essentially obtain a linear comparison between the observed values and model
predictions. The assumptions of a multiple linear regression model is that the response
variables are independent and normally distributed random variables with constant variance
and means depending linearly on the explanatory variables (Larsen and McCleary, 1972).
The normal probability plots of the residuals of MDT and MDTE showed clusters of residuals
however these clusters fell on a straight line, signifying the normal distribution of data with no
evidence of unidentified variables. Furthermore, a residual plot of the standardized residuals
of MDT and MDTE show a random distribution of points fluctuating around zero, with no
discernable pattern, indicating a non-violation of the assumptions of zero means and
constant variance of the regression model despite the presence of two outliers in these plots.
Evidence of this non-violation was provided by histograms of the residuals of MDT and
MDTE. The residuals versus the order of data showed a random distribution, with rapid
changes in signs (+/-) between consecutive residuals for both MDT and MDTE (Figure 5.10).
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Figure 5.10: Residual plots of a) mean dissolution time in simulated colonic fluid without
enzymes and b) mean dissolution time in simulated colonic fluid with enzymes.
Based on a full ANOVA analysis of the measured formulation responses it was determined
that none of the factors exhibited any significant influence (p≤0.05). Only the CHT*XG
(p=0.083) term of the MDT response possessed an almost significant effect, even though
p≥0.05 (Table 5.4).
a)
b)
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Table 5.4: Estimated p-values for mean dissolution time in simulated colonic fluid with and
without enzymes
Term p-valueMDT MDTE
CHT 0.165 0.693
[TPP] 0.235 0.564
XG 0.219 0.450
CHT*CHT 0.675 0.268
[TPP]*[TPP] 0.447 0.267
XG*XG 0.211 0.674
CHT*[TPP] 0.755 0.750
CHT*XG 0.083 0.261
[TPP]*XG 0.411 0.762
The complete regression equations generated for mean dissolution time in the absence
(MDT) and presence of enzymes (MDTE) are depicted in Equations 5.7 and 5.8 respectively.
XG]*PP0.338889[TXG]*CHT0.0278926[-
TPP]*[CHT0.00417708XG]*G0.595761[XTPP]*PP0.415781[T-
CHT]*6[CHT0.00010689]4.58070[XGPP]0.709931[T-CHT]0.0287699[-38.4154MDT



Equation 5.7
XG]*TPP0.0963889[XG]*CHT0.0122870[-
TPP]*[CHT0.00348958XG]*G0.142922[XTPP]*PP0.530469[T-
CHT]*04[CHT-2.56354E-]3.68471[XGP]3.66632[TPCHT][237775.08445.10MDTE



Equation 5.8
5.3.2.5 Constrained optimization of the enzyme-responsive colon-targeted oral tablet
Optimization of the enzyme-responsive colon-targeted oral tablet was performed employing
Minitab® V15 statistical software (Minitab® Inc., PA, USA) to determine the optimum level for
each variable. The optimization approach resulted in the attainment of a formulation with a
desirability of 0.94 and the fabrication of this formulation included the employment of
403.837mg of CHT per tablet, a TPP concentration of 8.253%w/v and a XG concentration of
4.087%w/w of the tablet matrix as depicted in Figure 5.11.
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Figure 5.11: Optimization plots displaying factor levels and desirability values for the
optimized formulation.
Table 5.5: Comparison of the predicted and experimental values of the response parameter
Response parameter Predicted
1Desirability
(%) Experimental
2Deviation
(%)
Mean Dissolution Time (MDT)
(no enzymes) 18.0420 89.95 25.91725 5.569
Mean Dissolution Time (MDTE)(with enzymes) 49.5471 99.09 47.67721 1.322
1Statistical desirability values of the predicted optimized formulation (%)
2Deviation of the experimental response values from the predicted
The predicted optimized formulation had a statistical desirability of ≥90% for both response
parameters. Minimization of MDT and maximization of MDTE was achievable with a single
optimized formulation (Table 5.5). The experimental response parameters achieved with the
constrained settings for the optimized formulation were in close agreement with the predicted
response values. This identified the reliability of the optimization process in predicting the
dissolution behaviour in the presence of colonic enzymes more so than when enzymes are
absent. In vitro release studies of the optimized formulation exhibited no drug release for the
first 6 hours in SGF and SIF and a substantial elevation in the 5-ASA release rate was
evident when in the presence of colonic enzymes (Figure 5.12). Furthermore, the observable
zero-order-like release behaviour would in theory result in a more targeted and uniform
distribution of the drug throughout the colon with standard deviations of only 0-0.26317.
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Figure 5.12: Release profile of 5-aminosalicylic acid from the optimized formulation in the
presence (E) and absence of colonic enzymes.
The optimized formulation achieved a fractional drug release of 0.8030±0.039 in the 24 hour
period in the presence of colonic enzymes, however in the absence of the enzymes the
same formulation achieved 0.304±0.050 fractional release in the same time. Essentially, this
release profile provided the fundamental evidence of the enzyme-responsiveness of the
colon-targeted tablet.
In contrast, the conventionally employed 5-ASA loaded system used in the treatment of UC,
namely Asacol® is based on the technology of pH-responsive drug delivery where 5-ASA is
coated by a copolymer of methacrylic acid and methyl methacrylate that dissolves above a
pH of 7 (Basit, 2005). However based on the data obtained from drug release studies of
these tablets (N=3) it was established that 5-ASA began releasing from as low as pH 1.2
(SGF), and showed significant deviations from the average (SD: 0.001-0.5495) as depicted
in Figure 5.13. Furthermore irrespective of the presence of pectinase and β-glucosidase in
SCF, the first 6 hours of release studies should be identical in both cases, which did not
occur. The variation in the release profiles over the entire 24 hour period was attributed to
inter-batch variability of the conventional system and a non-uniform coating surrounding the
tablets. This postulation was confirmed by the observable formation of fissures/fractures
along the edges of the tablets through which the 5-ASA was released (the points of least
resistance) (Figure 5.14).
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Figure 5.13: Release profiles of 5-aminosalicylic acid from the conventional commercially
available 5-aminosalicylic acid-loaded system (Asacol®) in the presence and absence of
colonic enzymes.
Figure 5.14: Digital images of the varying extents of fracturing/fissuring of Asacol® in
simulated colonic fluid with and without enzymes after 24 hours.
 After 24 hours in SCF each
Asacol® tablet experienced
significant variations in
coating erosion.
 Consequently vastly
differing release profiles
were achieved irrespective
of the presence of colonic
enzymes in SCF.
 Even though the target pH
for dissolution of the coating
was not met, the tablets
formed ‘fissures’ along the
edges through which 5-ASA
was released.
 This formulation did not
comply with the
specifications for its release
namely, pH-dependent drug
release.
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5.3.3 Influence of colonic enzymes on the uptake of SCF and erosion of the optimized
enzyme-responsive colon-targeted oral tablet
Gravimetrical data revealed a gradual increase in the weight of the optimized tablet with an
increase in exposure time to SCF. Despite the occurrence of this trend both in the presence
and absence of enzymes, the extent of SCF uptake in the presence of colonic enzymes was
substantially greater, for example 54.57% in the absence of colonic enzymes compared to
101.68% swelling in the presence of enzymes after 12 hours (Figure 5.15). Therefore the
greater rate of fractional drug release in SCF with colonic enzymes can be correlated to the
greater degree of SCF permeation into the tablet at each time point specifically due to the
influence of β-glucosidase and pectinase in the medium. Furthermore, it is evident that this
elevated release rate can also be correlated to the greater degree of erosion of the
formulation in the presence of colonic enzymes, which in turn is due to the enzymatic
cleavage of the crosslinked polymeric chains.
Hydrated Dehydrated
Figure 5.15: 3D-scatter plot of the time after initiation of drug release studies vs. the
percentage of simulated colonic fluid uptake vs. the percentage erosion with accompanying
digital images of the formulation in its hydrated and dehydrated states.
5.3.4 The influence of colonic enzymes on the structural and polymeric vibrations of
the coating and tablet of the enzyme-responsive colon-targeted oral tablet
FTIR spectra of the native polymers employed in the crosslinked 5-ASA-loaded CHT
granules were analyzed in relation to the spectrum attained of the optimized granules. CHT
showed a distinctive band at 3357cm-1 indicative of primary amine NH- stretching and a peak
at 1583cm-1 indicative of NH2 deformation. A peak at 1025cm-1 indicated the presence of an
alcohol group with C-OH stretching. 5-ASA has numerous characteristic peaks such as the
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two distinct peaks at 2775cm-1 and 2521cm-1 which are representative of carboxylic acid
groups with H- bonded OH- stretching. Furthermore, peaks at 684cm-1, 772cm-1, 883cm-1,
1484cm-1, and 1617cm-1 can all be related to the basic structure of 5-ASA being a 1,3-
substituted aromatic compound. The structure of 5-ASA can also be confirmed by the
presence of peaks at 1572cm-1, 1190cm-1, 1238cm-1, 1262cm-1, 883cm-1, 931cm-1 which are
representative of an arylamino compound.
The exploitation of CHT in the field of drug delivery is derived from various factors based on
its non-toxicity, biodegradability, biocompatibility, bioadhesiveness and the fact that it is the
second most abundant polysaccharide in nature. Its abundance originates from its derivation
from the deacetylation of chitin which forms a major component of shells of crustaceans, the
exoskeletons of insects and the cell walls of fungi, to form a copolymer of glucosamine units
linked by β-(1→4)-glycosidic linkages (Illum, 1998; Lin and Lin, 2003; Krajewska, 2004).
Analysis of the crosslinked optimized granules showed that all characteristic peaks present in
the spectrum of 5-ASA were unaltered proving no covalent interactions between 5-ASA and
CHT. The principle between CHT crosslinking with TPP is essentially based on the fact that
when an acid is added to CHT –NH+3 sites on the CHT chain become available. In addition,
an aqueous solution of TPP (Na5P3O10) dissociates to give both hydroxyl and phosphoric
ions. Therefore, the concurrent presence of the oppositely charges ions allow the interaction
of CHT with the negatively charged species of TPP. Bearing this in mind, the preparatory
process of the crosslinked 5-ASA-loaded CHT granules involved the incorporation of a 1M
solution of acetic acid solution directly onto the CHT prior to TPP addition. The
disappearance of the peak at 3357cm-1 indicative of primary amine NH- stretching was
substantiated by Figure 5.16 which indicates the formation of an NH3+ bond (peaks at
1573cm-1 and 2540cm-1) resulting in an ionized compound (amine hydrohalide). In addition,
the peak at 1082cm-1 indicates the presence of P-O-C stretching due to the TPP.
Since CHT is enzymatically degradable by chitinases and chitosanases the presence of an
existing chitinase in β-glucosidase from almond emulsion permits the depolymerization of
CHT (Grassmann et al., 1934; Tracey, 1955; Wadsworth and Zikakis, 1984; Il’ina et al.,
2001; Zhang and Neau, 2001). However, any substitution on the carbon atoms 2, 3 and 4
such as the amine group on the second carbon atom of CHT completely prevents hydrolysis
by β-glucosidase (Dixon and Webb, 1964; Dale et al., 1986). The chitosanolytic activity of β-
glucosidase is substantiated by the elevated fractional drug release rate, and degree of SCF
uptake and erosion in the presence of this enzyme. A simplistic analysis of the postulated
mechanism behind the effect of β-glucosidase on the crosslinked 5-ASA-loaded granules is
illustrated in Figure 5.16.
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Figure 5.16: Mechanistic illustration of the action of β-glucosidase on 5-aminosalicylic acid-
loaded granules with a) representative of 5-aminosalicylic acid entrapped within the
tripolyphosphate-crosslinked chitosan granules, b) the resultant oligosaccharides, and c)
glucosamine units that result from depolymerization of chitosan, d) release of 5-
aminosalicylic acid.
O
o
H
H
NH3+
OH
H
C 2OH
OH
H
O
O-
P O
O
HO
P O
O
HO
P O
O
HO
O
OH
CH2OH
H
OH
NH3+
H O
o
H
H
NH3+
OH
H
CH2OH
OH
H
O
O-
P O
O
HO
P O
O
HO
P O
O
HO
O
OH
CH2OH
H
OH
NH3+
H O
o
H
OH
H
CH2OH
OHH
H
O
O
OH
CH2OH
H
OH
NH3+
H
H
NH3+
o
H
OH
H
CH2OH
OHH
H
O
O
OH
CH2OH
H
OH
NH3+
H O
H
NH3+
O
o
H
H
NH3+
OH
H
CH2OH
OH
H
O
O-
P O
O
HO
P O
O
HO
P O
O
HO
O
OH
CH2OH
H
OH
NH3+
H O
o
H
H
NH3+
OH
H
CH2OH
OH
H
O
O-
P O
O
HO
P O
O
HO
P O
O
HO
O
OH
CH2OH
H
OH
NH3+
H O
o
H
OH
H
CH2OH
OHH
O
2
H
OH
NH3+
H
H
NH3+
o
H
OH
H
CH2OH
OHH
H
O
O
OH
CH2OH
H
OH
NH3+
H O
H
NH3+
O
o
H
H
NH3+
OH
H
CH2OH
OH
H
O
O-
P OHO
P
O
HO
P O
O
HO
O
OH
CH2OH
H
OH
NH3+
H O
o
H
H
NH3+
OH
H
CH2OH
OH
H
O
O-
P O
O
HO
P O
O
HO
P O
O
HO
O
OH
CH2OH
H
OH
NH3+
H O
o
H
CH2OH
OHH
H
O
O
OH
CH2OH
H
OH
NH3+
H
H
NH3+
o
H
OH
H
CH2OH
OHH
H
O
O
OH
CH2OH
H
OH
NH3+
H O
H
NH3+
O
o
H
H
NH3+
OH
H
CH2OH
OH
H
O
O-
P O
O
HO
P O
O
HO
P O
O
HO
O
OH
CH2OH
H
OH
NH3+
H O
o
H
H
NH3+
OH
H
CH2OH
OH
H
O
O-
P O
O
HO
P O
O
HO
P O
O
HO
O
OH
CH2OH
H
OH
NH3+
H O
o
H
OH
CH2OH
OHH
H
O
O
OH
CH2OH
H
OH
NH3+
H
H
NH3+
o
H
OH
H
CH2OH
OHH
H
O
O
OH
CH2OH
H
OH
NH3+
H O
H
NH3+
β-glucosidase in SCF
b)
c)
d)
a)
122
Figure 5.17: SEM images of the a-c) crosslinked granules at magnifications of x405, x1040,
and x1540 respectively, and d-f) granules after exposure to colonic enzymes at T=9, T=15
and T=21 hours respectively at magnifications between x305 to x430.
In addition to the influence of β-glucosidase on the release of 5-ASA from crosslinked CHT
granules, the initiation of drug release is considerably influenced by the presence of
pectinase in SCF. Pectinase is comprised of pectin methylesterase and two types of pectin
depolymerases. The methylesterase is responsible for removing the methoxy groups from
the pectin while the polygalacturonase hydrolyzes the glycosidic linkages next to the free
carboxyl groups in the galacturonan chain (Sriamornsak, 1998).
The influence of pectinase on the enzyme-responsive coating is evident from FTIR spectra of
the coating of the optimized formulation after exposure to SCF with enzymes after
predetermined time points. The distinguishing characteristic of these spectra is the
disappearance of peaks from 1589-1512cm-1 when exposed to colonic enzymes for 9 hours
(T=9, 12 and 15) as indicated in Figure 5.18.
e) f)
c)b)a)
d)
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Figure 5.18: FTIR spectra of the coating of the optimized formulation after 9, 12 and 15
hours of release studies, where ‘E’ denotes simulated colonic enzymes containing pectinase
and β-glucosidase. The red blocks highlight the peaks that disappear when exposed to
colonic enzymes.
Based on the mechanism of action of pectinase on pectin the disappearance of these peaks
is postulated to be due to the hydrolization of the glycosidic linkages of the pectin backbone
chain resulting in the formation of minute pores through which dissolution media was capable
of entering. However after 15 hours of exposure to SCF no difference was evident in the
FTIR spectra of the coating exposed to enzymes compared to those that were not exposed
to enzymes. Since pectin is a highly hydrophilic polymer it is believed that after 15 hours the
majority of the pectin present in the coating has dissolved in the release media and is no
longer susceptible to the enzymatic activity of pectinase.
FTIR spectra of the inner component of the oral tablet (enclosed by the coating) after specific
time-points in SCF with and without enzymes is illustrated in Figure 5.19. Based on these
spectra it is evident that at T=9, where the tablets had been exposed to SCF for a period of
only 3 hours no significant difference is observable between the formulations in the presence
of enzymes and those in the absence of enzymes. However with an increase in exposure
time to SCF containing enzymes there is a gradual disappearance of peaks between
1646cm-1 and 1132cm-1. This is due to the steady increase in the rate of SCF permeation
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into the tablet, which consequently results in an increased quantity of colonic enzymes
entering the delivery system causing cleavage of the relevant bonds as well as the gradual
release of 5-ASA.
Figure 5.19: FTIR spectra of the tablet at various time points in the presence and absence
of colonic enzymes with accompanying SEM images (x1120) elucidating the basic
morphological differences that occur as a result of increasing exposure time to simulated
colonic fluid with and without colonic enzymes.
Surface morphological evaluation of the 5-ASA-loaded crosslinked CHT granules revealed
the presence of distinct twig-like structures with sizes ranging from less than 70µm up to
250µm (Figure 5.17a-c). This provides a visual indication of crosslinking between CHT and
TPP. However after exposure of the formulation to SCF a vivid morphological difference is
evident from the tablet exposed to colonic enzymes to the tablet that is exposed to enzyme-
free SCF. In the presence of colonic enzymes the tablets initially appear almost fibre-like with
several porous regions. However with an increase in exposure time these tablets generate a
less fibrous appearance with more sites of ‘polymeric clumping’ (Figure 5.17d-f). In contrast,
in the absence of colonic enzymes the tablets present with a gradually increasing uniform
and smooth morphology with fewer porous sites (Figure 5.19).
5.3.5 Molecular mechanics energy relationship (MMER) analysis of the enzyme-
responsive colon-targeted oral tablet
It is evident form Figure 5.20 that TPP can crosslink the chitosan by forming both intra- and
inter-molecular bonding. The formation of highly stabilized structure of CHT-TPP with
ΔEBINDING = -132.867kcal/mol (equation 5.9, 5.10, and 5.11) also favours the crosslinking
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action of TPP. The complex is mainly stabilized by non-bonding interactions in terms of
London dispersion forces, H-H bonding and ion pair-ion pair electrostatic interactions.
Figure 5.20: Visualization of geometrical preferences of tripolyphosphate (stick rendering) in
complexation with chitosan (tube rendering) after molecular mechanics simulations.  Color
codes: C (cyan), O (red), N (blue), P (yellow) and H (white).
ECHT =35.555V∑= 3.120Vb + 18.035Vθ + 25.774Vφ + 13.323Vij - 24.697Vel Equation 5.9
ETPP = 199.744V∑= 1.927Vb+ 93.088Vθ + 1.599Vφ + 0.046Vij + 103.082Vel Equation 5.10
ECHT-TPP = 901.408V∑ = 18.542Vb + 514.621Vθ + 54.501Vφ + 28.920Vij - 1.065Vhb+ 285.889Vel[ΔEBINDING = -132.867kcal/mol]
Equation 5.11
Therefore, the controlled release behaviour of the enzyme-responsive colon-targeted oral
tablet may be attributed to the dense polymeric matrix formed due to this very crosslinking
mechanism of TPP. However, the enzymatic stimuli-responsive behaviour of this formulation
can be accredited to the action of the enzymes on specific bonding/functional sites on the
polysaccharides as shown in Figure 5.21 and Figure 5.22.
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Figure 5.21: Visualization of a) the polygalacturonase (PGU) (A Chain) and b) geometrical
preference of polygalacturonase (blue stick rendering and yellow secondary structure) in
complexation with pectin (tube rendering) after molecular mechanics simulations.  Color
codes: C (cyan), O (red) and H (white).
a)
b)
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Figure 5.22: Visualization of a) β-glucosidase (βGD) (A,B,C,D Chains), and b) geometrical
preference of β-glucosidase (yellow stick rendering and red secondary structure) in
complexation with chitosan (tube rendering) after molecular mechanics simulations. Color
codes: C (cyan), O (red), N (blue) and H (white).
b)
a)
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Equations 5.12 and 5.13 also confirmed the interaction potential of the enzymes with
polysaccharides accounting for stabilized negative binding energies of -146.042kcal/mol and
-64.283kcal/mol for PEC-PGU and CHT-βGD molecular complexes, respectively. The
complexes are mainly stabilized by London dispersion forces and ion pair-ion pair
electrostatic nonbonding interactions.
EPEC-PGU = -658.584V∑ = 13.458Vb + 78.405Vθ + 76.139Vφ - 80.142Vij - 21.833Vhb - 724.613Vel
[ΔEBINDING = -146.042kcal/mol]
Equation 5.12
ECHT- βGD = -518.293V∑ = 11.187Vb + 90.6291Vθ + 80.424Vφ - 86.47Vij - 12.503Vhb - 601.561Vel
[ΔEBINDING = -64.283kcal/mol]
Equation 5.13
5.4 Concluding Remarks
A novel enzyme-responsive colon-targeted oral tablet has been successfully formulated. The
tablet comprised of a range of naturally-derived polysaccharide polymers that imparted a
distinct responsiveness of the formulation to colonic enzymes. This responsiveness was
evidenced by the initiation and acceleration of 5-ASA release in the presence of these
enzymes as opposed to when the enzymes were absent from the simulated media. The
achievement of the desirable drug release characteristics were accompanied with evidence
relating the drug release to the effect of pectinase and β-glucosidase on the chemical
structure of the incorporated polymers, and consequently the degree of SCF uptake and
erosion by the tablet. In addition, SEM images further augmented the magnitude of the effect
of the enzymes on tablet. Moreover, the promise of the developed system is further
pronounced by evidence of the erratic, irreproducible and non-dependable 5-ASA release
from the conventional commercially available marketed 5-ASA containing product, Asacol®.
Therefore, the developed enzyme-responsive colon-targeted oral tablet imparted the benefits
of a multiparticulate system into a single-unit tablet.
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CHAPTER 6
FABRICATION AND STATISTICAL OPTIMIZATION OF THE PEPSIN-RESPONSIVE
POLYMERIC COATING THROUGH AN EXPERIMENTAL DESIGN STRATEGY
6.1 Introduction
6.1.1 Optimization of loperamide HCl treatment of chronic diarrhoea associated with
Ulcerative Colitis
Since its introduction in 1973, loperamide HCl has been widely employed for the effective
control and symptomatic relief of acute non-specific diarrhoea as well as chronic diarrhoea
associated with inflammatory bowel diseases such as Crohn’s Disease (CD) and Ulcerative
Colitis (UC) (Lavrijsen et al., 1995; Chen et al., 2000). Even though loperamide HCl exhibits
a strong affinity for opiate receptors in both the brain and myenteric plexus, in contrast to
opioids such as diphenoxylate, oral doses of loperamide HCl do not reach the blood-brain
barrier to any significant extent. Therefore, it does not cause opiate-like central nervous
system side-effects (Niemegeers et al., 1974; Schuermans et al., 1974; Wuster and Herz,
1978; Ooms et al., 1984; Ruppin, 1987; Schinkel et al., 1996; Baker and Meert, 2002).
The myenteric and submucosal plexuses of the enteric nervous system essentially comprise
of 3 types of opiate receptors namely, mu (µ), delta (δ) and kappa (κ) receptors. However
loperamide HCl exhibits preferential selectivity for the µ subtype of the opioid receptor (Ruoff
et al., 1991; DeHaven-Hudkins et al., 1999; Chen et al., 2000; Bohn and Raehal, 2006). This
µ-receptor resides within the myenteric plexus and through its binding with loperamide the
anti-motility effect is exhibited.
A study conducted by Verhaegen and co-workers established that the optimal therapeutic
dose of loperamide HCl for the treatment of chronic diarrhea due to IBD was as high as
18mg/day (Verhaegen et al., 1974). Thus based on the site and mechanism of the
therapeutic action of loperamide it is expected that by targeting the drug to the myenteric
plexus of the small and/or large intestine a greater therapeutic benefit will be experienced at
the same or reduced dosage. Therefore, the novel enzyme-responsive outer crosslinked
polymeric coating aims to exploit the stomach-specific enzyme, pepsin, to prevent/minimize
the premature release of loperamide HCl in the stomach, thus allowing a greater quantity of
the drug to reach the small intestine where its therapeutic action is achieved.
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6.1.2 Polymer vs. Pepsin
Unlike the activity of the proteolytic enzymes of the pancreas and small intestine the
behaviour of pepsin is peculiar. Essentially, pepsin is capable of accomplishing extensive
degradation of proteins without significantly resulting in an increase in titratable groups. Thus
it has been postulated that the specific character of peptic digestion by pepsin is due to the
disintegration of protein molecules into smaller fragments which are then united in the
original molecule by forces other than those of primary valence. Generally, the proteolytic
activity of pepsin results in a considerable excess of carboxyl groups released in relation to
the simultaneously released amino groups, leading to the impression that the –COOH groups
may form linkages within the  protein molecule with some other group other than the primary
–NH2 groups. However, this postulation is difficult to definitively prove (Cannan and
Muntwyler, 1930).
The biomacromolecule, gelatine, is obtained through the hydrolysis of collagen which exists
as the most abundant protein in the skin, connective tissue, bone and cartilage of animals.
This biopolymer is typically readily and extensively digested by pepsin. Apart from the
biocompatibility, biodegradability and low toxicity of gelatine, its natural origin also offers so-
called social advantages such as reduced waste disposal management (Farris et al., 2010).
Therefore, gelatine has typically been employed as a wall material for microcapsules and
microspheres, as a sealant for vascular prostheses and wound dressing, or furthermore as
an adsorbent pad for surgical purposes in clinical applications (Schrieber and Gareis, 2007;
Farris et al., 2010). More recently however it has been investigated for potential application in
tissue engineering and has also been used in conjunction with synthetic, biological or
inorganic molecules (Kang et al., 2006; Heydarkhan-Hagvall et al., 2008; Lien et al., 2008;
Farris et al., 2010).
Despite the numerous benefits of gelatine as a biopolymer its poor mechanical properties
and water sensitivity are recognized as the major hindrances that limit its more extensive use
(Lee and Mooney, 2001; Lee et al., 2004; Yasuda et al., 2005). Among the several
investigated approaches of overcoming these hurdles, chemical crosslinking remains the
most attractive and widely used technique that improves the thermal, mechanical and water-
sensitivity properties of gelatine (Liu et al., 2007; Farris et al., 2010). Several crosslinking
agents such as glyoxal, epoxides, isocyanates, formaldehyde and carbodiimides have been
investigated however glutaraldehyde is suggested to be the most effective due to its low cost
and excellent efficiency in stabilizing collagenous materials which ultimately improves the
strength and water resistance of gelatine (Sung et al., 1996; Khor, 1997; Sung et al., 1999;
Liang et al., 2004; Carvalho and Grosso, 2006; Bertoldo et al., 2007; Liu et al., 2007).
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Therefore, the outer pepsin-responsive intestinally-targeted polymeric coating aims to exploit
selected characteristic behaviours of pepsin on the protein molecule, gelatine, to achieve a
minimization of loperamide HCl release in the stomach and therefore a targeted delivery of a
greater quantity of the drug at the site of action in the small intestine. The loperamide HCl
containing coating, its passage through the gastrointestinal tract (GIT) as well as its site of
action is depicted in Figure 6.1.
Figure 6.1: Illustration of the stimuli-responsive oral tablet system (SROT) with the outer
pepsin-responsive coating and the site of action of encapsulated loperamide HCl in the
myenteric plexus of the small intestinal wall.
Outer pepsin-responsive coating
containing loperamide HCl
Inner colon-targeted tablet
containing 5-ASA
1. Oral administration
2. Minimal/no loperamide
HCl release in the stomach
3. Loperamide HCl release
targeted to the small intestine
Enlarged
cross-
section
Longitudinal muscle
Circular muscleMy nteric plexus
with µ-receptors
Serosa
Submucosa
Intestinal lumen
Mucosa
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Thus this chapter focussed on the development of an optimized outer pepsin-responsive
intestinally-targeted polymeric coating, through a statistically robust experimental design
approach.
6.2 Materials and Methods
6.2.1 Materials
Gelatine, glutaraldehyde (GA), loperamide HCl, and ethanol were obtained as described in
Chapter 4, sections 4.2.1 and 4.4.1. Lactose was supplied by Saarchem-Merck (UniLAB®,
Wadeville, Gauteng, South Africa). Imodium® was supplied by Janssen Pharmaceutica (Pty)
Ltd. (Woodmead, Johannesburg, South Africa). De-ionized water was obtained from a Milli-Q
water purification system (Milli-Q, Millipore, Billerica, MA, USA) and all other reagents were
of analytical grade and used without further purification.
6.2.2 Preparation of the outer pepsin-responsive intestinally-targeted polymeric
coating in accordance with a randomized Box-Behnken experimental design template
The outer pepsin-responsive loperamide HCl-loaded coating was prepared according to a 3
factor, 3 tier Box-Behnken experimental design (Minitab® V15, Minitab Inc., PA, USA) that
investigated 15 experimental formulations. The 15 formulations were derived from a set of
points lying at the mid-point of each edge and the replicated centre point of a multi-
dimensional cube (Patel et al., 2010). The coatings encapsulated the colon-targeted 5-ASA
loaded tablet as illustrated in Figure 6.1 and were prepared by a dip-coating process that
involved submerging the tablets in the aqueous drug-loaded gelatine solution. The dried
gelatine coatings were subsequently crosslinked in a moist mixture of GA and lactose for
various time periods. The response surface methods of the employed Box-Behnken design
enabled the examination of the relationship between the response variables and the set
experimental parameters which ultimately allowed the prediction of an optimized formulation.
The independent formulation variables were selected based on their influence in ensuring
minimal loperamide HCl release in the presence of pepsin, thus ensuring improved drug
targeting to the small intestine. The formulation input factors and the dependent measured
responses are shown in Table 6.1.
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Table 6.1: Independent variables and dependent measured responses of the outer pepsin-
responsive intestinally-targeted coating based on a 3 factor, 3 tier Box-Behnken experimental
design
Independent variables Values
Minimum Maximum
Gelatine (%w/v) 10 40
Crosslinking ratio (GA:lactose) 0.1250 0.2500
Crosslinking time (hours) 3 15
Dependent variables Objective
Maximize
Minimize
MDT (no pepsin)
MDT (pepsin)
 Gelatine concentration (%w/v) - the gelatine concentration range of 10-40%w/v was
selected based on the ability of the gelatine solution to form a uniform and reproducible
coating in preliminary screening studies. Concentrations <10%w/v and >40%w/v were
ineffective in forming the coating due to the solution viscosities encountered at each
extremity.
 Crosslinking ratio of GA to lactose - the crosslinking ratios of 0.1250, 0.1875 and 0.2500
denoted a GA:lactose ratio (mL/g) of 1:8, 1:6 and 1:4 respectively.
 Crosslinking  time (hours) - the crosslinking ratios and durations were selected based on
preliminary screening studies which identified a relationship between the concentration of
the gelatine solution, the crosslinking ratio and crosslinking time with the ability of the
coating to respond to pepsin for example, a shorter duration of crosslinking of a higher
concentration of gelatine provided an equivalent/improved pepsin-responsiveness
compared to a low concentration of gelatine and longer duration of crosslinking. In
addition, logistically it was also more suitable to investigate the shorter crosslinking
durations.
Quadratic response surfaces and second order polynomial models were generated to predict
the in vitro drug release characteristics of loperamide HCl in SGF with and without pepsin in
terms of the independent variables investigated. The drug release data and thus the
response parameters were analyzed by establishing the mean dissolution time of the
formulations in the presence (MDTP) and absence (MDT) of pepsin in SGF. By determining
the ability of the formulations to prevent drug release in the presence of pepsin the intestinal
targeting ability of the formulations can be indirectly established. The 15 formulations
investigated are depicted in Table 6.2.
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Table 6.2: Box-Behnken design template of the 15 statistically derived formulations for the
fabrication of the outer pepsin-responsive coating
Experimental Formulation Gelatin(%w/v)
Crosslinking ratio
(GA:lactose)
Crosslinking
time (hours)
1 10 0.1875 3
2 10 0.2500 9
3 25 0.1250 15
4 40 0.2500 9
5 25 0.2500 15
6 25 0.2500 3
7 25 0.1875 9
8 10 0.1875 15
9 25 0.1875 9
10 10 0.1250 9
11 40 0.1875 3
12 25 0.1875 9
13 40 0.1250 9
14 25 0.1250 3
15 40 0.1875 15
6.2.3 Preparation of the outer pepsin-responsive intestinally targeted polymeric
coating
6.2.3.1 Preparation of the crosslinked gelatine coatings prior to crosslinking
The fabrication process of the gelatine coatings prior to crosslinking is outlined in detail in
Chapter 4, section 4.4.2 with the exception that the concentrations of gelatine solutions,
crosslinking concentrations and crosslinking durations are prescribed according to the Box-
Behnken experimental design as depicted in Table 6.2. This preparatory process is
schematically illustrated in Figure 6.2. For the purpose of preparation of the experimental
design formulations the inner tablet was a placebo tablet comprising of lactose. The placebo
tablets were compressed into tablets of 13.6x4.5mm dimensions using a mini rotary tablet
press (Karnavati Mini Press II, Rimek Products, Gujarat, India) that ensured the identical
dimensions and shape of the 5-ASA loaded colon-targeted tablet as described in Chapter 5.
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Figure 6.2: Schematic illustration of the preparation of the outer gelatine coating surrounding
the inner tablet prior to crosslinking.
6.2.3.2 Crosslinking of the gelatine coatings
Crosslinking of the dried gelatine coatings surrounding the tablets was performed in the
relevant GA-lactose (v/w) concentrations. The crosslinking blend was prepared by thoroughly
combining the GA with lactose until ‘loose’ moist granules were obtained. The sealed mixture
was then placed in a convection oven (Memmert, Schwabach, Germany) maintained at 35°C
for 3 hours. Thereafter the tablets were submerged within the blend and allowed to crosslink
in the oven maintained at 35°C for the required period of time.
Maintain at 35°C
Gelatine powder
Stir for 3 hours
Water-Ethanol-
drug solution
Placebo
tablet
Dry at room temperature
Loperamide HCl
+ 3mL ethanol
Stir until completely dissolved
+ 50mL water
Ethanol-drug
solution
Gelatine-
drug
solution
Tablet with outer
gelatine coating
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6.2.4 Elucidation of the influence of the gelatine concentrations and crosslinking
parameters on the gravimetrical and dimensional properties of the formulations
In order to establish the influence of the concentration of the gelatine solution and the
crosslinking concentrations and durations on the physical properties of the tablets a
gravimetrical and dimensional study was conducted on all 15 experimental formulations
before and after coating with the gelatine solution, as well as after crosslinking. The relevant
weights were recorded and the weight increases calculated according to Equation 6.1.
100(%) 
i
if
Wt
WtWtWt Equation 6.1
Where Wt (%) is the percentage weight increase of each tablet, Wtf is the final weight after
coating or crosslinking and Wti is the initial weight of the tablets before coating and
crosslinking.
The dimensions of the formulations before and after coating with the gelatine solution, as
well as after crosslinking, were recorded in terms of the height (mm) and diametrical (mm)
changes using an electronic digital calliper. The points at which the height and diameter were
measured in each formulation were kept consistent and are depicted in Figure 6.3.
Figure 6.3: Points of dimensional measurements of each formulation.
The change in dimensions, expressed as a percentage, was then expressed based on
Equation 6.2.
100(%) 
i
if
D
DDD Equation 6.2
Where D (%) is the percentage increase in the dimensions, Df is the final dimensions after
coating and crosslinking in mm2 and Di is the initial dimensions before coating and
crosslinking in mm2. Note: Di and Df = height x diameter.
Diameter (mm)
Height (mm)
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6.2.5 Construction of calibration curves by spectroscopic determination of loperamide
HCl in simulated gastric and intestinal fluid
Calibration curves for loperamide HCl were conducted in simulated gastric fluid (SGF) (pH
1.2; 37°C) with and without pepsin as described in Chapter 4, section 4.4.3. A calibration
curve was also generated for loperamide HCl in simulated intestinal fluid (SIF) (pH 6.8; 37°C)
at a concentration range of 0-0.051mg/mL analyzed at a wavelength of 260nm. Linear curves
were plotted such that the observed absorbances from spectroscopic analysis were plotted
on the y-axis and the concentrations (mg/mL) on the x-axis. In SIF a regression coefficient of
0.997 was attained.
6.2.6 Determination of the quantity of drug entrapped within each non-crosslinked
gelatine coating
The determination of the quantity of loperamide HCl contained in each coating was
performed on the non-crosslinked coatings as these were capable of undergoing complete
dissolution thus ensuring release of all entrapped drug in the simulated medium.
Furthermore, since crosslinking of the gelatine coatings was not conducted in solution, the
possibility of ‘leaching out’ of drug during the crosslinking procedure bore no influence. Thus
determination of the quantity of loperamide HCl contained in each coating prepared
according to the Box-Behnken experimental design was conducted as described in Chapter
4, section 4.4.4.
6.2.7 In vitro drug release assessment of the outer loperamide HCl-loaded crosslinked
coatings in response to pepsin present in SGF
In vitro drug release studies were conducted according to parameters and conditions
specified in Chapter 4, section 4.4.5. In addition to subjecting the formulations to SGF (with
and without pepsin) for a period of 2 hours, these were also exposed to SIF for a period of 4
hours following the 2 hours in SGF. The dip rate, fluid temperature, mesh sizes and fluid
volume were kept consistent and sink conditions maintained throughout the study. Samples
were withdrawn at 30 minute intervals for the 2 hours in SGF, and every 2 hours in SIF.
Sample withdrawal, analysis and loperamide HCl quantification were performed as described
in Chapter 3, section 3.4.7. Samples were however analyzed at a maximum excitation
wavelength of 260nm in both SGF and SIF. Data was subsequently computed in a model-
independent manner. This involved the determination of the mean dissolution time of all
formulations after the 2 hours in SGF (MDT2), thus permitting a quantitative comparison of
the drug release behaviour of the formulations in the presence and absence of the gastric
enzyme pepsin and consequently establishing the pepsin-responsiveness of the coatings.
Furthermore, the gold-standard marketed loperamide HCl formulation, Imodium® was also
subjected to in vitro release studies based on identical parameters.
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6.2.8 Constrained statistical optimization of the outer pepsin-responsive intestinally-
targeted polymeric coating
Optimization of the outer pepsin-responsive intestinally-targeted coating was performed by
generating polynomial equations that related the dependent formulation responses and
independent variables. This statistical model was performed under constrained conditions
and incorporated the interactive and polynomial terms that enabled the establishment of a
formulation that possessed the desirable formulation characteristics. Therefore, for
optimization purposes the mean dissolution time (MDT) at 2 hours in the presence (MDTP) of
pepsin was minimized and MDT in the absence of pepsin was maximized.
6.2.9 Evaluation of the influence of pepsin on the SGF uptake ability and erosion of the
gelatine coatings
Since gelatine is primarily derived from collagen, it essentially consists of a mixture of water
soluble proteins that are readily and extensively digested by pepsin (Cannan and Muntwyler,
1930; Gold et al., 1997). However, it has been noted that crosslinking of gelatine results in a
polymer structure with improved strength and water resistance (Liu et al., 2007). Therefore to
elucidate the influence of pepsin on the crosslinked gelatine coating a simulated fluid uptake
study was conducted where the optimized formulation was subjected to identical conditions
as those employed during drug release studies however at 30 minute intervals for the first 2
hours in SGF and every 2 hours in SIF each formulation was removed from the dissolution
medium and allowed to drip-dry for a period of 2 minutes at room temperature to remove
excess SGF. The drip-drying process was conducted in a manner that ensured no
introduction of bias since the formulations were left remaining on the bottom mesh of the
glass cylinder of the Bio-Dis® apparatus and no physical ‘blotting’ of the formulations was
performed. As a control, this process was replicated in SGF without pepsin. Fresh samples
were used for each individual time point.
The degree of SGF and SIF uptake at each time point, expressed as a percentage, was then
determined based on the increase in weight of the formulations calculated according to
Equation 6.3. The weight of the hydrated coatings could be distinguished from the weight of
the tablets since once subjected to simulated media the coatings were detachable from the
tablets.
100(%))( 
i
ifuptake Wt
WtWtSIFSGF Equation 6.3
Where, Wtf is the weight of the hydrated coating at the relevant time point and Wti is
calculated by Equation 6.4.
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iWt Weight of tablet after crosslinking – weight of tablet before gelatine coating
Equation 6.4
The physical dimensions of the formulations could not be determined after exposure to SGF
since the outer coatings detached from the inner tablet structure.
Subsequent to establishing the influence of pepsin on the gravimetrical changes of the
formulations, the hydrated samples were dried in a convection oven at 40°C for 48 hours,
and allowed to cool under a fume hood for a further 30 minutes after which they were re-
weighed. The influence of pepsin on the erosion of the coating was then determined based
on Equation 5.4 (in Chapter 5), where Wti was calculated according to Equation 6.4.
6.2.10 Evaluation of the polymeric structural and vibrational frequency variations of
the outer pepsin-responsive coating and its components
The structures of gelatine, loperamide HCl, GA and the crosslinked gelatine coating were
assessed based on a FTIR method described in Chapter 5 section 5.2.10. Furthermore, the
samples acquired at each time point from the previously described erosion study (in the
presence and absence of pepsin) were also assessed by FTIR. This was performed to
categorically elucidate the influence of pepsin on the polymeric backbone structure of the
crosslinked gelatine coatings and to divulge critical mechanistic characteristics of the action
of pepsin on the structure of the crosslinked coatings and to relate this information to the
relevant drug release characteristics.
6.3 Results and Discussion
6.3.1 Processing conditions for preparation of the outer pepsin-responsive
crosslinked gelatine coatings
6.3.1.1 Temperature of gelatine solutions during coating
Gelatine exhibits gel-forming properties at ±35°C. Below this temperature aqueous gelatine
solutions, irrespective of the concentration, solidify to form a semi-solid gel. Consequently,
this solidification makes it impossible to apply the gelatine as a coating surrounding the
tablets. Therefore, in preparation of the gelatine coatings, each solution in concentrations
prescribed by the Box-Behnken experimental design was maintained at 35°C for the duration
of the coating procedure.
6.3.1.2 Crosslinking method and process parameters
The method of crosslinking the gelatine coatings was based on a method of stressing hard
gelatine capsules established by Colé and colleagues in 1997. However this method was
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substantially altered in that instead of contaminating the lactose with the vapour of GA, a
known volume of GA with a known concentration was added to the lactose. The GA-lactose
combinations invariably resulted in the formation of slightly moist granules. Crosslinking of
the gelatine coatings was then performed by submerging each tablet within the moist mixture
and allowing crosslinking to occur at 35°C. The gel-forming property of gelatine at this
temperature ensured that the GA from the GA-lactose combination was capable of
permeating the gelatine coating to ensure crosslinking.
6.3.2 The influence of gelatine concentrations and crosslinking parameters on the
dimensional and gravimetrical properties of the formulations
Dimensional analysis of the 15 experimental formulations revealed a correlation between the
concentration of the gelatine solution employed for preparation of the coating and the
percentage increase in the dimensions of the tablet inclusive of the coating and the average
thickness of the coatings alone. This relationship is depicted in Figure 6.4 where the values
above each bar represent the concentration of gelatine (%w/v) employed in that formulation.
Based on the histogram it is evident that with increasing gelatine concentrations there is a
complementary increase in the average thickness of the coatings and consequently an
increase in the overall dimensions of the tablets. Conversely, it is also established that the
tablets coated with the lowest concentration of gelatine (10%w/v) underwent the greatest
increase in the dimensions of the tablets (%) after crosslinking of the gelatine coatings,
irrespective of the crosslinking concentrations and durations.
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Formulation no.
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Figure 6.4: Stacked histogram of all 15 formulations depicting the relationship between the
concentrations of gelatine employed, the increase in dimensions of the tablets and the
thickness of the coatings.
Furthermore a comprehensive assessment of the changes of various aspects of the
dimensions of the formulations is also provided in Table 6.3. Despite the manual dip-coating
process, all formulations exhibited a relatively consistent thickness. This is evident from the
thickness of the coatings when determined from the height and diametrical aspect of the
tablet which exhibited a standard deviation of 0.03-0.3, dependent on the concentration of
gelatine employed.
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Table 6.3: Increase in dimensions of the tablets after each preparatory step and the average
thickness of the coatings after crosslinking
Form. Increase in dimensions of tablets (%) Thickness of coating (mm)
1After
gelatine
2After
crosslinking
3Total
increase
4Height 5Diameter Average Difference
1 2.39 10.23 14.32 0.76 0.56 0.66 0.14
2 1.73 9.35 11.24 0.69 0.31 0.50 0.27
3 10.17 11.56 22.90 1.12 1.06 1.09 0.04
4 29.63 2.54 32.92 1.58 1.41 1.50 0.12
5 11.55 8.23 20.74 1.09 0.81 0.95 0.20
6 9.52 4.46 14.41 0.73 0.66 0.70 0.05
7 16.09 4.97 21.85 1.09 0.94 1.02 0.12
8 3.74 11.97 16.16 0.86 0.62 0.74 0.16
9 14.64 3.74 18.93 0.96 0.80 0.88 0.11
10 2.55 16.25 19.21 1.03 0.71 0.87 0.23
11 27.93 3.62 32.57 1.57 1.38 1.48 0.14
12 12.29 4.06 16.84 0.92 0.86 0.89 0.04
13 23.65 6.71 31.94 1.49 1.45 1.47 0.03
14 12.79 5.90 19.45 0.85 1.03 0.94 0.13
15 30.98 3.37 35.41 1.79 1.37 1.58 0.30
1Df=dimensions after gelatine coating, Di=dimensions of the tablet before coating2 Df=dimensions after crosslinking of gelatine coating, Di=dimensions after gelatine coating3 Df=dimensions after crosslinking of gelatine coating, Di=dimensions of tablet before coating4 Average height of tablet after crosslinking - average height of tablet before gelatine coating
5 Average diameter of tablet after crosslinking - average diameter of tablet before gelatine
coating
The 3D-scatter plot depicted in Figure 6.5 revealed that formulations 5, 6, 7, 9, and 12
showed ‘clumping’ since they all exhibited similar increases in weight after gelatine coating
and crosslinking. These formulations possessed a commonality of being coated with a
25%w/v gelatine solution, with a crosslinking concentration of either 0.1875 or 0.2500.
Furthermore, the formulations coated with a 10%w/v concentration of gelatine exhibited a
greater percentage increase in weight after crosslinking compared to after coating with the
gelatine solution.
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Figure 6.5: 3D-scatter plot of the experimental formulations vs. the percent increase in
weight after coating with gelatine vs. the percent increase in weight after crosslinking.
Furthermore, irrespective of the gelatine concentration, a crosslinking ratio of 0.1250 resulted
in the highest percentage of increase in weight after crosslinking as depicted in Figure 6.6.
Figure 6.6: Stacked histogram of the influence of crosslinking durations and concentrations
on the percent increase in weight of the formulations after crosslinking.
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6.3.3 Drug content per coating in relation to the concentration of gelatine employed
The quantity of drug contained within each coating appeared to increase with increasing
concentrations of the gelatine solutions employed, as depicted in Figure 6.7. Furthermore,
the variation in drug content between different formulations prepared with a 10%w/v solution
of gelatine was substantially greater than the formulations prepared with the 25%w/v and
40%w/v concentrations.
Figure 6.7: Drug content within the coatings based on the concentration of the gelatine
employed.
6.3.4 Box-Behnken experimental design for the optimization of the outer pepsin-
responsive intestinally-targeted coating
6.3.4.1 Measured responses for experimental optimization
The in vitro drug release profiles of all 15 experimental formulations revealed that
irrespective of the concentration of gelatine employed, the crosslinking concentration or the
crosslinking duration all formulations exhibited a distinct responsiveness to the enzyme
pepsin present in the simulated gastric medium. However the degree of this responsiveness
varied between all formulations. Figure 6.8 shows that formulations 1-5 exhibit less than 0.2
fractional release of loperamide HCl in the 2 hours in SGF with pepsin, however only
formulations 1, 2, 3, and 5 have between 0.8-1.0 fractional release in SIF. Even though
formulation 4 only releases 0.0928 of loperamide HCl in the presence of pepsin, in the
absence of pepsin only a relatively small quantity of the contained drug is released thus
making the degree of pepsin-responsiveness less prominent. Formulations 6-10 exhibited
similar responsiveness to pepsin with less than 0.2 fractional release in the presence of
pepsin compared to 100% release in the absence of pepsin. Furthermore, these formulations
exhibited complete drug release in SIF. Figure 6.8c provides evidence that formulations
coated with 40%w/v gelatine solutions showed the least distinct pepsin-responsiveness since
Drug content (mg)
0 5 10 15 20 25 30
Ge
lat
ine
co
nc
en
tra
tio
n (
%w
/ v)
10%w/v gelatine
25%w/v gelatine
40%w/v gelatine
145
Time (hours)
0 1 2 3 4 5 6
Fra
ctio
na
l D
rug
 Re
lea
se
0.0
0.2
0.4
0.6
0.8
1.0
F9 (P)
F9
F10 (P)
F10
Time (hours)
0 1 2 3 4 5 6
Fra
ctio
na
l D
rug
 Re
lea
se
0.0
0.2
0.4
0.6
0.8
1.0
F5 (P)
F5
F6 (P)
F6
Time (hours)
0 1 2 3 4 5 6
Fra
ctio
na
l D
rug
 Re
lea
se
0.0
0.2
0.4
0.6
0.8
1.0
F7 (P)
F7
F8 (P)
F8
Time (hours)
0 1 2 3 4 5 6
Fra
ctio
na
l D
rug
 Re
lea
se
0.0
0.2
0.4
0.6
0.8
1.0
F1 (P)
F1
F2 (P)
F2
Time (hours)
0 1 2 3 4 5 6
Fra
ctio
na
l D
rug
 Re
lea
se
0.0
0.2
0.4
0.6
0.8
1.0
F3 (P)
F3
F4 (P)
F4
Time (hours)
0 1 2 3 4 5 6
Fra
ctio
na
l D
rug
 Re
lea
se
0.0
0.2
0.4
0.6
0.8
1.0
F11 (P)
F11
F12 (P)
F12
for example in formulation 11, 0.0778 fractional release was observed in the presence of
pepsin compared to 0.1456 in the absence of pepsin.
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Figure 6.8: Composite fractional drug release profiles of formulations a) 1 and 2, b) 3 and 4,
c) 5 and 6, d) 7 and 8, e) 9 and 10, f) 11 and 12, g) 13 and 14, and h) 15, where ‘P’ denotes
simulated gastric fluid containing pepsin.
A model independent time-point approach was employed as a means of effectively
assessing the pepsin-responsiveness of all 15 experimental formulations by essentially
determining the mean dissolution time (MDT) of all formulations in the presence and absence
of pepsin in SGF after 2 hours. MDT was calculated by Equation 5.5 in Chapter 5. As
previously described all 15 experimental formulations exhibited responsiveness to pepsin,
however the optimum degree of responsiveness had to be established by identifying a
formulation that provided minimal release in SGF containing pepsin whilst ensuring
maximum release when SGF is void of pepsin. Based on the tabulated MDT values depicted
in Table 6.4 it is evident that formulations 4, 11, 13 and 15 provided the least preferable MDT
with MDT and MDTP both<1. This correlates with the in vitro drug release profiles which
previously identified the formulations coated with a 40%w/v gelatine solution as the least
pepsin-responsive.
g) h)SGF SGF
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Table 6.4: Mean dissolution time (MDT2) of all 15 experimental formulations in the presence
and absence of pepsin in simulated gastric fluid
Experimental Formulation MDT2 (hours) 1MDT2 (P) (hours)
1 2.72 0.25
2 2.47 0.00
3 2.93 0.21
4 0.91 0.24
5 2.27 0.48
6 2.53 0.27
7 2.88 0.18
8 3.16 0.57
9 2.76 0.14
10 3.01 0.42
11 0.42 0.22
12 2.81 0.20
13 0.50 0.29
14 1.76 0.34
15 0.60 0.24
1MDT calculated in SGF containing pepsin
6.3.4.2 Correlation of the experimental and predicted response values
A comparison of the experimental and predicted MDT values of the outer pepsin-responsive
coating in SGF revealed the suitability of the regression model of the Box-Behnken
experimental design. This was deduced based on the close correlation of the predicted and
experimental MDT values (in the absence of pepsin) as depicted in Figure 6.9 which
presented with an R2 value of 0.996.
Figure 6.9: Regression plot of the experimental vs. predicted mean dissolution time values in
simulated gastric fluid void of pepsin.
Similarly, the regression plot of the predicted vs. experimental MDT values in the presence of
pepsin also presented with an overall close correlation, however several formulations
deviated substantially from the predicted MDT values resulting in a R2 of 0.806 (Figure 6.10).
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Figure 6.10: Regression plot of the experimental vs. predicted mean dissolution time values
in simulated gastric fluid containing pepsin.
6.3.4.3 Analysis of the Box-Behnken Response Surface Design
6.3.4.3.1 Response analysis for MDT
Response surface plots of the mean dissolution time (MDT) of the experimental formulations
in the absence of pepsin identified a maximization of the MDT principally with a 10-20%w/v
gelatine concentration, at crosslinking times ranging from 3-15 hours, when a GA-lactose
ratio of 0.1875 is implemented. Conversely, a reduced MDT is observed with a 40%w/v
gelatine solution across the 3-15 hour crosslinking time periods (Figure 6.11a). A similar
relationship is observed between the gelatine concentration and GA-lactose concentration
ratios where an increased MDT is evident from formulations with gelatine concentrations
between 10-20%w/v, across all GA-lactose ratios (Figure 6.11b). Furthermore, with a gelatine
concentration hold value of 25%w/v a maximal MDT is only achievable at a GA-lactose ratio
of 0.15 or 1:4, when crosslinking is performed for 12-15 hours (Figure 6.11c).
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Figure 6.11: Response surface plots correlating mean dissolution time in simulated gastric
fluid without pepsin with a) gelatine concentration and crosslinking time (glutaraldehyde-
lactose hold value of 0.1875), b) gelatine concentration and glutaraldehyde-lactose ratio
(crosslinking time hold value of 9 hours), and c) glutaraldehyde-lactose ratio and crosslinking
time (gelatine concentration hold value of 25%w/v).
6.3.4.3.2 Response analysis for MDTP
To analyse the efficacy of the outer pepsin-responsive coating, the mean dissolution time in
the presence of pepsin (MDTP) should be minimized thus enabling the determination of the
intestinal targeting ability of the formulation. Thus based on response surface plots a minimal
MDTP is achieved at a gelatine concentration of 10-20%w/v and crosslinking duration of 4-6
hours. However, this reduced MDTP is also achievable across the entire gelatine
concentration range (10-40%w/v) when crosslinking is performed for between 6-12 hours
(Figure 6.12a). Figure 6.12b illustrates the trend where with an increasing concentration of
gelatine, a higher GA-lactose ratio is required to obtain a minimal MDTP, for example at a
gelatine concentration of 10%w/v a GA-lactose ratio of 0.25 is necessary for a reduced MDTP,
whereas at a concentration of 40%w/v a GA-lactose ratio of 0.15 is required. Furthermore,
with a 25%w/v gelatine concentration hold value, a GA-lactose ratio between 0.1875-0.25 and
crosslinking time of 3-6 hours is required for minimization of MDTP (Figure 6.12c).
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Figure 6.12: Response surface plots correlating mean dissolution time in simulated gastric
fluid with pepsin with a) gelatine concentration and crosslinking time (glutaraldehyde-lactose
hold value of 0.1875), b) gelatine concentration and glutaraldehyde-lactose ratio (crosslinking
time hold value of 9 hours), and c) glutaraldehyde-lactose ratio and crosslinking time
(gelatine concentration hold value of 25%w/v).
6.3.4.4 Residual analysis of the Box-Behnken experimental design for optimization of
the outer pepsin-responsive intestinally-targeted coating
The suitability of the multiple regression model was assessed based on the residual plots for
MDT and MDTP as depicted in Figure 6.13. The normal probability plots of the residuals of
MDT showed a normal distribution of data points on a linear line with ‘clustering’ along the
line. MDTP also showed data points falling uniformly on a linear line with the absence of
‘clustering’. The residual plots of the standardized residuals versus the fitted values for both
MDT and MDTP exhibited a random distribution of data points with no discernible pattern.
Furthermore, since the points fluctuated around zero, the assumptions of zero-means and
constant variance of the regression model held true. Finally, the plot of the residuals versus
the order of data also showed a random distribution of data points with rapid changes in the
signs (+/-) between consecutive residuals.
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Figure 6.13: Residual plots of a) mean dissolution time in the absence of pepsin and b)
mean dissolution time in the presence of pepsin.
A full ANOVA analysis of the measured formulation responses revealed that none of the
factors of MDTP exhibited any significant influence with p≥0.05. However numerous factors of
MDT showed statistical significance with p-values ≤0.05. These are depicted in Table 6.5.
a)
b)
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Table 6.5: Estimated p-values for mean dissolution time in the absence (MDT) and presence
of pepsin (MDTP)
Term p-valueMDT MDTP
[Gelatine] 0.000 0.567
[GA:lactose ratio] 0.965 0.523
Crosslinking time 0.013 0.333
[Gelatine]*[Gelatine] 0.000 0.681
[GA:lactose ratio]*[GA:lactose ratio] 0.032 0.626
Crosslinking time*crosslinking time 0.032 0.172
[Gelatine]*[GA:lactose ratio] 0.021 0.235
[Gelatine]*Crosslinking time 0.424 0.329
[GA:lactose ratio]*Crosslinking time 0.004 0.268
The complete regression equations generated for mean dissolution time in the absence of
pepsin (MDT) and presence of pepsin (MDTP) are depicted in Equations 6.5 and 6.6
respectively.
time]ngCrosslinki*ratiolactose:A0.949119[G-time]ngCrosslinki*e04[Gelatin-6.94367E-
ratio]lactose:GA*elatine0.253747[Gtime]ngCrosslinki*timeing[Crosslink0.00612126-
ratio]lactose:GA*ratiolactose:56.3748[GA-Gelatine]*[Gelatine0.00386296-
time]grosslinkin0.337375[Cratio]lactose:23.3017[GAGelatine]0.0773553[-1.06288MDT


Equation 6.5
time]ngCrosslinki*ratiolactose:A0.229599[G-time]ngCrosslinki*e04[Gelatin-8.31791E-
ratio]lactose:GA*Gelatine0.0995970[time]ngCrosslinki*timeing[Crosslink0.00319061
ratio]lactose:GA*ratiolactose:9.57342[GAGelatine]*4[Gelatine0.00013950
time]ngCrosslinki0.0709428[-ratio]lactose:8.68395[GA-Gelatine][0201592.059332.1MDTP



Equation 6.6
6.3.4.5 Constrained optimization of the outer pepsin-responsive intestinally-targeted
coating
The optimization process and thus determination of the optimum level for each formulation
variable was performed employing Minitab® V15 statistical software. Ultimately the
optimization approach resulted in a formulation with a desirability of 1.00 and which included
a gelatine concentration of 14.379%w/v, a GA:lactose ratio of 0.1810 and a crosslinking time
of 6.060 hours (Figure 6.14).
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Figure 6.14: Optimization plots displaying factor levels and desirability values for the
optimized formulation.
The optimization approach provided an optimized formulation with a predicted MDT of 3.00
and a statistical desirability of 100% however data on the experimental formulation resulted
in an MDT of 2.84 with a deviation of 0.114 from the predicted value. In comparison, the
experimental MDTP value deviated from the predicted MDTP value by only 0.059 (Table 6.6).
Table 6.6: Comparison of the predicted vs. experimental values of the response parameters
Response parameter Predicted
1Desirability
(%) Experimental
2Deviation
(%)
Mean Dissolution Time (MDT)
(no pepsin) 3.00 100 2.8382 0.114
Mean Dissolution Time (MDTP)(with pepsin) 0.20 100 0.2836 0.059
1 Statistical desirability values of the predicted optimized formulation
2 Deviation of the experimental response values from the predicted
The close correlation of the experimental and predicted MDT and MDTP values suggest the
reliability of the optimization process. Moreover, the optimization process proved efficient in
predicting the in vitro drug release behaviour of the outer polymeric coating in response to
pepsin which ultimately insinuated toward the intestinal targeting ability of the formulation.
The optimized formulation contained an average of 6.731±0.861mg of loperamide HCl.
Subsequent to coating and crosslinking of the gelatine coatings the tablets experienced an
average of 2.92±0.049% increase in the overall dimensions and an average weight increase
of 7.93±0.033%.
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The in vitro release profile depicted in Figure 6.15 illustrates the pepsin-responsiveness of
the optimized formulation. It is evident that within the 90 minutes in SGF void of pepsin
complete loperamide HCl release was achieved whereas in this same time only 0.182
fractional drug release was achieved in the presence of pepsin. Essentially complete drug
release was then achieved within the 4 hours in SIF cementing the intestinal targeting ability
of the optimized outer coating.
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Figure 6.15: Fractional drug release profile of loperamide HCl from the optimized outer
coating in the presence and absence of pepsin in simulated gastric fluid.
In vitro drug release studies conducted on the conventional commercially available
loperamide HCl formulation, Imodium®, resulted in complete disintegration and thus complete
release of loperamide HCl within the first 5 minutes of dissolution studies in SGF (N=3), in
the presence and absence of pepsin.
6.3.5 The effect of pepsin on the swelling and erosion of the outer pepsin-responsive
coating
The influence of pepsin on the outer crosslinked gelatine coatings was assessed
gravimetrically and the results depicted in Figure 6.16. Figure 6.16a illustrates the
substantially greater percentage weight gain of the formulations in SGF without pepsin for
the entire 6 hour duration, signifying the greater degree of swelling in the absence of pepsin.
Nevertheless, despite the reduced weight increase in the presence of pepsin, the
formulations follow an almost identical pattern of weight increase to those not exposed to
pepsin (Figure 6.16b).
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Figure 6.16: a) Histogram of the weight increase (%) of the optimized outer coating in the
presence and absence of pepsin, b) illustration of the similar pattern of weight increase (%)
in the presence and absence of pepsin.
Subsequent to the weight increase study, the hydrated samples were dried and also
gravimetrically evaluated to assess the loss in weight of the formulations as a consequence
of its exposure to pepsin for the various time periods. Figure 6.17 illustrates the difference in
the weight of the optimized formulation in the presence and absence of pepsin and distinctly
shows the greater loss in weight of the formulations exposed to pepsin in SGF.
Figure 6.17: Histogram of the difference in the loss in weight of the optimized coatings due
the presence of pepsin in simulated gastric fluid.
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Figure 6.18: Digital images of the stimuli-responsive oral tablet system with a) the outer
pepsin-responsive coating, b) the hydrated coating after 2 hours in simulated gastric fluid
with pepsin and c) the hydrated coating after 2 hours in simulated gastric fluid without pepsin.
6.3.6 Explication of the reaction mechanism involved in crosslinking gelatine with
glutaraldehyde
Essentially, gelatine contains extended left-handed proline helix conformations which are
incorporated with 300 to 4000 amino acids. However the most prominent of these amino acid
residues include glycine which is arranged to every third residue in its structure, proline and
4-hydroxyproline. The other constituting amino acids are depicted in Table 6.7.
Table 6.7: Amino acid composition of pigskin and bovine hide gelatine (Talebian et al., 2007;
Farris et al., 2010)
Amino acid
Pigskin
gelatine
(mol %)
Bovine hide
(mol %) Amino acid
Pigskin
gelatine
(mol %)
Bovine hide
(mol %)
Alanine 11.05 10.88 Leucine 2.35 3.00
Arginine 4.96 9.90 Lysine 2.65 3.46
Asparagine 0.60 - Methionine 0.32 0.42
Aspartic acid 4.4 7.46 Phenylalanine 1.38 1.99
Glutamic acid 7.10 11.28 Proline 13.10 12.52
Glycine 32.20 32.63 Serine 3.40 3.62
Histidine 0.45 0.77 Threonine 1.80 2.11
Hydroxyproline 9.80 - Tyrosine 0.35 0.40
Hydroxylysine 0.75 - Valine 1.90 2.18
Isoleucine 1.02 1.44
a)
c)
b)
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The strength of gelatine is attributed to its triple helix conformation such that the greater the
triple-helix content, the higher the strength of the film and as a consequence the lower the
swelling property of gelatine in water (Oakenfull and Scott, 2003; Bigi et al., 2004). However,
the gelling/swelling properties of gelatine can be altered by introducing chemical crosslinks
between particular amino acid residues (Pal et al., 2007).
The fundamental evidence of crosslinking of gelatine with GA is essentially observable from
the obvious improvement in the mechanical properties, water resistance, and proteolytic
resistance of the coating, however evidence may also be provided based on the FTIR
spectra obtained of the crosslinked coatings in relation to the components thereof. Generally,
the crosslinking chemistry of the aldehyde groups of GA with the free non-protonated ε-
amino groups (-NH2) of lysine or hydroxylysine occurs through a nucleophilic addition type
reaction. In addition, it has been established that neutral to slightly alkaline pH values are
more favourable to crosslinking gelatine since pH directly influences the charge density and
charge distribution of gelatine thus affecting the degree of protonation of –NH2 groups and
the presence of negative charges on the carboxylic groups (Farris et al., 2010).
FTIR spectra of gelatine revealed several characteristic bands such as the very broad band
at 2600-3400cm-1 attributable to H-bonded OH stretching of the –COOH groups present on
the protein molecule. Furthermore, the broad band at 3284cm-1 of gelatine presented with a
‘shoulder’ at the region of 3500cm-1. This ‘shoulder-like’ peak corresponds to the non-bonded
–OH stretching band of gelatine. However, this peak disappears in the spectrum of the
crosslinked gelatine coating and thus provides evidence of the involvement of the –OH
groups with GA during crosslinking (Figure 6.19).
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Figure 6.19: FTIR spectra of the components of the outer pepsin-responsive coating, as well
as the spectrum of the crosslinked coating.
In the gelatine molecule the peak at 1626cm-1 is indicative of an amide I band, mainly
associated with the C=O stretching vibration, however since this peak shifts to 1631cm-1 in
the FTIR spectrum of the crosslinked gelatine coating it suggests that the carbonyl groups of
the amino acids are also likely involved in the crosslinking reaction. Moreover, the peak at
1523cm-1 of gelatine due to an amide II band originating from N-H bending vibration and the
C-N stretching vibration shifts to 1535cm-1 in the spectrum of the crosslinked coating. This
shifting of peaks essentially provides evidence that the amide groups may be involved in the
crosslinking reaction to form Schiff bases. Based on the evident shifts of these prominent
peaks it can be deduced that the crosslinking reaction between GA and gelatine occurs at an
acidic pH value where GA interacts with other functional groups on the gelatine molecule
along with the few unprotonated amino groups that still exist at low pH’s. The crosslinking
chemistry can thus be explained by the reaction mechanism proposed by Farris and
colleagues in 2010 (Figure 6.20).
Essentially, the α-carbon of GA forms a highly reactive carbocation resulting in the
nucleophilic attack of the –OH groups of hydroxyproline and hydroxylysine of gelatine. A
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hemiacetal is thus formed and H+ is regenerated. Due to the homogenous charge distribution
along the hemiacetal oxygen bridge a stable system is obtained.
Figure 6.20: Proposed crosslinking reaction mechanism between gelatine and
glutaraldehyde (Farris et al., 2010).
In addition, nucleophilic addition of the free unprotonated amino groups to the C=O groups of
GA occurs to form a tetrahedral unstable intermediate, carbinolamine. Thereafter, the –OH
groups become protonated and a water molecule is lost. Consequentially, a conjugated
Schiff base is formed (Farris et al., 2010).
6.3.7 The effect of pepsin on the structural variations and polymeric backbone of the
loperamide HCl-loaded crosslinked gelatine coatings
A significant peculiarity of pepsin lies in its ability to accomplish extensive proteolytic
degradation without significantly increasing the presence of titratable groups. It has been
suggested that this may be due to the disintegration of the protein molecule into smaller
fragments which become united in the original molecule. The fundamental basis of pepsin
action on gelatine occurs due to the hydrolysis of peptide linkages between the α-amino and
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α-carboxyl groups of amino acids. However, the inequivalent liberation of –COOH and –NH2
molecules leads to the impression that linkages may occur in the protein molecule in which –
COOH is united to some other group other than primary -NH2 groups (Cannan and
Muntwyler, 1930). This theory may be supported by the FTIR spectra attained of the
crosslinked gelatine coatings after exposure to simulated media with and without pepsin for
0.5 hours and 2 hours (Figure 6.20).
Figure 6.21: FTIR spectra of crosslinked gelatine coatings after exposure to simulated
gastric fluid with and without pepsin for a) 0.5 hours, and b) 2 hours.
Date: Monday, September 06, 2010
4000.0 3000 2000 1500 1000 650.0
33.8
40
45
50
55
60
65
70
75
80
85
90
95
99.5
cm-1
%T
0.5 P
0.5 NP
3280.23
2936.40
1627.27
1529.32
1445.35
1333.52
1233.73
1080.281031.11
3282.61
2934.68
1529.85
1447.53
1333.84
1233.50
1079.73
1031.09
a)
b)
No pepsin
With pepsin
No pepsin
With pepsin
161
Since an excess of –COOH is liberated during proteolytic degradation of pepsin, the FTIR
spectra suggest that at 0.5 hours (in the absence of pepsin) the reduction in the intensity of
the peak at ~3280cm-1 is attributable to the loss of –COOH in SGF due to the dissolution of
the uncrosslinked gelatine (Figure 6.21a). Similarly, there is a reduction in the intensity of the
peak at 1627cm-1 due to loss of –NH2 groups in solution. In contrast, the peaks at 3282cm-1
and 1627cm-1 from formulations exposed to pepsin, showed a relatively greater intensity
suggesting that both the –COOH and –NH2 groups remain on the crosslinked molecule
probably due to the formation of a complex on the existing molecule subsequent to
proteolytic cleavage of the relevant groups.
After exposure of the crosslinked formulations to SGF with and without pepsin for 2 hours,
the relative difference in the intensity of the 2 spectra are much less pronounced. This may
be due to the subsequent dissolution of the newly formed complexes. In addition, the peaks
between 1445-1031cm-1 of the spectra attained from the formulations exposed to SGF for 0.5
hours and 2 hours are indicative of loperamide HCl presence in the coating (Figure 6.21b).
These FTIR spectra provide the reason for the minimization of loperamide HCl in the
presence of pepsin, where only 0.233 fractional release was observed compared to complete
loperamide HCl release in the absence of pepsin after 2 hours. In addition the reduced ability
of the crosslinked coatings to absorb SGF containing pepsin and the reduced erosion of the
formulations exposed to pepsin is also validated.
6.4 Concluding Remarks
Through the construction and experimental investigations performed in accordance with the
Box-Behnken experimental design, an optimized outer pepsin-responsive intestinally-
targeted coating was formulated. The pepsin-responsive ability of the formulation was
evident from the minimal loperamide HCl release in SGF containing pepsin compared to
when pepsin was absent. Furthermore, on entry to simulated small intestinal conditions
complete drug release was achieved. The drug release characteristics of the formulation
could also be related to its ability to absorb SGF and its erosion at each time point.
Ultimately, the pepsin-responsiveness and the intestinal-targeting ability of the formulation
were as a result of the unique crosslinking method employed as well as the distinct action of
pepsin on these crosslinked formulations.
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CHAPTER 7
IN VIVO EVALUATION OF THE STIMULI-RESPONSIVE ORAL TABLET SYSTEM IN
THE PIG MODEL
7.1 Introduction
In the evolving and critical field of human medical research in particular, drug delivery design,
the search for an ideal experimental animal model which is analogous to humans in as many
aspects as possible, proves to be daunting. Nevertheless, even prior to the 1960’s it had
been noted that “pigs are just not pigs, but almost humans” (Douglas, 1972). Pigs have
extensively been used to study the rate of passage of food through the gastrointestinal tract
(GIT) due to the anatomical comparability of the GIT as well as the similar total body weight
ranges to humans (Castle and Castle, 1956; Castle and Castle, 1957; Kidder et al., 1961;
Ochia, 1973; Pond and Houpt, 1978). Furthermore, due to the many biological similarities,
data obtained from the pig model is sufficient for extrapolation to man (Bustad and
McClellan, 1968; Oberle and Das, 1994).
7.1.1 The stomach
The anatomical and functional diversities of the GIT of different species exist as a direct
influence of their dietary preferences (Steves and Humes, 1995; Cunningham, 1997). The
stomach of the pig, like humans, is differentiated into 4 regions with each region responsible
for specific physiological functions. Essentially, only the proper gastric region (fundus) and
pyloric region secretes pepsinogen, intrinsic factor, hydrochloric acid and gastrin. The top 2
regions namely, the nonglandular stratified squamous region and the cardiac region, are
relatively larger in man than in pigs and are solely responsible for mucus and bicarbonate
production (Martinez et al., 2002).
Normally food is emptied in a bimodal manner from the stomach of pigs with 30-40% of
ingested material entering the duodenum within 15 minutes. Essentially, food passes through
the stomach and small intestine much more rapidly than through the large intestine (Auffrey
and Martinent, 1967; Pond and Houpt, 1978). Gastric emptying is typically incomplete so
food may constantly be present in the stomach leading to the false perception regarding the
fasted state of the pig. The migrating myoelectric complex (MMC) responsible for the gastric
emptying of indigestible solids occurs with a periodicity of 2 hours in man in the fasted state
compared to 75-80 minutes in pigs (Szurszewski, 1969; Code and Marlett, 1975, Feldman et
al., 1984; Kumar et al., 1986; Gupta and Robinson, 1988).
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7.1.2 The small intestine
Pigs, as omnivores, possess a well-developed small intestine and a more complex lower
intestine to compensate for their diverse diet. The differences in the transit time through the
small intestine of different species may be related to the disproportionate relationship
between the body length and intestinal length. However, pigs in particular have a body length
to intestinal length ratio of 1:14, and an approximate small intestinal length of 16-21m
(Argenzio, 1984). Furthermore, due to the low pH of the stomach, jejunum and upper ileum
there are a limited number of microorganisms that can exist in these regions resulting in the
minor role played by intestinal microflora on the metabolism of most drugs (Martinez et al.,
2002).
7.1.3 The large intestine/colon
In the GIT of monogastric species the colon houses the largest population of microorganisms
and thus is a major site of production and absorption of volatile fatty acids in sheep, pigs,
rabbits, rats, dogs and humans (Kararli, 1995). Furthermore, due to the particularly similar
diets of man and pig the population of colonic flora in these species are greatly similar
(Yamada et al., 1995; Gardner et al., 1996). The structural and anatomical differences of the
large intestine of monogastric mammalian species in particular pigs vs. humans are
illustrated in Figure 7.1.
Even though the GIT of the pig has numerous anatomic differences from humans, the
physiology however remains similar and thus has extensively been used as a gastrointestinal
model. The specific functional characteristics of pigs GIT that relate them directly to humans
include the ion transport, motility, and splenic blood flow characteristics. These physiological
characteristics of the GIT-like in humans-is probably due to their omnivorous diet (Brown and
Terris, 1996; Reeds and Odle, 1996; Tumbleson and Schook, 1996).
164
Figure 7.1: Structural/anatomical differences of the human vs. the pig colon.
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The fundamental purpose of this chapter was to elucidate the plasma-concentration profiles
of 5-ASA and loperamide HCl from the stimuli-responsive oral tablet (SROT) system thus
allowing the quantitative and qualitative comparison of the SROT with the commercially
available conventional systems of Asacol® and Imodium®. However, a prerequisite to the
achievement of this aim necessitated the establishment of a suitable and effective method of
blood sampling from the pig that avoided excessive stress and pain for the animal. In
addition, effective chromatographic methods of analysis for the relevant drugs had to be
developed.
7.2 Materials and Methods
7.2.1 Materials
Chemicals employed for plasma sample preparation for 5-ASA and loperamide HCl
determination by UPLC analysis included ortho-phosphoric acid (H3O4P) (85-90%)
purchased from Fluka (Sigma-Aldrich Chemie GmbH, Steinheim, Switzerland), perchloric
acid (69-72%) from Saarchem (Merck Laboratory Supplies (Pty) Ltd., Midrand, Gauteng,
South Africa), propionic anhydride (99+%) obtained from Sigma-Aldrich (St. Louis, MO,
USA), ethyl acetate (CH3OOC2H5) (min. 98.0%) purchased from Saarchem (Merck
Chemicals (Pty) Ltd., Wadeville, Gauteng, South Africa) and tert-Butyl-Methyl-Ether (MTBE)
purchased from Fluka Chemika (Fluka Chemie, Buchs, AG, Swtzerland). The buffer salts
employed for mobile phase and sample preparation included di-sodium hydrogen phosphate
anhydrous (Na2HPO4), potassium dihydrogen orthophosphate (KH2PO4), and sodium
carbonate anhydrous (Na2CO3) purchased from Rochelle Chemicals (Johannesburg,
Gauteng, South Africa), Merck Chemicals (Pty) Ltd. (Wadeville, Gauteng, South Africa) and
Associated Chemical Enterprises (South-Dale) respectively. Acetonitrile 200 (ROMIL-SpSTM
Super Purity Solvent (CH3CN), Assay>99.9%) was purchased from Romil Pure Chemistry
(Waterbeach, Cambridge, England) and double de-ionized water was obtained from a Milli-Q
water purification system (Milli-Q, Millipore, Billerica, MA, USA). 4-ASA, barium sulphate.
7.2.2 Experimental subjects and conditions
Healthy female adult white pigs weighing approximately 35-45kg were employed in the study.
The pigs were maintained on a commercially available pig feed diet for the duration of the
study and were allowed two medium sized meals twice a day until 12 hours prior to dosing.
During the 24 hour study period pigs were fed smaller meals throughout the day, with the
occasional ‘treat’ of raisins or vegetable peels at each sampling point. Water was allowed ad
libitum. Pigs were cared for by the personnel at the Central Animal Service (CAS) at the
University of Witwatersrand and were housed in small adjacent individual pens with metal
‘cage-like’ divisions and concrete floors with a bed of hay. Each pen was cleaned out twice a
166
day and the bed of hay regularly replaced. The pens allowed for free movement and ‘normal’
activity of the pig thus maintaining normal gastrointestinal motility. The housing area was
kept lit during the day and dark at night so as to not affect the circadium rhythms of the pigs.
7.2.3 Determination of an effective method and route of blood sampling
7.2.3.1 Pilot study of the viability of blood sampling via the marginal ear vein
Prior to dosing with the SROT and conventional commercially available systems (Asacol®
and Imodium®) it was necessary to establish a simple, yet effective method of performing
blood sampling from the conscious pig. Thus, as a pilot study and in accordance with Animal
Ethics Clearance no. 2007/56/04 (see appendix), a catheter was inserted into the marginal
ear vein of the pig after anaesthesia was induced by a cocktail of midazolam (0.3mg/kg I.M)
and buprenorphine (0.05mg/kg I.M) with anaesthesia being maintained with 2%
isoflurane/100% oxygen. The process of catheter insertion and the blood sampling procedure
is visually explicated in the sequential digital images shown in Figure 7.2.
Figure 7.2: Sequential digital images of the process of catheter insertion in an anaesthetized
pig and blood sampling via the marginal ear vein catheter from the conscious pig.
Briefly, after the administration of the anaesthetic cocktail, the pig was maintained under
anaesthesia and its vitals (blood pressure, oxygen saturation etc) constantly monitored. The
a) b) c)
d) e)
g)
f)
i)h)
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catheter was inserted and the tubing sutured from the ear to neck of the pig. The tubing was
flushed with heparinized saline (500IU of heparin in 1000mL of 0.9% saline) to prevent
clotting within the tubing and to maintain a clear pathway for blood flow. For blood sampling
the conscious pig had to be coaxed into a narrow pen that limited excessive movement of the
pig. Blood sampling was then attempted/performed from the open top of the cage.
7.2.3.2 Surgical insertion of a chronic jugular catheter
For the surgical placement of the chronic jugular catheters, the pigs were anaesthetized with
11mg/kg ketamine (I.M) and 0.3mg/kg midazolam (I.M). Buprenorphine (0.05mg/kg) and
carpofen (4mg/kg) were both administered intramuscularly for analgesia. Pigs were then
intubated and anaesthesia maintained with 2% isoflurane in 100% oxygen. Under aseptic
conditions, a 7 FR gauge double lumen 35cm catheter (CS-28702) (Arrow Deutschland
GmbH, Erding, Germany) impregnated with chlorhexidine gluconate was surgically inserted
into the left jugular vein. The jugular vein was exposed by an incision made dorsal to the
jugular groove on the left lateral aspect of the neck. Via blunt dissection, the vein was
isolated and the catheter inserted 10cm into the lumen of the vein. The lumen of the catheter
was then fastened to the wall of the vein using a purse suture technique. The remaining
length of the catheter (25cm) was tunnelled subcutaneously, with the use of a trocar, to an
exit point on the dorsal aspect of the scapular. The externalized injection ports of the catheter
were sutured to the skin of the pig so as to limit excessive movement and kinking. Blood was
drawn and the catheter flushed with heparinized saline (1000IU of heparin in 1000mL of
0.9% saline). The pigs were subsequently allowed to recover for approximately 8 days post
surgery. During this time, pigs were continually habituated to the process of blood sampling
and catheters were flushed with heparinized saline every ±12 hours to prevent clotting and
infection due to the catheter.
7.2.4 Dosage administration process
Prior to dosage administration, pigs were anaesthetized with a cocktail of midazolam
(0.3mg/kg I.M) and buprenorphine (0.05mg/kg I.M) injected directly into the jugular vein
catheter. Anaesthesia was then maintained with 2% isoflurane and 100% oxygen. As
depicted in Figure 7.3 whilst being held upright, an intragastric tube (with a lumen diameter of
15mm) containing the delivery system in the modified aperture was inserted from the mouth
into the stomach, and the delivery system was subsequently flushed out of the tube with
20mL of water. Pigs were then allowed to recover from anaesthesia under observation.
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Figure 7.3: Digital images of a-c) the intragastric tube with the modified aperture for tablet
insertion, d-e) the process of insertion of the intragastric tube into the stomach of the pig with
subsequent ‘flushing out’ of the delivery system from the tube.
7.2.5 Determination of the in vivo drug release characteristics of 5-ASA from Asacol®
and the SROT using UPLC analysis
7.2.5.1 Preparation of solvents used for sample preparation and UPLC analysis
7.2.5.1.1 Priming solvents
The solvents used to prime the UPLC pumps prior to analysis included a weak wash solution
of 10%v/v acetonitrile and 90%v/v double de-ionized water, and a strong wash solution of
90%v/v acetonitrile and 10%v/v double de-ionized water. These solutions were also used for
‘washing-out’ the system after sample analysis.
7.2.5.1.2 Mobile phases
The binary mobile phase employed for sample analysis included acetonitrile and 0.01M
Na2HPO4 buffer at pH 3 in a 17:83 ratio (v/v). The Na2HPO4 buffer was prepared by
dissolving 3.58g of sodium hydrogenphosphate dodecahydrate (Na2HPO4) in 998mL of
a)
b)
c)
d) e) f)
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double de-ionized water. Ortho-phosphoric acid (2mL) was added to this solution which
resulted in a buffer pH of 3.
7.2.5.1.3 Buffer for sample preparation
A phosphate buffer (pH 7.4) was required for incorporation with the sample prior to analysis.
This buffer solution was prepared by dissolving 23.976g of Na2HPO4 in 1000mL of double
de-ionized water. Potassium dihydrogen phosphate (KH2PO4) (2.27g) was dissolved in
250mL of double de-ionized water. 800mL of the 0.067M Na2HPO4 solution was then
combined with 200mL of the 0.067M KH2PO4 solution to result in a buffer solution of pH 7.4.
Note: only double de-ionized water (Milli-Q, Millipore, Johannesburg) with a resistivity of
18.2MΩcm-1 was used for all UPLC solvents employed for sample analysis. In addition, the
mobile phases, weak and strong washes and all solvents used for sample preparation were
filtered using a 0.22μm pore size Cameo Acetate membrane filter (Millipore Co., Bedford,
Massachusetts).
7.2.5.2 Blood sampling and sample preparation
At predetermined time points (0, 2, 4, 6, 8, 10, 12, 16, 20 and 24 hours) after the oral
administration of either Asacol® or Imodium® 5mL blood samples were withdrawn via the
jugular catheter (Figure 7.4). It must be noted that after the oral administration of the SROT,
10mL blood samples were withdrawn with 5mL set aside for 5-ASA analysis and 5mL for
loperamide HCl analysis. The blood samples were collected into heparinized Monovette®
syringes (Sarstedt, Germany) and centrifuged immediately at 3000rpm for 15 minutes. The
resultant plasma was separated and subsequently stored in 1mL eppendorf tubes at -70°C
until analysis.
Figure 7.4: Blood sampling from the conscious pig.
Blood was drawn via the brown port of the
catheter. However both ports were flushed with
heparinized saline (5mL each) before and after
sampling point.
The pigs were conscious during blood
sampling and were ‘distracted’ with food.
Ports were thoroughly disinfected before
and after blood sampling.
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To each 1mL of defrosted plasma, 20µL of perchloric acid was added to facilitate
deproteinization. The samples were subsequently vortexed (Vortex-Genie 2, Scientific
Industries Inc., Bohemia, NY, USA) for 1 minute and centrifuged (Desktop Centrifuge TD5A-
WS, Shanghai Luxiangyi Centrifuge Intrument Co., Ltd., Shanghai, China) at 2000rpm for 12
minutes. The clear supernatant (500µL) was transferred to a clean test tube to which 500µL
of phosphate buffer (pH 7.4) was added. The internal standard employed in the study, 4-
ASA, was added to each sample at a constant concentration of 0.208mg/mL (100µL). This
solution was vortexed for 30 seconds after which 40µL of propionic anhydride was added to
facilitate the derivatization of 5-ASA present in the plasma. The contents were vigorously
shaken and allowed to derivatize for 20 minutes at 25°C. Concentrated HCl (50µL) was then
added and the sample vortexed for a further 30 seconds. The acyl derivatives of 4-ASA and
5-ASA were then extracted into 3mL of ethyl acetate. After centrifugation (2000rpm for 12
minutes) the tubes were stored at -45°C for 45 minutes until the inorganic layer froze. The
organic layer containing the analytes was then decanted into a 10mL glass test tube and the
solvent evaporated (under a stream of nitrogen, in a water bath maintained at 45°C). The dry
extract was then reconstituted in 1mL of the mobile phase (0.01M Na2HPO4, pH 3) and
transferred into the UPLC vial (Waters® LCMS certified vials with a pre-slit screw top, Waters,
Milford, MA, USA)  for injection.
7.2.5.3 Preparation of analytical standards for the calibration series
Primary stock solutions of 5-ASA (0.254mg/mL) and 4-ASA (0.208mg/mL) were prepared in
double de-ionized water maintained at 37°C. The 5-ASA stock solution was serially diluted to
obtain solution concentrations ranging from 0.0079375mg/mL to 0.254mg/mL. Drug-free
plasma (1mL) was then spiked with 100µL of these serial concentrations of 5-ASA and
100µL of the internal standard (IS) 4-ASA, to result in a final 5-ASA plasma concentration in
the range of 0.795-25.452µg/mL. Spiked plasma samples underwent an identical sample
preparation process, liquid-liquid extraction procedure and analysis method as described in
section 7.2.5.2. The calibration curve was plotted with the peak area ratios of the analyte and
IS against the corresponding analyte concentrations (expressed as µg/mL). Linearity
equations and correlation coefficients (R2) were obtained by means of the least square
method. The limit of detection (LOD) of the derivatized 5-ASA was determined based on the
concentration of N-propionyl-5-ASA that achieved a peak height of 10 and a signal-to-noise
ratio of 3 (Mandrioli et al., 2006, Nobilis et al., 2006).
All solutions were filtered through a 0.22μm pore size Cameo Acetate membrane filter
(Millipore Co., Bedford, Massachusetts) prior to incorporation with drug-free plasma.
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7.2.5.4 UPLC analysis with tandem photodiode-array (PDA) detection
Ultra Performance Liquid Chromatography (UPLC) analysis was performed on an Acquity®
Ultra Performance Liquid Chromatography system (Waters®, Milford, MA, USA) coupled with
a PDA detector. Separation of analytes was achieved on the Acquity UPLC® BEH Shield
RP18 column (2.1mm x100mm, 1.7µm particle size) maintained at 25°C. The binary mobile
phase employed included acetonitrile and 0.01M Na2HPO4 buffer at pH 3 in a 17:83 ratio
(v/v), with an isocratic analysis run time of 15 minutes, an injection volume of 6.00µL, and a
flow rate of 0.1mL/min. UV detection was performed at a maximum excitation wavelength of
313nm.
7.2.6 Barium X-ray imaging of the SROT through the GIT of the pig
X-ray imaging was undertaken as a means of determining the position of the SROT in the
GIT of the pig at which 5-ASA release was initiated. This required the incorporation of a
sufficient quantity of BaSO4 into the optimized SROT formulation to ensure detection by the
imaging equipment. Tablets were prepared as previously described (Chapter 5, section
5.2.3) except for the incorporation of 600mg of BaSO4 with the rest of the tablet components.
However the large weight (600mg+1350mg) and corresponding dimensions of the tablet
made it incapable of passing through the intragastric tube. Therefore only 1350mg of the
combination of tablet components and the BaSO4 were compressed into tablets and
subsequently coated with the enzyme-responsive coating solution as described in Chapter 5,
section 5.2.5. Prior to X-ray imaging, pigs were anaesthetized with a mixture of midazolam
(0.3mg/kg I.M) and buprenorphine (0.05mg/kg I.M) and were maintained under anaesthesia
with 2% isoflurane in 100% oxygen. The vital signs of the pigs were constantly monitored
during the X-raying procedure. X-ray imaging was conducted on a 240V FDA compliant
mobile X-ray unit (Shimadzu Mobileart Plus MUX-100H, Shimadzu Europa GmbH, Duisburg,
Germany), with image capturing on an IP Cassette imaging plate, type-CC in black and white
with dimensions of 24x30cm (FCR Fuji IP Cassette), and image development on a Prima
System CR-20 (Fujifilm FCR Primax). Pigs were X-rayed at the relevant time-points post-
dosing and X-rayed in the dorsoventral, right and left lateral views to enable a more definitive
indication of where in the GIT the SROT is at a particular time-point. Subsequently, the pigs
were returned to their pens and observed until recovery from the anaesthetic.
7.2.7 Determination of the in vivo drug release characteristics of loperamide HCl from
Imodium® and the SROT using UPLC analysis
7.2.7.1 Sample preparation
Priming of the UPLC pumps, washing-out of the sample column and blood sampling was
performed identical to the relevant procedures described in section 7.2.5. A simplistic
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schematic of the sample preparation process for extraction of loperamide HCl from plasma
prior to analysis is outlined in Figure 7.5.
Figure 7.5: Schematic illustration of the plasma sample preparation process employed prior
to UPLC analysis.
Essentially, this preparatory process required the gradual defrosting of frozen plasma
(without dramatic changes in temperature). To 500µL of the defrosted plasma, 20µL of
perchloric acid was added and vortex mixed for 30 seconds to facilitate the deproteinization
of loperamide HCl from plasma proteins. The murky plasma solution was then centrifuged at
2000rpm for 15 minutes. The clear supernatant (300µL) was then transferred to a clean test
tube to which 50µL of a 0.5M aqueous Na2CO3 solution was added. The test tube was
vortexed for 10 seconds after which 3mL of MTBE was added. This was subsequently
vortexed for 5 minutes and allowed to extract for a further 5 minutes at 25°C. The test tube
was then centrifuged at 2000rpm for 20 minutes. The organic layer was decanted into a
clean 10mL glass test tube and the solvent evaporated under a stream of N2 gas, and
maintained at 40°C in a water bath. The sample residue was then reconstituted in 2mL of
50%v/v acetonitrile and 50%v/v double de-ionized water. To each 2mL sample, 100µL of the
internal standard 4-ASA (0.2mg/mL) was pipetted, agitated until homogenously distributed
and subsequently filtered through a 0.22µm Cameo Acetate membrane filter into the UPLC
vial for injection.
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7.2.7.2 Preparation of analytical standards for the calibration series
The primary stock solution of loperamide HCl (0.1mg/mL) was prepared by dissolving
loperamide HCl in 10mL of acetonitrile and subsequently making up the solution to 50mL
with double de-ionized water. The stock solution of the internal standard 4-ASA
(0.216mg/mL) was prepared in double de-ionized water maintained at 37°C. The loperamide
HCl stock solution was serially diluted to obtain solution concentrations ranging from
0.003125mg/mL to 0.1mg/mL. Drug-free plasma (500µL) was then spiked with 100µL of
these dilute solutions and 100µL of 4-ASA to result in final loperamide HCl plasma
concentrations of 0.377875-3.023µg/mL after consideration of the sample preparatory steps
as well as the liquid-liquid extraction procedure described in section 7.2.7.1. Plotting of the
calibration curve and LOD determination was then performed as described in section 7.2.5.3.
7.2.7.3 UPLC analysis with PDA detection of loperamide HCl
Separation of analytes was achieved on the Acquity UPLC® BEH Shield RP18 column
(2.1mmx100mm, 1.7µm particle size) maintained at 25°C. The binary mobile phase
employed included acetonitrile and double de-ionized water in a 50:50 ratio (v/v), with an
isocratic analysis run time of 6 minutes, an injection volume of 6.00µL, and a flow rate of
0.22mL/min. UV detection was performed at a maximum excitation wavelength of 200nm for
detection of loperamide HCl and 313nm for detection of 4-ASA.
7.3 Results and Discussion
7.3.1 Assessment of the marginal ear vein vs. the jugular vein as an efficient blood
sampling route
Prior to investigating chronic catheterization of a suitable vein in the pig model, a pilot
attempt was made to withdraw blood samples at regular periods from the pig via a catheter
inserted in the marginal ear vein. This catheter was temporary and in theory would remain
viable for a maximum of 24 hours. Despite the efficiency and speed of the catheterization
procedure, blood sampling via this route proved challenging in various aspects. Essentially,
the major drawback of this method of blood sampling originated from the vulnerability and
weakness of the structure of the marginal ear vein which consequently led to the numerous
tributary obstacles. The fundamental cause of the failure of this method is due to the
collapsing/ballooning of the ear veins which subsequently resulted in a cascade of
challenges as is depicted in Figure 7.6.
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Figure 7.6: Schematic of the challenges experienced during blood sampling via the marginal
ear vein.
There is an obvious intertwining of the challenges experienced with this method of blood
sampling which led to inconsistent and unrepresentative blood samples based on the
following reasons:
 The time it takes to coax the pig into the sampling pen and the actual time it takes to
withdraw 5mL of blood can range from 5 minutes to 90 minutes if the vein remains
viable.
 If the veins collapse or balloon various sampling points are missed especially since
the pig may only be anaesthetized a maximum of 3 times per 24 hour period, with at
least 4 hours between each dose.
 The time it takes to withdraw each sample also provides variable plasma
concentrations of the relevant drug in each bit of the collected blood.
 The stress experienced by the pig considerably alters the physiology and motility of
the GIT which directly influences the plasma concentration profiles of drug delivery
systems that are intended for release in specific regions of the GIT.
Variable time required per
blood sample
Increase stress for the pig
Increase in 'flight-or-fight'
response = increase in
gastrointestinal motility
COLLAPSING/
BALLOONING OF
EAR VEINS
Required re-
catheterization of marginal
ear vein of the other ear
Required re-
anaesthetization (only
allowed ≥4hrs after
administration of the first
anaesthetic)
Missed samples
Premature removal of
catheter/'kinking' of
catheter tubing
Painful for the pig
Pig became aggressive
and dangerous for the
researcher
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Thus, chronic jugular catheterization was investigated with the aim of establishing a more
long-term and reliable means of withdrawing blood samples from the conscious pig. The
process of catheter insertion into the jugular vein was explained in section 7.2.3.2, and is
visually explicated in Figure 7.7.
Despite the lengthy catheterization process the ultimate benefits of blood sampling via this
route was numerous. However several essential process conditions had to be maintained for
this route of blood sampling to remain viable for an extended period of time and to assist in
the actual blood sampling procedure. These process conditions included the necessary
habituation of the pig/pigs at least 7 days prior to surgery and 10 days after surgery (during
the post-operative recovery period). This process of habituation allowed the pig to become
accustomed to the presence of humans in its pen and also allowed the pig to ‘enjoy’ human
contact. By enabling the close contact between the pig and the researcher it facilitated the
withdrawing of blood samples in less than 2 minutes. Thus no stress was placed on the pig
and consequently the gastrointestinal motility was not influenced. Another fundamental
procedure that had to be regularly and strictly performed involved the flushing of the
catheters with heparinized saline at each sampling point and at least 3 times a day during
days when no sampling was required. Due to the susceptibility of chronic catheters to
infection and the sensitivity of the jugular region this process had to be conducted by
thoroughly disinfecting the ports before and after flushing and blood sampling. These
stringent procedures allowed the catheters to remain viable for at least 30 days, without any
incidences of infection. After the research period the catheters were removed by the
registered vet and pigs were returned to stock.
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Figure 7.7: A graphical illustration of the process of jugular vein catheterization from pre-
operative preparation to post-operative care.
Pre-operative
preparation
Post-operative
recovery
Surgical
implantation
1 2 3
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7.3.2 In vivo analysis of plasma samples after administration of Asacol® and the SROT
7.3.2.1 Sample preparatory processes
7.3.2.1.1 Deproteination
Even though 5-ASA is extensively metabolized in the GIT wall and the liver to numerous
phase II biotransformation products such as N-acetyl-5-ASA, N-formyl-5-ASA, N-butyryl-5-
ASA and N-β-ᴅ-glucopyranosyl-5-ASA essentially only the active 5-ASA and its principle
inactive metabolite (N-acetyl-5-ASA) are representative of the plasma concentrations of the
parent drug itself (Tjornelund et al., 1989; Tjornelund Hansen, 1991; Tjornelund et al., 1991).
However due to the high plasma protein binding ability of 5-ASA (40-50%) and N-acetyl-5-
ASA (80%), plasma samples required deproteinatization prior to analysis of samples (Klotz,
1985; Parfitt, 1999). Thus concentrated perchloric acid was added to precipitate the plasma
proteins thus allowing liberation of the analytes.
7.3.2.1.2 Derivatization
Due to the presence of the primary aromatic amino group (-NH3+, pKa=6), carboxylic group (-
COOH, pKa=3), and phenolic group (-OH, pKa=13.9) in the molecule of 5-ASA, the
compound exhibits amphoteric properties, which together with its considerable polarity
complicates the extraction and UPLC analysis procedure (Allgayer et al., 1985). Therefore, it
was important to derivatize the amino groups in order to suppress its amphoteric properties.
The lipophilicity increasing derivatization procedure was thus conducted in the presence of
propionic anhydride as it was the only acceptable agent for N-acylation since the other
derivatives of the homologous series could be present in the plasma as authentic metabolites
of 5-ASA.
Figure 7.8: Derivatization of amphoteric 5-aminosalicylic acid and 4-aminosalicylic acid by
propionic anhydride (Nobilis et al., 2006).
5-ASA
4-ASA
N- propionyl-5-ASA
N- propionyl-4-ASA
Propionic anhydride
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The reactions conditions applied were based on the optimum derivatization obtained in the
study conducted by Nobilis and co-workers in 2006. Acylation occurs due to the nucleophilic
nitrogen of the primary amino groups in 5-ASA and 4-ASA reacting readily with the deficient
acyl anhydride (propionic anhydride) at ambient temperature as depicted in Figure 7.8.
7.3.2.1.3 Extraction
From preliminary method development it was established that due to the extensive sample
preparation process, the most appropriate solid phase extraction (SPE) procedure could not
be determined despite the numerous methods evaluated. Therefore liquid-liquid extraction in
ethyl acetate was performed which was based on a previously established and validated
chromatographic method for 5-ASA analysis in plasma (Nobilis et al., 2006). This was
basically conducted to remove plasma constituent interferences and to isolate the drug from
the blood sample. Furthermore, to optimize the extractability of the drug and internal
standard, concentrated HCl was added to the sample prior to extraction.
7.3.2.2 Chromatograms of the derivatized drug and internal standard
Subsequent to the application of the sample preparatory process to blank (drug-free) plasma
samples spiked either with a dilute aqueous solution of 5-ASA (Figure 7.9a) or 4-ASA (Figure
7.9b) it was established that the deproteinization, derivatization and extraction procedures
were effective for eluting the derivatives of both 5-ASA and 4-ASA as the chromatograms
revealed peaks of a high resolution and achieved level chromatographic baselines.
N-propionyl-5-ASA
Surplus underivatized 5-ASA
a)
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Asacol
Figure 7.9: Typical chromatograms of the propionyl derivatives of a) plasma spiked with 5-
ASA with peaks for N-propionyl-5-ASA (RT=5.790 minutes) and the excess underivatized 5-
ASA (RT=2.006 minutes), b) plasma spiked with 4-ASA with the peak for N-propionyl-4-ASA
(RT=12.111 minutes).
The principle metabolite, N-acetyl-5-ASA, was also assessed by UPLC analysis and the
chromatogram revealed a peak at a retention time of 3.470 minutes. As indicated in Figure
7.10, this chromatogram also showed a peak at RT=2.014 minutes indicative of the non-
acetylated 5-ASA in the sample.
Figure 7.10: Chromatogram of a blank plasma sample spiked with a dilute aqueous solution
of N-acetyl-5-ASA.
N-acetyl-5-ASA
N-propionyl-4-ASA
b)
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N-acetyl-5-ASA was synthesized in the laboratory by dissolving 5-ASA (1g, 0.0065mol) in
acetic anhydride and stirring the reaction mixture for 3 hours at 25°C. The reaction mixture
was allowed to stand for 24 hours after which the crude crystalline product was filtered off
and washed with double de-ionized water and subsequently dried over P2O5 (Nobilis et al.,
2006). Since the purity of the sample was not established it was expected that non-
acetylated 5-ASA would remain present in the crystalline product and would be evidenced by
UPLC analysis.
Nevertheless, analysis of plasma samples from pigs dosed with both the SROT and Asacol®
showed no peaks at the region of 3-4 minutes over the 24 hour period demonstrating the
absence of a significant quantity of the metabolite in the plasma. Furthermore, the difference
in the plasma concentrations of N-propionyl-5-ASA from the SROT vs. Asacol® can be
observed from the difference in the area under the curves (AUC) of the drug from the 2
formulations, when the AUC of N-propionyl-4-ASA (IS) remains relatively consistent (Figure
7.11a and b).
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Figure 7.11: Chromatograms of 5-ASA released from a) Asacol®, and b) the SROT 24 hours
after administration.
7.3.2.3 Calibration curve of the derivatized 5-ASA in plasma
The calibration curve of N-propionyl-5-ASA in plasma performed by UPLC analysis is
depicted in Figure 7.12. Samples were analyzed at a maximum excitation wavelength of
313nm for both the drug and internal standard. The samples at concentration ranges of 0-
25.452µg/mL showed good linearity with a correlation coefficient (R2) of 0.999. Furthermore,
the limit of detection (LOD) for N-propionyl-5-ASA was determined to be 0.0083µg/mL.
a)
b)
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Figure 7.12: Calibration curve of the derivatives of the drug (5-aminosalicylic acid) and
internal standard (4-aminosalicylic acid) in plasma.
7.3.2.4 In vivo drug release of 5-ASA from the SROT and Asacol®
The release of 5-ASA from both formulations was assessed over a period of 24 hours (Figure
7.13). Various distinctive release characteristics of the two formulations were identified based
on the resultant plasma concentrations at each time point. One such of these characteristics
is the significantly lower plasma concentration of 5-ASA from the SROT compared to that of
Asacol® over the entire 24 hour period. The SROT identified a Cmax of only
4.556±1.661µg/mL whilst that of Asacol® was 12.813±3.440µg/mL. The substantially lower
concentration of 5-ASA in plasma forms fundamental evidence of the minimal release of 5-
ASA in the upper GIT, as well as of the sustained release of 5-ASA in the colon. The minimal
5-ASA absorption will ultimately result in reduced side-effects and improved efficacy due to
the minimized systemic absorption. In contrast, Asacol® presented with a high variation in the
plasma concentration profiles of 5-ASA in each pig, with several peaks and troughs
throughout the 24 hour period. This will obviously result in the occurrence of numerous side-
effects, reduced efficacy and patient compliance.
Based on the physiological characteristics of the GIT of the pig it can be estimated that the
time of arrival of both formulations in the colon should be approximately 3-4 hours post
dosing in the ‘fasted’ pig. However plasma concentrations of Asacol® show a significant
premature release of 5-ASA with C2hrs=10.563±4.444µg/mL compared to the SROT with
C2hrs=0.070±0.121µg/mL, where the delivery system is theoretically still in the proximal small
intestine.
y=0.249x
R2=0.999
Linear Regression Curve
95% Confidence Band
95% Prediction Band
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Figure 7.13: Plasma concentration profiles of the stimuli-responsive oral tablet (the 5-
aminosalicylic acid-loaded colon-targeted component) in comparison to the gold-standard
marketed comparator product, Asacol®.
7.3.2.5 Barium x-ray imaging of the SROT in the GIT of the pig
A right lateral view of the abdominal section of the pig, 3 hours post-dosing, the SROT
appears to be present in the stomach (Figure 7.14a), however when compared to the left
lateral view of the same region the SROT appears to be in the small intestine (Figure 7.14b).
Thus to more definitively determine the location of the SROT a dorsoventral image of the
abdominal region was acquired. This x-ray image clearly depicts the presence of the SROT
in the region succeeding the stomach in particular the proximal small intestine (Figure 7.14c).
Colon
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Figure 7.14: X-ray images of the abdominal region of the pig in the a) right lateral view, b)
left lateral view, and c) dorsoventral view 3 hours post-dosing with the stimuli-responsive oral
tablet.
Another dorsoventral view of the pig (Figure 7.15), approximately 30 minutes after the first
dorsoventral x-ray was taken showed that the SROT had moved from the small intestine to
the caecum or had just entered the proximal colon.
a)
b)
c)
SROT appears intact 3
hours post-dosing
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Figure 7.15: Dorsoventral x-ray image of the pig 3.5 hours post-dosing with the stimuli-
responsive oral tablet.
Figure 7.16a and b obtained 6.5 hours post-dosing showed that the SROT was visible below
the ribs of the pig (in the dorsoventral view). It appeared to be in the stomach however the
positioning and physiology of the GIT is such that a portion of the ascending and transverse
colon is situated behind the stomach, causing the illusion. The tablet also appears ‘fuzzy’
indicating that erosion of the enzyme-responsive polymer coating had begun which can also
be substantiated by the identification of 5-ASA in plasma at this time point (Figure 7.13)
Figure 7.16: X-ray images of the stimuli-responsive oral tablet in a) the dorsoventral view,
and b) the lateral view 6.5 hours post-dosing.
a) b)
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7.3.3 In vivo analysis of plasma samples after administration of Imodium® and the
SROT
7.3.3.1 Sample preparatory process and method development
There exists an extensive methodology database for the determination of loperamide HCl in
biological fluids such as plasma, however the principle drawback of these methods lie in their
insufficient sensitivity to the drug for pharmacokinetic studies (Yu et al., 2004). The
fundamental reason for the poor sensitivity of typical chromatographic methods is attributed
to the low molar absorptivity of the UV chromophores in loperamide and the presence of UV
absorbing interference in plasma (He et al., 2000). Thus a supplementary analysis technique
has to be implemented in conjunction with the chromatographic technique to improve the
method sensitivity for example, HPLC with mass spectrometry (MS), GC-MS, LC-MS, HPLC
with electrospray ionization (ESI-MS), HPLC with a radioimmunoassay technique as well as
HPLC with tandem mass spectrometry using electrospray ionization and selective reaction
monitoring (SRM) (Leung et al., 1988; Leis and Gleispach, 1989; Kamali et al., 1992; De
Luca et al., 1993; Knupp et al., 1993; Doser et al., 1995; Hewala, 1995; He et al., 2000).
In contrast, the UPLC allows for analysis of samples with the shortest run time and highest
sensitivity without compromising the selectivity of the assay (Dongre et al., 2008).
Furthermore, by optimizing UPLC parameters such as pH, flow rate, column type, and buffer
concentration the optimum sensitivity, peak shape and selectivity can be achieved (Everley
and Croley, 2008). Therefore, based on selected principles of previously established HPLC
methods, a unique UPLC method was developed, where perchloric acid was used as a
deproteinating agent, Na2CO3 was used to alkalinize the sample prior to extraction, and
MTBE was used as the extraction solvent.
7.3.3.2 Chromatograms of loperamide HCl and the internal standard
The plasma sample preparation process which included the deproteinization and extraction
procedure of loperamide HCl resulted in a chromatogram which showed a peak at a retention
time (RT) of 2.310 minutes at 200nm (Figure 7.17a). A chromatogram of the internal
standard (4-ASA) showed a peak at RT=1.777 minutes for 4-ASA at 313nm (Figure 7.17b).
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Figure 7.17: Chromatograms of a) loperamide HCl in plasma at 200nm and b) 4-ASA in
plasma at 313nm.
Due to the ability of the PDA detector to concurrently process chromatograms at 2 different
wavelengths, 4-ASA was used as the internal standard even though the maximum excitation
wavelength of this molecule was different to that of the drug. Nevertheless 4-ASA also
showed an absorbance at 200nm as is evident from the chromatogram of a combination of
loperamide HCl and 4-ASA (Figure 7.18). This chromatogram also showed a clear resolution
of the separate peaks and a level chromatographic baseline.
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b)
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Figure 7.18: Chromatogram of a spiked plasma sample with a combination of loperamide
HCl and 4-ASA analyzed at a wavelength of 200nm.
7.3.3.3 Calibration curve of loperamide HCl
A calibration curve calculated based on the ratio of the AUC of loperamide HCl at 200nm and
the AUC of 4-ASA at 313nm showed good linearity with a correlation coefficient (R2) of 0.959
(Figure 7.19). The wavelength of 313nm was preferentially used for 4-ASA as a significantly
more resolute peak was obtained comparatively. The sample concentrations analyzed were
between 0.189-1.512µg/mL.
Figure 7.19: Calibration curve of loperamide HCl in plasma.
Loperamide HCl4-ASA
y=0.159x + 0.585
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7.3.3.4 In vivo drug release of loperamide HCl from the SROT and Imodium®
The efficacy of the outer pepsin-responsive intestinally targeted coating can essentially only
be recognized based on a quantitative and qualitative comparative analysis of in vivo
loperamide HCl release from the SROT and Imodium®. Using the x-rays described in section
7.3.2.5 the time of arrival of the SROT into the small intestine can be estimated to be
between 1.5-3 hours post-dosing and thus plasma presence of loperamide HCl is essentially
required only 90 minutes post-dosing.
The in vivo plasma concentration profiles of the SROT and Imodium® shown in Figure 7.20
show that for the first 2 hours post-dosing minimal loperamide HCl is released from the
SROT, whereas a concentration of 0.334µg/mL is achieved from Imodium in this same time.
Essentially, the results from the plasma samples acquired in the first 2 hours post-dosing
provided the fundamental evidence of the efficiency and pepsin-responsiveness of the
SROT. The minimization of drug release in the stomach enabled a greater quantity of the
contained drug to target the small intestine where its local therapeutic action is seen.
Furthermore, the prevention of loperamide HCl release in the stomach minimizes the
systemic absorption and consequently the side-effect profile of the drug. A bio-equivalence
study conducted in 2006 of 2 different solid-dose formulations of loperamide HCl, showed
that a single oral dose of loperamide HCl (4mg) resulted in peak plasma concentrations at
approximately 6 hours, and an elimination half-life (t1/2) of ±19 hours in humans (McNeil
Study Report 15-003, 2006). Thus, similarly a Cmax of 0.390µg/mL is evidenced 4 hours post-
dosing of Imodium® however the SROT achieved a Cmax of 0.267µg/mL after only 8 hours.
The long t1/2 of loperamide HCl is responsible for the presence of loperamide HCl in plasma
even after the 24 hour study period.
Figure 7.20: Plasma concentration profiles of loperamide HCl due to the pepsin-responsive
coating (SD:0.094-0.386) and Imodium®(SD:0.118-0.470).
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7.4 Concluding Remarks
Ultimately, this chapter served to provide evidence of the efficiency of the outer loperamide
HCl-loaded coating and 5-ASA-loaded colon-targeted tablet of the SROT to target the small
intestine and colon respectively, with the administration of a single delivery system. This
simultaneous targeting ability of the 2 different drugs is depicted in Figure 7.21. Apart from
the benefits associated with the targeted delivery of the respective drugs, the SROT
augmented the therapeutic effect of each drug by providing a more reproducible, consistent
and non-fluctuating release behaviour. This ultimately generally results in the reduction of
dosage required for therapeutic efficacy, an improvement in pill burden and patient
compliance and most importantly an improved quality of life for the patient.
Figure 7.21: Plasma concentration profiles of loperamide HCl and 5-aminosalicylic acid from
a single administration of the stimuli-responsive oral tablet system.
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CHAPTER 8
SYNTHESIS OF A NOVEL COMPOSITE POLYACRYLAMIDE-POLYSACCHARIDE
HYDROLYZED ELECTROLYTIC MATRIX FOR POTENTIAL APPLICABILITY AS A
COLON-TARGETED DRUG DELIVERY SYSTEM
8.1 Introduction
As the biomedical and biotechnological sciences make huge strides in advancing drug
delivery technology, increased pressure is being placed on the development of novel
polymeric materials derived from natural polymers. An effective and simple means of
creating these new materials is by a process termed ‘blending’. Blends of ‘natural-natural’
polymers and ‘synthetic-synthetic’ polymers have been widely investigated. Even though
natural polymers may possess superior biocompatibility, their mechanical properties are
often unsatisfactory (Yu et al., 2006). On the other hand, synthetic polymers have desirable
mechanical properties and only satisfactory biocompatibility. Therefore, blends of natural-
synthetic polymers are targeted as a more efficacious means of meeting the needs of
modern materials science (Xiao et al., 2001; Coombes et al., 2002; Fares et al., 2003; Zeng
et al., 2004; Barnes et al., 2007; Li et al., 2009).
Chemically modified natural polysaccharides have shown diverse potential due to their
enhanced hydrophilic properties and their intrinsic polyelectrolyte character (Pedram et al.,
2000; Reis et al., 2006; Derkaoui et al., 2008). The latter characteristic provides for the
electrostatic interaction between two oppositely charged polyelectrolytes when blended in
aqueous solutions to form what is known as polyelectrolyte complexes (PEC’s) (Michaels
and Miekka, 1961; Lee et al., 1997; Simsek-Ege et al., 2003; Lammertz et al., 2009). These
PEC’s have been shown to exhibit unique physical and chemical properties due to the
considerably stronger electrostatic interactions compared to most other secondary binding
interactions (Lee et al., 2003). Oppositely charged polysaccharides are also capable of
interacting in the same manner and considering their numerous desirable properties such as
their biodegradability, biocompatibility, hydrophilicity and protective properties, increased
interest is being placed on them (Barichello et al., 1999; Chellat et al., 2000; Peniche and
Argüelles-Monal, 2001; Shchipunov and Postnova, 2009). A variety of polysaccharide-based
PEC’s have been formulated and evaluated for diverse applications (Macleod et al., 1999a;
Qiu et al., 2001; Nichifor et al., 2004; Nagahata et al., 2005; Sarmento et al., 2006; Schoeler
et al., 2006; Argin-Soysal et al., 2009; Sæther et al., 2008). Amongst their numerous benefits
these complexes are also capable of providing a greater barrier to drug release in the upper
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gastrointestinal tract (GIT) than either material alone and thus show increasing promise in
colon-targeted drug delivery.
8.1.1 The polymers
Polyacrylamide (PAAm) is a water-soluble non-ionic synthetic polymer typically obtained by
free radical polymerization of acrylamide in an aqueous medium (Lipp and Kozakiewicz,
1991). It is generally used as a strengthening agent, an erosion-preventing and infiltration-
enhancing polymer. It is also commonly applied in gel electrophoresis (Seshi, 1994; Sharma
et al., 2005; Byrne and Toscano, 2006; Entry et al., 2008; Yan and Forster, 2009).
Transformation of the essentially neutral PAAm molecule into a strong anionic molecule is
generally achieved as a consequence of hydrolysis which results in a partially hydrolyzed
PAAm (HPAAm) molecule due to the partial conversion of its amide groups to carboxylate
groups (Volk and Friedrich, 1980). Therefore when in aqueous solution this polymer presents
with a polyelectrolyte character. The fundamental process of HPAAm synthesis is based on a
so-called simultaneous polymerization-hydrolysis process whereby the hydrolysis reaction of
PAAm is conducted concurrently with the polymerization of the acrylamide (Zeynali and
Rabbii, 2002). The most prevalent means of HPAAm formation is by alkaline hydrolysis of
PAAm using hydrolyzing agents such as alkali metal carbonates, alkali metal hydroxides,
alkali metal sulphates or alkali metal chlorides (Kurenkov et al., 2001).
Chitosan (CHT) is a partially de-acetylated derivative of chitin which possesses unique
physicochemical and biological properties such as an enhanced biocompatibility and
antimicrobial capability. However apart from these factors, its cationic nature and high charge
density in solution along with its mucoadhesive properties has made it one of the most
popular natural polymers for use in oral controlled drug delivery technology (Sokker et al.,
2009). In addition, the ability of CHT to form non-covalent complexes with other
polyelectrolytes (bio-polyelectrolytes, modified natural polyanions or synthetic polyanions)
adds to its attractiveness for use in controlled drug delivery (Krayukhina et al., 2008).
Pectin, a naturally occurring anionic polysaccharide has also been greatly explored for its
potential in drug delivery technology, especially for targeted colonic delivery (Ashford et al.,
1994; Wakerly et al., 1996a, b; Macleod et al., 1999b; Ahrabi et al., 2000; Liu et al., 2003a;
Wei et al., 2006; Maestrelli et al., 2008). However, the high hydrophilicity of pectin warrants
the need to identify methods of effectively reducing the premature solubility whilst
maintaining its polymeric backbone. By polyelectrolyte complexation of this phyto-
polysaccharide with CHT, the intrinsic beneficial properties of pectin can be maintained whilst
allowing a reduction in the hydrophilicity thus facilitating its use in many controlled release
drug delivery systems (Macleod et al., 1999a; Bernabé et al., 2005; Bigucci et al., 2008). In
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addition, the susceptibility of polysaccharide polymers to colonic enzymatic degradation may
be enhanced by reducing the premature solvation of the relevant polymer in the upper GIT,
thus facilitating a more targeted and site-specific delivery of pharmaceutical agents in the
distal small intestine and colon.
Accordingly, this chapter focused on the formulation of a lyophilized polyelectrolyte matrix
constituting combinations of natural polymers such as pectin and CHT and a partially
hydrolyzed synthetic polymer, hydrolyzed polyacrylamide (HPAAm), derived from
polyacrylamide. This formulation approach was aimed at the facilitation of a reduction in the
premature solvation of the polysaccharide polymer, either CHT or pectin or a combination
thereof, in turn reducing upper gastrointestinal release of the model highly water-soluble
drug, diphenhydramine HCl (DPH), and providing an intact matrix for entry into the colon.
8.2 Materials and Methods
8.2.1 Materials
The natural polysaccharide polymers employed included chitosan (CHT) (food grade
powder) (Wellable Group Marine Biological & Chemical Co., Ltd., Shishi City, Fujian, China)
and pectin (Classic Cu 701) (DE: 34-38%) (Herbstreith & Fox KG, Neuenbürg, Baden-
Württemberg, Germany) of molecular weights (Mw) 160.9g/mol and 70000g/mol respectively.
Polyacrylamide (PAAm) (Mw=5×106-6×106g/mol), the synthetic non-ionic polymer, was
purchased from Fluka Biochemika (St. Louis, MO, USA) and glacial acetic acid was acquired
from Rochelle Chemicals (Johannesburg, Gauteng, South Africa). Sodium persulphate (SPS)
(SigmaUltra, minimum 98%) as the hydrolyzing agent was purchased from Sigma-Aldrich
(St. Louis, MO, USA) and N,N,N’,N’-tetramethylethylenediamine (TEMED) (absolute ≥99%,
GC) as the accelerant was purchased from Fluka (Buchs, AG, Switzerland).
Diphenhydramine HCl (DPH) with a water solubility of 100mg/mL at 25°C was employed as
the model drug and was purchased from Sigma-Aldrich-Chemie GmbH (Steinheim,
Luxembourg, Germany). All materials employed were of analytical grade and used without
further purification.
8.2.2 Synthesis of the composite polyelectrolyte matrices
Three formulations consisting of various combinations of the polysaccharide (CHT and/or
pectin) and PAAm were synthesized (Table 1). Briefly, a 10%w/v aqueous solution of the
relevant polysaccharide was blended with a 5%w/v solution of PAAm in a 2:1 (v/v) ratio. All
solutions were agitated until a visibly homogenous solution was obtained. DPH was then
dissolved into the homogenous blend and was further agitated to facilitate a uniform
distribution of the drug. Hydrolization of PAAm was permitted with the addition of SPS, in
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conjunction with TEMED as an accelerant in a 4:1 ratio. The reaction was allowed to proceed
under constant agitation at 25°C for 3 hours. Matrices consisting of pectin, CHT and HPAAm
were prepared in an identical manner as described above and in the same concentrations.
However all three polymers were used in equal volumes i.e. in a 1:1:1 ratio. After 3 hours of
constant agitation, 1mL aliquots of each polyelectrolyte blend was pipetted into pre-lubricated
cylindrical moulds (13mm×5mm) and were subsequently frozen at -70°C for 24 hours prior to
lyophilization (FreeZone® 2.5, Labconco®, Kansas City, Missouri, USA) at 25mtorr for 48
hours. Lyophilization of the polyelectrolyte DPH-loaded blends was performed with the aim of
removing excess solvent involved in the hydrolysis and complexation process, thus ensuring
a more stable and robust formulation of defined dimensions.
Table 8.1: Composition of each lyophilized polyelectrolyte matrix formulation
Formulation Polymer Type Concentration(%w/v)
Volume
Ratio (v/v)
1SPS: 2TEMED
(w/v)
1 CHT:HPAAm 10:5 2:1 4:1
2 pectin:HPAAm 10:5 2:1 4:1
3 CHT:pectin:HPAAm 10:10:5 1:1:1 4:1
1Sodium persulphate (hydrolyzing agent)
2N,N,N’,N’-Tetramethylethylenediamine (accelerant)
8.2.3 Elucidation of the successful synthesis of the polyelectrolyte matrices
Fourier Transmission Infrared Spectroscopy (FTIR) was performed on all native polymers
involved in matrix formulation as well as on the lyophilized matrices as a means of validating
the successful synthesis of the polyelectrolyte complex between HPAAm and the relevant
polysaccharides. The method of FTIR analysis is described in Chapter 5, section 5.2.10.
8.2.4 Chemometric molecular mechanics for polyelectrolyte modelling
All modeling and computations, including energy minimizations in Molecular Mechanics,
were performed using HyperChemTM 8.0.8 Molecular Modeling Software (Hypercube Inc.,
Gainesville, FL, USA) and ChemBio3D Ultra 11.0 (CambridgeSoft Corporation, Cambridge,
UK). The decamer of acrylamide (polyacrylamide) was drawn using ChemBio3D Ultra in its
syndiotactic stereochemistry as a 3D model, whereas the structures of CHT (10 glucosamine
saccharide units) and pectin (10 galactopyranosyl uronic acid units) were built from standard
bond lengths and angles using the polysaccharide Builder Module on HyperChem 8.0.8. The
models were initially energy-minimized using MM+ Force Field and the resulting structures
were once again energy-minimized using the Amber 3 (Assisted Model Building and Energy
Refinements) Force Field. The conformer having the lowest energy was used to create the
polymer-polymer complex. A complex of one polymer molecule with another was assembled
by parallel disposition of the molecules and an identical procedure of energy-minimization
was repeated to generate the final models: CHT-HPAAm, pectin-HPAAm and pectin-CHT-
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HPAAm. Full geometrical optimization was performed in vacuum employing the Polak–
Ribiere Conjugate Gradient method until a Root Mean Square (RSM) gradient of
0.001kcal/mol was reached. Force Field options in the AMBER (with all hydrogen atoms
explicitly included) and MM+ (extended to incorporate non-bonded limits, restraints, and
periodic boundary conditions) methods were set as defaults. For Molecular Mechanics
computations, the Force Fields were utilized with a distance-dependent dielectric constant
scaled by a factor of 1. The 1-4 scale factors were electrostatic 0.5 and Van der Waals 0.5.
Furthermore, various energies and hydrogen bond lengths involved in the molecular
interactions between CHT-HPAAm, pectin-HPAAm and CHT-pectin-HPAAm were computed.
8.2.5 Determination of the influence of the polymer blends on the physicomechanical
properties of the polyelectrolyte matrices
The physicomechanical properties of the matrices were evaluated in terms of their Matrix
Resilience (MR), Matrix Hardness (MH) and Deformation Energy (DE). A calibrated Texture
Analyzer (TA.XTplus, Stable Microsystems, Surrey, UK) fitted with a cylindrical steel probe
(50mm diameter; for MR) and a flat-tipped steel probe (2mm diameter; for MH and DE) was
employed. The parameters employed for the analysis is outlined in Table 8.2. All studies
(N=3) were conducted at room temperature (25°C).
Table 8.2: Textural profiling parameter settings employed for physicochemical
characterization of the polyelectrolyte matrices
Parameters 1MR (%) 2MH (N/mm2) 3DE (J)
Pre-test speed 1mm/sec 1mm/sec 1mm/sec
Test speed 0.5mm/sec 0.5mm/sec 0.5mm/sec
Post-test speed 10mm/sec 10mm/sec 10mm/sec
Trigger type Auto Auto Auto
Trigger force 0.05N 0.05N 0.05N
Load cell 5kg 5kg 5kg
Compression strain Variable N/A N/A
Target mode Strain (40%) Distance Distance
1Matrix Resilience
2Matrix Hardness
3Deformation Energy
MR (%) was calculated by the percentage of the ratio between the area under the curve
(AUC) of the peak to baseline (after the force is removed) (AUC2-3) and the baseline to peak
(before the force is removed) (AUC1-2) from a Force-Time profile (Figure 8.1a). MH (N/mm2)
and DE (J) were both determined based on Force-Distance profiles, in particular, MH was
elucidated from the gradient between the initial force and the maximum force attained, and
DE from the AUC (Figure 8.1b).
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Figure 8.1: Typical Force-Time and Force-Distance profiles of the polyelectrolyte matrices
for determining a) Matrix Resilience, and b) Matrix Hardness and Deformation Energy.
8.2.6 Elucidation of the influence of the polymer blends on the porositometric
characteristics of the polyelectrolyte matrices
Surface area and porosity analysis was performed on all polyelectrolyte matrices using a
Porositometric Analyzer (Micromeritics ASAP 2020, Norcross, GA, USA). Samples were
initially degassed to aid the removal of surface moisture and contaminants prior to analysis.
Sample preparation briefly involved the weighing of each matrix (13mm×5mm) with
subsequent division of the matrices into quadrants capable of passing through the neck of
the sample tube (I.D=9.53mm). A glass filler-rod was then inserted into the sample tube to
reduce the total free space volume within the tube facilitating a reduction in the time required
for complete degassing to occur. Samples were completely degassed after a period of
between 7-9 hours, the process of which encompassed an evacuation and heating phase.
The respective parameter settings are shown in Table 8.3.
Table 8.3: Evacuation and heating phase parameters employed for porositometric analysis
Parameter Rate/Target
Evacuation phase
Temperature ramp rate 10°C/min
Target temperature 40°C
Evacuation rate 50.0mmHg/s
Unrestricted evacuation from 30mmHg
Vacuum set point 500µmHg
Evacuation time 60 min
Heating phase
Temperature ramp rate 10°C/min
Hold temperature 30°C
Hold time 900 min
Subsequent to complete degassing, the sample tube was transferred to the analysis port
where data such as surface area, pore volume and pore size was obtained in accordance
Distance (mm) Distance (mm)
Force (N) Force (N)
a) b)a) b)
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with Barrett, Joyner and Halenda (BJH) and Brunauer-Emmett-Teller BET computations. The
most widely used standard procedure for the determination of surface area of porous
materials is based on the BET gas adsorption method which occurs in a two-stage process
(Sing et al., 1985). Firstly, the BET equation was used in the linear form to determine the
monolayer capacity based on Equation 8.1.
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Where, na refers to the quantity of N2 adsorbed at the relative pressure P/P0, nam was the
monolayer capacity and C was exponentially related to the enthalpy of adsorption in the first
adsorbed layer.
The surface area was then determined from the monolayer capacity using Equations 8.2 and
8.3 in the determination of the total and specific surface areas. This, however, required data
regarding the molecular cross-sectional area am occupied by the adsorbate in the complete
monolayer.
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Where As(BET) and as(BET) are the total and specific surface areas, respectively, of the
adsorbent (of mass m) and L is the Avogadro constant.
8.2.7 Surface morphological analysis of the polyelectrolyte matrices in relation to the
isothermic porositometry data
The surface morphology of the polyelectrolyte matrices were characterized by Scanning
Electron Microscopy (SEM) (JSM-840 Scanning Electron Microscope, JEOL 840, Tokyo,
Japan), at an accelerating voltage of 19kV. This was performed to assess the surface
characteristics of the matrices in relation to the nature and blend of polymers employed.
Matrix samples were mounted on aluminum stubbs and sputter-coated with a thin layer of
gold-palladium. Samples were then stored in a desiccator until analysis to avoid absorption
of moisture onto the lyophilized matrices. Photomicrographs were captured at magnifications
of x1400 and x2300.
198
8.2.8 Construction of calibration curves of DPH
The construction of the calibration curves for DPH in simulated gastric fluid (SGF) (pH 1.2;
37°C) and simulated intestinal fluid (SIF) (pH 6.8; 37°C) was performed as described in
Chapter 3, section 3.2.6.
8.2.9 Determination of the drug entrapment efficiency within the polyelectrolyte matrix
With the aim of ascertaining the quantity of DPH entrapped within each matrix, individual
matrices (N=3) were finely triturated and subsequently dissolved in 100mL of SGF (pH 1.2;
37°C). After complete dissolution, the solutions were filtered through a hydrophilic 0.45µm
Millipore membrane filter (Millipore® Millex-HV) (Millipore Corporation, Billerica, MA, USA)
and analyzed spectroscopically (Lambda 25, UV/VIS Spectrometer, PerkinElmer®, Waltham,
MA, USA) at a wavelength of 254nm. The absorbances attained were then fitted to relevant
calibration curves (R2=0.996) for the calculation of DPH content per matrix.
8.2.10 In vitro drug release characteristics of the polyelectrolyte matrices as a function
of the polymer blends employed
In vitro drug release studies were performed in a USP Bio-Dis® Apparatus (Caleva RRT 8)
(Caleva Ltd, Sturminster Newton, Dorset, England) based on identical parameters and
sample withdrawal processes as described in Chapter 3, section 3.4.7, except the pH
differential employed included test media of: SGF (pH 1.2; 37°C) (R2=0.996) for 2 hours and
SIF) (pH 6.8; 37°C) for the subsequent 4 hours to complete the 6-hour study period. Samples
were removed at predetermined time-points and analyzed by UV spectroscopy (Lambda 25,
UV/VIS Spectrometer, PerkinElmer®, Waltham, MA, USA) at a wavelength maximum of
254nm (N=3). The fractional drug release achieved at each time point was then quantified
based on the calibration curves constructed in the relevant simulated fluids.
8.3 Results and Discussion
8.3.1 Synthesis validation of the polyelectrolyte matrices
Band shifts, changes in the peak intensity and peak broadening revealed by FTIR spectra of
the various polymer blends in relation to the native polymers provided evidence that these
modifications were specifically derived from chemical interactions and/or electrostatic
interactions due to synthesis of the polyelectrolyte matrices. From the FTIR spectra of CHT
the presence of amine groups was substantiated by a broad band from 3360-3340cm-1
signifying NH2 stretching. The peak at 2870cm-1 and 1587cm-1 was assigned to the C-H
stretching and NH2 deformation respectively. The native PAAm was dominated by primary
amide groups (-CONH2) that essentially resulted in spectra indicating NH2 stretching (3400-
3150cm-1) and C=O stretching (1680-1660cm-1). Without the application of hydrolyzing
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agents, PAAm remained resistant to hydrolysis in aqueous solutions maintained at room
temperature (Veitser and Mints, 1984). However with the inclusion of SPS to the polymeric
blend partial alkaline hydrolysis of PAAm occurred. This resulted in the partial conversion of
the amide groups to randomly distributed polar carboxyl groups carrying negative charges
that rendered PAAm as a strong anionic polyelectrolyte. Furthermore, due to the employment
of acetic acid as a solvent, the –NH2 groups on the CHT molecule were converted to -NH3+
groups, resulting in the cationic nature of the polymer solution. Thus a combination of these
polymers results in an electrostatic attraction between the relevant oppositely charged
polyions to form a polyelectrolyte complex (PEC). The proposed reaction mechanism is
illustrated in Figure 8.2.
Figure 8.2: Proposed reaction mechanism between chitosan and polyacrylamide
subsequent to hydrolysis with a) depicting the ionization of chitosan in a dilute acetic acid
solution, and b) depicting the hydrolysis of polyacrylamide due to sodium persulphate.
The corresponding FTIR spectra of these matrices revealed unique distinctive peaks
between 1425-1390cm-1 indicating the presence of –COO- symmetrical stretching and a
distinctive peak at 1535cm-1 signifying –NH3+ deformation. These peaks essentially form the
necessary validation for the formation of a PEC between CHT and HPAAm. However there
was still evidence of the presence of remaining amide groups from the non-hydrolyzed amide
groups of HPAAm.
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According to Liu and co-workers (2003b), typically at low ionization, polyacids function as
hydrogen donors and can thus form intermolecular hydrogen bonds with the non-ionic
PAAm, which is a proton acceptor, to form an intermolecular complex. In addition, the
intermolecular interaction between a polyacid and PAAm is also dependent on the degree of
ionization of the polyacid as well as the structural compatibility between the two polymers.
Since PAAm was only partially hydrolyzed the numerous remaining –NH2 groups present on
the polymer backbone provided the basis for the electrostatic interaction with the –COO-
groups of pectin in this study. The FTIR spectrum of these matrices revealed a predominant
broad band between 2500cm-1 and 3500cm-1 indicative of H-bonded OH stretching due to
the free carboxylic groups of the HPAAm. However, the characteristic feature of these
matrices was the disappearance of the peak at 1590cm-1 which signified NH2 deformation of
the primary amine groups. Reactions between anionic and cationic macromolecules in
aqueous solutions lead to the formation of inter-polymeric complexes and since pectin and
CHT are electrostatically complementary macromolecules, it is theorized that an electrostatic
interaction between the positively charged amino groups at C-2 of the CHT pyranose ring
and negatively charged carboxyl groups at C-5 of the pectin pyranose ring may have led to
the formation of a PEC (Rashidova et al., 2004; Tripathi et al., 2010).
Figure 8.3: FTIR spectra of a) CHT-HPAAm matrices, and b) CHT-pectin-HPAAm with inset
c) possible chemical structure of the electrostatic interaction between CHT, pectin and
HPAAm with 1) indicative of the chitosan polymeric chain, 2) partially hydrolyzed
polyacrylamide, and 3) pectin.
Black=CHt-PAAm
Blue=CHt-P-PAAM
Date: 24 May 2010
4000.0 3000 2000 1500 1000 650.0
23.9
30
35
40
45
50
55
60
65
70
75
80
85
90
95
99.1
cm-1
%T
O
H
NH3+
H
O
H
H
OH
OH
CH2OH
O
O
H
CH2OH
OH
OH
H
H
NH3+
H
O
H
H
OH
OH
CH2OH
CH2OH
OH
NH3+
H
NH3+
H
O O O
OH
H
H
C
C
C C
C
C
O O
NH3+OH- COO-
OH
OH
H
O
H
O
COO-
OH
OH
H
O
H
O
OH-NH3+
O O
C
C
C C
C
C
1
3
2
a)
b)
c)
201
Based on FTIR spectra of CHT-pectin-HPAAm matrices relative to the spectra of CHT-
HPAAm matrices it was found that the spectra were identical except for the disappearance of
the peak at 1535cm-1 in the CHT-pectin-HPAAm matrices. As described previously, this peak
was indicative of NH3+ deformation. Thus the existence of this peak in CHT-HPAAm matrices
indicated a surplus of NH3+ sites due to the partial hydrolization of PAAm and thus an
insufficient number of COO- sites available for ‘total’ electrostatic interaction. However, the
inclusion of pectin as part of the blend provided additional COO- anionic sites that facilitated
the electrostatic interaction between the NH3+ ions of CHT and the COO- ions of pectin. In
addition to these electrostatic interactions, a further interaction was observed between the
remaining –NH2 groups of HPAAm and the –COO- groups of pectin (Figure 8.3).
8.3.2 Mechanistic elucidation of polyelectrolyte formation employing chemometric
molecular mechanics modelling
In order to further support the synthesis validation and the FTIR results obtained, Molecular
Mechanics simulations was undertaken in the form of energy minimizations to demonstrate
electro- and structure-selective binding of saccharidic moieties, CHT and pectin, to partially
hydrolyzed PAAm. Molecular Mechanics described the energy of the molecules in terms of a
simplified function that accounted for distortion from ideal bond distances and angles, as well
as for non-bonded Van der Waals and Coulombic interactions. The molecular tectonics of
PECs in this study was found to be affected by various types of attractive interactions such
as Van der Waals contacts, H-bonds and electrostatic interactions. Table 8.4 and Figure 8.4
show the results of Molecular Mechanics computations performed in vacuum. The final
conformation models of molecular networks were generated by the Molecular Mechanics
computations for formable complex structures in relation to the cooperative ion-pair binding
between the carboxyl (-COO) and the protonated amine (-NH3+) groups.
The strong binding affinity in CHT-HPAAm was due to the electrostatic interaction caused by
the –NH3+ and –COO ions that proceed in accordance with the short-range Van der Waal
attractions and secondary interactions such as H-bonding. In contrast, -COO ions of pectin
interacted with the –NH3+ of HPAAm. Although the pectin-HPAAm complex was
electrostatically more stable than CHT-HPAAm, the Eelec (CHT-HPAAm - CHT) and Eelec (pectin-HPAAm -
pectin) were computed to be 5kcal/mol and 1kcal/mol, respectively indicating that the
electrostatic interactions in pectin-HPAAm complexes were weaker than the interactions in
the CHT-HPAAm complexes. Hence, HPAAm was playing a dual role as an anionic
electrolyte in the presence of CHT and a cationic polysaccharide in the vicinity of pectin.
Interestingly, the Van der Waals energy was more stabilized in the case of pectin-HPAAm
(decreased by 58kcal/mol) than in CHT-HPAAm (44kcal/mol) which demonstrated the
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significance of a structural backbone fit between the host and guest molecule. In addition,
pectin-HPAAm was more stabilized by H-bonds as shown in Table 8.4 and Figure 8.4a-c.
Figure 8.4: Energy minimized geometrical preferences of the polyelectrolyte complexes
derived from molecular mechanics calculations: a) CHT-HPAAm, b) pectin-HPAAm and c)
CHT-pectin-HPAAm complex. The HPAAm color codes for elements C12, N2 and O2 are also
shown.
Finally, these complex interactions were also explored through the CHT-pectin-HPAAm
complex and observed the formation of a PEC represented by a novel tri-polymeric ionic-
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quadrilateral (TPIQ) consisting of –NH3+ ions of CHT, -COO- ions of pectin and –NH3+ and -
COO- ions of HPAAm as shown in the FTIR spectra of Figure 8.3. Figure 8.4c clearly
demonstrates the polyelectrolyte selection of the pectin-CHT, pectin-HPAAm and CHT-
HPAAm polymers. Figure 8.4c also depicts the energy minimized structures of CHT-pectin-
HPAAm where due to the flexibility of the polymer chain, the relevant segments of polymers
orientated their configuration to form a remarkable structure fit between the –NH3+ and –COO
ions, the electrostatic, Van der Waals and H-bond interactions being pseudo-optimized.
Comparison of the complexes revealed that the CHT-pectin-HPAAm complex was superiorly
stable in total energy, Van der Waals, H-bond and electrostatic interactions by 92, 17, 0.88
and 136kcal/mol respectively in comparison to CHT-HPAAm and 45, 20, 1.38 and 70kcal/mol
respectively in comparison to pectin-HPAAm. The difference in the electrostatic interactions
of the TPIQ and the biopolymer complexes of approximately 136 and 70kcal/mol suggested
that the complex was stabilized mainly by Coulombic attractions (Table 8.4) and supported
by the Van der Waals forces with a difference of 17 and 20kcal/mol, respectively. Although
their H-bond lengths ranged from 2.1579-3.1772A˚ (Figure 8.5) and may be considered as H-
bonds of medium strength, it is likely that these interactions may be significant for the stability
of the TPIQ. Therefore, the highly stable structure of TPIQ was due to the formation of a
pectin-CHT PEC in the vicinity of HPAAm which again demonstrated the significance of a
structural backbone fit due to the superior fit between the location of the positive charges and
the position of the negatively charged groups.
Table 8.4: Computed energy parameters (kcal/mol) of the polyelectrolyte complexes formed
between chitosan, hydrolyzed polyacrylamide and pectin
Structure Energy (kcal/mol)
Total Bond Angle Dihedral VDW H bond Elec
CHT 35.556 3.1201 18.035 25.7749 13.3231 0 -24.6973
Pectin -7.5603 5.0315 24.4993 28.571 29.0303 0 -94.6923
HPAAm 10.3568 1.4247 5.46554 8.5739 -5.0725 -0.0349 0
CHT-HPAAm 13.1292 5.8508 27.9893 42.3994 -31.8998 -0.576 -29.7597
Pectin-HPAAm -34.2502 7.5611 36.3226 46.28 -28.8202 -0.0748 -95.5188
CHT-pectin-HPAAm -79.0868 10.868 57.0293 68.2813 -48.8639 -1.4509 -165.825
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Figure 8.5: H-bond lengths (Å) involved in the pectin-CHT-HPAAm complex as computed via
AMBER Force Field. Color codes for the elements C12, N2 and O2.
8.3.3 Physicomechanical analysis of the polyelectrolyte matrices
Matrix resilience (MR) was employed as a measure of the cohesiveness of the
polyelectrolyte matrices and referred to the ability of the matrices to recover to their original
dimensions after a compressive stress was applied by the textural probe (Pillay and Fassihi,
1999b). It was determined that at a consistent strain of 40%, the CHT-HPAAm matrices
proved to be the most resilient at 6.1±0.03%, compared to pectin-HPAAm matrices with a
resilience of 5.3±0.02% (Figure 8.6). According to Platé (1976), on forming a complex the
reacting chains of components of a PEC lose their flexibility and intermolecular mobility.
Considering that CHT-pectin-HPAAm matrices had additional electrostatic interactions
between CHT-pectin and pectin-HPAAm, along with the interaction between CHT and
HPAAm, it was thus warranted that these matrices would have the least resilient nature.
The energy required to overcome the adhesive and cohesive forces within the matrices is
regarded as the Deformation Energy. As expected the energy dissipated in the causation of
this effect was markedly lower for CHT-pectin-HPAAm matrices compared to the other
variants. Furthermore, the Matrix Hardness of CHT-pectin-HPAAm matrices was lower than
pectin-HPAAm matrices and CHT-HPAAm matrices (Figure 8.6).
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Figure 8.6: Physicomechanical properties of the polyelectrolyte matrices produced from
different polymer blends.
8.3.4 Influence of the polymer blend on the porositometric properties of the
polyelectrolyte matrices
The technique of physical gas adsorption was used for assessing the pore characteristics of
the various polyelectrolyte matrices as a direct measure of its porous properties and
structure (Groen et al., 2003). When applied over a wide range of relative pressures (P/P0),
N2 adsorption isotherms provided critical data on the pore size distributions in terms of their
micro-, meso-, and macropore ranges (±0.5-200nm). The BJH model of determining pore
volume and pore size distribution (PSD) in the mesopore and macropore range was based
on the Kelvin equation and corrected for multi-layer adsorption (Barret et al., 1951). Several
assumptions were made with the BJH pore size distribution computation, namely pores were
rigid and of a well-defined shape, the distribution was confined to the mesopore range and
filling/emptying of pores did not depend on the location. It was generally considered that
matrices that were purely mesoporous and comprised of non-intersecting mesopores of
cylindrical geometry and similar size exhibited Type IV isotherms with a Type H1 hysteresis
loop (Groen et al., 2003). However, due to the random distribution of pores and an
interconnected pore system of the matrices, the hysteresis loop was of Type H2 or H3.
Figure 8.7 provides an illustration of typical isotherms and hysteresis models employed.
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Figure 8.7: Schematics depicting a) types of isotherms and b) types of hysteresis loops
according to the IUPAC classification system (adapted from Sing et al., 1985).
The isotherm of CHT-pectin-HPAAm matrices (Figure 8.8) was typical of a Type IV isotherm
accompanied by a H3 hysteresis. The characteristic hysteresis loop was associated with
capillary condensation that took place in mesopores. This was supported by data obtained
where the pore sizes of the matrices were found to be 22.46nm according to the desorption
curve of the isotherm. Furthermore, according to the isotherm a forced closure of the
hysteresis occurred at P/P0>0.45 which was due to a sudden drop in the volume of N2
adsorbed along the desorption curve. This phenomenon was referred to as the Tensile
Strength Effect (TSE). The isotherm increased rapidly near P/P0=1 that was indicative of the
presence of macropores with a significant vertical rise signifying the large diameters of the
macropores.
a) b)
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Figure 8.8: A linear isothermic plot of CHT-pectin-HPAAm matrices with insets of SEM
micrograph images at magnifications of x1400 and x2300.
In contrast, pectin-HPAAm matrices exhibited an isotherm not characteristic of any
isothermic types according to the IUPAC classification system. However, certain regions of
the isotherm were similar to that of a Type IV isotherm accompanied with a H4 hysteresis
loop (Figure 8.9). According to the data obtained pectin-HPAAm matrices had a pore size of
5.15nm based on the desorption isotherm. This was within the mesopore range and
explained the presence of the H4 hysteresis of the isotherm. Furthermore, the presence of a
low pressure hysteresis (P/P0<0.45) suggested that micropores were also present in the
matrices. However, Groen and co-workers (2003) described that a high degree of
mesoporosity may lead to a higher mesopore surface area, and this can in turn significantly
affect the low-pressure region (micropore range) of the isotherm. This explanation is
validated by the elevated surface area of the matrices despite the smaller pore sizes
compared to the CHT-pectin-HPAAm and CHT-HPAAm matrices (Table 8.5).
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Figure 8.9: A linear isothermic plot of pectin-HPAAm matrices with insets of SEM
micrograph images at magnifications of x1400 and x2300.
CHT-HPAAm matrices exhibited a similar isotherm to that of CHT-pectin-HPAAm matrices,
with similar pore sizes (Table 8.5). However, it deviated from the CHT-pectin-HPAAm
matrices with its reduced surface area due to the reduced number of pores present in the
matrix.
Table 8.5: Surface area and porosity characteristics of the various polyelectrolyte matrices
Surface Area(m2/g) Pore Volume (cm3/g) Pore Size (nm)
BET 1A 2B 1A 2B
CHT-HPAAm 2.70 0.021 0.021 26.069 21.647
Pectin-HPAAm 22.67 0.005 0.005 5.425 5.152
CHT-pectin-HPAAm 10.50 0.078 0.078 25.379 22.462
1BJH adsorption branch
2BJH desorption branch
SEM micrographs of all matrices showed highly porous surface characteristics. Surface area
and porosity studies suggested that the porosity of the matrices followed a random
distribution and an interconnected pore system. This was evidenced from SEM images at
various magnifications for each matrix formulation (Figure 8.8 and 8.9). According to a Type
II and Type IV isotherm, the point marked ‘B’ on Figure 8.7a refers to the point at which
monolayer adsorption was complete and was visible at the beginning of the almost linear
mid-section of the isotherm. This point was clearly visible as a ‘sharp knee’ in the isotherm
when C≈100 (Equation 8.1). However, when C<20 this point was not present as a single
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point on the isotherm (Sing et al., 1985). CHT-pectin-HPAAm matrices exhibited a Type IV
isotherm with no discernable point ‘B’ that correlated with its C value of 28.19. CHT-HPAAm
matrices also had no discernible point ‘B’ with a C value of 12.16. This difference in the
enthalpy of adsorption resulted in the difference in the surface areas of these matrices.
8.3.5 Effect of the polymer blend on the drug release performance of the
polyelectrolyte matrices
It has been reported that pore diameter may have a significant effect on the rate of drug
release and can also affect the migration of the drug from the matrix into the release media
(Jelvehgari et al., 2006). However, such a relationship between pore diameters and release
rate is not always apparent. In addition to pore diameter, the number of pores may also be
an important factor in controlling the release rate of drug from matrices.
Figure 8.10: a) A digital image of the lyophilized polyelectrolyte matrix, and b) the drug
release profiles obtained for the polyelectrolyte matrices in conditions simulating the
gastrointestinal tract.
Drug release data indicated a marked difference in the release profiles of the various
polyelectrolyte matrices, particularly in the first 2 hours in simulated gastric conditions. In this
time, no drug was released from the CHT-HPAAm matrices, whereas 28.2% and 82.2% of
DPH was released from the pectin-HPAAm and CHT-pectin-HPAAm matrices respectively.
After 4 hours of dissolution in simulated intestinal conditions complete drug release was
achieved from the CHT-pectin-HPAAm matrices in contrast to only 35.0% release from CHT-
HPAAm matrices (Figure 8.10). The pH differential employed which simulated conditions of
]the gastric and small intestinal environments, showed that CHT-HPAAm matrices may hold
applicability in the targeted delivery of pharmaceutical agents to the small intestine and colon
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as no drug was released in the gastric region. This modulated release profile would prove to
be beneficial for the localized treatment of chronic intestinal pathologies such as ulcerative
colitis where distal small intestinal and colonic inflammation is prevalent. In contrast, since
pectin-HPAAm matrices exhibited controlled release of DPH in SGF and SIF with <40%
released, it may still allow for an almost 60% delivery of drug in the colonic region and thus
may be beneficial for the treatment of Crohn’s disease where the entire GIT is inflamed. The
drug release data complements results obtained from the surface area and porosity studies.
The surface area (m2/g) of CHT-HPAAm matrices was significantly lower than that of the
other matrices (2.7 vs. 22.7 and 10.5m2/g, respectively). The lower surface area sustained
the absorption of dissolution media into the matrix thus reducing the swelling rate and
subsequently the rate of DPH diffusion out of the matrix. On the contrary, despite the lower
surface area of CHT-pectin-HPAAm matrices compared to pectin-HPAAm matrices, the rate
of drug release was still higher. This finding may be supported by the higher pore volume
and pore sizes as well as the presence of macropores in the CHT-pectin-HPAAm matrices
compared to pectin-HPAAm matrices.
8.4 Concluding Remarks
After consideration of the numerous benefits of employing modified polysaccharides in
controlled drug delivery applications, the synthesis of these novel polyelectrolyte matrices
that remain resistant to conditions of the upper GIT prove to be immensely promising.The
interaction between partially hydrolyzed PAAm molecules to both anions (pectin) and cations
(CHT) formed three polymer complexes which were accommodated by electrostatic, van der
waals and H-bonding interactions. The polyelectrolyte matrices demonstrated controlled
release of the highly water-soluble model drug, DPH. Drug release behaviour was pivoted to
the porositometric properties of the various matrices. It was found that by modifying the
concentrations of the polymers employed (CHT, pectin and PAAm) and the combinations
thereof, the applicability of these matrices may be accentuated for effective targeted and
controlled oral drug delivery applications more specifically, for application in colon-targeted
drug delivery.
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CHAPTER 9
CONCLUSIONS, RECOMMENDATIONS, CHALLENGES AND POTENTIAL PROSPECTS
OF THE STIMULI-RESPONSIVE ORAL TABLET SYSTEM
9.1 Conclusions
Ulcerative colitis (UC), notorious for its unpredictable attacks of inflammation of the large
intestine, is estimated to affect as many as 1.4 million people in USA and 2.2 million people
in Europe with 15000-30000 new cases being diagnosed annually worldwide (Loftus, 2004),
however despite the prevalence of UC in South Africa there is an absence of definitive
statistics regarding the incidence rates. The chronic inflammatory process is limited to
various regions of the colonic mucosa and is postulated to occur due to a dysregulated
mucosal response in the intestinal wall, facilitated by defects in the protective barrier function
of the intestinal epithelium and mucosal immune system (Klotz, 2005).
Generally, UC is characterised by periods of remission and relapsing exacerbations with
symptoms including weight loss, diarrhoea accompanied with blood, and abdominal pain
(Podolsky, 2002a). Essentially 50% of patients remain asymptomatic, 30% experience mild
symptoms and 20% suffer from moderate to severe symptoms (Hendriksen et al., 1985).
Furthermore the cumulative probability of remaining ‘attack-free’ decreases with an increase
in years (Allan et al., 1997). Since a definitive aetiology of UC remains obscure, currently the
only curative option relies on performing a procto-colectomy (Farrell and Peppercorn, 2002;
Podolsky, 2002b; Klotz, 2005). However more appropriately the therapeutic goal in active UC
is to achieve and maintain a state of remission for which the aminosalicylates, in particular 5-
ASA, have been established as the best treatment option. Consequently, these
aminosalicylates should be ideally targeted directly to the affected area namely, the colon. By
acting at the luminal site, effective drug concentrations can be achieved in the colonic
mucosa and systemic availability limited, thus reducing the potential for drug-related adverse
effects. Furthermore, due to the chronicity of colonic inflammation, a consequent symptom of
diarrhoea is almost always present and therefore necessitates concurrent therapy with an
anti-diarrhoeal agent such as loperamide HCl.
Therefore, this research undertook to develop a novel stimuli-responsive oral tablet (SROT)
system that served to provide both symptomatic and chronic treatment for UC with a single
tablet administration. Essentially, the novelty of the system is based on its ability to target the
release of 2 different drugs to specific regions of the gastrointestinal tract (GIT) in response
to a stimulus specific to the relevant region. The stimulus serves as a trigger that either
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inhibits or initiates drug release, for example pepsin inhibits loperamide HCl release in the
stomach, whereas colonic enzymes initiate and accelerate 5-ASA release in the colon.
Extensive in vitro studies were conducted in lieu of the complexity of the proposed system.
These studies established an effective SROT as a direct result of the exhaustive preliminary
investigations undertaken to identify suitable polymers, polymeric combinations, crosslinking
agents, and release modifying agents that imparted not only a robust formulation but also
one that is enzyme-specific responsive. In vitro studies on the 2 components of the SROT
namely, the outer loperamide HCl shell and the 5-ASA loaded inner tablet, were conducted
separately since drug release from either component was mutually independent.
The optimization of the 5-ASA loaded colon-targeted tablet component was conducted
employing a Box-Behnken experimental design that identified 15 formulations which were
subjected to in vitro drug release studies to assess the enzyme-responsiveness and colon-
targeting ability of the tablets. Ultimately, the optimized tablet not only exhibited significant
enzyme-responsiveness when subjected to colonic enzymes but also prevented premature
drug release in the upper GIT, cementing its colon-targeting ability. The robustness of the
optimized formulation was assessed based on the matrix hardness and friability of the
tablets. The influence of colonic enzymes on the tablet was not only established based on
the comparative 5-ASA release in the presence and absence of colonic enzymes, but also on
the relevant degree of simulated fluid uptake and the corresponding erosion of the tablet,
which was also influenced by the structural and polymeric vibrational changes of the tablet
due to the enzymes.
The outer loperamide HCl loaded coating of the SROT was formulated to specifically target
drug release to the small intestine and thus required a mechanism that inhibited/minimized
the release of the drug in the stomach. In order to achieve this minimization in drug release,
preliminary in vitro studies served to identify suitable polymers, polymeric configurations and
methods of crosslinking that would provide a formulation that was capable of responding to
the enzyme pepsin in such a way that drug release was inhibited in its presence.
Optimization of the coating was conducted from a constructed Box-Behnken experimental
design where the pepsin-responsiveness of the coating was established based on the in vitro
drug release in the presence and absence of the enzyme. The small intestinal targeting
ability of the formulation was then determined based on drug release studies conducted in
simulated intestinal fluid.
In vitro studies not only established a successful SROT but also resulted in a formulation
design approach that was easily reproducible, requiring minimal preparatory processes and
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employing biocompatible, biodegradable and readily available polymeric materials. Thus
based on the promise of the SROT in vitro, in vivo evaluation of the system followed in the
pig model. The colon-targeted tablet component exhibited minimal 5-ASA release in the
upper GIT, followed by a sustained plasma concentration of 5-ASA throughout the rest of the
24 hour period. In contrast the commercially available 5-ASA-loaded formulation, Asacol®,
presented with greatly fluctuating plasma concentrations and ineffective targeting of the
colon. The success of the outer coating was evident from the inhibition of drug release in the
first 2 hours post-dosing (indicative of the stomach), with peak plasma concentrations
achieved 8 hours post-dosing. The gold-standard formulation, Imodium®, initiated drug
release immediately post-dosing resulting in peak plasma concentrations in only 4 hours.
Essentially, the SROT proved to be superior to the commercially available counterparts with
the added benefit of delivering both drugs with a single tablet administration.
Furthermore, preliminary in vitro investigations were undertaken to develop an alternative
polymeric matrix comprised of polysaccharide polymers and of a partially hydrolyzed
polyacrylamide that were degradable by colonic enzymes. Physicomechanical analysis of the
lyophilized polyelectrolyte matrices were performed to establish the matrix resilience, matrix
hardness and deformation energy, as well as the surface area and porosity of the matrices
comprised of varying polymeric combinations. In vitro drug release studies revealed the
differing release characteristics of the different polyelectrolyte matrices as a function of the
polymers employed. Ultimately, the promise of these matrices for sustaining and controlling
the release of a highly water-soluble drug implies the flexibility of the matrices for colon-
targeted drug delivery applications as well. In addition, the formulation exploits the attractive
properties of polysaccharide polymers whilst concurrently minimizing the hindering
characteristics thereof.
9.2 Recommendations
It has been said that as the first decade of the 21st century closes we stand at the threshold
of unprecedented advances in knowledge of the exact pathogenesis of UC. Furthermore, the
simultaneous progress in biotechnology is fostering the development of newer agents that
strategically target pivotal processes in the disease pathogenesis (Sands, 2000). However
until such time the potential of the existing therapeutic options for UC should be maximized.
Therefore, owing to the immense promise of the SROT as a treatment option, it is
recommended that further elaborative studies be performed to determine the exact location
in the human GIT at which the relevant drugs are released. It is recommended that this be
undertaken by employing gamma-scintigraphic technology which would safely and
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definitively establish the targeting efficacy of the SROT. Such data would allow a correlation
of the in vivo plasma concentrations of 5-ASA and loperamide HCl with the relevant
locations. Furthermore, identical gamma-scintigraphic studies should also be performed on
the conventional systems so that the SROT may be effectively compared to a ‘bench-mark’
formulation/s.
It is further recommended that in vivo pilot studies be performed in human subjects ascribed
to the success of in vivo studies conducted in the pig model. Such data would thus permit a
correlation between drug plasma concentrations and the location of the delivery system in
the GIT of humans.
In addition, it is recommended that the composite polyacrylamide-polysaccharide hydrolyzed
electrolytic matrices be further evaluated with the incorporation of 5-ASA and consequently
evaluated for the drug release characteristics in conditions simulating the entire GIT namely,
the stomach, small intestine and colon with the presence and absence of colonic enzymes.
9.3 Challenges experienced with regard to the study
Despite the success of the SROT and the potential future benefits of the formulation, the
process of formulation development was marred with several challenges.
Despite the potential of an easily scaled-up manufacturing process for the tablet, the manual
dip-coating process that had been employed for the production of the outer shell may
possess certain process limitations, principally due to its time-consuming manufacturing
process. However, this can be simply overcome by employing a similar manufacturing
process to that commonly used to produce gelatine capsules.
The most prominent challenge experienced in the completion of the study was experienced
during the in vivo study performed in the pig model. Numerous specific challenges were
encountered for example determination of an effective method of dosing the pig with the
delivery system which ensured that the SROT was not chewed, determination of an effective
method of blood sampling, and ensuring that the pigs remained free from infection due to the
chronic catheters. Nevertheless, the principle challenge is attributed to the time-consuming,
strenuous and at times dangerous experimental conditions experienced. Even though these
challenges were ultimately overcome, it is suggested that an alternative method of
determining the in vivo effectiveness of delivery systems be established, by developing a
more sophisticated in vitro gastrointestinal dissolution system which as close as possible
mimics the human physiological gastrointestinal functions such as fluid content, viscosity,
215
enzyme populations, elimination processes, absorption processes and distribution processes
etc. This would negate the need for performing in vivo drug release studies in the animal
model.
9.4 Potential prospects of the stimuli-responsive oral tablet system
While the SROT has been developed for the simultaneous symptomatic and chronic
treatment of UC, with the incorporation of loperamide HCl and 5-ASA, the delivery system
itself (excluding the drugs) is not exclusive to this disease. By substituting loperamide HCl
and 5-ASA with other pharmaceuticals or nutriceuticals or even a combination of both this
system can be employed for numerous other disease conditions.
Even though the SROT was developed for the incorporation of 2 different drugs for targeting
2 different sites in the human GIT, this technology can be easily modified for numerous drug
delivery purposes. The enzyme-responsive colon-targeted tablet component can be
manufactured without the outer pepsin-responsive coating, thereby allowing the incorporation
of numerous other pharmaceutical agents for specific colon-targeting. This tablet can thus
incorporate anti-cancer agents, laxatives, corticosteroids for localized action, and non-
steroidal anti-inflammatories (NSAIDs) (to prevent gastric and duodenal ulcers) amongst
others. Similarly, the outer pepsin-responsive coating can be employed exclusively. It holds
potential benefit for drugs with specific absorption windows in the small intestine, for
probiotics, vitamins, proteins, anti-tuberculosis drugs, several anti-retroviral drugs etc.
Ultimately, the optimum benefit of the SROT will be experienced if the system is employed in
its entirety. Thus the SROT holds immense potential in the nutriceutical market especially
since there is a markedly increased awareness by populations of the benefits of
supplemental vitamin and mineral administration in daily life. By incorporating vitamins into
the SROT, not only will the vitamins be protected from the harsh gastric environment but the
two phases of vitamin release, particularly in the small intestine and colon, will allow for a
sustained release of the incorporated vitamins throughout the 24 period, thus maximizing its
therapeutic benefit.
Ultimately, Sands (2000) most eloquently explained the benefit of novel drug delivery
systems by stating that:
“the refinements in drug formulation have provided the ability to target distinct sites of
delivery, enhancing the safety and efficacy of older agents.” – Sands, 2000
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Abstract
The purpose of this study was to formulate a stimuli-responsive colon-targeted oral tablet
(SROT) that was capable of preventing release of the therapeutic agent mesalamine (5-ASA)
in the upper gastrointestinal tract (stomach and small intestine) thus ensuring the delivery of
a maximal quantity of 5-ASA to the colon. The formulation comprised of 5-ASA-loaded
crosslinked chitosan (CHT) granules dispersed within a matrix of pectin, barium chloride
(BaCl2), carboxymethylcellulose (CMC) and xanthan gum (XG). The combination of matrix
components and granules were compressed into shallow concave tablets and coated with a
combination coating solution of pectin and ethylcellulose. Formulation batches were
prepared according to the Box-Behnken experimental design and each formulation was
evaluated for the in vitro drug release characteristics at various residence times and pH
gradients. The mean dissolution time (MDT) in the presence and absence of the colonic
enzymes was employed in the determination of the optimized SROT. In vitro drug release
studies revealed a distinct responsiveness of the SROT to colonic enzymes with a fractional
release of 0.402 in the presence of enzymes vs. 0.152 in the absence of enzymes, after 24
hours. The commercially available comparator product showed irreproducible release profiles
over the 24 hour period (SD: 0-0.550) compared to the SROT (SD: 0-0.037). FTIR spectra of
the coating showed a disappearance of peaks from 1589-1512cm-1 after exposure to colonic
enzymes. In addition, with increasing exposure time to colonic enzymes there was a
disappearance of peaks between 1646-1132cm-1 of the tablet indicating polymeric cleavage
by colonic enzymes and release of 5-ASA from the tablet. Plasma concentration profiles of
the SROT in the pig model produced a Cmax of only 3.77±1.375µg/mL compared to10.604±2.846µg/mL from the comparator product. Overall, the SROT proved beneficial over
the commercially available comparator product due to the mechanism of drug release and
responsiveness to colonic enzymes.
Keywords: Colon-targeting, enzyme-responsive, pH-independent, polysaccharides,
crosslinking, stimuli-responsive, ethylcellulose-pectin aqueous dispersion, chitosan, β-
glucosidase, pectinase, plasma concentrations
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Effect of the degree of esterification and amidation on drug release from crosslinked
zinc pectinate matrices
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Purpose
The purpose of this study was to compare the effects of the degree of esterification and
amidation on drug release from crosslinked zinc pectinate matrices intended for site-specific
drug release in the gastrointestinal tract.
Methods
Preparation of crosslinked zinc-pectinate tablets: Tablets were prepared by a direct
compression approach. Zinc sulphate (ZnSO4) crystals were ground in a pestle and mortar
and combined with magnesium stearate (1%w/w), model drug diphenhydramine HCl, andvarious grades of apple (Pectin A) and citrus (Pectin B and C) pectins. The degree of
amidation and esterification varied. Permutations were blended for 20 minutes until
homogeneity and subsequently compressed into tablets (13mm×5mm). Tablets serving as a
control were also prepared devoid of any crosslinking agent.  In vitro drug release studies:
Release studies were conducted in a rotating paddle apparatus in simulated gastric fluid
(SGF) (pH 1.2; 37ºC) and simulated intestinal fluid (SIF) (pH 6.8; 37ºC). Samples (5mL) were
withdrawn at pre-determined intervals over 24 hours and analyzed by UV spectrophotometry.
Results
Results in SGF indicated that pectin A crosslinked with ZnSO4 showed retardation of drug
release compared to the non-crosslinked pectin A (43.7% vs. 56.16% after 6 hours). A burst
effect was noted in the first 3 hours in both crosslinked and non-crosslinked formulations,
however was not significant for the crosslinked formulations (14.95% vs. 4.41% drug release
in 30 minutes). Citrus pectins B and C crosslinked with ZnSO4 displayed greater drug releasecompared to the non-crosslinked formulations. UV spectrophotometry analysis in SIF
showed similar results as conducted in SGF i.e. crosslinked pectin A retarded drug release.
Pectin B also showed greater drug release (17.6% in 30 minutes) when crosslinked
compared to 2.62% drug release from non-crosslinked formulations. In SIF Pectin C was the
only citrus pectin to control drug release over a period of 5 hours. A low methoxy pectin with
a degree of esterification between 38-44% proved to be the most efficient in retarding drug
release in both SIF and SGF. However, in SIF citrus pectins such as Pectin C also proved to
control drug release over a similar period.
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Purpose
The purpose of the study was to determine the drug release characteristics of drug-
entrapped granules prepared by wet granulation using different solvents and to determine
the most appropriate solvent for the preparation of granules intended for site-specific colonic
delivery.
Methods
Preparation of drug-entrapped granules:  Permutations of constant concentrations of a model
drug, Diphenhydramine HCl, Sodium Alginate, Chitosan and Zinc sulphate (ZnSO4) werethoroughly blended for 20 minutes until homogenous. Three different solvents were
investigated and samples were prepared in duplicate. A Eudragit® S100 latex was prepared
and investigated as a solvent in the first set of granules (Set A). The second and third sets
were prepared using de-ionized water as a solvent. All three sets of granules were prepared
by granulating through a 2mm mesh sieve and allowed to dry at 40ºC for 12 hours. After
drying, the second set of granules (Set B) were sprayed with the Eudragit® S100 latex and
the third set (Set C) of granules were sprayed with a 10% ethylcellulose solution. The first set
of granules were also sprayed with the Eudragit® S100 latex after drying. Each set of
granules was incorporated into a matrix of Pectin, Barium chloride, Poly(ethylene oxide) and
magnesium stearate. These were then compressed into tablets (13mmx5mm) with a
compression force of 8N.
In vitro drug release studies: Release studies were conducted in a rotating paddle apparatus
in simulated gastric fluid (SGF) (pH 1.2; 37ºC). Samples (5mL) were withdrawn at pre-
determined intervals over 6 hours and analyzed by UV spectrophotometry.
Results and Discussion
Since the average gastric transit time is approximately 2 hours, the first two hours after drug
administration remains the most important when analyzing drug release specifically in the
gastric region especially when trying to achieve minimal drug release in this region. After 2
hours of dissolution in SGF, Set B had a drug release of 5.58%. This was substantially lower
than the drug release achieved by Set A and C (8.85% and 17.12% respectively). After 5
hours of dissolution, Set C had the highest percentage of drug release (40%) vs. 25.53% and
18% from Set A and B respectively. When attempting to limit drug release in the stomach
and target drug release specifically to the distal part of the gastrointestinal tract, de-ionized
water as a solvent is most efficient as it facilitates crosslinking of the granules better than the
latex solution. Also, dried granules sprayed with Eudragit® S100 were more effective at
limiting drug release than the same granules sprayed with the hydrophobic ethylcellulose
solution.
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Introduction
The purpose of the study was to formulate a lyophilized graft co-polymerized sponge-like
drug delivery system using various combinations of natural and synthetic polymers.
Methods
Three combinations of the sponge-like delivery systems were prepared. Briefly, aqueous
stock solutions of 10%w/v pectin (PEC), 5%w/v polyacrylamide (PAAm), and 10%w/v chitosan
(CHT) were prepared in 1M acetic acid. The three combinations included PEC-PAAm in a
2:1 ratio, CHT-PAAm in a ratio of 2:1 and CHT-PEC-PAAm in a ratio of 1:1:1.
Diphenhydramine (DPH) was incorporated as a model drug in all formulations. The
respective combinations were combined until homogenous and underwent redox-initiation by
the addition of sodium persulphate (SPS) and N,N,N’,N’-tetramethylethylenediamine
(TEMED)  in a ratio of 2:1. 1mL aliquots of the composite solutions were placed into pre-oiled
cylindrical moulds and were frozen at -70°C for 24 hours prior to lyophilization for 48 hours at
25mtorr. Drug release studies were performed at 37±0.5ºC using USP25 Apparatus 3 (Bio-
Diss II Release Rate Tester, Vankel Industries) (220mL per vessel). Each formulation was
subjected to a continuous run under a pre-determined pH differential of pH 1.2 for 2 hours,
pH 6.8 for 4 hours and pH 7.4 for 6 hours. A standard oscillating rate of 10dpm was
employed throughout the study. Samples (5mL) were withdrawn at pre-determined intervals
over 12 hours and analyzed by UV spectrophotometry at 254nm. Sponges were completely
dissolved in 100mL of simulated gastric fluid (SGF) (pH 1.2; 37ºC) and analyzed via UV
spectrophotometry to determine DPH content. SEM was used to elucidate the morphology,
size and distribution of pores within the sponge-like delivery system and to relate this to the
DPH release dynamics.
Results
The DEE values of the three combinations differed significantly. PEC-PAAm sponges had a
DEE value of 93% vs. 38% for CHT-PAAm and 79% for PEC-CHT-PAAm. In order to
accurately simulate the passage of the delivery system through the GIT, pH differentials
simulating GIT conditions were employed. At t2hours in SGF, PEC-PAAm released 55.2±2.07%of DPH compared to 49±1.15% and 40.9±7.6% for the CHT-PAAm and PEC-CHT-PAAm
sponges respectively. The higher DPH release from PEC-PAAm may be attributed to the
greater DPH entrapment within the formulation. A х1400 magnification of the CHT-PAAm
sponges revealed an uneven distribution of pores of varying morphologies compared to the
more uniform and consistent pores of smaller sizes for the PEC-CHT-PAAm sponges at the
same magnification. DPH release from the CHT-PAAm sponges was therefore substantially
higher at specific time points (for instance 94.28±1.73% and 85.59±0.60% at t6 hours. Using
the time-point approach where tx% represented the time at which 100% DPH was released,results showed that PEC-PAAm and CHT-PAAm sponges had a t100% at 8 hours. However,
PEC-CHT-PAAm sponges had a t100% after only 12 hours. This may be a result of the moreconsistent and even pore distribution of the PEC-CHT-PAAm sponges.
Conclusions
The combination of PEC-CHT-PAAm proved to be promising for sustained drug delivery.
With careful manipulation of the polymeric ratios further modulation in drug release can be
achieved.
287
APPENDIX B4
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Introduction
This study investigated the viability of non-crosslinked and crosslinked chitosan formulations
prepared by two different approaches and to determine the most effective and reproducible
method of preparation to ensure gastric targeted drug delivery.
Methods
Solutions of chitosan (CHT) (2%-5%w/v) in 1M acetic acid were prepared and incorporated
with diphenhydramine (DPH) as a model drug. 1mL aliquots were placed in pre-lubricated
moulds, and were frozen at -70°C for 24 hours and subsequently lyophilized. Lyophilized
samples were crosslinked with ZnSO4 solutions (5% and 30%w/v) for 1 hour and underwent
further lyophilization. Non-crosslinked matrices were retained for comparative purposes.
DPH-loaded and placebo CHT solutions were prepared as above. 1mL aliquots were placed
into pre-lubricated moulds and solvent evaporation was allowed under a fume hood.  Dried
films were crosslinked with the ZnSO4 solutions for 1 hour and allowed to dry. Non-crosslinked films were also produced. Drug release studies were conducted in simulated
gastric fluid (SGF) (pH 1.2; 37ºC), employing a rotating paddle apparatus. Samples (5mL)
were withdrawn at 30 minute intervals for a period of 3 hours and analyzed by UV
spectrophotometry.
Results
Prior to DPH release studies on crosslinked and non-crosslinked formulations it was
established that the films were inconsistent. On the contrary, CHT lyophilized formulations
were consistent and were found to be reproducible. Release studies showed that the non-
crosslinked matrices disintegrated and resulted in complete DPH release in the first 30
minutes. The 30%w/v ZnSO4 crosslinked matrices showed higher DPH release in 30 minutes
compared to the 5%w/v ZnSO4 crosslinked matrices (65% vs. 49% DPH release). However,after 2.5 hours complete DPH release was obtained at lower crosslinker concentrations
whereas higher concentrations only influenced disintegrated after 3 hours. The 8%w/v CHT
matrices crosslinked at the two crosslinker concentrations both achieved complete DPH
release after 3 hours. The 30%w/v crosslinked matrices however achieved a burst of 58%
DPH release compared to 27% from the 5%w/v crosslinked matrices in the first 30 minutes.The 15%w/v CHT matrices crosslinked with either 5%w/v or 30%w/v ZnSO4 had an almostidentical release profile throughout the 3 hours.
Conclusions
The solvent evaporation method was ineffective as a means of preparing consistent CHT
films. The non-crosslinked matrices were ineffective for allowing modulated DPH release in
the gastric region over 3 hours. The most effective concentration of CHT was a 15%w/v matrix
with a ZnSO4 concentration of either 5%w/v or 30% w/v. Further studies are underway toascertain the potential of the matrices as a pepsin-responsive gastric targeted drug delivery
system.
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Purpose: To formulate a buoyant polymeric system and to assess the potential of sustained
drug  release by conducting in vitro release studies in simulated gastric fluid (SGF) and to
assess the physicomechanical properties in relation to the drug release dynamics.
Method: Two variants of a buoyant polymeric system encompassed the following polymers:
chitosan (CHT), sodium alginate (ALG) and polyacrylamide (PAAm). Diphenhydramine HCl
(DPH) (solubility of 1g/mL of water at 25.5°C) was incorporated as a model drug. The
variations viz. CHT-ALG-PAAm and ALG-PAAm underwent redox-initiation in a ratio of 4:1
(g/mL) of redox-intiatior. The solutions were agitated at room temperature until homogenous
and underwent lyophilization and subsequent drug release studies in SGF (pH 1.2; ±37°C).
Samples were analyzed with UV spectrophotometry. Physicomechanical analysis was
conducted by textural analysis (TA XT plus, Stablemicro Systems, England) to evaluate
formulation resilience and energy absorbed (EA) in the dry (t0 hours) and hydrated states (t5hours).
Results: Both variants demonstrated sustained release of DPH. Inclusion of chitosan (CHT-
ALG-PAAm) (N=3) resulted in considerably higher drug release with 91±6.08% at t5 hours,compared to formulations without chitosan (ALG-PAAm) (N=3) (52±2.61%). However, a
‘burst’ effect was observed with ALG-PAAm at t1 hours. At t0 hours, ALG-PAAm had an EAvalue of 11.21±1.45N.mm compared to 14.72±1.75N.mm of CHT-ALG-PAAm. This provided
an indication of pore size. A lower EA indicated smaller pore sizes and a greater swelling
ability which allowed an elevation in drug diffusion out of the polymeric system. At t5 hours,CHT-ALG-PAAm had an EA value of 1.5±0.11N.mm and ALG-PAAm had a value of
1.77±0.04N.mm. Both formulations remained buoyant for the duration of the study. A matrix
resilience of 56±2.04% at t0 hours was achieved by both formulations. At t5 hours ALG-PAAm
had an average resilience of 18±0.57% compared to CHT-ALG-PAAm which had a resilience
of only 10±1.52%.
Conclusion: Both formulations demonstrated potential as a prolonged release buoyant drug
delivery system with the appropriate modification of the polymeric constituents.
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Purpose: To formulate a buoyant stimuli-responsive drug delivery system and to assess the
drug release dynamics in relation to the physicomechanical properties.
Methods: Two variants of a diphenhydramine-loaded polymeric delivery system comprising
chitosan (CHT), alginate (ALG) and polyacrylamide (PAAm) were prepared. The variations
viz. CHT-ALG-PAAm and ALG-PAAm underwent redox-initiation and lyophilization. Drug
release studies were performed in SGF (pH 1.2; 37°C). Samples were analyzed at 254nm
under UV. Physicomechanical analysis was conducted on a Textural Analyzer where the
energy absorbed (EA) in the non-hydrated (t0 hours) and hydrated states (t5 hours) wasdetermined.
Results: Both variants demonstrated modulated release of DPH. Inclusion of CHT (N=3)
resulted in considerably higher drug release (91±6.08%) when hydrated, compared to
formulations without CHT (N=3) (52±2.61%). At t0 hours, ALG-PAAm had an EA value of
11.21±1.45N.mm compared to 14.72±1.75N.mm of CHT-ALG-PAAm. A lower EA indicated
smaller pore sizes and greater swelling ability which allowed an elevation in drug diffusion
and subsequent increase in drug release. At t5 hours, CHT-ALG-PAAm and ALG-PAAm hadan EA value of 1.5±0.11N.mm and 1.77±0.04N.mm, respectively. Both formulations
remained buoyant during the study.
Conclusion: A distinct correlation between the drug release dynamics and EA of the gastro-
stimulus drug delivery systems was established.
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Purpose
The purpose of this study was to formulate chemically modified matrices of natural and
synthetic polymers with the aim of reducing premature solvation of the polysaccharide
polymer and in turn reducing upper gastrointestinal release of drug.
Methods
Synthesis of modified matrices: Three formulations of various combinations of
polysaccharide polymer (CHT and/or pectin) and polyacrylamide (PAAm) were synthesized.
The DPH-loaded polymer blends were stirred until homogenous and initiation of radical
formation was permitted with the addition of SPS and TEMED. Aliquots (1mL) of each blend
were pipetted into pre-lubricated cylindrical moulds, frozen at -70°C for 24 hours and
subsequently lyophilized. In vitro release studies: Drug release studies were conducted in the
BioDiss apparatus in SGF (pH 1.2; ±37°C) for 2 hours and SIF (pH 6.8; ±37°C) for 4 hours.
Samples (5mL) were withdrawn after each hour and subsequently analyzed by UV
spectroscopy at a wavelength of 254nm. Drug Entrapment Efficiency (DEE): Matrices were
completely dissolved in 100mL of simulated gastric fluid (SGF) (pH 1.2; 37ºC) and analyzed
via UV spectrophotometry to determine DPH content. Physicomechanical analysis: Matrix
resilience (MR) was determined based on a force-time profile acquired by a textural analyzer.
Matrix hardness (MH) and deformation energy (DE) was determined based on a force-
distance profile for each formulation. Fourier Transmission Infrared Spectroscopy (FTIR):
FTIR was performed on all native polymers involved in matrix formulation as well as on
lyophilized matrices as a means of validating the successful synthesis of a modified
polymeric matrix.
Results
CHT-PAAm matrices only began releasing DPH after 2 hours of dissolution studies with less
than 40% of DPH release after 6 hours. Pectin-PAAm matrices began releasing DPH
immediately; however the rate of drug release was sustained with less than 40% DPH
release in the 6 hours. The combination matrix of Pectin-CHT-PAAm showed the least
favorable release profile as complete drug release was achieved in only 4 hours. CHT-PAAm
and Pectin-PAAm matrices showed a greater resilience (6.1% and 5.3% respectively) than
the combination matrix (3.9%). The MH and DE were also greater in matrices of CHT-PAAm
and Pectin-PAAm compared to the combination matrix. FTIR spectra validated the formation
of chemically modified matrices with distinct bands not present in the native polymers e.g.
the formation of a primary aliphatic alcohol represented by the band between 3500-3100cm-1
for Pectin-PAAm matrices.
Conclusions
All matrices remained intact after 6 hours of dissolution studies and displayed varying
physicochemical and physicomechanical properties dependent on the polymers employed.
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Purpose: To synthesize chemically modified matrices of natural polysaccharide polymers
and synthetic polymers and to assess their applicability in drug delivery.
Method: Graft co-polymerized polysaccharide-polyacrylamide (PAAm) matrices were
prepared using pectin (PEC), chitosan (CHT) and a combination thereof (PEC/CHT). The
three variants underwent a redox reaction by addition of sodium persulphate (SPS) and
N,N,N’,N’-Tetramethylethylenediamine (TEMED) (4:1 g/mL). Diphenhydramine HCl (solubility
of 1g/mL of water at 25.5°C) was incorporated as a model drug. Polymerization proceeded at
25°C for 3 hours. 1mL aliquots were pipetted into moulds and subsequently lyophilized. In
vitro release studies were conducted in the BioDis apparatus in SGF (pH 1.2; ±37°C) for 2
hours and SIF (pH 6.8; ±37°C) for 4 hours. The surface area, pore volume and pore sizes of
matrices were determined with the Micromeritics ASAP analyzer. FTIR analysis was
conducted on native polymers as well as matrices to validate the successful synthesis of a
graft co-polymerized matrix. SEM was used to elucidate the morphology and distribution of
pores within the matrices.
Results: PEC/CHT-g-PAAm matrices had a substantial burst of drug release in the first hour
(70.57%) compared to only 22.45% and 0% drug release from PEC-g-PAAm and CHT-g-
PAAm matrices respectively. Despite no drug being released from CHT-g-PAAm matrices in
the first 2 hours, this formulation proved to be the most effective in achieving an almost zero-
order drug release profile. The ‘burst’ in drug release from PEC/CHT-g-PAAm matrices may
be attributed to the substantially greater surface area according to the BJH adsorption and
desorption isotherms (12.29m2/g and 13.84m2/g respectively). PEC-g-PAAm matrices have
smaller pore sizes and pore volumes compared to CHT-g-PAAm matrices. The larger pore
volume of PEC/CHT-g-PAAm matrices (0.077cm3/g) compared to CHT-g-PAAm matrices
(0.021cm3/g) is also evident in SEM images. The low surface area of CHT-g-PAAm matrices
caused the lower rate of drug release. FTIR spectra validated the formation of chemically
modified polymers with distinct bands not present in the native polymers e.g. the formation of
a primary aliphatic alcohol indicative at a frequency range of 3500-3100cm3.
Conclusion: Chemically modified polymeric matrices demonstrated potential for achieving
various release profiles dependent on the polysaccharide polymer employed.
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Purpose:
To formulate an enzyme-responsive drug delivery system that targets the model drug
mesalamine directly to the colonic mucosa.
Methods:
Tablets were prepared by dispersing crosslinked chitosan-mesalamine granules within a
matrix of polysaccharides (pectin, xanthan gum, and carboxymethylcellulose). BaCl2 wasused to crosslink pectin in situ. Tablets were coated with a solution of pectin/ ethylcellulose to
a 9-10% weight increase. The enzyme-responsiveness was determined based on the drug
release in simulated human gastric, intestinal, and colonic fluids (SHGF:pH 1.2; SHIF:pH 6.8;
SHCF:pH 5.9) at 2, 4 and 18 hours respectively, with and without commercially available
colonic enzymes. The influence of colonic enzymes on the formulation (SHCF absorption
ability and erosion) was determined gravimetrically. FTIR was performed to assess the
influence of colonic enzymes on the vibrational/structural properties of the formulation while
energy refinement force field simulations (ERFFS) were performed to corroborate the
experimental findings.
Results:
For the first 6 hours in SHGF and SHIF no drug was released. However, after 12 hours in
SHCF with colonic enzymes 80.3% of drug was released compared to 30.4% in SHCF
without enzymes. The extent of uptake of SHCF-containing enzymes was 101.68%
compared to 54.57% without colonic enzymes. Colonic enzymes also resulted in greater
erosion of the formulations (45.14% vs. 27.74% after 18 hours in SHCF). FTIR spectra and
ERFFS revealed structural variations in the polymeric backbone chains of the tablet and
coating indicating cleavage of the polymer backbones by the colonic enzymes.
Conclusion:
A novel enzyme-responsive drug delivery system was successfully developed for colon-
targeted drug delivery.
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Purpose:
To formulate a novel drug delivery system comprised of an inner placebo tablet surrounded
by an outer polymeric shell that targets loperamide HCl to the small intestine by being
negatively-responsive to pepsin.
Methods:
Polymeric shells fabricated by dip-coating placebo lactose tablets into drug-loaded gelatine
solutions were crosslinked in a glutaraldehyde-lactose mixture for 6 hours. In vitro drug
release studies were conducted in simulated human gastric fluid (SHGF) (pH 1.2) with and
without pepsin for 2 hours and simulated human intestinal fluid (SHIF) (pH 6.8) for 4 hours.
The influence of pepsin on SHGF uptake ability and erosion of the gelatine shells was
determined gravimetrically. FTIR spectroscopy and Molecular Mechanics (MM) simulations
were performed to visualize the influence of pepsin on the polymeric backbone of the
crosslinked shells.
Results:
Only 18.2% drug was released in SHGF with pepsin compared to 100% release in SHGF
without pepsin in 90 minutes. Complete drug release was achieved within 4 hours in SHIF
indicating the intestinal targeting ability and pepsin-responsiveness of the shell. Formulations
unexposed to pepsin experienced a greater degree of swelling. A reduced intensity of the
peak at ~3280cm-1 in the shells is attributable to the loss of –COOH in SHGF while the peaks
at 3282cm-1 and 1627cm-1 from shells exposed to pepsin, showed a relatively greater
intensity suggesting that both the –COOH and –NH2 groups remained intact as corroborated
by MM geometrical preferences.
Conclusion:
A novel pepsin-responsive polymeric shell for the targeted delivery of loperamide HCl to the
small intestine was successfully developed.
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Abstract
Background:
Despite the fact that Parkinson’s disease (PD) was discovered almost 200 years ago, its
treatment and management remains an immense challenge since progressive loss of
dopaminergic nigral neurons, motor complications experienced by the patients as the
disease progresses and drawbacks of pharmacotherapeutic management still persists.
Various therapeutic agents have been employed in the management of PD, including
levodopa (L-dopa), selegiline, amantadine, bromocriptine, entacapone, pramipexole
dihydrochloride and more recently istradefylline and rasagiline. Of all agents, L-dopa though
the oldest, remains the most effective. L-dopa is easier to administer, better tolerated, less
expensive and is required by almost all PD patients. However, L-dopa’s efficacy in advanced
PD is significantly reduced due to metabolism, subsequent low bioavailability and irregular
fluctuations in its plasma levels. To date, significant strides have been made to improve the
delivery of L-dopa in order to enhance its bioavailability and reduce plasma fluctuations as
well as motor complications experienced by patients purportedly due to pulsatile stimulation
of the striatal dopamine receptors.
Objective:
The ultimate aim was to critically assess the attempts made thus far directed at improving L-
dopa absorption, bioavailability and maintenance of constant plasma concentrations,
including the drug delivery technologies implicated.
Methods:
Drug delivery systems that have been instituted for the delivery of L-dopa include immediate
release formulations, liquid formulations, dispersible tablets, controlled release formulations,
dual release formulations, microspheres, infusion and transdermal delivery, among others. In
this review, the L-dopa loaded drug delivery systems developed over the past three decades
were elaborated on.
Conclusion:
This review highlights the fact that neuropharmaceutics is at a precipice, which is expected to
spur investigators to take that leap to enable the generation of innovative delivery systems
for the effective management of PD.
Keywords: Bioavailability, Conventional dosage forms, Drug delivery systems, Levodopa,
Microspheres, Motor complications, Neuropharmaceutics, Nanotechnology, Parkinson’s
disease, Pulmonary delivery, Transdermal delivery.
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Abstract
Recent pharmaceutical research has focused on controlled drug delivery as an advantage
over conventional methods. Adequate controlled plasma drug levels, reduced side effects as
well as improved patient compliance are some of the benefits that these systems may offer.
Controlled delivery systems that can provide zero-order drug delivery have the potential for
maximizing efficacy while minimizing dose frequency and toxicity. Thus, zero order drug
release is ideal in a large area of drug delivery which has therefore led into the development
of various technologies with such drug release patterns. Systems such as multilayered
tablets and other geometrically altered devices have been created to perform this function.
One of the principles of multilayered tablets involves creating a constant surface area for
release. Polymeric materials play an important role in the functioning of these systems.
Technologies so far developed include among others, Geomatrix® multilayered tablets which
utilizes specific polymers that may act as barriers to control drug release; Procise® which
has a core with an aperture that can be modified to achieve various types of drug release,
core-in-cup tablets where the core matrix is coated on one surface while the circumference
forms a cup around it, donut-shaped devices which have a hole in the middle, Dome Matrix®
and “release modules assemblage” which can offer alternating drug release patterns. This
review discusses the novel altered geometric system technologies that have been developed
to provide controlled drug release, also focusing on polymers that have been employed in
such developments.
Keywords:
Controlled drug delivery, geometrically altered devices, multilayered tablets, Polymeric
materials, “Release modules assemblage”.
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CENTRAL ANIMAL SERVICE
Tel: 011 717-1312
Fax:  011 643-4318
__________________________________________________
DEAR ANIMAL USERS
It is with great satisfaction that we can relay to users, the positive outcome of their respective in vivo
research.
Central Animal Service acquired a batch of 30 pigs for in vivo research with the Department of
Pharmacy and Pharmacology, for disease screening.
An ongoing animal surveillance program pre and post studies continued on a daily basis to assess the
health and well being of the animals. We are confident to say that no unforeseen or fatal circumstance
due to researchers or the research material itself had occurred. All pigs maintained an acceptable
health status during and post studies.
Kind regards
Dr Leith Meyer (Director of the Central Animal Services) and the CAS team
06th September 2010.
…………………………………………
